0000950170-24-12251810-Q Outset Medical, Inc. 20241106202411061750491750491750491

INFORMATION Item 1. Financial Statements (unaudited). Outset Medical, Inc. Condensed Balance Sheets (Unaudited) (in thousands, except per share amounts) Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Assets Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Cash and cash equivalents Â $ 33,287 Â Â $ 68,509 Â Short-term investments Â Â 142,346 Â Â Â 134,815 Â Accounts receivable, net Â Â 34,259 Â Â Â 32,980 Â Inventories Â Â 61,436 Â Â Â 49,215 Â Prepaid expenses and other current assets Â Â 3,945 Â Â Â 5,700 Â Total current assets Â Â 275,273 Â Â Â 291,219 Â Restricted cash Â Â 3,329 Â Â Â 3,329 Â Property and equipment, net Â Â 9,492 Â Â Â 13,273 Â Operating lease right-of-use assets Â Â 4,312 Â Â Â 5,375 Â Other assets Â Â 484 Â Â Â 605 Â Total assets Â $ 292,890 Â Â $ 313,801 Â Liabilities and stockholders' equity Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Accounts payable Â $ 4,295 Â Â $ 5,827 Â Accrued compensation and related benefits Â Â 14,719 Â Â Â 19,005 Â Accrued expenses and other current liabilities Â Â 6,749 Â Â Â 13,459 Â Accrued warranty liability Â Â 2,156 Â Â Â 3,712 Â Deferred revenue, current Â Â 12,766 Â Â Â 11,727 Â Operating lease liabilities, current Â Â 1,745 Â Â Â 1,593 Â Total current liabilities Â Â 42,430 Â Â Â 55,323 Â Accrued interest Â Â 2,222 Â Â Â 896 Â Deferred revenue Â Â 77 Â Â Â 101 Â Operating lease liabilities Â Â 3,157 Â Â Â 4,482 Â Term loans Â Â 197,182 Â Â Â 130,113 Â Total liabilities Â Â 245,068 Â Â Â 190,915 Â Commitments and contingencies (Note 6) Â Â Â Â Â Â Stockholders' equity: Â Â Â Â Â Â Preferred stock, $0.001Â par value; 5,000Â shares authorized, and noÂ shares issued and outstanding as of September 30, 2024 and December 31, 2023 Â Â â€” Â Â Â â€” Â Common stock, $0.001Â par value; 300,000Â shares authorized as of September 30, 2024 and December 31, 2023; 52,538Â and 50,317Â shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Â Â 52 Â Â Â 50 Â Additional paid-in capital Â Â 1,111,503 Â Â Â 1,084,515 Â Accumulated other comprehensive income Â Â 352 Â Â Â 68 Â Accumulated deficit Â Â (1,064,085) Â Â (961,747) Total stockholders' equity Â Â 47,822 Â Â Â 122,886 Â Total liabilities and stockholders' equity Â $ 292,890 Â Â $ 313,801 Â The accompanying notes are an integral part of these unaudited condensed financial statements. 1 Â Outset Medical, Inc. Condensed Statements of Operations (Unaudited) (in thousands, except per share amounts) Â Â Â Three Months Ended Â Â Nine Months Ended Â Â Â September 30, Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenue: Â Â Â Â Â Â Â Â Â Â Â Product revenue Â $ 20,305 Â Â $ 23,531 Â Â $ 59,971 Â Â $ 80,640 Â Service and other revenue Â Â 8,361 Â Â Â 6,831 Â Â Â 24,251 Â Â Â 19,229 Â Total revenue Â Â 28,666 Â Â Â 30,362 Â Â Â 84,222 Â Â Â 99,869 Â Cost of revenue: Â Â Â Â Â Â Â Â Â Â Â Cost of product revenue Â Â 11,532 Â Â Â 16,837 Â Â Â 34,680 Â Â Â 59,866 Â Cost of service and other revenue Â Â 7,314 Â Â Â 6,368 Â Â Â 21,725 Â Â Â 18,715 Â Total cost of revenue Â Â 18,846 Â Â Â 23,205 Â Â Â 56,405 Â Â Â 78,581 Â Gross profit Â Â 9,820 Â Â Â 7,157 Â Â Â 27,817 Â Â Â 21,288 Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â 8,139 Â Â Â 16,076 Â Â Â 30,508 Â Â Â 44,775 Â Sales and marketing Â Â 15,417 Â Â Â 24,720 Â Â Â 54,593 Â Â Â 74,038 Â General and administrative Â Â 10,103 Â Â Â 11,815 Â Â Â 34,231 Â Â Â 34,892 Â Total operating expenses Â Â 33,659 Â Â Â 52,611 Â Â Â 119,332 Â Â Â 153,705 Â Loss from operations Â Â (23,839) Â Â (45,454) Â Â (91,515) Â Â (132,417) Interest income and other income, net Â Â 2,149 Â Â Â 2,573 Â Â Â 7,718 Â Â Â 7,889 Â Interest expense Â Â (6,068) Â Â (3,213) Â Â (18,046) Â Â (9,258) Loss before provision for income taxes Â Â (27,758) Â Â (46,094) Â Â (101,843) Â Â (133,786) Provision for income taxes Â Â 182 Â Â Â 86 Â Â Â 495 Â Â Â 411 Â Net loss Â $ (27,940) Â $ (46,180) Â $ (102,338) Â $ (134,197) Â Â Â Â Â Â Â Â Â Â Â Net loss per share, basic and diluted Â $ (0.55) Â $ (0.93) Â $ (1.98) Â $ (2.72) Shares used in computing net loss per share, basic and diluted Â Â 50,501 Â Â Â Â 49,913 Â Â Â Â 51,685 Â Â Â Â 49,364 Â The accompanying notes are an integral part of these unaudited condensed financial statements. 2 Â Outset Medical, Inc. Condensed Statements of Comprehensive Loss (Unaudited) (in thousands) Â Â Â Three Months Ended Â Â Nine Months Ended Â Â Â September 30, Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net loss Â $ (27,940) Â $ (46,180) Â $ (102,338) Â $ (134,197) Other comprehensive (loss) income: Â Â Â Â Â Â Â Â Â Â Â Unrealized gain on available-for-sale securities Â Â 654 Â Â Â 140 Â Â Â 284 Â Â Â 311 Â Comprehensive loss Â $ (27,286) Â $ (46,040) Â $ (102,054) Â $ (133,886) The accompanying notes are an integral part of these unaudited condensed financial statements. 3 Â Outset Medical, Inc. Condensed Statement of Stockholdersâ€™ Equity (Unaudited) (in thousands) Â Â Common Stock Â Â AdditionalPaid-in Â Â AccumulatedOtherComprehensive Â Â Accumulated Â Â TotalStockholders' Â Â Shares Â Â Amount Â Â Capital Â Â Income (Loss) Â Â Deficit Â Â Equity Â Balance as of December 31, 2023 Â 50,317 Â Â $ 50 Â Â $ 1,084,515 Â Â $ 68 Â Â $ (961,747) Â $ 122,886 Â Issuance of common stock through employee stock Â Â purchase plan Â 776 Â Â Â 1 Â Â Â 2,079 Â Â Â â€” Â Â Â â€” Â Â Â 2,080 Â Issuance of common stock for settlement of RSUs Â 607 Â Â Â 1 Â Â Â 294 Â Â Â â€” Â Â Â â€” Â Â Â 295 Â Stock option exercises Â 2 Â Â Â â€” Â Â Â 6 Â Â Â â€” Â Â Â â€” Â Â Â 6 Â Stock-based compensation expense Â â€” Â Â Â â€” Â Â Â 8,203 Â Â Â â€” Â Â Â 8,203 Â Unrealized loss on available-for-sale securities Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (326) Â Â Â â€” Â Â Â (326) Net loss Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (39,944) Â Â Â (39,944) Balance as of March 31, 2024 Â 51,702 Â Â $ 52 Â Â $ 1,095,097 Â Â $ (258) Â $ (1,001,691) Â $ 93,200 Â Issuance of common stock for settlement of RSUs Â 312 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Stock option exercises Â 70 Â Â Â â€” Â Â Â 77 Â Â Â â€” Â Â Â â€” Â Â Â 77 Â Stock-based compensation expense Â â€” Â Â Â â€” Â Â Â 9,820 Â Â Â â€” Â Â Â â€” Â Â Â 9,820 Â Unrealized loss on available-for-sale securities Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (44) Â Â Â â€” Â Â Â (44) Net loss Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (34,454) Â Â Â (34,454) Balance as of June 30, 2024 Â 52,084 Â Â $ 52 Â Â $ 1,104,994 Â Â $ (302) Â $ (1,036,145) Â $ 68,599 Â Issuance of common stock through employeeÂ Â stock purchase plan Â 264 Â Â Â â€” Â Â Â 121 Â Â Â â€” Â Â Â â€” Â Â Â 121 Â Issuance of common stock for settlement of RSUs Â 190 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Stock-based compensation expense Â â€” Â Â Â â€” Â Â Â 6,388 Â Â Â â€” Â Â Â â€” Â Â Â 6,388 Â Unrealized gain on available-for-sale securities Â â€” Â Â Â â€” Â Â Â 654 Â Â Â â€” Â Â Â 654 Â Net loss Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (27,940) Â Â (27,940) Balance as of September 30, 2024 Â 52,538 Â Â $ 52 Â Â $ 1,111,503 Â Â $ 352 Â Â $ (1,064,085) Â $ 47,822 Â The accompanying notes are an integral part of these unaudited condensed financial statements. 4 Â Outset Medical, Inc. Condensed Statement of Stockholdersâ€™ Equity (Unaudited) (in thousands) Â Â Common Stock Â Â AdditionalPaid-in Â Â AccumulatedOtherComprehensive Â Â Accumulated Â Â TotalStockholders' Â Â Shares Â Â Amount Â Â Capital Â Â Income (Loss) Â Â Deficit Â Â Equity Â Balance as of December 31, 2022 Â 48,465 Â Â $ 48 Â Â $ 1,035,456 Â Â $ (564) Â $ (788,950) Â $ 245,990 Â Issuance of common stock through employee stock Â Â purchase plan Â 307 Â Â Â 1 Â Â Â 4,593 Â Â Â â€” Â Â Â â€” Â Â Â 4,594 Â Issuance of common stock for settlement of RSUs Â 282 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Stock option exercises Â 162 Â Â Â â€” Â Â Â 684 Â Â Â â€” Â Â Â â€” Â Â Â 684 Â Stock-based compensation expense Â â€” Â Â Â â€” Â Â Â 8,538 Â Â Â â€” Â Â Â â€” Â Â Â 8,538 Â Unrealized gain on available-for-sale securities Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 451 Â Â Â â€” Â Â Â 451 Â Net loss Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (43,971) Â Â (43,971) Balance as of March 31, 2023 Â 49,216 Â Â $ 49 Â Â $ 1,049,271 Â Â $ (113) Â $ (832,921) Â $ 216,286 Â Issuance of common stock for settlement of RSUs Â 165 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Stock option exercises Â 248 Â Â Â 1 Â Â Â 1,042 Â Â Â â€” Â Â Â 1,043 Â Stock-based compensation expense Â â€” Â Â Â â€” Â Â Â 10,105 Â Â Â â€” Â Â Â â€” Â Â Â 10,105 Â Unrealized loss on available-for-sale securities Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (280) Â Â Â â€” Â Â Â (280) Net loss Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (44,046) Â Â (44,046) Balance as of June 30, 2023 Â 49,629 Â Â $ 50 Â Â $ 1,060,418 Â Â $ (393) Â $ (876,967) Â $ 183,108 Â Issuance of common stock through employeeÂ Â stock purchase plan Â 252 Â Â Â â€” Â Â Â 2,916 Â Â Â â€” Â Â Â â€” Â Â Â 2,916 Â Issuance of common stock for settlement of RSUs Â 117 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Stock option exercises Â 175 Â Â Â â€” Â Â Â 1,186 Â Â Â â€” Â Â Â â€” Â Â Â 1,186 Â Stock-based compensation expense Â â€” Â Â Â â€” Â Â Â 10,893 Â Â Â â€” Â Â Â â€” Â Â Â 10,893 Â Unrealized gain on available-for-sale securities Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 140 Â Â Â â€” Â Â Â 140 Â Net loss Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (46,180) Â Â (46,180) Balance as of September 30, 2023 Â 50,173 Â Â $ 50 Â Â $ 1,075,413 Â Â $ (253) Â $ (923,147) Â $ 152,063 Â The accompanying notes are an integral part of these unaudited condensed financial statements. 5 Â Outset Medical, Inc. Condensed Statements of Cash Flows (Unaudited) (in thousands) Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Cash flows from operating activities: Â Â Â Â Â Â Net loss Â $ (102,338) Â $ (134,197) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Â Â Stock-based compensation expense Â Â 24,411 Â Â Â 29,536 Â Depreciation and amortization Â Â 4,322 Â Â Â 4,364 Â Non-cash lease expense Â Â 1,063 Â Â Â 919 Â Non-cash interest expense Â Â 1,898 Â Â Â 1,377 Â Amortization of premium on investments, net Â Â (3,890) Â Â (5,099) Provision for inventories Â Â 644 Â Â Â 672 Â Loss on disposal of property and equipment Â Â 34 Â Â Â 106 Â Allowance for credit losses Â Â 1,813 Â Â Â 141 Â Changes in operating assets and liabilities: Â Â Â Â Â Â Accounts receivable Â Â (3,092) Â Â (7,564) Inventories Â Â (12,989) Â Â 2,607 Â Prepaid expenses and other assets Â Â 1,848 Â Â Â 440 Â Accounts payable Â Â (1,507) Â Â 2,251 Â Accrued compensation and related benefits Â Â (3,991) Â Â 25 Â Accrued expenses and other current liabilities Â Â (6,327) Â Â (4,108) Accrued warranty liability Â Â (1,556) Â Â 447 Â Deferred revenue Â Â 1,015 Â Â Â 2,114 Â Operating lease liabilities Â Â (1,173) Â Â (962) Net cash used in operating activities Â Â (99,815) Â Â (106,931) Cash flows from investing activities: Â Â Â Â Â Â Purchases of property and equipment Â Â (869) Â Â (2,387) Purchases of investment securities Â Â (150,467) Â Â (121,262) Maturities of investment securities Â Â 147,121 Â Â Â 183,250 Â Net cash (used in) provided by investing activities Â Â (4,215) Â Â 59,601 Â Cash flows from financing activities: Â Â Â Â Â Â Proceeds from stock option exercises and ESPP purchases Â Â 2,284 Â Â Â 10,423 Â Proceeds from issuance of term loans, net of issuance costs Â Â 66,524 Â Â Â â€” Â Net cash provided by financing activities Â Â 68,808 Â Â Â 10,423 Â Net decrease in cash, cash equivalents and restricted cash Â Â (35,222) Â Â (36,907) Cash, cash equivalents and restricted cash as of beginning of period Â Â 71,838 Â Â Â 76,533 Â Cash, cash equivalents and restricted cash as of end of period Â $ 36,616 Â Â $ 39,626 Â Â Â Â Â Â Â Â Supplemental cash flow disclosures: Â Â Â Â Â Â Cash paid for income taxes Â $ 472 Â Â $ 403 Â Cash paid for interest Â $ 15,537 Â Â $ 1,836 Â Cash paid for amounts included in the measurement of operating lease liabilities Â $ 1,173 Â Â $ 962 Â Â Â Â Â Â Â Â Supplemental non-cash investing and financing activities: Â Â Â Â Â Â Capital expenditures included in accounts payable and accrued expenses Â $ 8 Â Â $ 207 Â Transfer of inventories to property and equipment Â $ 148 Â Â $ â€” Â Right-of-use assets obtained in exchange for operating lease liabilities Â $ â€” Â Â $ 528 Â The accompanying notes are an integral part of these unaudited condensed financial statements. 6 Â Outset Medical, Inc. Notes to Unaudited Condensed Financial Statements 1. Description of Business Outset Medical, Inc. (the Company) is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. TabloÂ® Hemodialysis System (Tablo), cleared by the U.S. Food and Drug Administration (FDA) for use from the hospital to the home, represents a significant technological advancement designed to transform the dialysis experience for patients and operationally simplify it for providers. Tablo serves as a single enterprise solution designed to be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. The integration of water purification and on-demand dialysate production in a single 35-inch compact console enables Tablo to serve as a dialysis clinic on wheels. With a simple-to-use touchscreen interface, two-way wireless data transmission and a proprietary data analytics platform, Tablo is a new holistic approach to dialysis care. The Companyâ€™s headquarters are located in San Jose, California. LiquidityLiquiditySince inception, the Company has incurred net losses and negative cash flows from operations. During the nine months ended September 30, 2024 and 2023, the Company incurred a net loss of $102.3 million and $134.2 million, respectively, and cash outflow from operating activities of $99.8 million and $106.9 million, respectively. As of September 30, 2024, the Company had an accumulated deficit of $1.1 billion.As of September 30, 2024, the Company had cash, cash equivalents, restricted cash and short-term investments of $179.0 million. The Company is required to comply with certain covenants under the SLR Credit Facility Agreements (as defined in Note 7) including ones relating to financial reporting and the delivery of an unqualified audit opinion, the maintenance of minimum cash or revenue, the incurrence of additional debt, and its ability to make capital expenditures or declare dividends. If the Company fails to comply with any covenants, payments or other terms of either SLR Credit Facility Agreement, its agent or lender, as applicable, could declare an event of default, which would give it the right to declare all borrowings outstanding, together with accrued and unpaid interest and fees, to be immediately due and payable. Further details of obligations under the SLR Credit Facility Agreements are described in Note 7.While the Company has taken actions to reduce operating expenses and working capital to align with anticipated revenue growth including implementing restructuring plans to streamline its overall organizational structure and renegotiating commitments with suppliers to reduce inventory, management expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth.Furthermore, on September 23, 2024, the Company received notice from the Listing Qualifications staff of the Nasdaq Stock Market LLC (Nasdaq) that it no longer complied with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. If the Company is unable to regain compliance with the minimum bid price requirement within the applicable compliance period, or is unable to otherwise maintain compliance with other applicable Nasdaq listing rules, it may not be able to maintain the listing of its common stock on Nasdaq, which could adversely affect its ability to issue additional securities or obtain additional financing on terms acceptable to it, or at all.Management believes that the Companyâ€™s existing cash, cash equivalents, short-term investments, cash generated from sales, and proceeds received from the debt financing described in Note 7, will be sufficient to meet its anticipated needs for at least the next 12 months from the issuance date of the accompanying condensed financial statements.Basis of PresentationThe accompanying condensed financial statements are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, that are necessary for the fair statement of the Companyâ€™s financial position, results of operations, comprehensive loss, and cash flows for the interim periods presented. The financial data and the other financial information disclosed in these notes to the condensed financial statements related to the three- and nine-month periods are also unaudited. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results of operations to be anticipated for any other future annual or interim period. The condensed balance sheet as of December 31, 2023 included herein was derived from the audited financial statements as of that date. These unaudited condensed financial statements should be read in conjunction with the Companyâ€™s audited financial statements and related notes for the year ended December 31, 2023, which are included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) on February 21, 2024 (2023 Annual Report).All share amounts disclosed in the notes to the condensed financial statements are rounded to the nearest thousand except for per share data. 7 Â 2. Summary of Significant Accounting PoliciesRecently Issued Accounting PronouncementsIn November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07), which requires that an entity disclose significant segment expenses impacting profit and loss that are regularly provided to the chief operating decision maker. The update is required to be applied retrospectively to prior periods presented, based on the significant segment expense categories identified and disclosed in the period of adoption. This ASU guidance is effective for our Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent interim periods, with early adoption permitted. The Company is currently evaluating the impact of the adoption of ASU 2023-07 on its financial statements and disclosures.In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (ASU 2023-09), which requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, this ASU requires certain disclosures of state versus federal income tax expense and taxes paid. This ASU is effective for our Annual Report on Form 10-K for the year ended December 31, 2025, with early adoption permitted. The Company does not expect the adoption of ASU 2023-09 to have a material impact on its financial statements.In March 2024, the SEC adopted rules intended to enhance and standardize climate-related disclosures in registration statements and annual reports. The new rules will require disclosure of material climate-related risks, including the material impacts of these risks to the Company, the quantification of material impacts to the Company as a result of severe weather events and other natural conditions and Board of Directors' oversight and risk management activities. The new rules follow a compliance phase-in timeline based on a company's filing status. Large accelerated filers and accelerated filers (other than smaller reporting companies) are required to first incorporate such disclosures for fiscal years 2025 and 2026, respectively, followed by greenhouse gas-related disclosures, if material, for fiscal years 2026 and 2027, respectively. Smaller reporting companies are required to first incorporate such disclosures for fiscal year 2027 and are not required to report greenhouse gas emissions data. In April 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. The Company is currently evaluating the impact of these new rules on its financial statements and disclosures.Significant Accounting PoliciesThere have been no new or material changes to the Companyâ€™s significant accounting policies as described in its 2023 Annual Report that have had a material impact on the Companyâ€™s condensed financial statements and related notes. 3. Revenue and Deferred Revenue Disaggregation of RevenueRevenue by source consists of the following (in thousands): Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Consoles Â $ 7,709

Â Â $ 12,506 Â Â $ 24,080 Â Â $ 51,053 Â Â Consumables Â Â 12,596 Â Â Â 11,025 Â Â Â 35,891 Â Â Â 29,587 Â Â Total product revenue Â Â 20,305 Â Â Â 23,531 Â Â Â 59,971 Â Â Â 80,640 Â Â Service and other revenue Â Â 8,361 Â Â Â 6,831 Â Â Â 24,251 Â Â Â 19,229 Â Â Total revenue Â $ 28,666 Â Â $ 30,362 Â Â $ 84,222 Â Â $ 99,869 Â Â Remaining Performance Obligations and Contract LiabilitiesAs of September 30, 2024, the aggregate amount of the transaction price allocated to the remaining performance obligations related to customer service contracts that are unsatisfied or partially unsatisfied was $12.9 million, which is recorded as deferred revenue on the Companyâ€™s condensed balance sheets. Of that amount, $12.8 million will be recognized as revenue during the next 12 months and $0.1 million thereafter. The contract liabilities consist of deferred revenue which represents payments received in advance of revenue recognition. Revenue under these agreements is recognized over the related service period. During the three and nine months ended September 30, 2024, the Company recognized $2.0 million and $10.9 million of previously deferred revenue, respectively. 8 Â 4. Fair Value Measurements The following tables summarize the Companyâ€™s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): Â Â Â Â Â September 30, 2024 Â Â Â ValuationHierarchy Â AmortizedCosts Â Â GrossUnrealizedGains Â Â GrossUnrealizedLosses Â Â AggregateFair Value Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â Level 1 Â $ 16,136 Â Â $ â€” Â Â $ â€” Â Â $ 16,136 Â Short-term investments: Â Â Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury securities Â Level 1 Â 72,762 Â Â Â 158 Â Â Â â€” Â Â Â 72,920 Â U.S. government-sponsored enterprises Â Â Â debt securities Â Level 2 Â Â 11,520 Â Â Â 14 Â Â Â â€” Â Â Â 11,534 Â Corporate debt Â Level 2 Â Â 57,712 Â Â Â 181 Â Â Â (1) Â Â 57,892 Â Commercial paper Â Level 2 Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â Total cash equivalents and Â Â Â short-term investments Â Â Â $ 158,130 Â Â $ 353 Â Â $ (1) Â $ 158,482 Â Â Â Â Â Â December 31, 2023 Â Â Â ValuationHierarchy Â AmortizedCosts Â Â GrossUnrealizedHolding Gains Â Â GrossUnrealizedHolding Losses Â Â AggregateFair Value Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â Level 1 Â $ 44,883 Â Â $ â€” Â Â $ â€” Â Â $ 44,883 Â Short-term investments: Â Â Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury securities Â Level 1 Â Â 53,790 Â Â Â 58 Â Â Â (32) Â Â 53,816 Â U.S. government-sponsored enterprises Â Â Â debt securities Â Level 2 Â Â 29,645 Â Â Â 24 Â Â Â (38) Â Â 29,631 Â Corporate debt Â Level 2 Â Â 33,214 Â Â Â 56 Â Â Â â€” Â Â Â 33,270 Â Commercial paper Â Level 2 Â Â 18,097 Â Â Â 5 Â Â Â (4) Â Â 18,098 Â Total cash equivalents and Â Â Â short-term investments Â Â Â $ 179,629 Â Â $ 143 Â Â $ (74) Â $ 179,698 Â Â As of September 30, 2024, the remaining contractual maturities for available-for-sale securities were one month to thirteen months. The following tables present the breakdown of the available-for-sale debt securities with unrealized losses as of September 30, 2024, and December 31, 2023 (in thousands): Â Â September 30, 2024 Â Â Â Unrealized losses less than 12 months Â Â Unrealized losses 12 months or greater Â Â Total Â Â Â Fair Value Â Â Unrealized Losses Â Â Fair Value Â Â Unrealized Losses Â Â Fair Value Â Â Unrealized Losses Â Corporate debt Â $ 2,659 Â Â $ (1) Â $ â€” Â Â $ â€” Â Â $ 2,659 Â Â $ (1) Total Â $ 2,659 Â Â $ (1) Â $ â€” Â Â $ â€” Â Â $ 2,659 Â Â $ (1) Â 9 Â Â Â December 31, 2023 Â Â Â Unrealized losses less than 12 months Â Â Unrealized losses 12 months or greater Â Â Total Â Â Â Fair Value Â Â Unrealized Losses Â Â Fair Value Â Â Unrealized Losses Â Â Fair Value Â Â Unrealized Losses Â U.S. Treasury securities Â $ 8,416 Â Â $ (16) Â $ 17,925 Â Â $ (16) Â $ 26,341 Â Â $ (32) U.S. government-sponsored enterprises Â Â Â debt securities Â Â 18,757 Â Â Â (22) Â Â 8,488 Â Â Â (16) Â Â 27,245 Â Â Â (38) Corporate debt Â Â 11,291 Â Â Â (4) Â Â â€” Â Â Â â€” Â Â Â 11,291 Â Â Â (4) Total Â $ 38,464 Â Â $ (42) Â $ 26,413 Â Â $ (32) Â $ 64,877 Â Â $ (74) The unrealized losses on the Companyâ€™s available-for-sale debt securities were caused by interest rate increases. The contractual terms of those investments do not permit the issuer to settle the securities at a price less than the amortized cost basis of the investments. As of September 30, 2024, the Company does not intend to sell the investments, and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. Additional factors considered in determining the treatment of unrealized losses include the financial condition and near-term prospects of the investee, the extent of the loss related to the credit of the issuer, and the expected cash flows from the security. For the three and nine months ended September 30, 2024 and 2023, the Company did not recognize credit loss related to available-for-sales debt securities. 5. Balance Sheet ComponentsCash, Cash Equivalents and Restricted CashAs of September 30, 2024 and December 31, 2023, the restricted cash balance of $3.3 million, was related to collateral for the Companyâ€™s building leases in San Jose, CA and Tijuana, Mexico. The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the amounts shown in the accompanying condensed statements of cash flows (in thousands): Â Â September 30, Â Â Â 2024 Â Â 2023 Â Cash and cash equivalents Â $ 33,287 Â Â $ 36,297 Â Restricted cash Â Â 3,329 Â Â Â 3,329 Â Total cash, cash equivalents and restricted cash Â $ 36,616 Â Â $ 39,626 Â Accounts ReceivableAccounts receivable are recorded at invoice value, net of any allowance for credit losses. The allowance for credit losses is based on the Companyâ€™s assessment of its best estimate of the amount of credit losses in customer accounts. The Company regularly reviews the allowance by considering factors such as existing contractual payment terms, historical collection experience, the financial position of the customer and information provided by credit rating services, the age of the accounts receivable balances, and current economic conditions that may affect a customerâ€™s ability to pay. The Company writes off accounts receivable when the Company has exhausted collection efforts without success, and payments subsequently received on such receivables are credited to the allowance in the period the payment is received. Credit losses from continuing operations have consistently been within managementâ€™s expectations.The following table presents the activity in the Companyâ€™s allowance for credit losses (in thousands): Balance as of December 31, 2023 Â Â Â $ 203 Â Increase in allowance Â Â Â Â 1,821 Â Write-offs Â Â Â Â (7) Balance as of September 30, 2024 Â Â Â $ 2,017 Â Â 10 Â InventoriesInventories consist of the following (in thousands): Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Raw materials Â $ 25,138 Â Â $ 18,706 Â Work in process Â Â 13,911 Â Â Â 8,728 Â Finished goods Â Â 22,387 Â Â Â 21,781 Â Total inventories Â $ 61,436 Â Â $ 49,215 Â Accrued Expenses and Other Current LiabilitiesAccrued expenses and other current liabilities consist of the following (in thousands): Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Inventory Â $ 1,384 Â Â $ 3,395 Â Research and development expenses Â Â 116 Â Â Â 1,050 Â Professional services Â Â 716 Â Â Â 1,153 Â Customer rebates Â Â 1,738 Â Â Â 2,100 Â Â Other Â Â 2,795 Â Â Â 5,761 Â Total accrued expenses and other current liabilities Â $ 6,749 Â Â $ 13,459 Â Â 6. Commitments and ContingenciesLitigationOn August 29, 2024, a purported stockholder class action lawsuit (the Porcelli Complaint), Porcelli, et al. v. Outset Medical, Inc., et al., 5:24-cv-06124-EJD, was filed in the U.S. District Court for the Northern District of California, naming the Company, its Chief Executive Officer, and Chief Financial Officer as defendants. On October 18, 2024, a second purported stockholder class action lawsuit (the Plymouth Complaint), Plymouth County Retirement Association v. Outset Medical, Inc, et al., 5:24-cv-06124-HSG, was filed in the U.S. District Court for the Northern District of California. The second lawsuit additionally names the Company's former Chief Financial Officer as a defendant. The Porcelli Complaint alleges that between August 1, 2022 and August 7, 2024, the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (Exchange Act) by making false or misleading statements about the Companyâ€™s business, operations and prospects related to the sale and marketing of the Tablo Hemodialysis System and TabloCart with Prefiltration, including concerning the impact of certain FDA processes for these products on the Companyâ€™s revenue growth. The Plymouth Complaint alleges the same violations between September 15, 2020 and August 7, 2024. The Company intends to vigorously defend against this litigation. The cases are at a very early stage and there can be no assurance that the Company will be successful in its defense. For this same reason, the Company cannot currently estimate the loss or the range of possible losses it may experience in connection with this litigation.In addition, from time to time, the Company may become involved in other legal proceedings or investigations, which could have an adverse impact on its reputation, business and financial condition and divert the attention of the Companyâ€™s management from the operation of the Companyâ€™s business. IndemnificationIn the ordinary course of business, the Company often includes standard indemnification provisions in its arrangements with its partners, customers and suppliers. Pursuant to these provisions, the Company may be obligated to indemnify such parties for losses or claims suffered or incurred in connection with its service, breach of representations or covenants, intellectual property infringement or other claims made against such parties. These provisions may limit the time within which an indemnification claim can be made. It is not possible to determine the maximum potential amount under these indemnification obligations due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. To date, the Company has not incurred any material costs as a result of such indemnification obligations and has not accrued any liabilities related to such obligations in these financial statements. 7. Term LoansTerm loans consist of the following (in thousands): Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Principal of term loans Â $ 200,000 Â Â $ 133,476 Â 11 Â Unamortized debt discount Â Â (2,818) Â Â (3,363) Term loans, noncurrent Â $ 197,182 Â Â $ 130,113 Â SLR Credit FacilitiesOn November 3, 2022 (the Closing Date), the Company entered into two senior secured credit facilities, which collectively provide for borrowings of up to $300.0 million as follows: (i) up to a $250.0 million term loan facility pursuant to a loan and security agreement (the SLR Loan Agreement) among SLR Investment Corp., as collateral agent (Agent), the lenders from time to time party thereto (the Term Loan Lenders) and the Company (the SLR Term Loan Facility), and (ii) up to a $50.0 million asset-based revolving credit facility pursuant to a credit agreement (the SLR Revolving Credit Agreement, together with the SLR Loan Agreement, the SLR Credit Facility Agreements) among Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL, as lender (ABL Lender), and the Company (the SLR Revolver, together with the SLR Term Loan Facility, the SLR Credit Facilities).The maximum amount the Company is permitted to borrow under the SLR Credit Facilities is subject to certain overall borrowing limitations that are tied to achieving certain specified revenue milestones and limit the maximum principal amount outstanding under the SLR Credit Facilities. As of September 30, 2024, the Company borrowed an aggregate principal amount of $200.0 million under the SLR Term Loan Facility, the full amount available under the borrowing limitations.SLR Term Loan FacilityUnder the SLR Loan Agreement, as subsequently amended on December 11, 2023, the Term Loan Lenders agreed to extend term loans to the Company in an aggregate principal amount of up to $250.0 million, comprised of (i) a term loan of $100.0 million (the Term A Loan), (ii) term loans in an aggregate principal amount of up to $100.0 million that was provided for in two increments, one of $33.5 million (the Term B-1 Loan) and one of $66.5 million (the Term B-2 Loan) and (iii) one or more term loans in an aggregate principal amount of up to $50.0 million (Term C Loans). Each Term A Loan, Term B Loan and Term C Loan is referred to single as a Term Loan and are referred to collectively as the Term Loans. The Term C Loans are subject to compliance with the borrowing limitations, Term Loan Lendersâ€™ credit approval and the achievement of a specified net revenue milestone on or before June 30, 2025 and if available, would remain available for funding until one business day prior to November 1, 2027.Any principal amount outstanding under the Term Loans will accrue interest at a rate per annum equal to one-month term Secured Overnight Financing Rate (term SOFR) (subject to a 2.75% floor), plus 5.15% (10.32% as of September 30, 2024), payable monthly in arrears. The Company is permitted to make interest-only payments on the Term Loans through November 30, 2026. Any principal amounts outstanding under the Term Loans, if not repaid sooner, are due and payable on November 1, 2027 (the Maturity Date). The Company is obligated to pay Agent (i) a non-refundable facility fee in the amount of $750,000 in respect of the Term A Loan, (ii) a non-refundable facility fees in the aggregate amount of $750,000 in respect of the Term B-1 and B-2 Loans and (iii) a non-refundable facility fee in the amount of $375,000 in respect of the Term C Loan, to be due and payable upon the earliest to occur of (a) the funding of the first Term C Loan, (b) one day prior to the Maturity Date and (c) the prepayment of the Term Loans. In addition, the Company is obligated to pay a final fee equal to 4.75% of the aggregate amount of the Term Loans funded, such final fee to be due and payable upon the earliest to occur of (i) the Maturity Date, (ii) the acceleration of the Term Loans and (iii) the prepayment of the Term Loans. The Company may voluntarily prepay the outstanding Term Loans, subject to a prepayment premium of (i) 3.0% of the principal amount of the Term Loan, if prepaid prior to or on the first anniversary of the Closing Date, (ii) 2.0% of the principal amount of the Term Loan, if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) 1.0% of the principal amount of the Term Loan if prepaid after the second anniversary of the Closing Date and prior to the Maturity Date. SLR RevolverThe SLR Revolving Credit Agreement provides for an asset-based revolving credit facility with aggregate revolving commitments of $25.0 million (the Initial Revolver Commitment). The Company may request to increase the aggregate revolving commitments by $25.0 million (the Additional Tranche) to an aggregate amount of $50.0 million, subject to ABL Lenderâ€™s approval. Amounts available to be drawn under the SLR Revolver are equal to the lesser of (i) outstanding revolving commitments under the SLR Revolving Credit Agreement and (ii) a borrowing base (the Borrowing Base) equal to the sum of (a) 85% of eligible accounts receivable, plus (b) 25% of eligible inventory (not to exceed the lesser of 50% of the Borrowing Base and $5.0 million), minus (c) customary reserves, minus (d) unposted cash. As of September 30, 2024, no amounts were outstanding under the SLR Revolver. As a result of the overall borrowing limitations set forth in the SLR Credit Facilities, amounts under the SLR Revolver are not currently available. As of September 30, 2024, the Company has not requested or received ABL Lenderâ€™s approval of the Additional Tranche.Any principal amount outstanding under the SLR Revolver will accrue interest at a rate per annum equal to one-month term SOFR (subject to a 2.75% floor), plus 3.20%, payable monthly in arrears. Interest on any borrowing is payable monthly. The Company is obligated to pay Lender (i) a non-refundable facility fee in the amount of $187,500 in respect of the Initial Revolver Commitment, (ii) a non-refundable facility fee in the amount of $187,500 in respect of the Additional Tranche, to be due and payable upon activation of the Additional Tranche, (iii) a commitment fee of 0.50% per annum of the average daily unused portion of the then commitment amount, payable monthly and (iv) a collateral monitoring fee of 0.10% per month of the average daily Borrowing Base 12 Â during the prior month, payable monthly. The Company may terminate the SLR Revolver at any time, subject to a termination fee of (i) 2.0% of the aggregate revolving commitments then in effect, if terminated prior to or on the first anniversary of the Closing Date, (ii) 1.0% of the aggregate revolving commitments then in effect, if terminated after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) 0.5% of the aggregate revolving commitments then in effect, if terminated after the second anniversary of the Closing Date through and including the third anniversary of the Closing Date. Such termination fee is waived if the SLR Revolver is terminated after the third anniversary of the Closing Date and prior to the Maturity Date.Subject to customary exceptions and restrictions, the Company may borrow, repay and reborrow varying amounts under the SLR Revolver at any time subject to the overall borrowing limitations. If at any time the outstanding amount under the SLR Revolver exceeds the lesser of (i) the aggregate revolving commitments then in effect and (ii) the Borrowing Base then in effect, the Company will be required to prepay outstanding amounts under the SLR Revolver.The SLR Revolver shall expire on November 1, 2027.Other Terms of the SLR Credit FacilitiesAs security for its obligations under the SLR Credit Facilities, the Company granted Agent, for the benefit of the Term Loan Lenders, and ABL Lender a security interest in substantially all of the assets of the Company, including the Companyâ€™s intellectual property, subject to certain exceptions.The SLR Credit Facility Agreements contain customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to financial reporting and insurance and restrictions on the Companyâ€™s ability to dispose of its business or property, to change its line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on its property or to pay any dividends or other distributions on capital stock. The agreements also include a financial covenant that, beginning with the fiscal quarter ended December 31, 2023, the Company must either (i) maintain certain levels of cash and cash equivalents in accounts subject to control agreements in favor of Agent and ABL Lender of at least 50% of the sum of (a) the outstanding obligations under the Term Loans (as defined below) and (b) the amount of the Companyâ€™s accounts payable that have not been paid within 120 days from the invoice date thereof or (ii) generate net product and product related revenue in excess of specified amounts and maintain gross profit margins in excess of specified percentages, in each case, for applicable measuring periods.In addition, the SLR Credit Facility Agreements contain customary events of default that entitle Agent, under the SLR Loan Agreement, and ABL Lender, under the SLR Revolving Credit Agreement, to cause the Companyâ€™s indebtedness under the SLR Loan Agreement or SLR Revolving Credit Agreement, as applicable, to become immediately due and payable, and to exercise remedies against the Company and the collateral securing the obligations owed under the applicable SLR Credit Facility Agreement. Under the SLR Credit Facility Agreements, an event of default will occur if, among other things, the Company fails to make payments under either SLR Credit Facility Agreement, the Company breaches covenants under either SLR Credit Facility Agreement, subject to specified cure periods with respect to certain breaches, the Agent or ABL Lender, as applicable, determine that a material adverse change has occurred under the SLR Loan Agreement or SLR Revolving Credit Agreement, as applicable, or the Company or its assets become subject to certain legal proceedings, such as bankruptcy proceedings. Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to 4.0% per annum will apply to all obligations owed under the SLR Credit Facility Agreements.The debt issuance costs and the facility fees related to the Term A and B Loans were recorded as a direct deduction from the term loans balance on the balance sheets and are being recognized as non-cash interest expense over the term of the loans using the effective interest method, along with the final payment fee. The facility fees related to the Initial Revolver Commitment were recorded as deferred financing costs and are being recognized as non-cash interest expense over their respective commitment period using straight-line method. 8. Equity

Incentive PlanEquity Incentive PlansAs of September 30, 2024, 3,218,000 shares were reserved for future issuance under the 2020 Equity Incentive Plan (2020 Plan).Employee Share Purchase Plan (ESPP)As of September 30, 2024, 667,000 shares of common stock were reserved for issuance in connection with the current and future offering periods under the ESPP. 13 Â Restricted StockThe Company issues restricted stock units (RSUs) and performance stock units (PSUs), both of which are considered restricted stock. The Company grants restricted stock pursuant to the 2020 Plan and satisfies such grants through the issuance of new shares. RSUs are share awards that, upon vesting, will deliver to the holder shares of our common stock.RSUs with a service-based vesting condition granted to a grantee, beginning in February 2022, generally vest over a three-year period as follows either: (i) 25% on the first anniversary of the original vesting date, 25% quarterly over the course of the second year, and 50% quarterly over the course of the third year, or (ii) 33% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining two years. Annual RSUs granted to non-executive employees in 2024 vest over a two-year period at a rate of 50% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining one year. Prior to February 2022, RSUs with a service-based vesting condition granted to a grantee generally vest at a rate of 25% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining three years. Since 2022, the Company has granted a mix of 50% PSUs and 50% RSUs to its CEO, and a mix of 20% PSUs and 80% RSUs to its other executive officers and certain other senior leaders on an annual basis. The PSUs are earned and vest based on achievement against two metrics:â€¢The â€œHome PSUsâ€ are earned based on the number of patients treating at home on Tablo as of the end of the second or third year following the grant date (Year 2 or Year 3), with earned units vesting either (i) 50% after certification of achievement following the end of Year 2 and 50% at the end of Year 3 or (ii) 100% after certification of achievement following the end of Year 3 (performance-based vesting conditions).â€¢The â€œRelative TSR PSUsâ€ are earned based on the Company's relative total stockholder return (relative TSR) at the end of a two-year or three-year performance period as compared to companies in a pre-determined index of medical device companies, in each case, with 100% of earned units vesting on, or after certification of achievement following, the third anniversary of the grant date (market-based vesting conditions). The number of units earned varies based on actual performance as follows: (i) from 0% to 200% (250% for the CEO) of the target number of the Home PSUs granted, (ii) from 75% to 150% (250% for the CEO) of the target number of Relative TSR PSUs granted in 2022 and 2023 and (iii) from 0% to 200% (250% for the CEO) of the target number of Relative TSR PSUS granted in 2024.The grant date for the Home PSUs is not considered established until the Compensation Committee of the Board approves the target and it is communicated to the award recipients, which then triggers the service inception date, the fair value of the awards, and the associated expense recognition period. Once the grant date for the Home PSUs has been established, the related stock-based compensation expense is recorded based on the forecasted performance, which is reassessed each reporting period based on the probability of achieving the performance conditions. In 2024, the Company also granted a new type of PSU award to executive officers and certain other senior leaders which is earned and vests based on appreciation of the Companyâ€™s stock price above pre-determined stock price triggers or achievement of specified operating income targets over a performance period of up to three years.Stock-Based Compensation ExpenseThe following table sets forth stock-based compensation expense included in the accompanying condensed statements of operations (in thousands): Â Â Three Months Ended Â Â Nine Months Ended Â Â Â September 30, Â Â September 30, Â Â Â 2024 Â Â Â 2023 Â Â 2024 Â Â Â 2023 Â Cost of revenue Â $ 296 Â Â $ 620 Â Â $ 1,092 Â Â $ 1,381 Â Research and development Â Â 1,400 Â Â Â 2,793 Â Â Â 6,025 Â Â Â 8,232 Â Sales and marketing Â Â 945 Â Â Â 3,765 Â Â Â 4,898 Â Â Â 9,908 Â General and administrative Â Â 3,747 Â Â Â 3,715 Â Â Â 12,396 Â Â Â 10,015 Â Total stock-based compensation expense Â $ 6,388 Â Â $ 10,893 Â Â $ 24,411 Â Â $ 29,536 Â Â 14 Â 9. Income TaxesFor each of the three and nine months ended September 30, 2024 and 2023, the Company incurred an income tax provision of an insignificant amount, which primarily related to foreign income taxes related to the Companyâ€™s Mexico operations. The U.S. federal and state net deferred tax assets have been fully offset by a valuation allowance, as the Company believes it is not more likely than not that the deferred tax assets will be realized. 10. Net Loss Per ShareThe following outstanding potentially dilutive shares were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands): Â Â Three and Nine Months Ended Â Â Â September 30, Â Â Â 2024 Â Â Â 2023 Â Stock options to purchase common stock Â Â 1,521 Â Â Â 1,978 Â Restricted stock units Â Â 3,961 Â Â Â 2,760 Â Performance stock units Â Â 273 Â Â Â 95 Â Shares committed under ESPP Â Â 319 Â Â Â 42 Â Warrant to purchase common stock Â Â 63 Â Â Â 63 Â Total Â Â 6,137 Â Â Â 4,938 Â Â 11. Workforce reductionIn order to improve operational efficiencies, reduce operating expenses and streamline its overall organizational structure, the Company implemented two organizational restructuring plans to reduce its workforce in the fourth quarter of 2023 and May 2024 and incurred restructuring charges of $2.5 million in fiscal year 2023 and $2.7 million through the first half of fiscal year 2024 for employee severance and other termination benefits.In connection with steps the Company is taking to help optimize its commercial organization, and to help improve operational efficiencies and reduce operating expenses to align with anticipated revenue growth, in the third quarter of 2024, the Company completed an additional restructuring primarily impacting its commercial organization. The Company incurred restructuring charges of $1.4 million in the third quarter of 2024 for employee severance and other termination benefits associated with this restructuring.The following table sets forth severance and related benefits charges included in the accompanying condensed statements of operations (in thousands): Â Â Nine Months Ended Â Â Â September 30, 2024 Â Cost of revenue Â $ 530 Â Research and development Â Â 1,260 Â Sales and marketing Â Â 1,884 Â General and administrative Â Â 475 Â Total Â $ 4,149 Â The changes in liabilities resulting from the restructuring accruals, which were recorded in accrued expenses and other current liabilities on the accompanying condensed balance sheets, were as follows (in thousands): Balance as of December 31, 2023 Â Â Â $ 854 Â Charges Â Â Â Â 4,149 Â Payments and other adjustments Â Â Â Â (4,920) Balance as of September 30, 2024 Â Â Â $ 83 Â Â 12. Subsequent EventOn October 18, 2024, a second purported stockholder class action lawsuit was filed against the Company, certain of its officers and a former officer (see Note 6). 15 Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations. The following discussion of our financial condition and results of operations should be read together with our unaudited condensed financial statements and related notes and other financial information included elsewhere in this Quarterly Report, as well as our audited financial statements and notes thereto and the related Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations included in our 2023 Annual Report. As used in this Quarterly Report, references to the â€œCompany,â€ â€œwe,â€ â€œus,â€ â€œour,â€ or similar terms refer to Outset Medical, Inc. In addition to historical financial information, this discussion and other parts of this report contain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this Quarterly Report are forward-looking statements. In some cases, you can identify these statements by forward-looking words such as â€œbelieve,â€ â€œmay,â€ â€œwill,â€ â€œestimate,â€ â€œcontinue,â€ â€œanticipate,â€ â€œintend,â€ â€œcould,â€ â€œwould,â€ â€œproject,â€ â€œpredict,â€ â€œplan,â€ â€œexpectâ€ or the negative or plural of these words or similar expressions. The forward-looking statements in this report are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Such risks and uncertainties include those described throughout this Quarterly Report, including in this discussion as well as in the section titled â€œRisk Factorsâ€ under Part II, Item 1A below and in Part I, Item 1A, â€œRisk Factorsâ€ and in Part II, Item 7, â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ in our 2023 Annual Report. The forward-looking statements in this Quarterly Report are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements, like all statements in this report, speak only as of their date, and, except as required by law we undertake no obligation to update or revise these statements, whether as a result of any new information, future developments or otherwise. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. Overview Our technology is designed to elevate the dialysis experience for patients and help providers overcome traditional care delivery challenges. Requiring only an electrical outlet and tap water to operate, our TabloÂ® Hemodialysis System (Tablo) frees patients and providers from the burdensome infrastructure required to operate traditional dialysis machines. The integration of water purification and on-demand dialysate production in a single 35-inch compact console enables Tablo to serve as a dialysis clinic on wheels. With a simple-to-use touchscreen interface, two-way wireless data transmission and a proprietary data analytics platform, Tablo is a holistic approach to dialysis care. Unlike existing hemodialysis machines, which have limited clinical versatility across care settings, Tablo can be used seamlessly across multiple care settings and a wide range of clinical applications. Tablo is cleared by the FDA for use in the hospital, clinic, or home setting. Tablo leverages cloud technology, making it possible for providers to monitor devices remotely, view treatment data, perform patient and population analytics, and automate clinical recordkeeping. Tablo's wireless connectivity enables us to release training, new features and enhancements over-the-air without interventions by field service engineers (FSEs). Tabloâ€™s connectedness allows continuous streaming of over 500,000 device performance data points to the cloud for every treatment. We use this data, in conjunction with our diagnostic and predictive algorithms, to monitor device performance, identify and diagnose failures and, in some instances, predict and prevent potential future device failures or malfunctions. In effect, this contributes to a reduction in service hours and an increase in device uptime. We have generated meaningful evidence to demonstrate that providers can realize significant operational efficiencies, including reducing the cost of their dialysis programs by up to 80% in the intensive care unit. In addition, Tablo has been shown to deliver robust clinical care. In studies and surveys we have conducted, patients have reported quality of life benefits on Tablo compared to other dialysis machines. We believe Tablo empowers patients, who have traditionally been passive recipients of care, to regain agency and ownership of their treatment. Driving adoption of Tablo in the acute care setting has been our primary focus to date. We have invested in growing our economic and clinical evidence, built a veteran sales and clinical support team with significant expertise, and implemented a comprehensive training and customer experience program. Our experience in the acute care market has demonstrated Tabloâ€™s clinical flexibility and operational versatility, while also delivering meaningful cost savings to the providers. We plan to continue leveraging our commercial infrastructure to broaden our installed base in the acute care market, as well as driving utilization and fleet expansion with our existing customers. 16 Â Tablo is also utilized for home-based dialysis. We believe our ability to reduce training time, patient dropout, and the supplies and infrastructure required to deliver dialysis in the home can drive efficiency and economic improvements to the home care model. In our home investigational device exemption (IDE) trial, patients reported specific quality of life improvements compared to their experience on the incumbent home dialysis machine. To penetrate this market successfully, we continue to focus on refining our home distribution, logistics and support systems to help ensure they are ready for scale. We are also working with providers, patients, and payors to increase awareness and adoption of transitional care units (TCUs) as a bridge to home-based therapy. We generate revenue from the placement of Tablo consoles along with accessories, and shipping and handling charged to customers, which revenue is recognized up-front. We also earn recurring revenue from sales of consumables, including Tablo cartridges, and services, which generates significant total revenue over the life of Tablo consoles. Our total revenues were $28.7 million and $30.4 million for the three months ended September 30, 2024 and 2023, respectively, and $84.2 million and $99.9 million for the nine months ended September 30, 2024 and 2023, respectively. We primarily sell our solutions through our direct sales organization, which covers most major metropolitan markets in the United States. Our sales organization is comprised of our capital sales team, responsible for generating new customer demand for Tablo, and our clinical sales team, responsible for driving utilization and fleet expansion of Tablo at existing customer sites. In addition, our field service team provides maintenance services and product support to our customers. Our field sales and service teams represent 50% of our total full-time employees as of September 30, 2024. The same sales organization and field service team drive Tablo penetration in both the acute and home markets. We believe the ability to leverage one team to serve both markets will result in significant productivity and cost optimization as we continue to scale our business. Recent Developments In July 2023, we received a warning letter (the Warning Letter) from the FDA that raised two observations. The first observation asserted that certain content reviewed by the FDA and found on our website promoted continuous renal replacement therapy (CRRT), a modality outside of the current indications for Tablo. The second observation asserted that TabloCart with Prefiltration requires prior 510(k) clearance for marketing authorization. TabloCart with Prefiltration is an accessory to Tablo launched in the third quarter of 2022. We believe the concern raised by the first observation regarding CRRT promotion has been effectively addressed through a thorough review of existing promotional materials and practices. We believe the concern raised by the second observation regarding TabloCart with Prefiltration has also been effectively addressed. Although we evaluated TabloCart with Prefiltration prior to marketing and distributing the product and concluded that no marketing authorization was necessary, we paused distribution of TabloCart with Prefiltration pending the FDAâ€™s review and clearance of a 510(k) application that we submitted in September 2023. In early May 2024, we received 510(k) clearance from the FDA for TabloCart with Prefiltration, and we have resumed distribution of TabloCart with Prefiltration. We believe we have now taken appropriate measures to fully address the matters raised in the Warning Letter. Key Factors Affecting Our Performance We believe that our financial performance has been and in the foreseeable future will continue to be primarily driven by the following factors. While we believe each of these factors presents significant opportunities for our business, they also pose important challenges that we must successfully address in order to sustain our growth and improve our results of operations. Our ability to successfully address the factors below is subject to various risks and uncertainties, including those described in the section titled â€œRisk Factors.â€ Market Acceptance of Tablo in Acute Setting We plan to further broaden our installed base by continuing to target national and regional integrated delivery networks and health systems, sub-acute long-term acute care hospitals (LTACHs) and skilled nursing facilities (SNFs). In addition, we focus on driving utilization and fleet expansion with existing customers by providing an exceptional user experience delivered through our commercial team and a steady release of software enhancements that amplify Tabloâ€™s operational reliability and clinical versatility. Our ability to successfully execute on this strategy, and thereby increase our revenue in the acute market, will depend on several factors. These factors include our ability to recover from the adverse impact in the field from the Warning Letter as we resume distribution of TabloCart with Prefiltration, as well as the success of our initiatives to optimize our commercial organization, infrastructure and sales processes to support the growth of our business in the acute care market as we focus more heavily on enterprise selling and transition beyond earlier stage adoption of Tablo. Expansion of Tablo within the Home Setting We believe that a significant growth opportunity exists within the home hemodialysis market. We are partnering with innovative dialysis clinic providers, health systems and other adjacent healthcare providers who are motivated to grow their home hemodialysis population, and who share our vision of creating a seamless and supported transition to the home. We are also investing in market development over the longer term to expand the home hemodialysis market itself. The expansion of the home hemodialysis market and our ability to penetrate this market will be an important factor in driving the future growth of our business. In addition, the 17 Â success of our efforts to expand within the home market, help grow new home programs and increase our revenue generated from home-based dialysis on the timeline that we anticipate will depend on several factors. These factors include the success of our initiatives to optimize and further evolve our commercial organization, infrastructure and sales processes as we scale our business in the home market. Gross Margin Expansion Our ability to expand our gross margins depends on: first, our ability to continue to sell Tablo cartridges, services, and accessories for Tablo consoles; second, our ability to reduce the cost of service and third, our ability to reduce the cost of Tablo consoles. Our ability to expand gross margins will also depend in part on our ability to control the average selling prices of our products and services, including by selling higher-margin accessories, consumables and services. Further, we will continue to utilize our cloud-based data system, as well as enhanced product performance, to better support our field service team and drive down service costs per console. In addition, over the past several years, we have moved the production of Tablo consoles and a majority of Tablo cartridges in-house to our manufacturing facility in Tijuana, Mexico which we operate in collaboration with TACNA as part of our cost reduction activities. This has helped further our long-term gross margin expansion and supply continuity strategies while reducing the costs of Tablo console production and improving the flexibility of our operations. We will continue our cost reduction activities by using our design, engineering, supply chain and manufacturing capabilities to help further advance and improve the efficiency of our manufacturing processes, lowering the cost of parts and components and lowering our costs of production. Our ability to expand gross margins depends on our ability to successfully execute these strategies. Profitability Initiatives Our ability to achieve and sustain profitability depends on several key factors: first, our ability to grow our revenue while expanding gross margins, as discussed above; second, our ability to optimize operating expenses; and third, our ability to optimize working capital. We have undertaken various initiatives designed to improve operational efficiencies, reduce operating expenses to align with anticipated levels of revenue growth and streamline our overall cost structure, including two organizational restructurings implemented in the fourth quarter of 2023 and second quarter of 2024. In connection with steps we are taking to help optimize our commercial organization, in the third quarter of 2024, we completed an additional restructuring primarily impacting our commercial organization.

We are also taking steps to improve our ability to efficiently manage working capital, including inventory. Our ability to transition to profitability will depend on the success of our efforts to optimize spending and working capital, including inventory. Impacts of Macroeconomic Factors Global macroeconomic conditions, including inflationary pressures, rising interest rates, increased labor costs, staffing shortages and global supply chain disruptions, may impact our business and results of operations, and those of our customers, manufacturing partners and suppliers. As the duration and severity of these macroeconomic conditions remain uncertain and depend on various factors, we cannot predict what effects these macroeconomic conditions will ultimately have on our business and results of operations, our customers, or our suppliers. Beginning in the third quarter of 2023, we began to observe an increasing number of our existing and prospective customers deferring their decisions to purchase Tablo in an environment of rising interest rates and more cautious capital spending. These deferrals served to elongate our sales cycle and the timing of delivery and installations, which, in turn, contributed to an adverse impact on our bookings and revenues starting in the second half of 2023, and we expect these negative impacts to continue through at least the remainder of 2024. Beginning in 2022, our existing and prospective customers faced shortages of skilled nurses and other clinical personnel as well as increased labor costs, combined with economic pressures resulting from general economic and financial market conditions, primarily escalating inflation, tightening hospital operating budgets and increased scrutiny of capital purchase decisions, all of which generally have the effect of lengthening the average sales cycle and elongating the timing of installations. These factors negatively impacted our customer base on pipeline development and installation schedules, which, in turn, negatively impacted our bookings, delayed our shipments and adversely impacted our revenues for 2022 and, to a lesser extent, 2023. We have generally seen some stabilization in these challenging labor market dynamics for healthcare providers during 2023 and thereafter as compared to 2022. Moreover, we believe Tablo offers automation and ease-of-use benefits over traditional machines that can enhance our existing and potential customersâ€™ ability to support their patient populations despite staffing shortages. However, if our customers continue to face prolonged periods of rising interest rates, capital budget constraints, volatility, uncertainty, staffing shortages, cash flow challenges, rising costs and other financial pressures, whether due to general macroeconomic conditions, cybersecurity events or otherwise, it could ultimately adversely impact our ability to expand existing customer relationships or attract new customers of Tablo, timely collect amounts due, effectively manage our inventory levels, and have a material adverse effect on our bookings, revenues, results of operations, financial condition, and, ultimately, our future growth and profitability. In 2022, we launched a pilot clinical and administrative services program designed to help bridge our healthcare provider customers, particularly those challenged by staffing shortages, as they transition from using an outsourced inpatient dialysis provider to offering on-site inpatient dialysis services on their own. In return for a fair market value service fee, we assign members of our own employed nurses on a temporary basis to support participating providers to launch and manage an inpatient dialysis program using 18 Â Tablo and, as full-time staff is hired, to help train and onboard those nurses. However, our pilot clinical and administrative services program may not be successful in achieving the objectives we intend and anticipate, may fail to meet our customersâ€™ expectations, may not generate sufficient returns to justify our investment, or may result in unanticipated costs, which could harm our reputation and customer relationships, and adversely impact our operating margins and results of operations. From a supply chain perspective, we have worked closely with our manufacturing partners and suppliers to enable us to source key components and maintain appropriate inventory levels to meet customer demand, and have not experienced material disruptions in our supply chain to date. However, macroeconomic factors such as rising inflation, increasing labor costs, and surges and shifts in consumer demand have disrupted the operations of certain of our third-party suppliers, resulting, in some cases, in increased lead times and higher component costs. We believe that localizing production of a majority of Tablo cartridges in Mexico (to our Mexico-based contract manufacturer and, more recently, in-house at our manufacturing facility) has helped achieve cost reductions through lower freight costs, further our long-term gross margin expansion and supply continuity strategies and improve the flexibility of our operations. However, we may face increased supply chain constraints in the future, which could negatively impact our ability to meet customer demand on a timely basis, result in customer dissatisfaction and adversely impact our operating margins and results of operations. Results of Operations The following table summarizes our results of operations for the three and nine months ended September 30, 2024 and 2023 (in thousands): Â Â Three Months Ended Â Â Nine Months Ended Â Â September 30, Â Â September 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenue: Â Â Â Â Â Â Â Â Â Â Â Â Product revenue Â $ 20,305 Â Â $ 23,531 Â Â $ 59,971 Â Â $ 80,640 Â Service and other revenue Â Â 8,361 Â Â Â Â 6,831 Â Â Â Â 24,251 Â Â Â Â 19,229 Â Total revenue Â Â 28,666 Â Â Â Â 30,362 Â Â Â Â 84,222 Â Â Â Â 99,869 Â Cost of revenue: Â Â Â Â Â Â Â Â Â Â Â Â Cost of product revenue Â Â 11,532 Â Â Â Â 16,837 Â Â Â Â 34,680 Â Â Â Â 59,866 Â Cost of service and other revenue Â Â 7,314 Â Â Â Â 6,368 Â Â Â Â 21,725 Â Â Â Â 18,715 Â Total cost of revenue Â Â 18,846 Â Â Â Â 23,205 Â Â Â Â 56,405 Â Â Â Â 78,581 Â Gross profit Â Â 9,820 Â Â Â Â 7,157 Â Â Â Â 27,817 Â Â Â Â 21,288 Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â 8,139 Â Â Â Â 16,076 Â Â Â Â 30,508 Â Â Â Â 44,775 Â Sales and marketing Â Â 15,417 Â Â Â Â 24,720 Â Â Â Â 54,593 Â Â Â Â 74,038 Â General and administrative Â Â 10,103 Â Â Â Â 11,815 Â Â Â Â 34,231 Â Â Â Â 34,892 Â Total operating expenses Â Â 33,659 Â Â Â Â 52,611 Â Â Â Â 119,332 Â Â Â Â 153,705 Â Loss from operations Â Â (23,839) Â Â (45,454) Â Â (91,515) Â Â (132,417) Interest income and other income, net Â Â 2,149 Â Â Â Â 2,573 Â Â Â Â 7,718 Â Â Â Â 7,889 Â Interest expense Â Â (6,068) Â Â (3,213) Â Â (18,046) Â Â (9,258) Loss before provision for income taxes Â Â (27,758) Â Â (46,094) Â Â (101,843) Â Â (133,786) Provision for income taxes Â Â 182 Â Â Â Â 86 Â Â Â Â 495 Â Â Â Â 411 Â Net loss Â $ (27,940) Â $ (46,180) Â $ (102,338) Â $ (134,197) Comparison of the Three and Nine Months Ended September 30, 2024 and 2023 Revenue Â Â Three Months EndedSeptember 30, Â Â Change Â Â Nine Months Ended September 30, Â Â Change Â (dollars in thousands) Â 2024 Â Â 2023 Â Â $ Â Â % Â Â 2024 Â Â 2023 Â Â $ Â Â % Â Revenue: Â Â Â Â Â Â Â Â Â Â Â Â

Disclosure controls and procedures are also designed to provide reasonable assurance that such information is accumulated and communicated to our management, including our Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of the end of the period covered by this Quarterly Report. Changes in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 23 Â PART IIâ€”OTHER INFORMATION Item 1. Legal Proceedings. The information set forth under â€œLitigationâ€ in Note 6, Commitments and Contingencies, of the notes accompanying our unaudited condensed financial statements in this Quarterly Report is incorporated herein by reference. Item 1A. Risk Factors. You should carefully consider the risk factors discussed in Part I, â€œItem 1A. Risk Factorsâ€ in our 2023 Annual Report, as updated by the risk factors discussed in Part II, â€œItem 1A. Risk Factorsâ€ in our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2024 (Q1 2024 Quarterly Report) and June 30, 2024 (Q2 2024 Quarterly Report), which could materially affect our business, financial position, or future results of operations. There have been no material changes to the risk factors described in our 2023 Annual Report, as updated by our Q1 2024 Quarterly Report and Q2 2024 Quarterly Report, except as set forth below. The risks described in our 2023 Annual Report, Q1 2024 Quarterly Report and Q2 2024 Quarterly Report, as updated below, are not the only risks that we face. Additional risks and uncertainties not precisely known to us, or that we currently deem to be immaterial, may also arise and materially impact our business. If any of these risks occur, our business, results of operations and financial condition could be materially and adversely affected and the trading price of our common stock could decline. We may not be able to maintain the listing of our common stock on Nasdaq, which could adversely affect our liquidity and the trading volume and market price of our common stock. Our common stock is listed on The Nasdaq Global Select Market, which imposes continued listing requirements with respect to listed securities, including a minimum bid price requirement. On September 23, 2024, we received notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC (â€œNasdaqâ€) that, because the closing bid price for our common stock had fallen below $1.00 per share for 30 consecutive trading days, we no longer complied with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1). In accordance with Nasdaq listing rules, we have an initial compliance period of 180 calendar days, or until March 24, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of our common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive trading days prior to March 24, 2025. If we do not regain compliance by March 24, 2025, we may be eligible for an additional 180 calendar day compliance period if we apply to transfer the listing of our common stock to the Nasdaq Capital Market and meet the continued listing requirement for the market value of our publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement, and provide written notice of our intention to cure the minimum bid price deficiency during the second compliance period. As part of its review process, Nasdaq will make a determination as to whether it believes we will be able to cure this deficiency. If Nasdaq staff determines that we will not be able to cure the deficiency, or if we are otherwise not eligible for such additional compliance period, Nasdaq will provide notice that our common stock will be subject to delisting. We would have the right to appeal any determination to delist our common stock, and our common stock would remain listed on the Nasdaq Global Select Market until the appeal process is complete. There can be no assurance that we will be able to regain compliance with the minimum bid price requirement, otherwise maintain compliance with other applicable Nasdaq listing rules, or be successful in appealing any delisting determination. If Nasdaq delists our common stock, it is unlikely that we will be able to list our common stock on another national securities exchange and, as a result, we expect our securities would be quoted on an over-the-counter market. If this were to occur, we and our stockholders could face significant adverse consequences, including limited availability of market quotations and analyst coverage for our common stock, and reduced liquidity for trading of our securities, all of which would likely reduce the market price of our common stock. In addition, our common stock could be considered a â€œpenny stock,â€ which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in reduced trading activity in the secondary trading market for our common stock. Delisting could result in additional adverse consequences including reduced ability to issue additional securities or obtain additional financing on terms acceptable to us, or at all, as well as the potential loss of confidence of our customers, suppliers and employees, any of which could harm our business and future prospects. Even the perception that we are at heightened risk of delisting could also result in certain of the above these consequences, which could negatively impact the market price and trading volume of our common stock, and harm our stockholders and our business. Litigation and other legal proceedings may adversely affect our business. From time to time we may become involved in legal proceedings relating to patent and other intellectual property matters, product liability claims, employee claims, tort or contract claims, federal regulatory investigations, securities class action and other legal proceedings or investigations, which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. For example, on August 29, 2024 and October 18, 2024, two 24 Â purported stockholder class action lawsuits were filed against the Company, our Chief Executive Officer and our Chief Financial Officer, in the U.S. District Court for the Northern District of California alleging that the defendants violated federal securities laws by making false or misleading statements about our business, operations and prospects related to the sale and marketing of the Tablo Hemodialysis System and TabloCart with Prefiltration, including concerning the impact of certain FDA processes for these products on our revenue growth. The second lawsuit additionally names our former Chief Financial Officer as a defendant. For further information, see the section entitled â€œLitigationâ€ in Note 6, Commitments and Contingencies, to our unaudited condensed financial statements included in this Quarterly Report. Litigation is inherently unpredictable and can result in excessive or unanticipated verdicts and/or injunctive relief that affect how we operate our business. We could incur judgments or enter into settlements of claims for monetary damages or for agreements to change the way we operate our business, or both. There may be an increase in the scope of these matters or there may be additional lawsuits, claims, proceedings or investigations in the future, which could have a material adverse effect on our business, financial condition and results of operations. Adverse publicity about regulatory or legal action against us could damage our reputation and brand image, undermine our customersâ€™ confidence and reduce long-term demand for Tablo, even if the regulatory or legal action is unfounded or not material to our operations. The terms of our credit agreement require us to meet certain operating and financial covenants, place restrictions on our operating and financial flexibility and subject us to interest rate risk, and our ability to access additional borrowings is subject to us achieving certain net revenue milestones and obtaining lendersâ€™ credit approval. We entered into the SLR Credit Facilities on November 3, 2022, which provide for (i) up to $250.0 million of term loans pursuant to the SLR Loan Agreement and (ii) up to a $50.0 million asset-based revolving credit facility pursuant to the SLR Revolving Credit Agreement. We have already borrowed $200.0 million of term loans, the full amount available under certain borrowing limitations that limit the maximum principal amount outstanding under the SLR Credit Facilities. In addition, additional borrowings under the SLR Credit Facilities are subject to us achieving certain net revenue milestones and/or obtaining lendersâ€™ credit approval. As a result, we cannot rely on further borrowings under the SLR Credit Facilities to fund our operations. In addition, principal amounts outstanding under each of the SLR Term Loan Facility and the SLR Revolver accrue interest at variable interest rates tied to SOFR. As a result, our borrowings under the facilities are subject to interest rate risk. An adverse change in interest rates for our borrowings would increase our borrowing costs which may restrict our access to capital in the future and, ultimately, could adversely affect our financial condition and results of operations. See the section titled â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations â€“ Liquidity and Capital Resources â€“ Debt Obligations â€“ SLR Debt Financing.â€ The SLR Credit Facility Agreements contain customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to financial reporting (including the timely delivery of audited financial statements together with an unqualified report from our independent registered accountants thereon) and insurance and restrictions on our ability to dispose of our business or property, to change our line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on our property or to pay any dividends or other distributions on capital stock. Accordingly, the terms may restrict our current and future operations, particularly our ability to respond to certain changes in our business or industry or take future actions. In addition, the SLR Credit Facility Agreements also include a financial covenant that, beginning with the fiscal quarter ending December 31, 2023, requires us to either (i) maintain certain levels of cash and cash equivalents in accounts subject to control agreements in favor of Agent and ABL Lender of at least the sum of (a) 50% of the outstanding obligations under the SLR Term Loan Facility and (b) the amount of the Companyâ€™s accounts payable that have not been paid within 120 days from the invoice date thereof or (ii) generate net product and product related revenue in excess of specified amounts and maintain gross profit margins in excess of specified percentages, in each case, for applicable measuring periods. If we fail to comply with any covenants, payments or other terms of either SLR Credit Facility Agreement, our agent or lender, as applicable, could declare an event of default, which would give it the right to declare all borrowings outstanding, together with accrued and unpaid interest and fees, to be immediately due and payable. In addition, our agent or lender, as applicable, would have the right to proceed against the assets we provided as collateral pursuant to the applicable SLR Credit Facility Agreement. If the debt under either SLR Credit Facility Agreement was accelerated, we may not have sufficient cash or be able to sell sufficient assets to repay this debt, which would harm our business and financial condition. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. None. Item 3. Defaults Upon Senior Securities. None. 25 Â Item 4. Mine Safety Disclosures. Not applicable. Item 5. Other Information. During the period covered by this report, none of the Companyâ€™s directors or officers has adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5â€“1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Exchange Act). Â 26 Â Item 6. Exhibits. Â Â Â Â Â Â Incorporation by Reference ExhibitNumber Description Â Form Â File No. Â Exhibit Â Filing Date Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3.1 Â Form of Amended and Restated Certificate of Incorporation of Outset Medical, Inc. Â S-1/A Â 333-248225 Â 3.1 Â September 9, 2020 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3.2 Â Form of Amended and Restated Bylaws of Outset Medical, Inc. Â S-1/A Â 333-248225 Â 3.2 Â September 9, 2020 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4.1 Â Form of Common Stock Certificate Â S-1/A Â 333-248225 Â 4.1 Â September 9, 2020 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4.2 Â Amended and Restated Registration Rights Agreement Â S-1 Â 333-248225 Â 4.2 Â August 21, 2020 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4.3 Â Form of Series A Warrant Agreement #1 Â S-1 Â 333-248225 Â 4.3 Â August 21, 2020 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4.4 Â Form of Series A Warrant Agreement #2 Â S-1 Â 333-248225 Â 4.4 Â August 21, 2020 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 31.1* Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) of the Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Â 31.2* Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) of the Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Â 32.1* Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Â 101.INS* Inline XBRL Instance Document â€“ the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. Â Â Â Â Â Â Â Â Â Â 101.SCH* Â Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents Â Â Â Â Â Â Â Â 104 Â Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101) Â Â Â Â Â Â Â Â * Filed herewith. 27 Â SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Outset Medical, Inc. Date: November 6, 2024 By: /s/ Leslie Trigg Leslie Trigg President and Chief Executive Officer(Principal Executive Officer) Â Date: November 6, 2024 By: /s/ Nabeel Ahmed Nabeel Ahmed Chief Financial Officer(Principal Financial and Accounting Officer) Â 28 EX-31.1 2 om-ex31_1.htm EX-31.1 EX-31.1 Exhibit 31.1Â CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Leslie Trigg, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of Outset Medical, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): (a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and (b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 6, 2024 By: /s/ Leslie Trigg Â Â Leslie Trigg Â Â Chief Executive Officer(Principal Executive Officer) Â Â EX-31.2 3 om-ex31_2.htm EX-31.2 EX-31.2 Exhibit 31.2Â CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Nabeel Ahmed, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of Outset Medical, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): (a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting

which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and (b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 6, 2024 By: /s/ Nabeel Ahmed Â Â Nabeel Ahmed Â Â Chief Financial Officer(Principal Financial Officer) Â Â EX-32.1 4 om-ex32_1.htm EX-32.1 EX-32.1 Exhibit 32.1Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the Quarterly Report of Outset Medical, Inc. (the â€œCompanyâ€) on Form 10-Q for the period ending September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), each of the undersigned certifies, pursuant to 18 U.S.C. Â§1350, as adopted pursuant to Â§906 of the Sarbanes-Oxley Act of 2002, that, to her/his knowledge: 1.The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and 2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations the Company. Â November 6, 2024 By: /s/ Leslie Trigg Â Â Leslie Trigg Â Â Chief Executive Officer Â Â (Principal Executive Officer) Â November 6, 2024 By: /s/ Nabeel Ahmed Â Â Nabeel Ahmed Â Â Chief Financial Officer Â Â (Principal Financial Officer) Â The foregoing certification is being furnished to the Securities and Exchange Commission as an exhibit to the Report and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and it is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. Â Â EX-101.SCH 5 om-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Statement of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Statement of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Revenue and Deferred Revenue link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Term Loan link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Equity Incentive Plan link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Workforce reduction link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Revenue and Deferred Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Term Loan (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Equity Incentive Plan (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Workforce reduction (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Description of Business - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Revenue and Deferred Revenue - Summary of Revenue by Source (Detail) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Revenue and Deferred Revenue - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Revenue and Deferred Revenue - Additional Information (Detail) 1 link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Detail) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Fair Value Measurements - Schedule of breakdown of the available-for-sale debt securities with unrealized losses (Details) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Balance Sheet Components (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Balance Sheet Components - Schedule Of Cash And Cash Equivalents And Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Balance Sheet Components - Summary of Allowance for credit losses (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Balance Sheet Components - Schedule of Inventories (Detail) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Term Loan - Schedule of Term Loan (Detail) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Term Loan - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Equity Incentive Plans - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Equity Incentive Plans - Summary of Stock-based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Net Loss Per Share - Schedule of Outstanding Potentially Dilutive Shares were Excluded from Calculation of Diluted Net Loss Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Workforce reduction - Summary of Workforce Reduction Plan Included in the Accompanying Condensed Statements Of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Workforce reduction - Summary of Changes in Liabilities Resulting from the Severance Charges and Related Accruals (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Workforce reduction (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Subsequent Event - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink Statement [Line Items] Statement [Line Items] Debt Instrument Debt Instrument [Axis] Accounts receivable Increase (Decrease) in Accounts Receivable Plan Name Plan Name [Domain] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Other debt issuance costs Other Debt Issuance Costs Other debt issuance costs. Remaining performance obligations Revenue, Remaining Performance Obligation, Amount Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Restructuring Charges, Total Restructuring Charges One Time Restructuring Charges Charges Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive (loss) income: Proceeds From Stock Options Exercised And Employee Stock Purchase Plan Purchases Proceeds from stock option exercises and employee stock purchase plan purchases. Proceeds from stock option exercises and ESPP purchases Revenue: Revenues [Abstract] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities End Of Year 3 [Member] End Of Year 3 [Member] End Of Year 3 [Member] USGovernmentSponsoredEnterprisesDebtSecurities US Government-sponsored Enterprises Debt Securities [Member] Reverse stock split, description Stockholders' Equity, Reverse Stock Split SLR Term Loan Facility [Member] SLR Term Loan Facility [Member] SLR Term Loan Facility Issuance of common stock for settlement of RSUs Stock Issued During Period, Value, Restricted Stock Award, Gross Beginning Balance (shares) Ending Balance (shares) Shares, Outstanding Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Level 2 Fair Value, Inputs, Level 2 [Member] Term B Loan [Member] Term B Loan [Member] Term B Loan Operating lease liabilities Increase Decrease In Operating Lease Liabilities Increase (decrease) in operating lease liabilities. Unrealized losses less than 12 months [Member] Unrealized losses less than 12 months Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Restructuring Cost [Table] Restructuring Cost [Table] Product and Service Product and Service [Axis] Line of credit, collateral monitoring fee Collateral monitoring fee Collateral monitoring fee Depreciation and amortization Depreciation, Depletion and Amortization Depreciation, Depletion and Amortization, Total Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Supplemental non-cash investing and financing activities: Noncash Investing and Financing Items [Abstract] Shares Committed under ESPP Employee Stock [Member] Reversed Stock-Based Compensation Expense Reversed Stock-Based Compensation Expense Reversed Stock-Based Compensation Expense Term B1 Loan [Member] Term B1 Loan [Member] Term B1 Loan Title and Position [Axis] Title Of Individual Revenue and Deferred Revenue Revenue from Contract with Customer [Text Block] Temporary equity, Adjustment to redemption value on redeemable convertible preferred stock Temporary Equity Adjustment To Redemption Value On Redeemable Convertible Preferred Stock Temporary equity adjustment to redemption value on redeemable convertible preferred stock. One-time Termination Benefits [Member] One-time Termination Benefits Sale of Stock Sale of Stock [Domain] Workforce reduction Abstract Workforce reduction [Abstract] Cash and Cash Equivalents [Domain] Accrued warranty liability Increase Decrease In Accrued Warranty Liability Increase (decrease) in accrued warranty liability. Temporary Equity, Deemed dividend on settlement of accrued dividend Temporary Equity Deemed Dividend On Settlement Of Accrued Dividend Temporary equity deemed dividend on settlement of accrued dividend. Entity Central Index Key Entity Central Index Key Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Common stock, shares issued Common Stock, Shares, Issued Common Stock, Shares, Issued, Total Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Description of Business Business Description and Basis of Presentation [Text Block] Income Statement [Abstract] Entity Address, State or Province Entity Address, State or Province Issuance of common stock through employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Allowance for Credit Loss [Abstract] Loss before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-cash interest expense Non Cash Interest Expense Non-cash interest expense. Description Of Business [Line Items] Description Of Business [Line Items] Description of business. Revenue recognized Contract with Customer, Liability, Revenue Recognized Line of credit, expiration date Line of Credit Facility, Expiration Date Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges Balance as of December 31, 2023 Balance as of June 30, 2024 Inventory, Raw Materials, Gross Raw materials Inventory, Raw Materials, Gross, Total Cover [Abstract] Subsequent Event [Line Items] Net loss per share, basic Earnings Per Share, Basic Earnings Per Share, Basic, Total Gross Unrealized Holding Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Operating expenses: Operating Expenses [Abstract] Write-offs Accounts Receivable, Allowance for Credit Loss, Writeoff Write-off adjustments Deferred revenue, current Contract with Customer, Liability, Current Sales and Marketing Selling and Marketing Expense [Member] Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Revenue from Consoles Operating Lease Arrangements Revenue from Consoles Operating Lease Arrangements Revenue from operating lease arrangements Stock-based compensation expense Cumulative stock-based compensation Share-Based Payment Arrangement, Expense Debt Securities Available For Sale Remaining Contractual Maturities period. Remaining contractual maturities for available-for-sale securities Debt Securities Available For Sale Remaining Contractual Maturities Period Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Plan Name [Axis] Plan Name Stock options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance Supplemental cash flow disclosures: Supplemental Cash Flow Elements [Abstract] Current assets: Assets, Current [Abstract] Line of credit, borrowing base, amount Line of Credit, Borrowing Base, Amount Line of Credit, Borrowing Base, Amount Common stock shares reserved for issuance Common Stock, Capital Shares Reserved for Future Issuance After Second Anniversary [Member] After Second Anniversary [Member] After Second Anniversary of Closing Date Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities D. Keith Grossman [Member] D. Keith Grossman [Member] D. Keith Grossman Product and Service Product and Service [Domain] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Debt Instrument [Line Items] Debt Instrument [Line Items] Issuance of common stock on settlement of accrued dividend Stock Issued During Period, Value, Stock Dividend Stock options, description Share-Based Compensation Arrangement by Share-Based Payment Award, Description Property and equipment, net Property, Plant and Equipment, Net Property, Plant and Equipment, Net, Total Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Deferred revenue Contract with Customer, Liability, Noncurrent Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Type of Restructuring [Domain] Fair Value, Recurring Fair Value, Recurring [Member] Summary of Financial Assets Measured at Fair Value on Recurring Basis by Level Within Fair Value Hierarchy Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Vesting [Axis] Common stock, par value Common Stock, Par or Stated Value Per Share Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block] Schedule of cash, cash equivalents and restricted cash. Unrealized gain on available-for-sale securities Unrealized loss on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Temporary Equity, Beginning Balance Temporary Equity, Ending Balance Temporary Equity, Carrying Amount, Attributable to Parent Inventory Fair Value Adjustment to Inventory [Member] Statement of Cash Flows [Abstract] Temporary Equity Shares Conversion Of Convertible Redeemable Preferred Stock In to Common Stock Temporary Equity Shares Conversion Of Convertible Redeemable Preferred Stock In to Common Stock Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Total Restructuring Costs Restructuring charges Equity Components Equity Components [Axis] Entity Address, Address Line One Entity Address, Address Line One Schedule of Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Additional Tranche Additional Tranche [Member] Additional Tranche [Member] Subsequent Event Type [Axis] Nonoperating Income (Expense) Nonoperating Income (Expense), Total Interest income and other income, net Schedule of Outstanding Potentially Dilutive Shares were Excluded from Calculation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Amendment Flag Amendment Flag Loan Restructuring Modification [Axis] Operating lease liabilities Operating Lease, Liability, Noncurrent Corporate debt Corporate Debt Securities [Member] Debt Instrument, Name Debt Instrument, Name [Domain] Additional paid-in capital Additional Paid in Capital, Common Stock Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock, Ending Balance Restructuring Plan [Domain] Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] SOFR First Anniversary [Member] First Anniversary [Member] First Anniversary of Closing Date Net loss Net loss Restructuring Charges [Member] Restructuring Charges Stock option exercises (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Number of common stock issued Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Variable Rate Variable Rate [Domain] Research and Development Research and Development Expense [Member] Schedule of Term Loan Schedule of Debt [Table Text Block] Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Loss on disposal of property and equipment Loss on disposal of property and equipment Loss on disposal of property and equipment Equity Component Equity Component [Domain] Statistical Measurement Statistical Measurement [Domain] General and administrative General and Administrative Expense General and Administrative Expense, Total Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Revenue performance obligation revenue performance obligation 1 revenue performance obligation 1 Disaggregation Of Revenue [Table] Disaggregation of Revenue [Table] Proceeds from Lines of Credit Proceeds from Lines of Credit Proceeds from Lines of Credit, Total Preferred stock, shares issued Preferred Stock, Shares Issued Preferred Stock, Shares Issued, Total Unamortized debt discount Debt discount on Perceptive Term Loan Debt Instrument, Unamortized Discount Debt Instrument, Unamortized Discount, Total Stock options, nonvested, number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance Payables and Accruals [Abstract] Revenue Remaining

Performance Obligation Expected Timing Of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Issuance of common stock through employee stock purchase plan (shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Short-term investments Short-Term Investments Short-term Investments, Total Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total Shareholder Return [Member] Total Shareholder Return [Member] Total Shareholder Return Consumables Product Consumables Product [Member] Consumables product. Restricted cash Restricted Cash, Noncurrent Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Class of Stock Class of Stock [Domain] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Common stock, shares outstanding Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Purchases of investment securities Payments to Acquire Investments Payments to Acquire Investments, Total Customer rebates Accrued Exchange Fee Rebate, Current Line of credit, current borrowing capacity Line of Credit Facility, Current Borrowing Capacity Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Antidilutive Securities Antidilutive Securities [Axis] Service and Other Revenue Service And Other Revenue [Member] Service and other revenue. Entity Interactive Data Current Entity Interactive Data Current Temporary Equity, Issuance of common stock on settlement of accrued dividend Temporary Equity Settlement Of Accrued Dividends Temporary equity settlement of accrued dividend. Product Revenue Product [Member] Cost of Revenue Cost of Sales [Member] Provision for inventories Provision For Inventories Provision for inventories. Document Quarterly Report Document Quarterly Report Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance Statement of Financial Position Location, Balance [Axis] Statistical Measurement Statistical Measurement [Axis] Temporary Equity, Issuance of Series E redeemable convertible preferred stock, net of issuance costs (shares) Temporary Equity Stock Issued During Period Shares New Issues Temporary equity stock issued during period shares new issues. Cost of revenue Cost of Goods and Services Sold Cost of Goods and Services Sold, Total Cash, cash equivalents, restricted cash and short-term investments Cash Cash Equivalents Restricted Cash And Short Term Investments Cash cash equivalents, restricted cash and short term investments. Effect of Fourth Quarter Events, Type [Domain] Description of payment terms Debt Instrument, Payment Terms Underwriters Underwriters [Member] Underwriters. Summary of Revenue by Source Disaggregation of Revenue [Table Text Block] Sales and marketing Selling and Marketing Expense Selling and Marketing Expense, Total U.S. government-sponsored enterprises [Member] U.S. government-sponsored enterprises Commercial Paper [Member] Commercial paper [Member] Employees Share Purchase Plan (ESPP) Employees Share Purchase Plan [Member] Employees share purchase plan. Estimated weighted average period over which unamortized share-based compensation are expected to be recognize Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Accrued compensation and related benefits Accrued Employee Benefits, Current Income Statement Location Statement of Income Location, Balance [Axis] Cash and Cash Equivalents [Axis] Total assets Assets Restructuring Type [Axis] Restructuring Type Debt Instrument [Table] Schedule of Long-Term Debt Instruments [Table] Recently Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Entity Address, City or Town Entity Address, City or Town Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Research and development expenses Accrued Research And Development Expenses Accrued research and development expenses. Payments for Restructuring Payments and other adjustments Payments and other adjustments InterestRateFloor Interest Rate Floor [Member] SLR Credit Facilities [Member] SLR Credit Facilities [Member] SLR Credit Facilities Balance Sheet Components [Abstract] Balance Sheet Components Principal of term loan Debt Instrument, Face Amount Restructuring Cost and Reserve [Line Items] Share price Share Price Credit Losses Credit Loss, Financial Instrument [Policy Text Block] Equity Incentive Plan Share-Based Payment Arrangement [Text Block] Debt instrument principal repayment period Debt Instrument Principal Payment Term After Interest Only Period Expires Debt instrument principal payment term after interest only period expires. Stock Options to Purchase Common Stock Stock Options To Purchase Common Stock [Member] Stock options to purchase common stock. Fair Value Disclosures [Abstract] Adjustment to redemption value on redeemable convertible preferred stock Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock Debt instrument interest only payments end date Debt Instrument Interest Only Payments Year And Month Debt instrument interest only payments year and month. Stock Issued During Period, Value, New Issues Issuance of common stock upon initial public offering, net of issuance costs Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Percentage Vested In Period Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Percentage Vested In Period Earned units vesting percentage Stock option exercises Stock Issued During Period, Value, Stock Options Exercised Current liabilities: Liabilities, Current [Abstract] Accounts Receivable Accounts Receivable [Member] Cash outflow from operating activities Payments for Operating Activities Payments for Operating Activities, Total Document Type Document Type Provision for Other Credit Losses Allowance for credit losses Debt instrument, final payment amount Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid Title of 12(b) Security Title of 12(b) Security Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance Statement of Financial Position Location, Balance [Domain] Statement of Stockholders' Equity [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Research and development Research and Development Expense Research and Development Expense, Total Term loan Long-Term Debt, Excluding Current Maturities Term loan, noncurrent Schedule of Accounts Receivable, Allowance for Credit Loss Accounts Receivable, Allowance for Credit Loss [Table Text Block] Asset Class Asset Class [Domain] Subsequent Event Type [Domain] CEO [Member] CEO [Member] Ceo Member Reclassifications of Temporary to Permanent Equity 2020 Equity Incentive Plan Two Thousand Twenty Equity Incentive Plan [Member] Two thousand twenty equity incentive plan. Securities in unrealized loss position for more than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Financial Instruments [Domain] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Sale of Stock Sale of Stock [Axis] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Non-cash lease expense Non Cash Lease Expense Non-cash lease expense. Revenue Revenue from Contract with Customer, Excluding Assessed Tax Revenue from Contract with Customer, Excluding Assessed Tax, Total Statement of Comprehensive Income [Abstract] Income Taxes Income Tax Disclosure [Text Block] Credit Facility [Domain] Term A Loan [Member] Term A Loan [Member] Term A Loan Accounts payable Accounts payable Increase (Decrease) in Accounts Payable Increase (Decrease) in Accounts Payable, Total Liabilities and stockholders' equity Liabilities and Equity [Abstract] Term B2 Loan [Member] Term B2 Loan [Member] Term B2 Loan Document Period End Date Document Period End Date Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Issuance of common stock for settlement of RSUs (shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Term C Loan [Member] Term C Loan [Member] Term C Loan Anti-dilutive shares excluded from calculation of diluted net loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount The August Two Thousand Twenty Four Restructuring Plan [Member] The August Two Thousand Twenty Four Restructuring Plan [Member] August 2024 Restructuring Plan [Member] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Total accrued expenses and other current liabilities Accrued expenses and other current liabilities Accrued Expenses And Other Current Liabilities Accrued expenses and other current liabilities. Provision for income taxes Income Tax Expense (Benefit) Income Tax Expense (Benefit), Total Trading Symbol Trading Symbol Variable Rate Variable Rate [Axis] Total stockholders' equity Beginning Balance Ending Balance Equity, Attributable to Parent Unrealized Losses Caused By Change In Market Interest Rates unrealized losses caused by changes in market interest rates unrealized losses caused by changes in market interest rates May 2024 Workforce Reduction Plan [Member] May 2024 Workforce Reduction Plan [Member] May2024 Workforce Reduction Plan Stock-Based Compensation Expense Share-Based Payment Arrangement [Policy Text Block] Restricted Stock Units Restricted Stock Units (RSUs) [Member] RSUs Significant Accounting Policies Significant Accounting Policies [Policy Text Block] Significant Accounting Policies [Policy Text Block] Deferred revenue Increase (Decrease) in Deferred Revenue Yankee debt securities Yankee Debt Securities [Member] Yankee debt securities. Second Revenue Milestone [Member] Second Revenue Milestone [Member] Second Revenue Milestone Summary of Stock-based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Line of credit, termination fee Line of Credit, Termination Fee Line of Credit, Termination Fee Gross Unrealized Holding Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Unamortized stock-based compensation expense amount Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Restructuring and Related Costs [Table Text Block] Schedule of Severance and Related Benefits Charges Related to the May 2024 Workforce Reduction Plan Proceeds from Issuance of Long-Term Debt, Total Proceeds from Issuance of Long-Term Debt Proceeds from issuance of term loans, net of issuance costs Stock Issued During Period, Value, Conversion of Convertible Securities Issuance of common stock on settlement of accrued dividend (shares) Stock Issued During Period Shares Stock Dividend Stock issued during period shares stock dividend. Cash and cash equivalent maintain percentage Cash and Cash Equivalent Maintain Percentage Cash and Cash Equivalent Maintain Percentage Initial Revolver Commitment [Member] Initial Revolver Commitment [Member] Initial Revolver Commitment Scenario [Axis] Security Exchange Name Security Exchange Name Maturities of investment securities Proceeds from Sale, Maturity and Collection of Investments Proceeds from Sale, Maturity and Collection of Investments, Total Warrant to Purchase Common Stock Warrants To Purchase Common Stock [Member] Warrants to purchase common stock. Total operating expenses Operating Expenses Equity Incentive Plan [Table] Equity Incentive Plan [Table] Equity Incentive Plan [Table] Accrued interest Accrued Interest Noncurrent Accrued interest, noncurrent. Class of Stock Class of Stock [Axis] Fair Value Measurements Fair Value Disclosures [Text Block] Subsequent Event [Member] Subsequent Event Maximum Maximum [Member] Restructuring and Related Activities Disclosure [Text Block] Workforce reduction Total liabilities and stockholders' equity Liabilities and Equity Loss on extinguishment of term loan Gain (Loss) on Extinguishment of Debt Gain (Loss) on Extinguishment of Debt, Total Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Prime Rate Prime Rate [Member] Net loss per share,diluted Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Entity Ex Transition Period Entity Ex Transition Period Total liabilities Liabilities Schedule of Accrued Expenses and Other Current Liabilities Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block] Accrued expenses and other current liabilities. Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Line of Credit Facility, Commitment Fee Amount Non-refundable facility fee Total current assets Assets, Current Net Cash Provided by (Used in) Investing Activities Net cash (used in) provided by investing activities Equity Incentive Plan [Line Items] Equity Incentive Plan [Line Items] Equity Incentive Plan [Line Items] Forecast [Member] Forecast Stock issued during the period Issuance of common stock upon initial public offering, net of issuance costs (shares) Stock Issued During Period, Shares, New Issues Entity Filer Category Entity Filer Category First Revenue Milestone [Member] First Revenue Milestone [Member] First Revenue Milestone Unrealized losses 12 months or greater [Member] Unrealized losses 12 months or greater Line of credit, percentage of prepayment premium Line Of Credit, Percentage of Prepayment Premium Line Of Credit, Percentage of Prepayment Premium Line of credit, borrowing base, percentage Line of Credit, Borrowing Base, Percentage Line of Credit, Borrowing Base, Percentage Current Fiscal Year End Date Current Fiscal Year End Date Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Award vesting period, month and year Share Based Compensation Arrangement By Share Based Payment Award Vesting Period Month And Year Share based compensation arrangement by share based payment award vesting period month and year. Inventory Accrued Inventory Current Accrued inventory current. Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Share-based Payment Arrangement, Noncash Expense, Total Loan Restructuring Modification [Domain] Share Based Compensation Arrangement By Share Based Payment Award Shares Percentage of Issued In Period To CEO. Share Based Compensation Arrangement By Share Based Payment Award Shares Percentage of Issued In Period To CEO Percentage of restricted stock issued to CEO Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Accrued warranty liability Balance at the beginning of the period Balance at the end of the period Product Warranty Accrual, Current Entity Registrant Name Entity Registrant Name Gross profit Gross Profit Cost of Revenue, Total Cost of Revenue Cost of revenue Earnings Per Share [Text Block] Net Loss Per Share Loan maturity date Debt Instrument, Maturity Date Entity Emerging Growth Company Entity Emerging Growth Company Line of credit, default interest rate Line of Credit Facility, Interest Rate at Period End Money market funds Money Market Funds [Member] Other Other Liabilities, Current Other Liabilities, Current, Total Shares used in computing net loss per share, basic Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic, Total Vesting [Domain] Temporary Equity, Issuance of Series E redeemable convertible preferred stock, net of issuance costs Temporary Equity, Stock Issued During Period, Value, New Issues Common stock, shares authorized Common Stock, Shares Authorized Proceeds from Issuance of Common Stock Proceeds from issuance of common stock upon follow-on public offering, net of issuance costs Cash and Cash Equivalents [Abstract] Level 1 Fair Value, Inputs, Level 1 [Member] Debt Disclosure [Abstract] Financial Instrument [Axis] Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease), Total Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) Increase in allowance General and Administrative General and Administrative Expense [Member] Share-Based Payment Arrangement [Abstract] Restructuring Plan [Axis] Restructuring Plan Debt Securities, Available-for-Sale Debt Securities, Available-for-sale, Total Debt Securities, Available-for-Sale Accounting Policies [Abstract] Unrealised Losses [Domain] Unrealised Losses [Domain] Income Tax Disclosure [Abstract] Stockholders' equity: Equity, Attributable to Parent [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Shares Percentage of Issued In Period To Executive officers. Share Based Compensation Arrangement By Share Based Payment Award Shares Percentage of Issued In Period To Executive officers Percentage of restricted stock issued to other executive officers Temporary Equity Cash Exercises Of Redeemable Convertible Preferred Stock Warrants Shares Temporary Equity Cash Exercises Of Redeemable Convertible Preferred Stock Warrants Shares Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Statement [Table] Statement [Table] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expenses, Other Subsequent Event [Table] Preferred stock, shares authorized Preferred Stock, Shares Authorized Entity File Number Securities Act File Number Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net decrease in cash, cash equivalents and restricted cash Revenue from Contract with Customer [Abstract] Earnings Per Share [Abstract] Cash equivalents Cash Equivalents [Member] Inventory Disclosure [Abstract] Statement of Financial Position [Abstract] Interest expense Interest Expense, Operating and Nonoperating Interest Expense, Total IPO IPO [Member] Loss from operations Operating Income (Loss) Entity Shell Company Entity Shell Company Professional services Accrued Professional Fees, Current Cash paid for amounts included in the measurement of operating lease liabilities Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities Cash paid for amounts included in the measurement of operating lease liabilities. Debt interest rate Debt Instrument, Interest Rate, Effective Percentage Entity Tax Identification Number Entity Tax Identification Number Assets Assets [Abstract] Early Repayment of Senior Debt Early repayment fee Temporary Equity Conversion Of Convertible Redeemable Preferred Stock In to Common Stock Temporary Equity Conversion Of Convertible Redeemable Preferred Stock In to Common Stock Entity Current Reporting Status Entity Current Reporting Status Extended Maturity Extended Maturity [Member] Line of credit, interest rate Line of Credit Facility, Interest Rate During Period Subsequent Events [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Transfer of inventories to property and equipment. Transfer Of Inventories To Property And Equipment Transfer of inventories to property and equipment Cash, cash equivalents and short-term investments Cash, Cash Equivalents, and Short-Term Investments Cash, Cash Equivalents, and Short-term Investments, Total Preferred stock, $0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of September 30, 2024 and December 31, 2023 Preferred Stock, Value, Issued Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance Capital expenditures included in accounts payable and accrued expenses Capital Expenditures Incurred but Not yet Paid Cash, cash equivalents and restricted cash as of beginning of period Cash, cash equivalents and restricted cash as of end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Aggregate net proceeds from IPO Proceeds from Issuance Initial Public Offering City Area Code City Area Code Total current liabilities Liabilities, Current Cost of revenue: Cost of Revenue [Abstract] Schedule of Breakdown of the Available-for-Sale Debt Securities With Unrealized Losses Schedule of breakdown of the available-for-sale debt securities with unrealized losses Table Text Block Schedule of breakdown of the available-for-sale debt securities with unrealized losses Table Text Block Total inventories Inventories Inventory, Net Finished goods Inventory, Finished Goods, Gross Inventory, Finished Goods, Gross, Total Conversion Of Redeemable Convertible Preferred Stock Warrants To Common Stock Warrants Value Conversion Of Redeemable Convertible Preferred Stock Warrants To

Common Stock Warrants Value Conversion of Series A redeemable convertible preferred stock warrants to common stock warrants Stock Issued During Period, Shares, Conversion of Convertible Securities Operating Lease Arrangements Operating Lease Arrangements [Member] Operating lease arrangements. Organization, Consolidation and Presentation of Financial Statements [Abstract] Local Phone Number Local Phone Number Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] TwoSeniorSecuredCreditFacilities Two Senior Secured Credit Facilities [Member] Two Senior Secured Credit Facilities [Member] Commitments and Contingencies Disclosure [Abstract] Second Anniversary [Member] Second Anniversary [Member] Second Anniversary of Closing Date Consoles Product Consoles Product [Member] Consoles product. Description Of Business [Table] Description Of Business [Table] Description of business. Debt Issuance Costs Debt Issuance Costs, Net Debt Issuance Costs, Net, Total Amortized Costs Debt Securities, Available-for-Sale, Amortized Cost Operating lease liabilities, current Operating Lease, Liability, Current Accumulated Deficit Retained Earnings [Member] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Payments to Acquire Property, Plant, and Equipment, Total Document Transition Report Document Transition Report Percentage of fair market value of common stock Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Minimum Minimum [Member] Common Stock Common Stock [Member] Restricted Cash, Total Restricted Cash Restricted cash Restricted cash balance Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Additional Paid-in Capital Additional Paid-in Capital [Member] Fair Value Debt Securities, Available-for-Sale, Current Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Effect of Fourth Quarter Event Type [Axis] Effect of Fourth Quarter Event Type Short-term investments Short-Term Investments [Member] Line of credit, payment terms, description Line of Credit Facility, Frequency of Payment and Payment Terms Income Statement Location Statement of Income Location, Balance [Domain] SVB Term Loan Silicon Valley Bank Term Loan [Member] Silicon valley bank term loan. Other assets Other Assets, Noncurrent Other Assets, Noncurrent, Total Milestone [Domain] Milestone [Domain] Performance Shares [Member] Performance Stock Units PSUs Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Disaggregation Of Revenue [Line Items] Disaggregation of Revenue [Line Items] Offering costs, underwriting discounts and commissions expenses Offering Costs Underwriting Discounts And Commissions Expenses Offering costs, underwriting discounts and commissions expenses. Unrealised Losses [Axis] Unrealised Losses [Axis] Scenario [Domain] Title and Position [Domain] Warrants to Purchase Redeemable Convertible Preferred Stock Warrants To Purchase Redeemable Convertible Preferred Stock [Member] Warrants to purchase redeemable convertible preferred stock. Common stock, $0.001 par value; 300,000 shares authorized as of September 30, 2024 and December 31, 2023; 52,538 and 50,317 shares issued and outstanding as of september 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Accrued compensation and related benefits Increase (Decrease) in Employee Related Liabilities Increase (Decrease) in Employee Related Liabilities, Total Deemed dividend on settlement of accrued dividend Deemed dividend on settlement of accrued dividend Deemed Dividend On Settlement Of Accrued Dividend Deemed dividend on settlement of accrued dividend. Percentage of limitation on pledges of capital stock of foreign subsidiaries Percentage Of Limitation On Pledges Of Capital Stock Of Foreign Subsidiaries Percentage of limitation on pledges of capital stock of foreign subsidiaries. Temporary Equity Cash Exercises Of Redeemable Convertible Preferred Stock Warrants Value Temporary Equity Cash Exercises Of Redeemable Convertible Preferred Stock Warrants Value Measurement Frequency Measurement Frequency [Axis] Commitments and contingencies (Note 6) Commitments and Contingencies Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Cash paid for income taxes Income Taxes Paid Shares used in computing net loss per share, diluted Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted, Total Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Redeemable Convertible Preferred Stock, on an as-if Converted Basis Redeemable Convertible Preferred Stock Redeemable Convertible Preferred Stock [Member] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Accounts Receivable, after Allowance for Credit Loss, Current, Total Inventories Increase (Decrease) in Inventories Increase (Decrease) in Inventories, Total Entity Small Business Entity Small Business Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Term Loan Debt Disclosure [Text Block] Entity Bankruptcy Proceedings, Reporting Current Entity Bankruptcy Proceedings, Reporting Current Schedule of Changes in Liabilities Resulting from the Severance Charges and Related Accruals [Table Text Block] Schedule of Changes in Liabilities Resulting from the Severance Charges and Related Accruals [Table Text Block] Schedule of Changes in Liabilities Resulting from the Severance Charges and Related Accruals Stock split conversion ratio Stockholders' Equity Note, Stock Split, Conversion Ratio U.S. Treasury securities US Treasury Securities [Member] Credit Facility [Axis] Accretion (Amortization) of Discounts and Premiums, Investments Amortization of premium on investments, net Slr Revolver SLR Revolver [Member] SLR Revolver [Member] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Asset Class Asset Class [Axis] Milestone [Axis] Milestone [Axis] Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets obtained in exchange for operating lease liabilities Debt instrument prepayment fee percentage Debt Instrument Prepayment Fee Percentage Debt instrument prepayment fee percentage. Line of credit, commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Measurement Frequency Measurement Frequency [Domain] AllowanceFordebtExpense AllowanceFordebtExpense Bad debt expense Temporary Equity, Beginning Balance (shares) Temporary Equity, Ending Balance (shares) Temporary Equity, Shares Outstanding Work in process Inventory, Work in Process, Gross Follow-on Public Offering Follow On Public Offering [Member] Follow-On Public Offering [Member] Subsequent Events Subsequent Events [Text Block] Issuance of common stock upon net exercises of Series B redeemable convertible preferred stock warrants Stock Issued During Period Share Redeemable Convertible Preferred Stock Warrants Stock Issued During Period Share Redeemable Convertible Preferred Stock Warrants Accounts payable Accounts Payable, Current Accounts Payable, Current, Total Other-than-temporary impairment losses related to investments Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale, Recognized in Earnings Accounts Receivable, Allowance for Credit Loss Allowance for Credit Loss, Beginning Balance Allowance for Credit Loss, Ending Balance XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 01, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Amendment Flag false Â Document Quarterly Report true Â Document Transition Report false Â Document Period End Date Sep. 30, 2024 Â Document Fiscal Year Focus 2024 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Period Focus Q3 Â Entity File Number 001-39513 Â Entity Registrant Name Outset Medical, Inc. Â Entity Central Index Key 0001484612 Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 20-0514392 Â Entity Address, Address Line One 3052 Orchard Dr. Â Entity Address, City or Town San Jose Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 95134 Â City Area Code 669 Â Local Phone Number 231-8200 Â Title of 12(b) Security Common Stock, par value $0.001 per share Â Trading Symbol OM Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Large Accelerated Filer Â Entity Small Business false Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 52,542,024 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 8 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 33,287 $ 68,509 Short-term investments 142,346 134,815 Accounts receivable, net 34,259 32,980 Inventories 61,436 49,215 Prepaid expenses and other current assets 3,945 5,700 Total current assets 275,273 291,219 Restricted cash 3,329 3,329 Property and equipment, net 9,492 13,273 Operating lease right-of-use assets 4,312 5,375 Other assets 484 605 Total assets 292,890 313,801 Current liabilities: Â Â Accounts payable 4,295 5,827 Accrued compensation and related benefits 14,719 19,005 Accrued expenses and other current liabilities 6,749 13,459 Accrued warranty liability 2,156 3,712 Deferred revenue, current 12,766 11,727 Operating lease liabilities, current 1,745 1,593 Total current liabilities 42,430 55,323 Accrued interest 2,222

896 Deferred revenue 77 101 Operating lease liabilities 3,157 4,482 Term loan 197,182 130,113 Total liabilities 245,068 190,915 Commitments and contingencies (Note 6) Stockholders' equity: Â Â Preferred stock, $0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of September 30, 2024 and December 31, 2023 0 0 Common stock, $0.001 par value; 300,000 shares authorized as of September 30, 2024 and December 31, 2023; 52,538 and 50,317 shares issued and outstanding as of september 30, 2024 and December 31, 2023, respectively 52 50 Additional paid-in capital 1,111,503 1,084,515 Accumulated other comprehensive loss 352 68 Accumulated deficit (1,064,085) (961,747) Total stockholders' equity 47,822 122,886 Total liabilities and stockholders' equity $ 292,890 $ 313,801 X - DefinitionAccrued expenses and other current liabilities. + ReferencesNo definition available. + Details Name: om_AccruedExpensesAndOtherCurrentLiabilities Namespace Prefix: om_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued interest, noncurrent. + ReferencesNo definition available. + Details Name: om_AccruedInterestNoncurrent Namespace Prefix: om_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedEmployeeBenefitsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible

losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-

02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_ProductWarrantyAccrualClassifiedCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 9 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Balance Sheets (Parenthetical) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Preferred stock, par value $ 0.001 $ 0.001 Preferred stock, shares authorized 5,000,000 5,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock, par value $ 0.001 $ 0.001 Common stock, shares authorized 300,000,000 300,000,000 Common stock, shares issued 52,538,000 50,317,000 Common stock, shares outstanding 52,538,000 50,317,000 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 10 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenue: Â Â Â Â Revenue $ 28,666 $ 30,362 $ 84,222 $ 99,869 Cost of revenue: Â Â Â Â Cost of revenue 18,846 23,205 56,405 78,581 Gross profit 9,820 7,157 27,817 21,288 Operating expenses: Â Â Â Â Research and development 8,139 16,076 30,508 44,775 Sales and marketing 15,417 24,720 54,593 74,038 General and administrative 10,103 11,815 34,231 34,892 Total operating expenses 33,659 52,611 119,332 153,705 Loss from operations (23,839) (45,454) (91,515) (132,417) Interest income and other income, net 2,149 2,573 7,718 7,889 Interest expense (6,068) (3,213) (18,046) (9,258) Loss before provision for income taxes (27,758) (46,094) (101,843) (133,786) Provision for income taxes 182 86 495 411 Net loss $ (27,940) $ (46,180) $ (102,338) $ (134,197) Net loss per share, basic $ (0.55) $ (0.93) $ (1.98) $ (2.72) Net loss per share,diluted $ (0.55) $ (0.93) $ (1.98) $ (2.72) Shares used in computing net loss per share, basic 50,501 49,913 51,685 49,364 Shares used in computing net loss per share, diluted 50,501 49,913 51,685 49,364 Product Revenue Â Â Â Â Revenue: Â Â Â Â Revenue $ 20,305 $ 23,531 $ 59,971 $ 80,640 Cost of revenue: Â Â Â Â Cost of revenue 11,532 16,837 34,680 59,866 Service and Other Revenue Â Â Â Â Revenue: Â Â Â Â Revenue 8,361 6,831 24,251 19,229 Cost of revenue: Â Â Â Â Cost of revenue $ 7,314 $ 6,368 $ 21,725 $ 18,715 X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CostOfRevenueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-

32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services. + ReferencesNo definition available. + Details Name: us-gaap_SellingAndMarketingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=om_ServiceAndOtherRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 11 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Statement of Comprehensive Income [Abstract] Â Â Â Â Net Income (Loss) $ (27,940) $ (46,180) $ (102,338) $ (134,197) Other comprehensive (loss) income: Â Â Â Â Unrealized gain on available-for-sale securities 654 140 284 311 Comprehensive loss $ (27,286) $ (46,040) $ (102,054) $ (133,886) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract Namespace Prefix: us-gaap_ Data

Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 12 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Statement of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands Total Common Stock Additional Paid-in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Beginning Balance at Dec. 31, 2022 $ 245,990 $ 48 $ 1,035,456 $ (564) $ (788,950) Beginning Balance (shares) at Dec. 31, 2022 Â 48,465 Â Â Â Issuance of common stock through employee stock purchase plan 4,594 $ 1 4,593 Â Â Issuance of common stock through employee stock purchase plan (shares) Â 307 Â Â Â Issuance of common stock for settlement of RSUs (shares) Â 282 Â Â Â Stock option exercises 684 Â 684 Â Â Stock option exercises (shares) Â 162 Â Â Â Stock-based compensation expense 8,538 Â 8,538 Â Â Unrealized gain on available-for-sale securities 451 Â Â 451 Â Net Income (Loss) (43,971) Â Â Â (43,971) Ending Balance at Mar. 31, 2023 216,286 $ 49 1,049,271 (113) (832,921) Ending Balance (shares) at Mar. 31, 2023 Â 49,216 Â Â Â Beginning Balance at Dec. 31, 2022 245,990 $ 48 1,035,456 (564) (788,950) Beginning Balance (shares) at Dec. 31, 2022 Â 48,465 Â Â Â Unrealized gain on available-for-sale securities 311 Â Â Â Â Net Income (Loss) (134,197) Â Â Â Â Ending Balance at Sep. 30, 2023 152,063 $ 50 1,075,413 (253) (923,147) Ending Balance (shares) at Sep. 30, 2023 Â 50,173 Â Â Â Beginning Balance at Mar. 31, 2023 216,286 $ 49 1,049,271 (113) (832,921) Beginning Balance (shares) at Mar. 31, 2023 Â 49,216 Â Â Â Issuance of common stock for settlement of RSUs (shares) Â 165 Â Â Â Stock option exercises 1,043 $ 1 1,042 Â Â Stock option exercises (shares) Â 248 Â Â Â Stock-based compensation expense 10,105 Â 10,105 Â Â Unrealized gain on available-for-sale securities (280) Â Â (280) Â Net Income (Loss) (44,046) Â Â Â (44,046) Ending Balance at Jun. 30, 2023 183,108 $ 50 1,060,418 (393) (876,967) Ending Balance (shares) at Jun. 30, 2023 Â 49,629 Â Â Â Issuance of common stock through employee stock purchase plan 2,916 Â 2,916 Â Â Issuance of common stock through employee stock purchase plan (shares) Â 252 Â Â Â Issuance of common stock for settlement of RSUs (shares) Â 117 Â Â Â Stock option exercises 1,186 Â 1,186 Â Â Stock option exercises (shares) Â 175 Â Â Â Stock-based compensation expense 10,893 Â 10,893 Â Â Unrealized gain on available-for-sale securities 140 Â Â 140 Â Net Income (Loss) (46,180) Â Â Â (46,180) Ending Balance at Sep. 30, 2023 152,063 $ 50 1,075,413 (253) (923,147) Ending Balance (shares) at Sep. 30, 2023 Â 50,173 Â Â Â Beginning Balance at Dec. 31, 2023 122,886 $ 50 1,084,515 68 (961,747) Beginning Balance (shares) at Dec. 31, 2023 Â 50,317 Â Â Â Issuance of common stock through employee stock purchase plan 2,080 $ 1 2,079 Â Â Issuance of common stock through employee stock purchase plan (shares) Â 776 Â Â Â Issuance of common stock for settlement of RSUs 295 $ 1 294 Â Â Issuance of common stock for settlement of RSUs (shares) Â 607 Â Â Â Stock option exercises 6 Â 6 Â Â Stock option exercises (shares) Â 2 Â Â Â Stock-based compensation expense 8,203 Â 8,203 Â Â Unrealized gain on available-for-sale securities (326) Â Â (326) Â Net Income (Loss) (39,944) Â Â Â (39,944) Ending Balance at Mar. 31, 2024 93,200 $ 52 1,095,097 (258) (1,001,691) Ending Balance (shares) at Mar. 31, 2024 Â 51,702 Â Â Â Beginning Balance at Dec. 31, 2023 122,886 $ 50 1,084,515 68 (961,747) Beginning Balance (shares) at Dec. 31, 2023 Â 50,317 Â Â Â Unrealized gain on available-for-sale securities 284 Â Â Â Â Net Income (Loss) (102,338) Â Â Â Â Ending Balance at Sep. 30, 2024 47,822 $ 52 1,111,503 352 (1,064,085) Ending Balance (shares) at Sep. 30, 2024 Â 52,538 Â Â Â Beginning Balance at Mar. 31, 2024 93,200 $ 52 1,095,097 (258) (1,001,691) Beginning Balance (shares) at Mar. 31, 2024 Â 51,702 Â Â Â Issuance of common stock for settlement of RSUs (shares) Â 312 Â Â Â Stock option exercises 77 Â 77 Â Â Stock option exercises (shares) Â 70 Â Â Â Stock-based compensation expense 9,820 Â 9,820 Â Â Unrealized gain on available-for-sale securities (44) Â Â (44) Â Net Income (Loss) (34,454) Â Â Â (34,454) Ending Balance at Jun. 30, 2024 68,599 $ 52 1,104,994 (302) (1,036,145) Ending Balance (shares) at Jun. 30, 2024 Â 52,084 Â Â Â Issuance of common stock through employee stock purchase plan 121 Â 121 Â Â Issuance of common stock through employee stock purchase plan (shares) Â 264 Â Â Â Issuance of common stock for settlement of RSUs (shares) Â 190 Â Â Â Stock-based compensation expense 6,388 Â 6,388 Â Â Unrealized gain on available-for-sale securities 654 Â Â 654 Â Net Income (Loss) (27,940) Â Â Â (27,940) Ending Balance at Sep. 30, 2024 $ 47,822 $ 52 $ 1,111,503 $ 352 $ (1,064,085) Ending Balance (shares) at Sep. 30, 2024 Â 52,538 Â Â Â X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate value of stock related to Restricted Stock Awards issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 13 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Statement of Cash Flows (Unaudited) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities: Â Â Net Income (Loss) $ (102,338) $ (134,197) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Stock-based compensation expense 24,411 29,536 Depreciation and amortization 4,322 4,364 Non-cash lease expense 1,063 919 Non-cash interest expense 1,898 1,377 Amortization of premium on investments, net (3,890) (5,099) Provision for inventories 644 672 Loss on disposal of property and equipment 34 106 Allowance for credit losses 1,813 141 Changes in operating assets and liabilities: Â Â Accounts receivable (3,092) (7,564) Inventories (12,989) 2,607 Prepaid expenses and other assets 1,848 440 Accounts payable (1,507) 2,251 Accrued compensation and related benefits (3,991) 25 Accrued expenses and other current liabilities (6,327) (4,108) Accrued warranty liability (1,556) 447 Deferred revenue 1,015 2,114 Operating lease liabilities (1,173) (962) Net cash used in operating activities (99,815) (106,931) Cash flows from investing activities: Â Â Purchases of property and equipment (869) (2,387) Purchases of investment securities (150,467) (121,262) Maturities of investment securities 147,121 183,250 Net cash (used in) provided by investing activities (4,215) 59,601 Cash flows from financing activities: Â Â Proceeds from stock option exercises and ESPP purchases 2,284 10,423 Proceeds from issuance of term loans, net of issuance costs 66,524 0 Net cash provided by financing activities 68,808 10,423 Net decrease in cash, cash equivalents and restricted cash (35,222) (36,907) Cash, cash equivalents and restricted cash as of beginning of period 71,838 76,533 Cash, cash equivalents and restricted cash as of end of period 36,616 39,626 Supplemental cash flow disclosures: Â Â Cash paid for income taxes 472 403 Cash paid for interest 15,537 1,836 Cash paid for amounts included in the measurement of operating lease liabilities 1,173 962 Supplemental non-cash investing and financing activities: Â Â Capital expenditures included in accounts payable and accrued expenses 8 207 Transfer of inventories to property and equipment 148 0 Right-of-use assets obtained in exchange for operating lease liabilities $ 0 $ 528 X - DefinitionCash paid for amounts included in the measurement of operating lease liabilities. + ReferencesNo definition available. + Details Name: om_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities Namespace Prefix: om_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease (decrease) in accrued warranty liability. + ReferencesNo definition available. + Details Name: om_IncreaseDecreaseInAccruedWarrantyLiability Namespace Prefix: om_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease (decrease) in operating lease liabilities. + ReferencesNo definition available. + Details Name: om_IncreaseDecreaseInOperatingLeaseLiabilities Namespace Prefix: om_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNon-cash interest expense. + ReferencesNo definition available. + Details Name: om_NonCashInterestExpense Namespace Prefix: om_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNon-cash lease expense. + ReferencesNo definition available. + Details Name: om_NonCashLeaseExpense Namespace Prefix: om_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from stock option exercises and employee stock purchase plan purchases. + ReferencesNo definition available. + Details Name: om_ProceedsFromStockOptionsExercisedAndEmployeeStockPurchasePlanPurchases Namespace Prefix: om_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProvision for inventories. + ReferencesNo definition available. + Details Name: om_ProvisionForInventories Namespace Prefix: om_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTransfer of inventories to property and equipment. + ReferencesNo definition available. + Details Name: om_TransferOfInventoriesToPropertyAndEquipment Namespace Prefix: om_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3 + Details Name: us-gaap_GainLossOnDispositionOfAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (f) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in accrued expenses, and obligations classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidExpensesOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow associated with the purchase of all investments (debt, security, other) during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense related to credit loss from transactions other than loan and lease transactions. +

ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_ProvisionForOtherCreditLosses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowElementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Â Â Â Net Income (Loss) $ (27,940) $ (34,454) $ (39,944) $ (46,180) $ (44,046) $ (43,971) $ (102,338) $ (134,197) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 15 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Description of Business 1. Description of Business Outset Medical, Inc. (the Company) is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. TabloÂ® Hemodialysis System (Tablo), cleared by the U.S. Food and Drug Administration (FDA) for use from the hospital to the home, represents a significant technological advancement designed to transform the dialysis experience for patients and operationally simplify it for providers. Tablo serves as a single enterprise solution designed to be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. The integration of water purification and on-demand dialysate production in a single 35-inch compact console enables Tablo to serve as a dialysis clinic on wheels. With a simple-to-use touchscreen interface, two-way wireless data transmission and a proprietary data analytics platform, Tablo is a new holistic approach to dialysis care. The Companyâ€™s headquarters are located in San Jose, California. LiquiditySince inception, the Company has incurred net losses and negative cash flows from operations. During the nine months ended September 30, 2024 and 2023, the Company incurred a net loss of $102.3 million and $134.2 million, respectively, and cash outflow from operating activities of $99.8 million and $106.9 million, respectively. As of September 30, 2024, the Company had an accumulated deficit of $1.1 billion.As of September 30, 2024, the Company had cash, cash equivalents, restricted cash and short-term investments of $179.0 million. The Company is required to comply with certain covenants under the SLR Credit Facility Agreements (as defined in Note 7) including ones relating to financial reporting and the delivery of an unqualified audit opinion, the maintenance of minimum cash or revenue, the incurrence of additional debt, and its ability to make capital expenditures or declare dividends. If the Company fails to comply with any covenants, payments or other terms of either SLR Credit Facility Agreement, its agent or lender, as applicable, could declare an event of default, which would give it the right to declare all borrowings outstanding, together with accrued and unpaid interest and fees, to be immediately due and payable. Further details of obligations under the SLR Credit Facility Agreements are described in Note 7.While the Company has taken actions to reduce operating expenses and working capital to align with anticipated revenue growth including implementing restructuring plans to streamline its overall organizational structure and renegotiating commitments with suppliers to reduce inventory, management expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth.Furthermore, on September 23, 2024, the Company received notice from the Listing Qualifications staff of the Nasdaq Stock Market LLC (Nasdaq) that it no longer complied with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. If the Company is unable to regain compliance with the minimum bid price requirement within the applicable compliance period, or is unable to otherwise maintain compliance with other applicable Nasdaq listing rules, it may not be able to maintain the listing of its common stock on Nasdaq, which could adversely affect its ability to issue additional securities or obtain additional financing on terms acceptable to it, or at all.Management believes that the Companyâ€™s existing cash, cash equivalents, short-term investments, cash generated from sales, and proceeds received from the debt financing described in Note 7, will be sufficient to meet its anticipated needs for at least the next 12 months from the issuance date of the accompanying condensed financial statements.Basis of PresentationThe accompanying condensed financial statements are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, that are necessary for the fair statement of the Companyâ€™s financial position, results of operations, comprehensive loss, and cash flows for the interim periods presented. The financial data and the other financial information disclosed in these notes to the condensed financial statements related to the three- and nine-month periods are also unaudited. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results of operations to be anticipated for any other future annual or interim period. The condensed balance sheet as of December 31, 2023 included herein was derived from the audited financial statements as of that date. These unaudited condensed financial statements should be read in conjunction with the Companyâ€™s audited financial statements and related notes for the year ended December 31, 2023, which are included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) on February 21, 2024 (2023 Annual Report).All share amounts disclosed in the notes to the condensed financial statements are rounded to the nearest thousand except for per share data. X - DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Summary of Significant Accounting Policies 2. Summary of Significant Accounting PoliciesRecently Issued Accounting PronouncementsIn November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07), which requires that

an entity disclose significant segment expenses impacting profit and loss that are regularly provided to the chief operating decision maker. The update is required to be applied retrospectively to prior periods presented, based on the significant segment expense categories identified and disclosed in the period of adoption. This ASU guidance is effective for our Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent interim periods, with early adoption permitted. The Company is currently evaluating the impact of the adoption of ASU 2023-07 on its financial statements and disclosures.In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (ASU 2023-09), which requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, this ASU requires certain disclosures of state versus federal income tax expense and taxes paid. This ASU is effective for our Annual Report on Form 10-K for the year ended December 31, 2025, with early adoption permitted. The Company does not expect the adoption of ASU 2023-09 to have a material impact on its financial statements.In March 2024, the SEC adopted rules intended to enhance and standardize climate-related disclosures in registration statements and annual reports. The new rules will require disclosure of material climate-related risks, including the material impacts of these risks to the Company, the quantification of material impacts to the Company as a result of severe weather events and other natural conditions and Board of Directors' oversight and risk management activities. The new rules follow a compliance phase-in timeline based on a company's filing status. Large accelerated filers and accelerated filers (other than smaller reporting companies) are required to first incorporate such disclosures for fiscal years 2025 and 2026, respectively, followed by greenhouse gas-related disclosures, if material, for fiscal years 2026 and 2027, respectively. Smaller reporting companies are required to first incorporate such disclosures for fiscal year 2027 and are not required to report greenhouse gas emissions data. In April 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. The Company is currently evaluating the impact of these new rules on its financial statements and disclosures.Significant Accounting PoliciesThere have been no new or material changes to the Companyâ€™s significant accounting policies as described in its 2023 Annual Report that have had a material impact on the Companyâ€™s condensed financial statements and related notes. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 18 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue and Deferred Revenue 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] Â Revenue and Deferred Revenue 3. Revenue and Deferred Revenue Disaggregation of RevenueRevenue by source consists of the following (in thousands): Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Consoles Â $ 7,709 Â Â $ 12,506 Â Â $ 24,080 Â Â $ 51,053 Â Â Consumables Â Â 12,596 Â Â Â 11,025 Â Â Â 35,891 Â Â Â 29,587 Â Â Total product revenue Â Â 20,305 Â Â Â 23,531 Â Â Â 59,971 Â Â Â 80,640 Â Â Service and other revenue Â Â 8,361 Â Â Â 6,831 Â Â Â 24,251 Â Â Â 19,229 Â Â Total revenue Â $ 28,666 Â Â $ 30,362 Â Â $ 84,222 Â Â $ 99,869 Â Â Remaining Performance Obligations and Contract LiabilitiesAs of September 30, 2024, the aggregate amount of the transaction price allocated to the remaining performance obligations related to customer service contracts that are unsatisfied or partially unsatisfied was $12.9 million, which is recorded as deferred revenue on the Companyâ€™s condensed balance sheets. Of that amount, $12.8 million will be recognized as revenue during the next 12 months and $0.1 million thereafter. The contract liabilities consist of deferred revenue which represents payments received in advance of revenue recognition. Revenue under these agreements is recognized over the related service period. During the three and nine months ended September 30, 2024, the Company recognized $2.0 million and $10.9 million of previously deferred revenue, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurements Fair Value MeasurementsThe following tables summarize the Companyâ€™s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): Â Â Â Â Â September 30, 2024 Â Â Â ValuationHierarchy Â AmortizedCosts Â Â GrossUnrealizedHoldingGains Â Â GrossUnrealizedHoldingLosses Â Â AggregateFair Value Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â Level 1 Â $ 16,136 Â Â $ â€” Â Â $ â€” Â Â $ 16,136 Â Short-term investments: Â Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury securities Â Level 1 Â Â 72,762 Â Â Â 158 Â Â Â â€” Â Â Â 72,920 Â U.S. government-sponsored enterprises Â Â Â debt securities Â Level 2 Â Â 11,520 Â Â Â 14 Â Â Â â€” Â Â Â 11,534 Â Corporate debt Â Level 2 Â Â 57,712 Â Â Â 181 Â Â Â (1) Â Â 57,892 Â Commercial paper Â Level 2 Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Total cash equivalents and Â Â Â short-term investments Â Â Â $ 158,130 Â Â $ 353 Â Â $ (1) Â $ 158,482 Â Â Â Â Â Â December 31, 2023 Â Â Â ValuationHierarchy Â AmortizedCosts Â Â GrossUnrealizedHoldingGains Â Â GrossUnrealizedHoldingLosses Â Â AggregateFair Value Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â Level 1 Â $ 44,883 Â Â $ â€” Â Â $ â€” Â Â $ 44,883 Â Short-term investments: Â Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury securities Â Level 1 Â Â 53,790 Â Â Â 58 Â Â Â (32) Â Â 53,816 Â U.S. government-sponsored enterprises Â Â Â debt securities Â Level 2 Â Â 29,645 Â Â Â 24 Â Â Â (38) Â Â 29,631 Â Corporate debt Â Level 2 Â Â 33,214 Â Â Â 56 Â Â Â â€” Â Â Â 33,270 Â Commercial paper Â Level 2 Â Â 18,097 Â Â Â 5 Â Â Â (4) Â Â 18,098 Â Total cash equivalents and Â Â Â short-term investments Â Â Â $ 179,629 Â Â $ 143 Â Â $ (74) Â $ 179,698 Â Â As of September 30, 2024, the remaining contractual maturities for available-for-sale securities were one month to thirteen months. The following tables present the breakdown of the available-for-sale debt securities with unrealized losses as of September 30, 2024, and December 31, 2023 (in thousands): Â Â September 30, 2024 Â Â Â Unrealized losses less than 12 months Â Â Unrealized losses 12 months or greater Â Â Total Â Â Â Fair Value Â Â Unrealized Losses Â Â Fair Value Â Â Unrealized Losses Â Â Fair Value Â Â Unrealized Losses Â Corporate debt Â $ 2,659 Â Â $ (1) Â $ â€” Â Â $ â€” Â Â $ 2,659 Â Â $ (1) Total Â $ 2,659 Â Â $ (1) Â $ â€” Â Â $ â€” Â Â $ 2,659 Â Â $ (1) Â Â Â December 31, 2023 Â Â Â Unrealized losses less than 12 months Â Â Unrealized losses 12 months or greater Â Â Total Â Â Â Fair Value Â Â Unrealized Losses Â Â Fair Value Â Â Unrealized Losses Â Â Fair Value Â Â Unrealized Losses Â U.S. Treasury securities Â $ 8,416 Â Â $ (16) Â $ 17,925 Â Â $ (16) Â $ 26,341 Â Â $ (32) U.S. government-sponsored enterprises Â Â Â debt securities Â Â 18,757 Â Â Â (22) Â Â 8,488 Â Â Â (16) Â Â 27,245 Â Â Â (38) Corporate debt Â Â 11,291 Â Â Â (4) Â Â â€” Â Â Â â€” Â Â Â 11,291 Â Â Â (4) Total Â $ 38,464 Â Â $ (42) Â $ 26,413 Â Â $ (32) Â $ 64,877 Â Â $ (74) The unrealized losses on the Companyâ€™s available-for-sale debt securities were caused by interest rate increases. The contractual terms of those investments do not permit the issuer to settle the securities at a price less than the amortized cost basis of the investments. As of September 30, 2024, the Company does not intend to sell the investments, and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. Additional factors considered in determining the treatment of unrealized losses include the financial condition and near-term prospects of the investee, the extent of the loss related to the credit of the issuer, and the expected cash flows from the security. For the three and nine months ended September 30, 2024 and 2023, the Company did not recognize credit loss related to available-for-sales debt securities. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Balance Sheet Components 5. Balance Sheet ComponentsCash, Cash Equivalents and Restricted CashAs of September 30, 2024 and December 31, 2023, the restricted cash balance of $3.3 million, was related to collateral for the Companyâ€™s building leases in San Jose, CA and Tijuana, Mexico. The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the amounts shown in the accompanying condensed statements of cash flows (in thousands): Â Â September 30, Â Â 2024 Â Â 2023 Â Cash and cash equivalents Â $ 33,287 Â Â $ 36,297 Â Restricted cash Â Â 3,329 Â Â Â 3,329 Â Total cash, cash equivalents and restricted cash Â $ 36,616 Â Â $ 39,626 Â Accounts ReceivableAccounts receivable are recorded at invoice value, net of any allowance for credit losses. The allowance for credit losses is based on the Companyâ€™s assessment of its best estimate of the amount of credit losses in customer accounts. The Company regularly reviews the allowance by considering factors such as existing contractual payment terms, historical collection experience, the financial position of the customer and information provided by credit rating services, the age of the accounts receivable balances, and current economic conditions that may affect a customerâ€™s ability to pay. The Company writes off accounts receivable when the Company has exhausted collection efforts without success, and payments subsequently received on such receivables are credited to the allowance in the period the payment is received. Credit losses from continuing operations have consistently been within managementâ€™s expectations.The following table presents the activity in the Companyâ€™s allowance for credit losses (in thousands): Balance as of December 31, 2023 Â Â Â $ 203 Â Increase in allowance Â Â Â Â 1,821 Â Write-offs Â Â Â Â (7) Balance as of September 30, 2024 Â Â Â $ 2,017 Â Â InventoriesInventories consist of the following (in thousands): Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Raw materials Â $ 25,138 Â Â $ 18,706 Â Work in process Â Â 13,911 Â Â Â 8,728 Â Finished goods Â Â 22,387 Â Â Â 21,781 Â Total inventories Â $ 61,436 Â Â $ 49,215 Â Accrued Expenses and Other Current LiabilitiesAccrued expenses and other current liabilities consist of the following (in thousands): Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Inventory Â $ 1,384 Â Â $ 3,395 Â Research and development expenses Â Â 116 Â Â Â 1,050 Â Professional services Â Â 716 Â Â Â 1,153 Â Customer rebates Â Â 1,738 Â Â Â 2,100 Â Â Other Â Â 2,795 Â Â Â 5,761 Â Total accrued expenses and other current liabilities Â $ 6,749 Â Â $ 13,459 Â X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies 6. Commitments and ContingenciesLitigationOn August 29, 2024, a purported stockholder class action lawsuit (the Porcelli Complaint), Porcelli, et al. v. Outset Medical, Inc., et al., 5:24-cv-06124-EJD, was filed in the U.S. District Court for the Northern District of California, naming the Company, its Chief Executive Officer, and Chief Financial Officer as defendants. On October 18, 2024,

a second purported stockholder class action lawsuit (the Plymouth Complaint), Plymouth County Retirement Association v. Outset Medical, Inc, et al., 5:24-cv-06124-HSG, was filed in the U.S. District Court for the Northern District of California. The second lawsuit additionally names the Company's former Chief Financial Officer as a defendant. The Porcelli Complaint alleges that between August 1, 2022 and August 7, 2024, the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (Exchange Act) by making false or misleading statements about the Companyâ€™s business, operations and prospects related to the sale and marketing of the Tablo Hemodialysis System and TabloCart with Prefiltration, including concerning the impact of certain FDA processes for these products on the Companyâ€™s revenue growth. The Plymouth Complaint alleges the same violations between September 15, 2020 and August 7, 2024. The Company intends to vigorously defend against this litigation. The cases are at a very early stage and there can be no assurance that the Company will be successful in its defense. For this same reason, the Company cannot currently estimate the loss or the range of possible losses it may experience in connection with this litigation.In addition, from time to time, the Company may become involved in other legal proceedings or investigations, which could have an adverse impact on its reputation, business and financial condition and divert the attention of the Companyâ€™s management from the operation of the Companyâ€™s business. IndemnificationIn the ordinary course of business, the Company often includes standard indemnification provisions in its arrangements with its partners, customers and suppliers. Pursuant to these provisions, the Company may be obligated to indemnify such parties for losses or claims suffered or incurred in connection with its service, breach of representations or covenants, intellectual property infringement or other claims made against such parties. These provisions may limit the time within which an indemnification claim can be made. It is not possible to determine the maximum potential amount under these indemnification obligations due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. To date, the Company has not incurred any material costs as a result of such indemnification obligations and has not accrued any liabilities related to such obligations in these financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Term Loan 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â Term Loan 7. Term LoansTerm loans consist of the following (in thousands): Â Â September 30, Â Â Â December 31, Â Â Â Â 2024 Â Â 2023 Â Principal of term loans Â $ 200,000 Â Â $ 133,476 Â Unamortized debt discount Â Â (2,818) Â Â (3,363) Term loans, noncurrent Â $ 197,182 Â Â $ 130,113 Â SLR Credit FacilitiesOn November 3, 2022 (the Closing Date), the Company entered into two senior secured credit facilities, which collectively provide for borrowings of up to $300.0 million as follows: (i) up to a $250.0 million term loan facility pursuant to a loan and security agreement (the SLR Loan Agreement) among SLR Investment Corp., as collateral agent (Agent), the lenders from time to time party thereto (the Term Loan Lenders) and the Company (the SLR Term Loan Facility), and (ii) up to a $50.0 million asset-based revolving credit facility pursuant to a credit agreement (the SLR Revolving Credit Agreement, together with the SLR Loan Agreement, the SLR Credit Facility Agreements) among Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL, as lender (ABL Lender), and the Company (the SLR Revolver, together with the SLR Term Loan Facility, the SLR Credit Facilities).The maximum amount the Company is permitted to borrow under the SLR Credit Facilities is subject to certain overall borrowing limitations that are tied to achieving certain specified revenue milestones and limit the maximum principal amount outstanding under the SLR Credit Facilities. As of September 30, 2024, the Company borrowed an aggregate principal amount of $200.0 million under the SLR Term Loan Facility, the full amount available under the borrowing limitations.SLR Term Loan FacilityUnder the SLR Loan Agreement, as subsequently amended on December 11, 2023, the Term Loan Lenders agreed to extend term loans to the Company in an aggregate principal amount of up to $250.0 million, comprised of (i) a term loan of $100.0 million (the Term A Loan), (ii) term loans in an aggregate principal amount of up to $100.0 million that was provided for in two increments, one of $33.5 million (the Term B-1 Loan) and one of $66.5 million (the Term B-2 Loan) and (iii) one or more term loans in an aggregate principal amount of up to $50.0 million (Term C Loans). Each Term A Loan, Term B Loan and Term C Loan is referred to single as a Term Loan and are referred to collectively as the Term Loans. The Term C Loans are subject to compliance with the borrowing limitations, Term Loan Lendersâ€™ credit approval and the achievement of a specified net revenue milestone on or before June 30, 2025 and if available, would remain available for funding until one business day prior to November 1, 2027.Any principal amount outstanding under the Term Loans will accrue interest at a rate per annum equal to one-month term Secured Overnight Financing Rate (term SOFR) (subject to a 2.75% floor), plus 5.15% (10.32% as of September 30, 2024), payable monthly in arrears. The Company is permitted to make interest-only payments on the Term Loans through November 30, 2026. Any principal amounts outstanding under the Term Loans, if not repaid sooner, are due and payable on November 1, 2027 (the Maturity Date). The Company is obligated to pay Agent (i) a non-refundable facility fee in the amount of $750,000 in respect of the Term A Loan, (ii) a non-refundable facility fees in the aggregate amount of $750,000 in respect of the Term B-1 and B-2 Loans and (iii) a non-refundable facility fee in the amount of $375,000 in respect of the Term C Loan, to be due and payable upon the earliest to occur of (a) the funding of the first Term C Loan, (b) one day prior to the Maturity Date and (c) the prepayment of the Term Loans. In addition, the Company is obligated to pay a final fee equal to 4.75% of the aggregate amount of the Term Loans funded, such final fee to be due and payable upon the earliest to occur of (i) the Maturity Date, (ii) the acceleration of the Term Loans and (iii) the prepayment of the Term Loans. The Company may voluntarily prepay the outstanding Term Loans, subject to a prepayment premium of (i) 3.0% of the principal amount of the Term Loan, if prepaid prior to or on the first anniversary of the Closing Date, (ii) 2.0% of the principal amount of the Term Loan, if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) 1.0% of the principal amount of the Term Loan if prepaid after the second anniversary of the Closing Date and prior to the Maturity Date. SLR RevolverThe SLR Revolving Credit Agreement provides for an asset-based revolving credit facility with aggregate revolving commitments of $25.0 million (the Initial Revolver Commitment). The Company may request to increase the aggregate revolving commitments by $25.0 million (the Additional Tranche) to an aggregate amount of $50.0 million, subject to ABL Lenderâ€™s approval. Amounts available to be drawn under the SLR Revolver are equal to the lesser of (i) outstanding revolving commitments under the SLR Revolving Credit Agreement and (ii) a borrowing base (the Borrowing Base) equal to the sum of (a) 85% of eligible accounts receivable, plus (b) 25% of eligible inventory (not to exceed the lesser of 50% of the Borrowing Base and $5.0 million), minus (c) customary reserves, minus (d) unposted cash. As of September 30, 2024, no amounts were outstanding under the SLR Revolver. As a result of the overall borrowing limitations set forth in the SLR Credit Facilities, amounts under the SLR Revolver are not currently available. As of September 30, 2024, the Company has not requested or received ABL Lenderâ€™s approval of the Additional Tranche.Any principal amount outstanding under the SLR Revolver will accrue interest at a rate per annum equal to one-month term SOFR (subject to a 2.75% floor), plus 3.20%, payable monthly in arrears. Interest on any borrowing is payable monthly. The Company is obligated to pay Lender (i) a non-refundable facility fee in the amount of $187,500 in respect of the Initial Revolver Commitment, (ii) a non-refundable facility fee in the amount of $187,500 in respect of the Additional Tranche, to be due and payable upon activation of the Additional Tranche, (iii) a commitment fee of 0.50% per annum of the average daily unused portion of the then commitment amount, payable monthly and (iv) a collateral monitoring fee of 0.10% per month of the average daily Borrowing Base during the prior month, payable monthly. The Company may terminate the SLR Revolver at any time, subject to a termination fee of (i) 2.0% of the aggregate revolving commitments then in effect, if terminated prior to or on the first anniversary of the Closing Date, (ii) 1.0% of the aggregate revolving commitments then in effect, if terminated after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) 0.5% of the aggregate revolving commitments then in effect, if terminated after the second anniversary of the Closing Date through and including the third anniversary of the Closing Date. Such termination fee is waived if the SLR Revolver is terminated after the third anniversary of the Closing Date and prior to the Maturity Date.Subject to customary exceptions and restrictions, the Company may borrow, repay and reborrow varying amounts under the SLR Revolver at any time subject to the overall borrowing limitations. If at any time the outstanding amount under the SLR Revolver exceeds the lesser of (i) the aggregate revolving commitments then in effect and (ii) the Borrowing Base then in effect, the Company will be required to prepay outstanding amounts under the SLR Revolver.The SLR Revolver shall expire on November 1, 2027.Other Terms of the SLR Credit FacilitiesAs security for its obligations under the SLR Credit Facilities, the Company granted Agent, for the benefit of the Term Loan Lenders, and ABL Lender a security interest in substantially all of the assets of the Company, including the Companyâ€™s intellectual property, subject to certain exceptions.The SLR Credit Facility Agreements contain customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to financial reporting and insurance and restrictions on the Companyâ€™s ability to dispose of its business or property, to change its line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on its property or to pay any dividends or other distributions on capital stock. The agreements also include a financial covenant that, beginning with the fiscal quarter ended December 31, 2023, the Company must either (i) maintain certain levels of cash and cash equivalents in accounts subject to control agreements in favor of Agent and ABL Lender of at least 50% of the sum of (a) the outstanding obligations under the Term Loans (as defined below) and (b) the amount of the Companyâ€™s accounts payable that have not been paid within 120 days from the invoice date thereof or (ii) generate net product and product related revenue in excess of specified amounts and maintain gross profit margins in excess of specified percentages, in each case, for applicable measuring periods.In addition, the SLR Credit Facility Agreements contain customary events of default that entitle Agent, under the SLR Loan Agreement, and ABL Lender, under the SLR Revolving Credit Agreement, to cause the Companyâ€™s indebtedness under the SLR Loan Agreement or SLR Revolving Credit Agreement, as applicable, to become immediately due and payable, and to exercise remedies against the Company and the collateral securing the obligations owed under the applicable SLR Credit Facility Agreement. Under the SLR Credit Facility Agreements, an event of default will occur if, among other things, the Company fails to make payments under either SLR Credit Facility Agreement, the Company breaches covenants under either SLR Credit Facility Agreement, subject to specified cure periods with respect to certain breaches, the Agent or ABL Lender, as applicable, determine that a material adverse change has occurred under the SLR Loan Agreement or SLR Revolving Credit Agreement, as applicable, or the Company or its assets become subject to certain legal proceedings, such as bankruptcy proceedings. Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to 4.0% per annum will apply to all obligations owed under the SLR Credit Facility Agreements.The debt issuance costs and the facility fees related to the Term A and B Loans were recorded as a direct deduction from the term loans balance on the balance sheets and are being recognized as non-cash interest expense over the term of the loans using the effective interest method, along with the final payment fee. The facility fees related to the Initial Revolver Commitment were recorded as deferred financing costs and are being recognized as non-cash interest expense over their respective commitment period using straight-line method. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Equity Incentive Plan 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Equity Incentive Plan 8. Equity Incentive PlanEquity Incentive PlansAs of September 30, 2024, 3,218,000 shares were reserved for future issuance under the 2020 Equity Incentive Plan (2020 Plan).Employee Share Purchase Plan (ESPP)As of September 30, 2024, 667,000 shares of common stock were reserved for issuance in connection

with the current and future offering periods under the ESPP.Restricted StockThe Company issues restricted stock units (RSUs) and performance stock units (PSUs), both of which are considered restricted stock. The Company grants restricted stock pursuant to the 2020 Plan and satisfies such grants through the issuance of new shares. RSUs are share awards that, upon vesting, will deliver to the holder shares of our common stock.RSUs with a service-based vesting condition granted to a grantee, beginning in February 2022, generally vest over a three-year period as follows either: (i) 25% on the first anniversary of the original vesting date, 25% quarterly over the course of the second year, and 50% quarterly over the course of the third year, or (ii) 33% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining two years. Annual RSUs granted to non-executive employees in 2024 vest over a two-year period at a rate of 50% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining one year. Prior to February 2022, RSUs with a service-based vesting condition granted to a grantee generally vest at a rate of 25% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining three years. Since 2022, the Company has granted a mix of 50% PSUs and 50% RSUs to its CEO, and a mix of 20% PSUs and 80% RSUs to its other executive officers and certain other senior leaders on an annual basis. The PSUs are earned and vest based on achievement against two metrics:â€¢The â€œHome PSUsâ€ are earned based on the number of patients treating at home on Tablo as of the end of the second or third year following the grant date (Year 2 or Year 3), with earned units vesting either (i) 50% after certification of achievement following the end of Year 2 and 50% at the end of Year 3 or (ii) 100% after certification of achievement following the end of Year 3 (performance-based vesting conditions).â€¢The â€œRelative TSR PSUsâ€ are earned based on the Company's relative total stockholder return (relative TSR) at the end of a two-year or three-year performance period as compared to companies in a pre-determined index of medical device companies, in each case, with 100% of earned units vesting on, or after certification of achievement following, the third anniversary of the grant date (market-based vesting conditions). The number of units earned varies based on actual performance as follows: (i) from 0% to 200% (250% for the CEO) of the target number of the Home PSUs granted, (ii) from 75% to 150% (250% for the CEO) of the target number of Relative TSR PSUs granted in 2022 and 2023 and (iii) from 0% to 200% (250% for the CEO) of the target number of Relative TSR PSUS granted in 2024.The grant date for the Home PSUs is not considered established until the Compensation Committee of the Board approves the target and it is communicated to the award recipients, which then triggers the service inception date, the fair value of the awards, and the associated expense recognition period. Once the grant date for the Home PSUs has been established, the related stock-based compensation expense is recorded based on the forecasted performance, which is reassessed each reporting period based on the probability of achieving the performance conditions. In 2024, the Company also granted a new type of PSU award to executive officers and certain other senior leaders which is earned and vests based on appreciation of the Companyâ€™s stock price above pre-determined stock price triggers or achievement of specified operating income targets over a performance period of up to three years.Stock-Based Compensation ExpenseThe following table sets forth stock-based compensation expense included in the accompanying condensed statements of operations (in thousands): Â Â Three Months Ended Â Â Nine Months Ended Â Â Â September 30, Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Cost of revenue Â $ 296 Â Â $ 620 Â Â $ 1,092 Â Â $ 1,381 Â Research and development Â Â 1,400 Â Â Â 2,793 Â Â Â 6,025 Â Â Â 8,232 Â Sales and marketing Â Â 945 Â Â Â 3,765 Â Â Â 4,898 Â Â Â 9,908 Â General and administrative Â Â 3,747 Â Â Â 3,715 Â Â Â 12,396 Â Â Â 10,015 Â Total stock-based compensation expense Â $ 6,388 Â Â $ 10,893 Â Â $ 24,411 Â Â $ 29,536 Â X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes 9 Months Ended Sep. 30, 2024 Income Tax Disclosure [Abstract] Â Income Taxes 9. Income TaxesFor each of the three and nine months ended September 30, 2024 and 2023, the Company incurred an income tax provision of an insignificant amount, which primarily related to foreign income taxes related to the Companyâ€™s Mexico operations. The U.S. federal and state net deferred tax assets have been fully offset by a valuation allowance, as the Company believes it is not more likely than not that the deferred tax assets will be realized. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss Per Share 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Net Loss Per Share 10. Net Loss Per ShareThe following outstanding potentially dilutive shares were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands): Â Â Three and Nine Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Stock options to purchase common stock Â Â 1,521 Â Â Â 1,978 Â Restricted stock units Â Â 3,961 Â Â Â 2,760 Â Performance stock units Â Â 273 Â Â Â 95 Â Shares committed under ESPP Â Â 319 Â Â Â 42 Â Warrant to purchase common stock Â Â 63 Â Â Â 63 Â Total Â Â 6,137 Â Â Â 4,938 Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Workforce reduction 9 Months Ended Sep. 30, 2024 Workforce reduction [Abstract] Â Workforce reduction 11. Workforce reductionIn order to improve operational efficiencies, reduce operating expenses and streamline its overall organizational structure, the Company implemented two organizational restructuring plans to reduce its workforce in the fourth quarter of 2023 and May 2024 and incurred restructuring charges of $2.5 million in fiscal year 2023 and $2.7 million through the first half of fiscal year 2024 for employee severance and other termination benefits.In connection with steps the Company is taking to help optimize its commercial organization, and to help improve operational efficiencies and reduce operating expenses to align with anticipated revenue growth, in the third quarter of 2024, the Company completed an additional restructuring primarily impacting its commercial organization. The Company incurred restructuring charges of $1.4 million in the third quarter of 2024 for employee severance and other termination benefits associated with this restructuring.The following table sets forth severance and related benefits charges included in the accompanying condensed statements of operations (in thousands): Â Â Nine Months Ended Â Â Â September 30, 2024 Â Cost of revenue Â $ 530 Â Research and development Â Â 1,260 Â Sales and marketing Â Â 1,884 Â General and administrative Â Â 475 Â Total Â $ 4,149 Â The changes in liabilities resulting from the restructuring accruals, which were recorded in accrued expenses and other current liabilities on the accompanying condensed balance sheets, were as follows (in thousands): Balance as of December 31, 2023 Â Â Â $ 854 Â Charges Â Â Â Â 4,149 Â Payments and other adjustments Â Â Â Â (4,920) Balance as of September 30, 2024 Â Â Â $ 83 Â X - DefinitionWorkforce reduction Abstract + ReferencesNo definition available. + Details Name: om_WorkforceReductionAbstract Namespace Prefix: om_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/420/tableOfContentReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events 9 Months Ended Sep. 30, 2024 Subsequent Events [Abstract] Â Subsequent Events 12. Subsequent EventOn October 18, 2024, a second purported stockholder class action lawsuit was filed against the Company, certain of its officers and a former officer (see Note 6). X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Recently Adopted Accounting Pronouncements Recently Issued Accounting PronouncementsIn November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07), which requires that an entity disclose significant segment expenses impacting profit and loss that are regularly provided to the chief operating decision maker. The update is required to be applied retrospectively to prior periods presented, based on the significant segment expense categories identified and disclosed in the period of adoption. This ASU guidance is effective for our Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent interim periods, with early adoption permitted. The Company is currently evaluating the impact of the adoption of ASU 2023-07 on its financial statements and disclosures.In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (ASU 2023-09), which requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, this ASU requires certain disclosures of state versus federal income tax expense and taxes paid. This ASU is effective for our Annual Report on Form 10-K for the year ended December 31, 2025, with early adoption permitted. The Company does not expect the adoption of ASU 2023-09 to have a material impact on its financial statements.In March 2024, the SEC adopted rules intended to enhance and standardize climate-related disclosures in registration statements and annual reports. The new rules will require disclosure of material climate-related risks, including the material impacts of these risks to the Company, the quantification of material impacts to the Company as a result of severe weather events and other natural conditions and Board of Directors' oversight and risk management activities. The new rules follow a compliance phase-in timeline based on a company's filing status. Large accelerated filers and accelerated filers (other than smaller reporting companies) are required to first incorporate such disclosures for fiscal years 2025 and 2026, respectively, followed by greenhouse gas-related disclosures, if material, for fiscal years 2026 and 2027, respectively. Smaller reporting companies are required to first incorporate such disclosures for fiscal year 2027 and are not required to report greenhouse gas emissions data. In April 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. The Company is currently evaluating the impact of these new rules on its financial statements and disclosures. Significant Accounting Policies Significant Accounting PoliciesThere have been no new or material changes to the Companyâ€™s significant accounting policies as described in its 2023 Annual Report that have had a material impact on the Companyâ€™s condensed financial statements and related notes. X - DefinitionSignificant Accounting Policies [Policy Text Block] + ReferencesNo definition available. + Details Name: om_SignificantAccountingPoliciesPolicyTextBlock Namespace Prefix: om_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the

expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue and Deferred Revenue (Tables) 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] Â Summary of Revenue by Source Revenue by source consists of the following (in thousands): Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Consoles Â $ 7,709 Â Â $ 12,506 Â Â $ 24,080 Â Â $ 51,053 Â Â Consumables Â Â 12,596 Â Â Â 11,025 Â Â Â Â 35,891 Â Â Â 29,587 Â Â Total product revenue Â Â 20,305 Â Â Â 23,531 Â Â Â 59,971 Â Â Â 80,640 Â Â Service and other revenue Â Â 8,361 Â Â Â 6,831 Â Â Â 24,251 Â Â Â 19,229 Â Â Total revenue Â $ 28,666 Â Â $ 30,362 Â Â $ 84,222 Â Â $ 99,869 Â Â X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 30 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Summary of Financial Assets Measured at Fair Value on Recurring Basis by Level Within Fair Value Hierarchy The following tables summarize the Companyâ€™s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): Â Â Â Â Â September 30, 2024 Â Â Â ValuationHierarchy Â AmortizedCosts Â Â GrossUnrealizedHoldingGains Â Â GrossUnrealizedHoldingLosses Â Â AggregateFair Value Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â Level 1 Â $ 16,136 Â Â $ â€” Â Â $ â€” Â Â $ 16,136 Â Short-term investments: Â Â Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury securities Â Level 1 Â Â 72,762 Â Â Â 158 Â Â Â â€” Â Â Â 72,920 Â U.S. government-sponsored enterprises Â Â Â debt securities Â Level 2 Â Â 11,520 Â Â Â 14 Â Â Â â€” Â Â Â 11,534 Â Corporate debt Â Level 2 Â Â 57,712 Â Â Â 181 Â Â Â (1) Â Â 57,892 Â Commercial paper Â Level 2 Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Total cash equivalents and Â Â Â short-term investments Â Â Â $ 158,130 Â Â $ 353 Â Â $ (1) Â $ 158,482 Â Â Â Â Â Â Â December 31, 2023 Â Â Â ValuationHierarchy Â AmortizedCosts Â Â GrossUnrealizedHoldingGains Â Â GrossUnrealizedHoldingLosses Â Â AggregateFair Value Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â Level 1 Â $ 44,883 Â Â $ â€” Â Â $ â€” Â Â $ 44,883 Â Short-term investments: Â Â Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury securities Â Level 1 Â Â 53,790 Â Â Â 58 Â Â Â (32) Â Â 53,816 Â U.S. government-sponsored enterprises Â Â Â debt securities Â Level 2 Â Â 29,645 Â Â Â 24 Â Â Â (38) Â Â 29,631 Â Corporate debt Â Level 2 Â Â 33,214 Â Â Â 56 Â Â Â â€” Â Â Â 33,270 Â Commercial paper Â Level 2 Â Â 18,097 Â Â Â 5 Â Â Â (4) Â Â 18,098 Â Total cash equivalents and Â Â Â short-term investments Â Â Â $ 179,629 Â Â $ 143 Â Â $ (74) Â $ 179,698 Â Schedule of Breakdown of the Available-for-Sale Debt Securities With Unrealized Losses The following tables present the breakdown of the available-for-sale debt securities with unrealized losses as of September 30, 2024, and December 31, 2023 (in thousands): Â Â September 30, 2024 Â Â Â Unrealized losses less than 12 months Â Â Unrealized losses 12 months or greater Â Â Total Â Â Â Fair Value Â Â Unrealized Losses Â Â Fair Value Â Â Unrealized Losses Â Â Fair Value Â Â Unrealized Losses Â Corporate debt Â $ 2,659 Â Â $ (1) Â $ â€” Â Â $ â€” Â Â $ 2,659 Â Â $ (1) Total Â $ 2,659 Â Â $ (1) Â $ â€” Â Â $ â€” Â Â $ 2,659 Â Â $ (1) Â Â Â December 31, 2023 Â Â Â Unrealized losses less than 12 months Â Â Unrealized losses 12 months or greater Â Â Total Â Â Â Fair Value Â Â Unrealized Losses Â Â Fair Value Â Â Unrealized Losses Â Â Fair Value Â Â Unrealized Losses Â U.S. Treasury securities Â $ 8,416 Â Â $ (16) Â $ 17,925 Â Â $ (16) Â $ 26,341 Â Â $ (32) U.S. government-sponsored enterprises Â Â Â debt securities Â Â 18,757 Â Â Â (22) Â Â 8,488 Â Â Â (16) Â Â 27,245 Â Â Â (38) Corporate debt Â Â 11,291 Â Â Â Â (4) Â Â â€” Â Â Â â€” Â Â Â 11,291 Â Â Â (4) Total Â $ 38,464 Â Â $ (42) Â $ 26,413 Â Â $ (32) Â $ 64,877 Â Â $ (74) X - DefinitionSchedule of breakdown of the available-for-sale debt securities with unrealized losses Table Text Block + ReferencesNo definition available. + Details Name: om_ScheduleOfBreakdownOfTheAvailableForSaleDebtSecuritiesWithUnrealizedLossesTableTextBlock Namespace Prefix: om_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components (Tables) 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Schedule of Cash and Cash Equivalents The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the amounts shown in the accompanying condensed statements of cash flows (in thousands): Â Â September 30, Â Â Â 2024 Â Â 2023 Â Cash and cash equivalents Â $ 33,287 Â Â $ 36,297 Â Restricted cash Â Â 3,329 Â Â Â 3,329 Â Total cash, cash equivalents and restricted cash Â $ 36,616 Â Â $ 39,626 Â Schedule of Accounts Receivable, Allowance for Credit Loss The following table presents the activity in the Companyâ€™s allowance for credit losses (in thousands): Balance as of December 31, 2023 Â Â Â $ 203 Â Increase in allowance Â Â Â Â 1,821 Â Write-offs Â Â Â Â (7) Balance as of September 30, 2024 Â Â Â $ 2,017 Â Â Schedule of Inventories Inventories consist of the following (in thousands): Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Raw materials Â $ 25,138 Â Â $ 18,706 Â Work in process Â Â 13,911 Â Â Â 8,728 Â Finished goods Â Â 22,387 Â Â Â 21,781 Â Total inventories Â $ 61,436 Â Â $ 49,215 Â Schedule of Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following (in thousands): Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Inventory Â $ 1,384 Â Â $ 3,395 Â Research and development expenses Â Â 116 Â Â Â 1,050 Â Professional services Â Â 716 Â Â Â 1,153 Â Customer rebates Â Â 1,738 Â Â Â 2,100 Â Â Other Â Â 2,795 Â Â Â 5,761 Â Total accrued expenses and other current liabilities Â $ 6,749 Â Â $ 13,459 Â X - DefinitionAccrued expenses and other current liabilities. + ReferencesNo definition available. + Details Name: om_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock Namespace Prefix: om_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of cash and cash equivalents. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Term Loan (Tables) 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â Schedule of Term Loan Term loans consist of the following (in thousands): Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Principal of term loans Â $ 200,000 Â Â $ 133,476 Â Unamortized debt discount Â Â (2,818) Â Â (3,363) Term loans, noncurrent Â $ 197,182 Â Â $ 130,113 Â X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Equity Incentive Plan (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Summary of Stock-based Compensation Expense The following table sets forth stock-based compensation expense included in the accompanying condensed statements of operations (in thousands): Â Â Three Months Ended Â Â Nine Months Ended Â Â Â September 30, Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Cost of revenue Â $ 296 Â Â $ 620 Â Â $ 1,092 Â Â $ 1,381 Â Research and development Â Â 1,400 Â Â Â 2,793 Â Â Â 6,025 Â Â Â 8,232 Â Sales and marketing Â Â 945 Â Â Â 3,765 Â Â Â 4,898 Â Â Â 9,908 Â General and administrative Â Â 3,747 Â Â Â 3,715 Â Â Â 12,396 Â Â Â 10,015 Â Total stock-based compensation expense Â $ 6,388 Â Â $ 10,893 Â Â $ 24,411 Â Â $ 29,536 Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss Per Share (Tables) 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Schedule of Outstanding Potentially Dilutive Shares were Excluded from Calculation of Diluted Net Loss Per Share The following outstanding potentially dilutive shares were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands): Â Â Three and Nine Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Stock options to purchase common stock Â Â 1,521 Â Â Â 1,978 Â Restricted stock units Â Â 3,961 Â Â Â 2,760 Â Performance stock units Â Â 273 Â Â Â 95 Â Shares committed under ESPP Â Â 319 Â Â Â 42 Â Warrant to purchase common stock Â Â 63 Â Â Â 63 Â Total Â Â 6,137 Â Â Â 4,938 Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Workforce reduction (Tables) 9 Months Ended Sep. 30, 2024 Workforce reduction [Abstract] Â Schedule of Severance and Related Benefits Charges Related to the May 2024 Workforce Reduction Plan The following table sets forth severance and related benefits charges included in the accompanying condensed statements of operations (in thousands): Â Â Nine Months Ended Â Â Â September 30, 2024 Â Cost of revenue Â $ 530 Â Research and development Â Â 1,260 Â Sales and marketing Â Â 1,884 Â General and administrative Â Â 475 Â Total Â $ 4,149 Â Schedule of Changes in Liabilities Resulting from the Severance Charges and Related Accruals The changes in liabilities resulting from the restructuring accruals, which were recorded in accrued expenses and other current liabilities on the accompanying condensed balance sheets, were as follows (in thousands): Balance as of December 31, 2023 Â Â Â $ 854 Â Charges Â Â Â Â 4,149 Â Payments and other adjustments Â Â Â Â (4,920) Balance as of September 30, 2024 Â Â Â Â $ 83 Â X - DefinitionSchedule of Changes in Liabilities Resulting from the Severance Charges and Related Accruals [Table Text Block] + ReferencesNo definition available. + Details Name: om_ScheduleOfChangesInLiabilitiesResultingFromTheSeveranceChargesAndRelatedAccrualsTableTextBlock Namespace Prefix: om_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionWorkforce reduction Abstract + ReferencesNo definition available. + Details Name: om_WorkforceReductionAbstract Namespace Prefix: om_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business - Additional Information (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Description Of Business [Line Items] Â Â Â Â Â Â Â Â Â Net Income (Loss) $ (27,940) $ (34,454) $ (39,944) $ (46,180) $ (44,046) $ (43,971) $ (102,338) $ (134,197) Â Accumulated deficit (1,064,085) Â Â Â Â Â (1,064,085) Â $ (961,747) Restricted cash 3,329 Â Â Â Â Â 3,329 Â $ 3,329 Cash outflow from operating activities Â Â Â Â Â Â 99,800 $ 106,900 Â Cash, cash equivalents, restricted cash and short-term investments $ 179,000 Â Â Â Â Â $ 179,000 Â Â X - DefinitionCash cash equivalents, restricted cash and short term investments. + ReferencesNo definition available. + Details Name: om_CashCashEquivalentsRestrictedCashAndShortTermInvestments Namespace Prefix: om_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDescription of business. + ReferencesNo definition available. + Details Name: om_DescriptionOfBusinessLineItems Namespace Prefix: om_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -

Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionTotal amount of cash paid for operating activities during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_PaymentsForOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 37 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue and Deferred Revenue - Summary of Revenue by Source (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Disaggregation Of Revenue [Line Items] Â Â Â Â Revenue $ 28,666 $ 30,362 $ 84,222 $ 99,869 Consoles Product Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Revenue 7,709 12,506 24,080 51,053 Consumables Product Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Revenue 12,596 11,025 35,891 29,587 Product Revenue Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Revenue 20,305 23,531 59,971 80,640 Service and Other Revenue Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Revenue $ 8,361 $ 6,831 $ 24,251 $ 19,229 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=om_ConsolesProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=om_ConsumablesProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=om_ServiceAndOtherRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue and Deferred Revenue - Additional Information (Detail) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 USD ($) Sep. 30, 2024 USD ($) Remaining performance obligations $ 12.9 $ 12.9 Revenue recognized $ 2.0 $ 10.9 X - DefinitionAmount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of transaction price allocated to performance obligation that has not been recognized as revenue. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligation Namespace Prefix: us-gaap_ Data Type:

xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 39 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue and Deferred Revenue - Additional Information (Detail) 1 $ in Millions Sep. 30, 2024 USD ($) Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-10-01 Â Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] Â Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 12 months Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-04-01 Â Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] Â Revenue performance obligation $ 12.8 Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-10-01 Â Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] Â Revenue performance obligation $ 0.1 X - Definitionrevenue performance obligation 1 + ReferencesNo definition available. + Details Name: om_RevenuePerformanceObligation1 Namespace Prefix: om_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-10-01 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-04-01 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-01 Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Gross Unrealized Holding Losses $ (1) $ (74) Â Debt Securities, Available-for-Sale 0 Â $ 0 Fair Value, Recurring Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Amortized Costs 158,130 179,629 Â Gross Unrealized Holding Gains 353 143 Â Gross Unrealized Holding Losses (1) (74) Â Debt Securities, Available-for-Sale 158,482 179,698 Â Fair Value, Recurring | Level 1 | Short-term investments | U.S. Treasury securities Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Amortized Costs 72,762 53,790 Â Gross Unrealized Holding Gains 158 58 Â Gross Unrealized Holding Losses 0 (32) Â Debt Securities, Available-for-Sale 72,920 53,816 Â Fair Value, Recurring | Level 1 | Cash equivalents | Money market funds Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Amortized Costs 16,136 44,883 Â Gross Unrealized Holding Gains 0 0 Â Gross Unrealized Holding Losses 0 0 Â Debt Securities, Available-for-Sale 16,136 44,883 Â Fair Value, Recurring | Level 2 | Short-term investments | Commercial paper [Member] Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Amortized Costs 0 18,097 Â Gross Unrealized Holding Gains 0 5 Â Gross Unrealized Holding Losses 0 (4) Â Debt Securities, Available-for-Sale 0 18,098 Â Fair Value, Recurring | Level 2 | Short-term investments | Corporate debt Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Amortized Costs 57,712 33,214 Â Gross Unrealized Holding Gains 181 56 Â Gross Unrealized Holding Losses (1) 0 Â Debt Securities, Available-for-Sale 57,892 33,270 Â Fair Value, Recurring | Level 2 | Short-term investments | USGovernmentSponsoredEnterprisesDebtSecurities Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Amortized Costs 11,520 29,645 Â Gross Unrealized Holding Gains 14 24 Â Gross Unrealized Holding Losses 0 (38) Â Debt Securities, Available-for-Sale $ 11,534 $ 29,631 Â X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Schedule of breakdown of the available-for-sale debt securities with unrealized losses (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value $ 2,659 $ 64,877 Gross Unrealized Holding Losses (1) (74) US Treasury Securities [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value Â 26,341 Gross Unrealized Holding Losses Â (32) Corporate Debt Securities [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 2,659 11,291 Gross Unrealized Holding Losses (1) (4) U.S. government-sponsored enterprises [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value Â 27,245 Gross Unrealized Holding Losses Â (38) Unrealized losses less than 12 months [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 2,659 38,464 Gross Unrealized Holding Losses (1) (42) Unrealized losses less than 12 months [Member] | US Treasury Securities [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value Â 8,416 Gross Unrealized Holding Losses Â (16) Unrealized losses less than 12 months [Member] | Corporate Debt Securities [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 2,659 11,291 Gross Unrealized Holding Losses (1) (4) Unrealized losses less than 12 months [Member] | U.S. government-sponsored enterprises [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value Â 18,757 Gross Unrealized Holding Losses Â (22) Unrealized losses 12 months or greater [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 0 26,413 Gross Unrealized Holding Losses 0 (32) Unrealized losses 12 months or greater [Member] | US Treasury Securities [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value Â 17,925 Gross Unrealized Holding Losses Â (16) Unrealized losses 12 months or greater [Member] | Corporate Debt Securities [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 0 0 Gross Unrealized Holding Losses $ 0 0 Unrealized losses 12 months or greater [Member] | U.S. government-sponsored enterprises [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value Â 8,488 Gross Unrealized Holding Losses Â $ (16) X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=om_USGovernmentSponsoredEnterprisesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: om_UnrealisedLossesAxis=om_UnrealizedLossesLessThan12MonthsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: om_UnrealisedLossesAxis=om_UnrealizedLosses12MonthsOrGreaterMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Fair Value Disclosures [Abstract] Â Â Remaining contractual maturities for available-for-sale securities one month to thirteen months Â Debt Securities, Available-for-Sale $ 0 $ 0 X - DefinitionDebt Securities Available For Sale Remaining Contractual Maturities period. + ReferencesNo definition available. + Details Name: om_DebtSecuritiesAvailableForSaleRemainingContractualMaturitiesPeriod Namespace Prefix: om_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 43 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components (Additional Information) (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Balance Sheet Components Â Â Â Restricted cash balance $ 3,329 $ 3,300 $ 3,329 X - DefinitionBalance Sheet Components [Abstract] + ReferencesNo definition available. + Details Name: om_BalanceSheetComponents Namespace Prefix: om_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 44 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components - Schedule Of Cash And Cash Equivalents And Restricted Cash (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Cash and Cash Equivalents [Abstract] Â Â Â Cash and cash equivalents $ 33,287 $ 68,509 $ 36,297 Restricted cash 3,329 $ 3,300 3,329 Total cash, cash equivalents and restricted cash $ 36,616 Â $ 39,626 X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 45 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components - Summary of Allowance for credit losses (Details) $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Allowance for Credit Loss [Abstract] Â Allowance for Credit Loss, Beginning Balance $ 203 Increase in allowance 1,821 Write-offs (7) Allowance for Credit Loss, Ending Balance $ 2,017 X - ReferencesNo definition available. + Details Name: us-gaap_AllowanceForCreditLossAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of increase (decrease) in allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionAmount of direct write-downs of accounts receivable charged against the allowance. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 46 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components - Schedule of Inventories (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Inventory Disclosure [Abstract] Â Â Raw materials $ 25,138 $ 18,706 Work in process 13,911 8,728 Finished goods 22,387 21,781 Total inventories $ 61,436 $ 49,215 X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoods Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterials Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcess Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 47 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Payables and Accruals [Abstract] Â Â Inventory $ 1,384 $ 3,395 Research and development expenses 116 1,050 Professional services 716 1,153 Customer rebates 1,738 2,100 Other 2,795 5,761 Total accrued expenses and other current liabilities $ 6,749 $ 13,459 X - DefinitionAccrued expenses and other current liabilities. + ReferencesNo definition available. + Details Name: om_AccruedExpensesAndOtherCurrentLiabilities Namespace Prefix: om_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued inventory current. + ReferencesNo definition available. + Details Name: om_AccruedInventoryCurrent Namespace Prefix: om_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued research and development expenses. + ReferencesNo definition available. + Details Name: om_AccruedResearchAndDevelopmentExpenses Namespace Prefix: om_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for rebates of an exchange fee some mutual funds impose on shareholders if they exchange (transfer) to another fund within the same fund group. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedExchangeFeeRebateCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 48 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Term Loan - Schedule of Term Loan (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Debt Disclosure [Abstract] Â Â Principal of term loan $ 200,000 $ 133,476 Unamortized debt discount (2,818) (3,363) Term loan, noncurrent $ 197,182 $ 130,113 X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt discount. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DebtInstrumentUnamortizedDiscount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 49 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Term Loan - Additional Information (Detail) - USD ($) 9 Months Ended Sep. 30, 2024 Dec. 31, 2023 Dec. 11, 2023 Nov. 03, 2022 Debt Instrument [Line Items] Â Â Â Â Principal of term loan $ 200,000,000 $ 133,476,000 Â Â Debt discount on Perceptive Term Loan 2,818,000 $ 3,363,000 Â Â TwoSeniorSecuredCreditFacilities Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity Â Â Â $ 300,000,000 SLR Credit Facilities Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity $ 200,000,000 Â Â Â Cash and cash equivalent maintain percentage 50.00% Â Â Â Line of credit, default interest rate 4.00% Â Â Â SLR Credit Facilities | Maximum Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity Â Â Â 250,000,000 SLR Term Loan Facility Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity Â Â $ 250,000,000 Â Line of credit, interest rate 10.32% Â Â Â Line of credit, expiration date Nov. 30, 2026 Â Â Â Line of credit, commitment fee percentage 4.75% Â Â Â Line of credit, payment terms, description The Company may voluntarily prepay the outstanding Term Loans, subject to a prepayment premium of (i) 3.0% of the principal amount of the Term Loan, if prepaid prior to or on the first anniversary of the Closing Date, (ii) 2.0% of the principal amount of the Term Loan, if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) 1.0% of the principal amount of the Term Loan if prepaid after the second anniversary of the Closing Date and prior to the Maturity Date. Â Â Â SLR Term Loan Facility | First Anniversary of Closing Date Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of credit, percentage of prepayment premium 3.00% Â Â Â SLR Term Loan Facility | Second Anniversary of Closing Date Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of credit, percentage of prepayment premium 2.00% Â Â Â SLR Term Loan Facility | After Second Anniversary of Closing Date Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of credit, percentage of prepayment premium 1.00% Â Â Â SLR Term Loan Facility | InterestRateFloor Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of credit, interest rate 2.75% Â Â Â SLR Term Loan Facility | SOFR Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of credit, interest rate 5.15% Â Â Â Slr Revolver Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity $ 50,000,000 Â Â Â Line of credit, expiration date Nov. 01, 2027 Â Â Â Line of credit, commitment fee percentage 0.50% Â Â Â Line of credit, borrowing base, percentage 50.00% Â Â Â Line of credit, borrowing base, amount $ 5,000 Â Â Â Line of credit, collateral monitoring fee 0.10% Â Â Â Slr Revolver | Accounts Receivable Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of credit, borrowing base, percentage 85.00% Â Â Â Slr Revolver | Inventory Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of credit, borrowing base, percentage 25.00% Â Â Â Slr Revolver | First Anniversary of Closing Date Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of credit, termination fee 2.00% Â Â Â Slr Revolver | Second Anniversary of Closing Date Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of credit, termination fee 1.00% Â Â Â Slr Revolver | After Second Anniversary of Closing Date Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of credit, termination fee 0.50% Â Â Â Slr Revolver | Initial Revolver Commitment Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity $ 25,000,000 Â Â Â Non-refundable facility fee 187,500,000 Â Â Â Slr Revolver | Additional Tranche Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity 25,000 Â Â Â Non-refundable facility fee $ 187,500,000 Â Â Â Slr Revolver | Minimum Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity Â Â Â $ 50,000,000 Slr Revolver | InterestRateFloor Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of credit, interest rate 2.75% Â Â Â Slr Revolver | SOFR Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of credit, interest rate 3.20% Â Â Â Term A Loan | SLR Term Loan Facility Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity Â Â 100,000,000 Â Non-refundable facility fee $ 750,000,000 Â Â Â Term B Loan | SLR Term Loan Facility Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity Â Â 100,000,000 Â Non-refundable facility fee 750,000,000 Â Â Â Term B1 Loan | SLR Term Loan Facility Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity Â Â 33,500,000 Â Term B2 Loan | SLR Term Loan Facility Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity Â Â 66,500,000 Â Term C Loan | SLR Term Loan Facility Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity Â Â $ 50,000,000 Â Non-refundable facility fee $ 375,000,000 Â Â Â X - DefinitionCash and Cash Equivalent Maintain Percentage + ReferencesNo definition available. + Details Name: om_CashAndCashEquivalentMaintainPercentage Namespace Prefix: om_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionCollateral monitoring fee + ReferencesNo definition available. + Details Name: om_CollateralMonitoringFee Namespace Prefix: om_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine of Credit, Borrowing Base, Amount + ReferencesNo definition available. + Details Name: om_LineOfCreditBorrowingBaseAmount Namespace Prefix: om_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine of Credit, Borrowing Base, Percentage + ReferencesNo definition available. + Details Name: om_LineOfCreditBorrowingBasePercentage Namespace Prefix: om_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine Of Credit, Percentage of Prepayment Premium + ReferencesNo definition available. + Details Name: om_LineOfCreditPercentageOfPrepaymentPremium Namespace Prefix: om_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine of Credit, Termination Fee + ReferencesNo definition available. + Details Name: om_LineOfCreditTerminationFee Namespace Prefix: om_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt discount. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DebtInstrumentUnamortizedDiscount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of the fee for available but unused credit capacity under the credit facility. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityCommitmentFeeAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used. + ReferencesNo definition available. + Details Name: us-gaap_LineOfCreditFacilityCommitmentFeePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDate the credit facility terminates, in YYYY-MM-DD format. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityExpirationDate1 Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionDescription of the frequency of the required periodic payments of interest, principal, or both, and the amount, if set, or a description of a formula upon which payment is based. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe effective interest rate at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe effective interest rate during the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityInterestRateDuringPeriod Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_CreditFacilityAxis=om_TwoSeniorSecuredCreditFacilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=om_SlrCreditFacilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=om_SlrTermLoanFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=om_FirstAnniversaryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=om_SecondAnniversaryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=om_AfterSecondAnniversaryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_InterestRateFloorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=om_SlrRevolverMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_FairValueAdjustmentToInventoryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LoanRestructuringModificationAxis=om_InitialRevolverCommitmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LoanRestructuringModificationAxis=om_AdditionalTrancheMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=om_TermALoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=om_TermBLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=om_TermB1LoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=om_TermB2LoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=om_TermCLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Equity Incentive Plans - Additional Information (Detail) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Feb. 28, 2022 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Â Earned units vesting percentage Â Â Â 50.00% Â Stock-based compensation expense Â $ 6,388 $ 10,893 $ 24,411 $ 29,536 Ceo Member Â Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Â Earned units vesting percentage Â Â Â (250.00%) Â Ceo Member | Total Shareholder Return Â Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Â Earned units vesting percentage Â Â Â (250.00%) Â Maximum Â Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Â Earned units vesting percentage Â Â Â 200.00% Â Maximum | Total Shareholder Return Â Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Â Earned units vesting percentage Â Â Â 150.00% Â Minimum Â Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Â Earned units vesting percentage Â Â Â 0.00% Â Minimum | Total Shareholder Return Â Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Â Earned units vesting percentage Â Â Â 75.00% Â Employee Stock Option Â Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Â Stock options, description Â Â Â 25% quarterly over the course of the second year, and 50% quarterly over the course of the third year, or (ii) 33% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining two years. Annual RSUs granted to non-executive employees in 2024 vest over a two-year period at a rate of 50% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining one year. Prior to February 2022, RSUs with a service-based vesting condition granted to a grantee generally vest at a rate of 25% on the first anniversary of the original vesting date Â RSUs Â Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Â Percentage of restricted stock issued to CEO Â Â Â 50.00% Â Percentage of restricted stock issued to other executive officers Â Â Â 80.00% Â Earned units vesting percentage 25.00% Â Â Â Â Â PSUs Â Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Â Percentage of restricted stock issued to CEO Â Â Â 50.00% Â Percentage of restricted stock issued to other executive officers Â Â Â 20.00% Â Earned units vesting percentage Â Â Â 50.00% Â PSUs | Ceo Member Â Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Â Earned units vesting percentage Â Â Â (250.00%) Â PSUs | Maximum Â Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Â Earned units vesting percentage Â Â Â 200.00% Â PSUs | Minimum Â Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Â Earned units vesting percentage Â Â Â 0.00% Â PSUs | End Of Year 3 [Member] Â Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Â Earned units vesting percentage Â Â Â 100.00% Â 2020 Equity Incentive Plan Â Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Â Common stock shares reserved for issuance Â 3,218,000 Â 3,218,000 Â Employees Share Purchase Plan (ESPP) Â Â Â Â Â Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Â Â Â Â Â Common stock shares reserved for issuance Â 667,000 Â 667,000 Â X - DefinitionShare Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Percentage Vested In Period + ReferencesNo definition available. + Details Name: om_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageVestedInPeriod Namespace Prefix: om_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionShare Based Compensation Arrangement By Share Based Payment Award Shares Percentage of Issued In Period To CEO. + ReferencesNo definition available. + Details Name: om_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPercentageOfIssuedInPeriodToCeo Namespace Prefix: om_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionShare Based Compensation Arrangement By Share Based Payment Award Shares Percentage of Issued In Period To Executive officers. + ReferencesNo definition available. + Details Name: om_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPercentageOfIssuedInPeriodToExecutiveOfficers Namespace Prefix: om_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDescription of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_TitleOfIndividualAxis=om_CeoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=om_TotalShareholderReturnMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_EffectOfFourthQuarterEventsByTypeAxis=om_EndOfYear3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=om_TwoThousandTwentyEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=om_EmployeesSharePurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Equity Incentive Plans - Summary of Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Equity Incentive Plan [Line Items] Â Â Â Â Cumulative stock-based compensation $ 6,388 $ 10,893 $ 24,411 $ 29,536 Cost of Revenue Â Â Â Â Equity Incentive Plan [Line Items] Â Â Â Â Cumulative stock-based compensation 296 620 1,092 1,381 Research and Development Â Â Â Â Equity Incentive Plan [Line Items] Â Â Â Â Cumulative stock-based compensation 1,400 2,793 6,025 8,232 Sales and Marketing Â Â Â Â Equity Incentive Plan [Line Items] Â Â Â Â Cumulative stock-based compensation 945 3,765 4,898 9,908 General and Administrative Â Â Â Â Equity Incentive Plan [Line Items] Â Â Â Â Cumulative stock-based compensation $ 3,747 $ 3,715 $ 12,396 $ 10,015 X - DefinitionEquity Incentive Plan [Line Items] + ReferencesNo definition available. + Details Name: om_EquityIncentivePlanLineItems Namespace Prefix: om_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss Per Share - Schedule of Outstanding Potentially Dilutive Shares were Excluded from Calculation of Diluted Net Loss Per Share (Detail) - shares shares in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive shares excluded from calculation of diluted net loss per share 6,137 4,938 6,137 4,938 Stock Options to Purchase Common Stock Â Â Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive shares excluded from calculation of diluted net loss per share 1,521 1,978 1,521 1,978 Restricted Stock Units Â Â Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive shares excluded from calculation of diluted net loss per share 3,961 2,760 3,961 2,760 Warrant to Purchase Common Stock Â Â Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive shares excluded from calculation of diluted net loss per share 63 63 63 63 Shares Committed under ESPP Â Â Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive shares excluded from calculation of diluted net loss per share 319 42 319 42 Performance Stock Units Â Â Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive shares excluded from calculation of diluted net loss per share 273 95 273 95 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=om_StockOptionsToPurchaseCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=om_WarrantsToPurchaseCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_PerformanceSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Workforce reduction - Summary of Workforce Reduction Plan Included in the Accompanying Condensed Statements Of Operations (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Restructuring Cost and Reserve [Line Items] Â Â Â Â Research and development $ 8,139 $ 16,076 $ 30,508 $ 44,775 Sales and marketing 15,417 24,720 54,593 74,038 General and administrative $ 10,103 $ 11,815 34,231 $ 34,892 Restructuring Charges Â Â Â Â Restructuring Cost and Reserve [Line Items]

Â Â Â Â Cost of revenue Â Â 530 Â Research and development Â Â 1,260 Â Sales and marketing Â Â 1,884 Â General and administrative Â Â 475 Â Total Â Â $ 4,149 Â X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 - SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_RestructuringCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services. + ReferencesNo definition available. + Details Name: us-gaap_SellingAndMarketingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_RestructuringPlanAxis=us-gaap_RestructuringChargesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Workforce reduction - Summary of Changes in Liabilities Resulting from the Severance Charges and Related Accruals (Details) $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Workforce reduction [Abstract] Â Balance as of December 31, 2023 $ 854 Charges 4,149 Payments and other adjustments (4,920) Balance as of June 30, 2024 $ 83 X - DefinitionWorkforce reduction Abstract + ReferencesNo definition available. + Details Name: om_WorkforceReductionAbstract Namespace Prefix: om_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from restructuring reserve. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 - SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6 + Details Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17 + Details Name: us-gaap_PaymentsForRestructuring Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 55 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Workforce reduction (Additional Information) (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Jun. 30, 2024 Sep. 30, 2024 Dec. 31, 2023 Restructuring Cost and Reserve [Line Items] Â Â Â Â One Time Restructuring Charges Â Â $ 4,149 Â One-time Termination Benefits Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â One Time Restructuring Charges $ 1,400 $ 2,700 Â $ 2,500 X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 56 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

^^;YJ2CRS/%#L)597J[W;:;YC.:AO+S9^;[FIWI2$ M8@FASO$'>+PJ]E*+$RV3?#MR(;6647ZX%MP7RMP OR^EU+L3\X!J1WOR'U!+ M P04 " !5CF99QJB=,:(& !2' & 'AL+W=OD MG&:_?D=9MF218E*L_I!(]O'TW)%WST/]\E'(KVK#N4;?J[)65[.-UMN+Q4+E M&UXQ=2ZVO(9?UD)63,.M?%BHK>1LU0ZJR@4)@GA1L:*>+2 ;[V[E\E(TNBQJ M?BN1:JJ*R:?
WO!2/5S,\.WSQJ7C8://%8GFY90_\CNLOVUL)=XNCEU51\5H5 MHD:2KZ]F[_#%-8W,@-;B[X(_JL$U,J'<" _'5W'Q87SXS/-P.'UP?OO;? 0S#U3_%J4_Q0KO;F:I3.TXFO6E/J3>/R# M=P&U
'-1JO8O>NQL@QG*&Z5%U0T&!%51[_^S[UTB!@-P.#& = /(2P?0;@!M M]TC:\.Z89HM+Z5X1-)8@S=ST>:F'0W'1W+69QCLMX=<"QNGEM:A7,"E\A=ZS MDM4Y1W?
&ET)GZ,O=#7K]Z@UZA8H:?=Z(1K%ZI2X7&AYK!B_R[A'O]X\@$X^X MX]MS1(,Y(@$)'<.O_<-O> [#<3N6.SY:__H+CX*TKNI_D["16>HR5^KPOKYG: M()@UE)L+_JTI=JR$X)VSN'<5MZY,]>^6E)
(TN5SLAN'85G$:!=G1Z@1G>,09 M>G'>;8349YK+"M;:CBM=38'<^XD&C\B M 6#0OW(.J;PO^1S57+N 1A8"&I(H&^%T6)$L#=PPXR/,V OS Z2PUD(6W)G"
MV'IFC$,ZSJ!M%69D*H')$5GB178K^985*\2_;TW34>W:%'K#)?2Z85FZ<"=V MKK(P&L&VC:(DF,AG>D2==E% %J5+P"86L\F2402.H+H,,LPP1,EE!U!9EZ0 MGZ!J9)%KOB]V%
[[,3B"LMA&Z9XQ.L.&@9YG@F8D'X2'U4SOAI@]M385/%D_G M;8@B@^4W@NJPPG28[U PK$7K ? 2K31?V 2@X* 4DC!<[$^JR!F^GI[[R> ME S%%FC;*J+)1%WAGM2PET>6']LB\H C-
K@T'&.SC>)@"EK/0=A/0OOR\4"C MCH(@:1:,T=EV%-,TP!, >_+!X8L405FP^Z(L-/1-IRS 7A+[45WPL[R=!MU3 M&7XAEVW9DR$R9\ V/84D&[=&ZPV)P!V$06)Z&% MW[8"G1--M>N>\+"?
\0[X'YF4K(:V?4#[Y,3J8#0SG MO1N^YI!1LRQ]30@R+H,.Y:[(9)$EM0'68XF5K2I&=!XF?!,;,$,UH 7-G$0 M76))'Y=5E$VP(>G9D/C9\%3]/+-LB8,#24C'K=QA%D643&=;.W\+'A8MT4- M>PD01$Z(-
LD1^(P1VE9I%D_@ZZF0^*EPO%B=^&R:2\:;,(<-GN)!TO,@\>_ " M/,O3"=3>9%$<65!MJS!,)\]>]/1%_/3UV>P52\%J)S*;D7"6X-2:9(<=#3">
M6H<]=Q$_=^UKYKG\V>1#PB(TS%*)TEE4WLQTK,4\;/4M:BJ8K_5WA\2B-K, M/2402.H+H,,LPP1,EE!U!9EZ0 MGZ!J9)%KOB]V%
+JET1LABW_Y:MXND5H MK5:%4?'0<IT%E1HYQM"VB53IBV1L#PB8+Q>8K+,$C#:*I!TEY.T&?E1%,U M^]U&I]YA,R+YQKS&V %!"N4^2;7% [53[-ALIQ.(!^>]?H$Q1+R"W5%>.#40 MM?
7#&0[B,$C'HM)EF<6@/B?$,.W5!O6KC3U'*D<;=B)VR(@DM62;PPP3DJ83 MRHWV>H,^HS?&C-Y6WXO11]:IN?.(PV'G/.)8#%[XF+=M?S+Y4-0*=-L:!@;G M"?
B1^Q=8^QLMMNT[H'NAM:C:RPUG -L8P.]K 63?W9C72L?7B,O_ %!+ P04 M " !5CF99B('9X=T" #<"0 & 'AL+W=OBP85Q,OU[J\\GV5YE 0U1,E M\G8W90)9"Q6FE$.,XG4JBB(_'T# M3&PF7N
]W;BCRUS;&WXR+LD2YJ"_EC-I>G[CDM$"N**'(PF+B7<=7$T#; 4N MXAN%C=IJ(YO*O1 /MO,YFWC8$@%L+8BYKF)CULEP_*I-O69,*]QN/[E_ M=,F;9.Z)@JE@WVFF\XDW\E &"
[)B^DYL/D&=4&S]4L&4^T>;*C;N>RA=*2V* M6FP("LJK*WFL)V)+$.P3A+4@/%40U8+()5J1N;1NB2;)6(H-DC;:N-F&FQNG M-
ME0;E_C7$OSE!J=3J:"9^:E0(9N"",\!32W7@JG1$)7.>@:4K8. 0>O48^ M4KFYJ\:^-D-; S^MA[FIA@GW##.'LH:6E*[&=7JI5WO]O; MKKLK59(4)IY96 KD&KSDS:M@@#]T)?Z?
S%K3$#73$!UR3V9FR8"4YN6;.DL? M+E!))%H3MH*NM"NOH?.R7X=U@sL8!V-_O9W/L:@6:+\![9\'6M4A(BN="TG_M0-8%7'G&6R@Q=K]GR,?C6M!Q QV_")HJM>H&CG=
GJ,>BFA!#AK(P8L@S1=? M:<(SRI==I(.CI(EH M9Z8BC#L+]93(%O5E0WUY/O7^.KW<73!A'(UV@3L"<10,]_(&^-^VA<\G/E*T MM>4)W%V1W>#^UM9KSSU?
B%Q2KA"#A9'BWM!XR.HH476T*-UN?"^TV=M=,S?' M+Y VP#Q?"*&?.G:#;PYTR5]02P,$% @ 58YF69/[1:P"!P 62< !@ M !X;"]W;W)K@;K=GQ:9CH;;H2;23_?
M1LFQ9Y!4;MWI)+/G<0YW+2_*0ULV3 M++Z6*R$4>MZL_)VM%)J>ST>E_.5V^3EE=R*7'^SE,4F5?JR>!R7VT*DBSIH MLQX3SPO&FS3+1Y.;^MY],;F1.[7.URI MZL9X+O3#R59Y]1
M)>5!RJ_5Q?O%[G*IW<%/()%15:LU4?ZNS7T3I?65X5RDP5^MM,QZG)5.8+W>UB@68J54*7 M@"]17**/6U&D55>6Z/67/-TM,B46OZ"WZ,LL1J]?_8)>H2Q'GU=R5Z;YHKP9
M* TP%>5XWC1\=VB8]#1,T0>9JU6)$OT "R ^=L=`COBQ3L(I$^28B3OB)R) M[16BWAM$/,* YYF^/)Q"2[6^\D@Y[*@M9\M(?OD]B+?">NH7X]1#(X
MLIK8KLMM.A>W(SUSE:+8B]'DYY]PX/T*)75(LGA(LF0@LD[ZV2G]S,5^3#^4 M_4-@4 =6J\!^0G0!#?C_7E:;13U:$"ZJ-A&<4:(@4IL5!3Q(#JA.@K]DT+?
M66!36:IJGBD8/66A#DL5#DB4#D76Z(3AU0^ L-*,;H%XX$/AGW8\Y9V;! MV2A"B><;!6>C_("9J,1&A=SG&"ZX*0T="K]O9!EB;;%7&8*DAE:C4:<>(9* M&Q1B/S1$VB
2>P2'X2R9VCJEFU\T@;,W@ITF*^0MH=:>.ZUXY\6YDKJ#LBJQ0XII%1>C9/(VEH M#,/81E'/][A1>S:*L3#TX=K#7FLE/:?F6;H692U8[SF^BJH.05_HV5\)9@Z0 M*0 C+#2'9 S ?.9'U)
,P$+FT9[QAL_W9/*R+70VY=JTX7VJ!GI:J&X!Z< M2QNRCG0/>]24#L PQ^9L" H(Q2;TB$8CTB/=-)*)T[IGZ72PJ4UY8#"B?T, M-/#-(@=@/@DP-H7;,(PC2DWG N%\&GI]E=ZZ8^QT?
Y, _[5D6)X&R MJ?4 ;PGEUN"&<$R7,3.% [@(^V9E)! .4W(^R+K*6V.*W<[T?:Z$GBV5WOW- MY4;4=2_52A3-C32P"E3[W#'O;RKTE>J6Q$@'@6.!%5OT#.#V!!G%S80TA+:,YJ/_ Q<\?P[OR?5,^"#-
-2@S!\%5D:0=@Y"KL6=!)Z]^(V[\! MRA?9>]? X[F[ANQ;TF&8)1V" =(AF$-Z:^.(V\;-*K4EVE4'H5F.]*#>]FI3 MDU]2#<1V6KZVW]A,B0UC461-^Q ;#K@YZ$$V&K">E+3VCKCMW44I<=4)X.F@
MI-@P,"D &Y04B*T.*:WQ(VCIV?_Q6ZND.. SLUPZ>YZ4+9X4+9D*+9N7[16 ME+#O/J,F3A=[<2<,R18/RI8,Q=;MA-8-$[<;=@T$WSZ]]JAYVC>%8-0W=[$Q M
/.C*#0WNP",>\&9'^GJ;#TP"7[XO)HX;?3%13>N]O6F\(%G!J'ND",,H"T[TF ,R/>-"SYR"M R=N!S[3&E"T9BJW;&>W&B+HW1B]8?1J&KP>LCI[ND]L'?UVT_&_3M\/<7
M_1A?)X>WO%KZPTMG']+B,IA4AS>XSI<*+FM7U1ZD$K)3?UQ M)=*%*"J _GXII3I>5 V3'(C5Q&9M [/]]3U.0LK%@T8M+Q [W_G.[7-\ M!EIAOZH<0)/GLN!JZ.1:K_JNJ](<2JKNQ
HXOED(65*-2[ETU4H"S2JCLG # MSXO=DC+N)(-]TDF ['6!>/P)(E:ER65_S]"(;9#QW=V&Q_9,M=FPTT&*[]$ M*>C9ZDGBRFU9,E8"5TQP(F$Q=![_J1K\!7@,X.MVGLF)1.Y$% -XGTV=#P3
M$!20:L- \6\#(R@*0X1A_:=PJU+8[C_O&-_5^6.N ?+8#8+& M(#@VB%$XP"!N#\+4>HL8@>]V'3F-0I>[6N5>%&U--DX$46R(-&MG,0U7]RAKK MQ;C1R51+?,O03BJ8&K,2A#[:9- (]U ,$+ 83D@^
Z5V2" M@606^_%Y^_LS]BX6HZU(L*O(8W"6< JK.Q)ZOY/ "R)+/*/7FX>V='[-^^2G MO1\4(VSE$59\X4M\.U&<:N(]3T4)Y)^'N=(2S_N_MM[7()&=W7P#^VI%4Q@Z M2*Q
;L!)WOSFQJY;6^$O23:^)-GD0F0'+8K:%D7GV)._\#)I>G%MSNF-K0\U M15Q1F*MCD]P&W?O(&[B;_0I;8%'L]XY@8PO,1[V%O4/E:,LW >EO4'CI[FHD[T9%, M3S'^L93'IYB@=\0S.<6$OF_79K^-
$"7)9S7$*#]R:Z_KJ:'?;4?&AFI^.]A_] M_LBW[(]QM*PGP1_T]5SZ@:+&JAIFYT#@:58\Y MCL<@#0#?+X30NX5QT [:U-$&W# 8'T !@ M !X;"]W;W)KGO[ZD3A8$8+4BY+WD0WRZ6[PE]Q$D MW@,
(W7ZNZD_-HBS;Z,MZM6G>W"S:=OMZ/&YFBW)=-#]4VW+3 >6AJM=%VWVL M'\?-MBZ+^;[1>C7F<9R.U\5R_+!\7;?^+\=WMMG@LWY?MA^V[NOLT/J+,E^MRTRRK3527#V]N M?
F2O=9;V#?81_UF6GYN3GZ/^5#Y6U:?^PT_S-S=Q?T3EJIRU/431_?-43LO5 MJD?JCN.W ^C-,6??\/3GK^AZ?_+=R7PLFG):K?Z[G+>+-S>3FVA>/A2[5?M+ M]?GOY>&$9(\WJU;-_O_1YT-L?!/-
=DU;K0^-NR-8+S?/_Q9?#H4X:<"2,PWX MH0$?VB Y-$B='AKLR1P_%VM?Z?N8+>YN MZ^IS5/?1'5K_PYZN?>NNP,M-?V6];^ONK\NN77LWK3;S[CHIY]'[MFC+[III MH^J2\U#-
/BVJU;RLF]$ZK?=LOT]^O[#IMC-EVTY?Q6-H@_O[Z/OOWL5?1SPQ&\?3X"?N8(?JW:8@4TF^+-IM5ZW5V9^P,% M6M_CK7^<=^?17=G%*GI7+.>C[A2FQ78)'XFZ@#6;[=:[55>]>?3O=E'647=L
M73=?]/WOJ8S^63506?1PU/OR83E;MC;(N&/Z2#<_TLWWJ.(,ZMOR<;G9+#>/ MT=MB56QF952T'?SLARAA?XUXS#Ē$X#-FNL?L;U5/=US(/(]OQT^GA/EA8F*'
MW/LA+$ZDD*D=I_RXD4R%':2!H&PRR:4Y+JM&R%&26"-OF\615TVKP85"P7O M'Q2OFVTQ*]_<=)=(4]9/Y MI7S"'4HI$RI*,$T$9E&:'2G-4$KW@ZJHVN[_N67LIXMFQ(C=.)>T=$
M^\OREN.RE0'%CL?RXAZG*OVA.9. /H*9HVM#,-R:@H,VHB,(L3 M%ANM&Z.L?-C49;%:_]C\Y;'H)%_O;#P5RU7Q<56.NL?5J"E6W3BDG.WJ3AW" M=[Q#"GOXY@SQIOAQA-
)$BJ:&G("F2FD3=6)*,)2H?Y5M]-.FZSB=]NKE,WBK M.V"' M7]W38Y*Z["N0>X\8P L%HNW$#4).$Y/UH>],J8[Q-X9AF M!;ME0"!@ET%1F%_&C,1GN,;_1L<,1P^^\GTI#WEFI$D5*9JF0K/I-
(*>X8]> M9)CDJ^^$>4]F2L5\3XJF2-$T%9K-J-'S#!?TP\93OK8>L42P/'-I(U7TI&B* M%$U3H=FT&?G/E]ON7AHCHPA LTL>IXG+X<1[_LC8O44"6'$FA3N@ M4D#@B$MOV
5$Y3QA(COS_#%BF^%]6ZQEV72X8IZ=,E]2RYAEB5M9RJ2*%$U3 MH=GSDT:CX#^]#%#;)# -Q]PY&*MBIT.PJ&\'.<<%^Q6P) MCAC<32#M[ZV H4RI2-$T%9I-H+$1.&XC7#-
IPGVUSV(62[?'4.KS^V%)%6E2 M385FDV-, ?[RI(@#W38$1GWC+R$A= 5(T->@,-%5.FRJC]CF!VN> VAE')#>DX3%[G0P'R#C(:PXC05S9WJ! MP%'BKDS34-
0D2 /TC(SG1L;SJV7\Y8*1RGCNRWB11Q3BJ0RGA1-4Z'92VB- MC$]P&4^^^#(!%'[NRLLI?E2A=ZM!..15I3DV%9O-F/(4$]Q1>;KDFGCAX8;1O M-W#IKDTB3:E(T305FLVS,1N2/\YLP%,%,PN8#H
MS(8$\ B89YGBZ8)OJ4-R*M*3E?8G$5_5,N+8$ M?AS!5]':$D-.0%.EM(DRKD1"X$HDD 9/F><1X;F"R2!U)4C1).6*V'P85R(A M7UR0#%Q"+ I@00#G$V^D+/S%!=YE#V'%$R&9.WD !*:.8:>!
MF%&>LNS<12^,#2"^96G!Y8J1:GWA:WT9)YXF)$VJ2-$T%9I-IU'[XDJU?_6K MT,#J_MA[2@O@=7^7- @HR]W.0"K0J=!L,HQ %[A ?SF+#4\ MTI2*%$U3H=D\GVP_@.O^0(L-)!1849"
[<]N'(+2703CN:[/XZ007_R4TNS": M75RY[< 5_B:>*KA;^2(]];8:($VI2-$T%9K-K!\ A?\P_U-X:MB;\A&*NHO M)U2D"345FDV%D?3BFGT"\+Y$*8ZGPA?'[AP0:4)%BJ:IT&SZC ,@!FPO$.AK
M"E]G3WCL&@!XXN!N-22G(LVIJ=!L:HSI('#3@<+5%+Y=,$]X=PWLAX"A+W% ;YFA)0ZDF>"W>O%#Q7*!ND:(H435^NB,V'L2XD;EW@ M[ZH+D!W?8,@3'KMR]A!F^3ONXP: 8G$N8_,=,9?^AZ
9%GLE99TSI\435.AV5P:2T&&;EDXQ*63P%P\ MY&M*_W4#S]>L!?$PCT?$T@!O4UI='D$M?DW^AKXNC!U[VORB%?DS2I(D73 M5&@VG2=
["^(JGV*8)'T]SKT]S/#C"'XNT^XD2+N5X$NH>VG4O<35 ;#1%+ * MGW5=UMLM"T\63!OIG#TIFJ9"LVDS3H#$G0!\,AD>0_C:7603SET*LP&#+A^*
M=?])3R,"@8F+IH&@[NI*13R19QX_1G'+H#GWTH-3(!USU/M09J0'(:$!J %&HU$B-1$Y# M]JV#U :.'GKEI[[PA-0&:5)%BJ:IT&PZC<).KWQ'X)H=?TE7"J2^7$Z8QRSI M.@%2-$V%9C-
K/($4]P2&SZVDOF/W'V"\&2AHZ\!&15I1DV%9I-A1'UZS4)^ MO#>1+#!(@04 KNXGS:A(T305FLV?\1I2W&%NX9GHE]2V!?,+=T0&>.+AC#Q*#]%/F&P CGN7>&]!XKF R2)<Q2A[BOI*%Y4M*DBA1-
4Z$]UGU]>'JFJ_?NB_T?KXI>IW_P=02P,$ M% @ 58YF6<_2)5 A" E20 !@ !X;"]W;W)KRAV@?5:?)%LI8F!;/8.7:#;!I?;]C,CT3&[DNBC MZ+STUW=
(V98MOB0&\B6QY>'HF2%GGIF1+I^D^MFM.=?)UT00X_MPIG1SN:18>?]YK_\T:#\;..%H >OP+\&X!'B^@ M@05DMX!80WMDUJRO3+/EI9)/B3+2H,U\L+ZQJ\$:T9IMO-,*?A6P3B]O9%O! MIO
JN=-,<]@@GEU,$&T 6E[/'8T-\WFE9_IR:=%DEL*/ (1VS69@_F_<9WS,3O:,DPI M0J.-]4@5&Z."!=Q(-$ME-[MFH.SHVY<^'<':4Y&4%TA0I4^!$6!X3%VQ"*5G,X63H&
MLG!!+HIQ+'N$R#P0R"@=>"R-XKP^VF+#8' "&K&%Q-L"\D>^B_/)IJ];4Z MJ*9D4:0C[#ZQ+"T"/D9'+(RBZ&^5?!2V-(+*S)NM5205[Q8D0,BIW2,U"T MQP&<>,")HSA-
(CT^;A*A?;*3Q/[=B8USM!8X=3,3!['5T#%;.VY-:_I>)0T-@$'_ P\1QD-(XVGQ1% :@#;2(:KQS6K'W@ MW8AH "EPE/%P+=B]J,.D@Z*T?"[KO)>V4V<,_(RBM+:\+DNY->P,^9R+1W9? M>_/.3LMI]*;%.
(/[Q.99*(>C@1U1G!Z_O1*O+LE-$2X6Q1B>APSS-)09!S)$ M<3:\57S#1+7/V_TIDGK-U>Y8>3&[;(<6=)S*/5*4I@' R>B."D>-GW#7H([M[E+=%&5'SMH!=,4PSD(Q.G BBI,B(%3;
<2UDW*I5U4E=SSEJ]$P+4N 4Y) M48PK(X\8SOS \<"2^!66W 'WG(5RJY3I_H[RBP\]]C!@3O#8\3XQBM)%P("! M*'&<*/<&/#&E6 NDLX?[X@7KDH"Y\BM?<7"I.120 M'K;>8XQ];
(>R,3Y7"B,42%MX($4<)\5_'>BEKSY?VWF7[J8(S<>LZ!,K\D#E M@0=:Q*^WDZ]V85[8U(.G6+A.]LA!Y5&00+; XGA>)@;^D?\K@WD M>VD[|<) DCA.DK=;5:Z9R3EGU8S80YZ+?
$R=/BE,%J$8'K@3O*=QZ"'/B+I M.*3+\)%S:=&0$\V=+.D3Q @'PV7@4!SGT.],[P">A)S39M(Y0!H#]\@M",X" MW(\'9L6OM)O[,/^PB_./YJP\BLJ0ZHLW=+QV>#B68C?F7;&LN-- Q).!9DEZ M5L2O1
O-QUNF?U'Z/GO\]T[:3KTP<#5YM:DM.:]V/NC,# FR]FYNQ%4I]@7(MKW>WM\EF'VI>O[@,C?%BW#MZI%!*,0ELY\#D),[DIX:(KMO:5A("W5O0!) MVGZR8&-
M_W,I.W\!2%PZS_,,.]:X8H'P(D=3Z3CE'\+K.*A\I].+VV7V?+%(MQTV!1RRV"T,%0%ZO "H.O;NI5: ,'9\ZJTQ#/+(:CO'[AMHP,50&)M[8W;X8/;9HY6/?\0;2MV29#H%P)67D-
1F9Y<\8GE&0KLTT#R)T_S9G\3@40-,VB=U,P,I:=EL5RN31PN+L3/Y.VDY],%03)%Y-6#Z$OX1^ M/&F?ZFCV',@3;G% YTY<>832T.D;R@<2+Q_&0/N1M1>D9PR=961=LTC%>S6 MZ$#]%+T]:-
KA$<*A>H.@?W-11*-EQKFA]%[:3CTSU!(T7DO@8)(2:C0U%!XT7%'PKJGQ57^TYC-PHU MST[?WN=1WS#=P>*!4HB>O28.EY6V#=7IG(UA89C/V>7]YJ!F-T/_ES:B;R- MU'-#'T\N/7ZBY!')\'A,-
CMZP:/AZL&^]](E]J#'TKT@K;FV;Y2,KG]! M%S?]&S*#FOZ%G>],07G1@5TK4)E^GH.35?\.3/]%RXU]C>1>:BT;^W'-6<65 M$8#?5U+J_1=S@\.;2,O_ U!+ P04 " !5CF99>AV 1>L" !5"P & M
'AL+W=O9_W^, !G_Z6LE<>82S M6YH0/C B(;*>:?(@PBGB=S31*Y9498B(:=[=;]*,81064)J8CF6US13%Q/#[MQ=]"+7V:BR0F>,$ S]_4L?
$Q)8#AU<"XMWMSJ/2%X%>,MWQO#%0F+Y2^JLD\'B6VA!.<""4 Y)_M&_R DT09R6W\J3R-J0"]\<[JTF1N\SE!7'\0)/?<2BB@=$U0(A7*$_$$]W. M<)5/2_D%-.'%+]B6VE;+
$'.!4TK6.X2C4GYC]ZJ^['V*< IP*<8P"> -P* M<)L"L)@4Z!5 :VF0+L"VDV!3@5TFMZE;@5TFT;P*L KRJ%\?L7#'R&! #ZC M6\"46KJI05%!!2V?>4Q4K2\%DU=CR0E_@=
[!AH,%9L5[0P(,1C$/$LISAL$M M>%Z.P/75#;@",0$_(YIS1+>-X6,K1S,H(HS+..X)^*XX)$2$7$P)B$.-?S_ bM/_'=X4V9?P1,8G;)_%Q M\\V[&GS2?/,Z?-I\\SI\]GJW?OJAW *P:W? +?PCMU-O5X
MA@(\,.3APS';8,/__,EN6U)U579)L]$ES<:7-)M#Z.^7\1E>[I46[L%!MT,:_=3H>M/KF9K\J-3(7PA8\ ME(UT,L^#1[*Q1@;;=OQ#V4PCL^4'P^T>ZN8ZG0MM MKU/KRJ=A[IVQ*6;KHD'C(*
Y$>7'IEZM>\#[HO4Y6A_:O:FM69_)GK%L\[?9 MEPVG_-ZN8\)!@E%1IV-D:WD(,2SG6Q[56!"BDVA*PN1WA 1BS(*/QNV-Z_98V\7Q\ MHG]UM9M:#EC!@V" *-%%['WP$($,UTSO1/,-
NGIFEI<*IMP5-6WLY*.TEII M47;)QJ"DO+WCE^XJRC1SE M]J7LM31/J M!=>%0E\X ?)OOF_,>KWPI+<.!X%[]$9H$MRA, BG [Q)7^[$\297>)?*O$.' M5[3AA!XIJ3&
[5'4+G5Z&VN]FJ2J<0NR9#T.!/(*7O'\WG@>?!I2GO?)TB)[L M:@9H'!QF]^-S;,0BHM+_'W*K.PS,,%,P(#;KQ6:#G.^"W]\@-PQ]2V[>R\UO M.K4GD.8KPE??]8<29.ZZH$*IJ+EN6T6_VC?: M5=M?
_H:W7?H1RYQRA1AD)C48+8*" "%&@ &0 'AL+W=O M'S@T9J M.SH_Y7L?_?FIZZ+15GWT(G1-(_WJ4AFW/!L=C?H;G_2BCG3CX/RTE0MUH^(? M[4>/JX-I2]D;98-V5GA5G8TORECY2GM!Z7O ?
K99AX[<@3^;.W=+%N_)L=$@& M*:.*2!(D_MVI*V4,"8(9G[/,T:"2-F[^[J6_9=_ARUP&=>7,G[J,]=GHY4B4 MJI*=B9_<\A>5_7E&\@IG O\5R[SV<"2*+D37Y,VPH-$V_9?W.0[?LF&6-\S8
M[J2(K;R649Z?>K<4GE9#&OU@5WDWC-.6DG(3/9YJ[(OGURH47K<<(5>)RRY@ M00BG!Q'":D'<\>'K,\HZ_(.\WOY!6_RW)U;&X:BMMH:41-[BI
,08Q\'OYB%Z0.E_NR*4#@C9;0"5U^O0RD*=C5K2Y>_4 MZ/S"XZ>'[YYPKV3P;V3IZ1_3R*?%+3;S*.I^((\"5L7 \CC@RIU(NX(M-*)&T5=)B*W^7<.(3XQ,'^6!1&20@6\Q4+_F-
Z,Q5OG2M9^K7O%N*B1/5I2CY'8._M M]<6^ "F*+BA1>=?PQMJ%5D?RTN7K1HUAF%UA5#8N/:,(R/+.R". MD09BH76PB 1Y:0/Q+XLVZAA)1(*9C 1/&4FF(QTJHG6F-1+)1=R* M(%HC(^%CG
WE>K/HB#4H+F"))D"VV2W@(']:&(STIH+E2?_SAY>SHQ9L@:K3W MSYWTL!*BO!+&(;#(%()V(ZWXIPLP_4H"5,Y;+:?BO?[U3-H54\3)A5 BH;C(F';-XRF0B-
5FJ49M;PZM7TY4,%A\^GK_I[V_*GXH+W M/?;L85RIBJ"LZ)K.<*HPFN@"!9_\FAZ)>5;Z/3+)LW'R3R'1=](0Q;"-T>N" M]/!#?])7&$/?TR"S 1L'>0'DEM7M &H7)M3^ZE#]+_8I
M\Z8K*3%@$U)L4IJ@N!H:/O@:KG#VJ/W4 U=Q>T&<.XOJ /@:0:C$UP+$NC1 M3L-P)(-1"-A C.;!(R:8>(B'-YU*:S,4\)U)90AC3-E3.8X*7)E*?)P]A9R-O MJ492GZ$F8+&G\P0PCUV%H8(M-
3&\+5$R[ZJMM%92F_PT/1@"/(8O625D^>% MPV9$'&GE7"K-UT]&?YQ,7E C@P1#U>G'3)LM&E%!I I4N2+IUF;N:S?;8R8.^^YT02JQ1 1.EP@RFZAV.;D:5'X M3J7&WME6ZC*QL6C-.
R)GE3I3$0W>[Q@ M X"[L'W:T1QTRWR142D6"'(>K0N%NQC92A=<^.B@B8;1>)(1N*ED0Z,DIQY(M\]02MS%S0WF_<442H%<+%W6R&FAL=*8,MBUTA!5J=!ZB\B.@/&L M1
X7,6.:QP_JMJFRML:M(3(T!%%@\1]SF:*$BJH;+!LVKX.:^Q32PZT'TR*7 M!"'T09*H(,,6 U)\X PH)=7%1M!3L]C[[\1/148CJJ&J"**YE<92OD9QQI7W(H/TM^B!;Y_?R7VTH-] M+))D*H3#;[N
%%L,.8A7\0LO?Q!*IDVA*EBG%!%(&*!TX0? M26Y/BHD]<61 A1 _(;\4Q@>] A,D\=:ZJP0%7.=Q!/B>L *-Y[D)YF0QZ8,Q M@<;>8ATY2@ ("GR*M UE.$>/5'2,8/C$'6,E3FC)PR^-%;M'B+P2[82J$7AB
MM ?)<65.]JY0J@SKLACJ@;KHAE,[B!8!U=0]<,[I*AJ9R!=*#;T2>UBOEM54 M*0 X,X:8^> ^BJ-9/XT.VBG\C)22#A^Y_1*#/%)=$>^@3X*1R8_P(P_N&JB4 M-*ECY]K8=^_3PSW&
(":)I7<^FJ);CJGLPB.IBV??37/C\Z7:VSS.3C%G<]@ MC 0^\ %^]Z&@V*"NI5/2'B__^>+BXWX^@+&_03:*WIQI/F!R!*$MUEA[8*!% M&>:"R$,5SU #SFCXK)@RJ,/(\JN@$FJC-2YL-L:JC??
\$1'4Q9/=)L;&*D4 M' O@A$!'JZ$U2.W7=O6Y>XCHM0NM"SKV\SN&ES00#">7,?.&5S6]S[Q3W$\V M#@_YM)-U\T"BF\Q*0>2W!ZI,@_-::3X'IADU$='ZH;;IG2V?W'4HH#)E&>M M:& B%?
KW%%_!#X_)^65$3>T.T\LD'=K0\B<, ^\:-(%MT9<,GMG7 :26>2 M\NOG.L\>#(G3ADYU)3>\NZ'4=JM,P]UF67-!H]OD$/:3 *.46L)6/I(WZXBA MB7'%I)?HD$=PZQD\!$;?-RC$I6'61-
)6/+YQ&^S55^ANRLC)+< 6:(3-B-L MUO57D@ARI98QI[!(]@(V_-79]#IDZ*0/(?ZT33S')7 D0/7Y7-&(E-+W*!A] MI5(2A[CDFK](4?_$1S"B$'KYCB/RY%_KT@28L>0I#5AC-J>5FW7;(Y-_NB]J
MB<&&G.W?LNS=_'2USPK5W'=$!;.C#+8]%KEEV3Y.T:"?4#/:&V+#*C*OJO& M2)!W'?N3=]"8J;C%N"Z0W>J>"#B]PX.W23N1P%3L>H5\L/%=H%%^P5_:+"
MM>D3P7!W^,!RD;XKK)>GKS,8SQ8:M6-4A:V'TQ?/1ND4UE]$U_)7AKF+T3\ MD]XB*4\+\+QRB$6^(7#9Z?S-P-02P,$% @ 58YF621%9FZ&!@ XQ M !0 !X;"]W;W)K&ULM5CO]LV$/U7"]H&\")
M'2=MDC8)X+0-%FP=@KK=/@S[0$MGB2A%JB05)_OK]XZ49">QLP7;OL3ZP;M[M]^[=D'/+ZN.!714N_=BTXD[FU MW_CF*C\;C!D0:Y#XN:WI#4[HSOK<]!'Y(-UZ\[[Y6_V; MRD-Y-
C@>B)P6LM'ALUW^2&T^K]E?9K6/?\4RK3T\&(BL\<%6K3$05,JD7WG; M\K!F<#S>8C!I#281=PH447Z009Z?.KL4CE?#&U_$5*,UP"G#19D%A[<*=N%\ MEHHA[$+,5&'40F72!#'-
,MN8H$PAKJU6F2)_.@(QU:CK/5]D7Q/MO@^$9^L M":47'TU.^7W[$7#V8"<=V(O)DPYG5.^)@_%03,:3PR?\')73)'T1_!UO\;_B4 M]W]9JB=];T8^V1/_/*;X3!F9H. $E?<-Y?]
6.&MPG1&Z.7AQ9<0O]H:J.3FN MY,%0A)+$I3+29$KJ=M7GVQMFQC003ZH:P^*I+?;'NS_%)>S]CJ1#19BT#U!K%.#! M?AHGPPC(-W,/9AB]0I9.55WFJ+ *I:#(?0>.7U8J@([$[WN+"IH[!I@USJ5^
MH!NIFU03!I&*S"GR7>\)]VN'8OP#,EST3>$#6$5:7&..E;C'#=7GL]90:)6^ M4^'IZU0LGPT=BOS*9K4A\D;?;1'[R#)%#0"R&>Y5/!5[5+2"48$4ZRBQRU$]F M?=E+J)39I_FTE#I)RQ>] @S+I(,
(KN:R],=A5(*@%5?%Y1HKOC61H,@4L@;FT M&K6Z!S ..:IU5:?4T;H>8!=(YAK$^D7-^1\@ZI0CBYC,)$TSJ33.M<&]S"J MI-(1.E+E+J$P4&A\,4?*FT[FJ]YI7S[S-]&-PI_PWMCV+K)N^Z^ $O
MONUG*" N[X9R2W[B(JF1AV3'^2,O]\VX!R3@>APQHP@) B2TAV3U8K#T6=OX MP,C0L"[1$JEATLNT=<+^ [+.@G7^I; L93ZQQA6,&6 ,CN%QS,CS0(P(7 M5N,<#U10/K:,6+VZQ$ZPRPV.XSJ?
+%9;0UJ'5%ZR9F*7-7*4>T-VI>2$V';979:PH#P#OM-KG:WA;*^1![U6$UM[%O MH-%U37&S+7 /[KC??.RN" 07;X9<@GY/'+8D^:TO]N],NX("R."3GX ?DQ4C@=S5'H-2"'O;TBQ^.)_M'[_R]$Y-<
M1:B[". Z)Y\Y-4_'(\;.\ G!IA&WNXBCE/GF@;TI.H\WK#R[7QT6H8NF)>% CM0_/BM#/_'G-SI%,^@;MG_9?\-/TX;I:GC[_L7$4"JK2M(#I>._.H]0!C M*7Y2IYM@Z_@9.[(+>9!&UL
ME5;;;N,V$'W/5PRTBT4+*8NEBUE!0.YM&B!;C=(TO:AZ ,MC2QB)5(E*3ON MUW=(7>*T61=]D4;D7,Z(!IZ;6N@KKS*FO9S/=5YAP_1,MBAH MIY2J888^U6ZN6XL<$9-/8^"8#EO&!?
>9NW6[M5F+3M3T5?\\E+P1L4FDL!"LLK[SJ\O%E8?:?P M*\>#/I'!9K*5\NO}+&X\@(+"&O,C?7 Z+7'6ZQKZXA@_#GX]*:0UO!4'KU_ M[W%G7+9,XZVL?^,9HJ:Z:U(,"2];5YD$>?L
AG\3ZRV6MW1,.O>YBY4'>:2.; MP9@0-%ST;_8\\'!BD 9?,8@&@\CA[@,YE'?,L,U:R0,HJTW>K.!2==8$C@M; ME$>C:)>3G=D\X!Y%A\!$ 7=8HE)8P+*XGAN*8/7F^>#MIO<6?<5;!I^D,)6&
M[T2!Q6O[.2&;X$4CO)OHK,-';&<0!SY$0;0XXR^>THV=O_@_TBV5;."6L"IJ M"Z+<5'#KR$8%OU]OM5O_XRT">O^+M_W;$;K4+]Q3,XYQ#NN&:[G<(=< ,CRVEG?&^/H&6G*1R\
[QG4Q(+:K)*_7@9PM)/R8;P1$D(8>9'439$&?4(;>HOEQ8VI1HO(Q)2 MTH^LD&5^NLR(?'O66FKO4;E365#,$]N:]X72+Q[4XP5]QMN4U-YS2O7;U>4VW M)=%W-1N+35(C.V'&6I(?
H5E_B+;*)4C%S4FQ ".=BIHPM2>8Y DFA?5HD(^ MI@>^\@&K@]_ ,%,('44T7)><3*2"EBG#*>KQU<:!:5?H648G8UU;?#X<*IY7 MP&W$7"K;/J15C+T]$BV%PWTKFY:)XX=W:12N/FJ+I* ?
#BEN6>UR<">KGL'G M<@#GJ/'[N.D4]T!OV*(+NA/\KS[L&*WHE.7&1A3X;,@4FK[!;:G>0S +)T^V M;Y"5!M4,GJH70P;K9"_TJM)T"A.W\$D=JR8^,$ H?T"RR 11(5^[Y& MY60X8+?
U>CD9.B)$65#:-@B-;N]JX'=(5>Y[G:G*8V6I&[@L9G#W0H!Q\V_S M%G;0!Q[PC8/@I3.',IV&I$F9!1-I/8UA<-()E!@QL.=T\#=;_),EGP3=HKL2 MU,?96V?S _2G2MVZ3Z_RF_

<31B8=+"T$R<]*Z47BL-]\%0<]ON'Z=!&D)L&K*7,.,534QG$;:7I= N MKVN^1IQW CO8({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|-WK-#%G#&PU\]'XUP$E%HMP[@[<2Z]SE-:^XR@2[]QEPH^NE5D(Y M>SYP\$XV@ZSU=!T\)<]XFK&/6KG2LG[\$\8>DP M8LDP&1WQEW:AIMY?^HR_3V;!E?R'4S9$"%597XQ*6JBA?UY-;?.()?^.L10 # Z#(#]Z\PN>28N^DO:RZQ$__+5BW@R M?',DO%$7WNB8]Q]2\JBGPSC')^RY'=@-MV7D?]F[;XU<\-#31$__+."#97CZ]>G";Q]
(UE\T96N50+5@D4MS2L7NN MV* ;"H1TY7%]EG\W7/&(?1D/M,G[#,<%?"MU[32|7DEV-+HEQR*?,,>?3B"4-/HW,E=]0C"3U!=MH!/GS0 Z]U0PMMP=>*L/K)+ M!$1CL MG*-GPIO=9FV+@!5 ;-E/?IUN++:WK\]Z>VKTO!I$?L|+1A" PPW:TR@YG=)@ M$B6S:>_N211E":S\-O[["X 0]\UTD\H<$LFB03=H40?>!W2!&L)<*[.;.= MXT9X]@U:$ ./4JVT1*I@MP9Z*N0MN !5C)-Z/HTH,S(C)V%?3J[/O7K6M'Y+P-LH JMT(,2Z: MBIN*1BLZJ8* .#O+\D1+!(A|-)46!AJ4-TJ;)H*AE2&- "=GBNUD#@9;\T2-& MO=0V8B5,-%0AZ9#][2DJ'I9P*;!'],VB:Y)+;>4FW>G--@(H+%7X?]#W;:'D M'F2(VW"/AEH-U++!:-);X).J(.2-UV 1C[%&V,(?I+>;J6F:\#C}>&BJHY-"!* MA($"W6#;"C9'M:I'JCG0L_ UVD@GJ(:*@SC6I=A+ E9Z@DN./2BA=[@K0 (6 MK8RT5'Q5Y!OQM "WJI-'$W>QE7F%T[9-"JH84P<>?X8'%DJ]$2"K$Y<'-!2*G8+!5C?ZX\-VF MXY12)0O'J7VN9?H3MTU>^CXC#>0S-76D'I]VM,U)Q7WK^^Y805])AFGO@X(7 ME#'MN/4>1]BP]X5$_QF:PSF;LM=/7!XXP. S&L93]D&M$!,J![AVQRUUFY3> M^!W^G-=WS-J)48E![UXV0"DI!O%I-!U.>E_P+4QQH=@HQUB<1K,X M9GB9G/;P92/QR9BSA=:Y94D2I>CE21Q-3^.V6\L=Y" 9)(Y&*;7CT2Q*XC&U M7M-@_3M(K$@ RN!/",NPF[80?Y.AILC!QESLFFMOOJG:.L?|_V5]H|$CD8- M22=E2[,QG5F"FRR<<;E8X8:R] 72X8QQ!L71<#SLW1I=@$?D,LC9]"DV]>_ C M,<[*3;GE_YF,=<.P?MAB8NA,&2 JX76;O- &W17$$ &0O 'AL+W=OA- %4OVWG5-N XR4TNFL:(T]X/%_<#M3NK)E7T]!Z5F7:U)CI8C9[-FV4MJ/+\S1VXR_/71>-MGSC*71-H_SV M-1NWN1C-1\/ 9[VJHPQ,+\];M>);CK^U-QY?TYV54C=L@W:6/% <7HZOY]]>G MLCXM^%WS)AS\)HEDZ=R=?'PH+T8S <2&BR@6%/ZL^9J-$4. \4=O<[1S*1L/ M?P_6WZ78$YW- M+;YC[B5]A($ZT%M;DC]DYV\9XD M>R=_)UYZHT-A7.@\[T_^NEB%Z),W_C{&0G9P>=R*%]"JTJN"+$2HEL%_SZ/+' M'^,/9C_$L+I+H33QZS_=-_=L0H^3\HN.>J52#7VR=-6MD)6T>)DE&9.B MMO.M\Y%+0KH6=[4S)7LJC HA51TV&K4)G8[T]-9,-\X7*$,M?EN#QA&?CG>#_M8T(G4F9"ZPE]ZF+_UT+TIV+]T^S9'#_>_N<-C6FC M_E7: (J\V)+Y^F]Q.1-;H=1'AL/.1T,K2W*\|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|+!KBH*W_5FC59+;*?!'W"7)GN'^ ,M"K3N.\C^1)<>S1, #}Y**5>%@ M*K6\;|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|^?_%;*M;&5_J_*42"(08X8F+JLQ+&8#L|GYV* M3]/A[/E,#)ZT*@]%:#: ^'*K#>RO!-804&0T&5E1'5K MA%.E-@ KA?7Q?>976<15AN)V!;_5O%HPH-RHXDYLK+_U.?D6T&"L9?\Z\E"] M$1#\/3PZ'HU1MT7!$.1"&-P+1&$01DERXFDZ+OJW40!+U=;5$G[A"?P;PN?U MI=_ETBJU]L>QZ>0IR@AQT7P_$ @*G$&_O"MOE*MX])6QF]&0-"/+X"B+$.- M2= %_1,<5R@4N87^UJQ%!5@F1?C? C;18'V.LPE>]>DQ(<>VG#5C9- !1RW9L M".D=5J31Q[ЌCH=.N(YVJGA(:Y^@,-Z:XH3AW@[;ML !KCZ_^10DAN:+38+M9 M*K6\|_ -O-I[//% E.^-^>7YY?U1^A0Q$EZRP=39Y?C8BGU^S^2.Z-M39N(<,$Z4!A782S)O<>,D;C@LN]"*:%G%W:\/="*RG>)Y%BBXGI67GA<33*^ MJ\'^V"WJ@1-U(7XT_ 89R32F9"R@; M>|ADPEZ8>>UV8,$7(X=0?:T497+;60A?TOP]W=:@[H=-!T"V=8835B!,82[M,D%8]O6DX^L6PRY87509@U&BW&.TZ0KGY+V%\T+SR+E[4$M&%X(0Z_%B"#\J MK]QL-CKMT>WRZ<1KQ_D<1S]_OF?T-!D-A"8~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|,5F"NGN-QX=$NUH: XO.!M&\,W2VQ1Y'\CCU_G..#OS^ OL]&4V39 M86;^KEF?#@3CX0HI3SR]._%^6GL=#M> ^A0-.SL^&I[T<| "V/H3G/FZQW4 ? MY)U\(=;A0'T"&EK< ALKAAGC$2-!&_.&ZU%A+8F,$@FJ4=_P\H8N!-J5]+\R M%>D-W(VW1\8;KT \G\:O&CA%H8ZZ3!I=?++UZK*%5GEM&X;A.SA/W5%BMP=2 M)H.@5]JGX"O.13H9WV)WS23R0M#Z>)M@W==$V6T(O%HL()?95M3E#U.JR9^G MR?^1^B$K_WPK'L@=%)YM1K;2]=$(!(NU]MA,%:'4K&>SU8C?A|&NOR@]:\7[V MFAR3Q>Y-K&#CVR3-)PRV.@M'9-56K7A4'@]_% +CP]W #821)O?UT+:DTHJZ MMX>C0RPZD[QO7*. MW'-WTC5XB;Y#BQJE0+W;-U"^>P_AZL)4-TTMKH%'D*W0O514#+ (Z;,V%<^ MD6Q/=I$/,KD!)!4"T4>3 M:UJ9-4[+0>=EAG6F7T&Q].Q<]/NR)=9J>6-P8AG9_L+V%(X9; M2*DUHWOLFV>[NM]&-?;FQXFV^T1EQ8D]@K<)2GC|-!'R@>"M' MUU-(JKP.W:OY;%7!3*.YN@K@YC@D[>U6TY%H:HSATAK'J4I0#J1"QKA] I#- M& <'=4C%8"467B8BT\DT!FJQ"9YZF(SB>R6..GG^|%C9:L| T@//'S?N8R MQ9JA/=6';\@[J;0]^O"K$YA:AY.UW:[3PL%!#2BHJZTD7>+*L%T$YCTCAR0;.J^;05=-ZX<<1K4U) ME]&<+3U5F%_J$EW']PTMDRS_/6!7G0:(O'H ;P. MJK'U*L12#E: !3%- M(U[O@\IW39 ^E^476V^[("[J'5G57#,%4QJT]#2O&XOD7KRBI,M:>1-ND5& MRDB;7)EUSU\81L,9[[$'&-_J1Q.>]_6^3$F&%+-G"TS+@ T-^O.]6J#\F&? M%:YG^=*TN?!7_PC,Y:Z.C_3R$&%X'+\7?LGU['E)*]+YK+@U8-CFS_Y!;.+ M[SOFRA^K9V99\CM2/@0MGW*KC^[#_@44R&|#VW5"X_3+U:Z!&;_^] (A8T\@10:NW]@'K^-S _O_*OT=0A_ MV_\^]/!+3!U/#H[+6OY?W?U1FPV_4YZ9" ^:/*R61VS0 OR^,J9H_:('X M?UIX_3]02P,$% @ 58YF67-3MK-M' R!8 !D !X;"JW;W)KA&ULO5AM;^,V$OZ>7T&XW5X"*+$LVXF330(D>]MK/[0U MDO0.A|-]H&7:)E8BM22UWOS[>V8HR[+KI-M=X(@U$LY\|S,,R_4]=JZ#WZE M5!"?R|+XF]XJA.JJW_?Y2I72G]E*&;Q96%?*@%NW[/O*"3GG3671S]+TO%]* M;7JWU_QLZFZO;1T*;=34"5^7I73/]ZJPZYO>H++Y*"7JT /^K?7E5RJ1Q5^ MKZ8.=_U6RER7RGAMC7!J<=.[&US=CV@]+_BG5FO? N19DRQ>;Z3_R+;#EIGTZITM_J7G8773F_3$ M7"UD780'N_M7"UD780'N_Q3JN'0U[(JJ]L&6S&0A*;>*O -SXH;-ADKZP M(6LV9(P[*F*4?Y=!WEX[NQ:.5D,:7; "IO!0Q@M*&@/ :'MQK[PNW[C[4.S^)G MDRM#_A'30IKK?H!H6M#/&S'W44SV@IA+\8LU8>7%>S-7\JW]?4!J<64;7/?9 MJP(?574FAFDBLC0;O2)OV-HY9'G#E^2MI%.G]XC??$SE,V@5Q)USTBP57__G M;N:# T? ^>|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|<<+8H>]V.$AJO^\ MD8, <+RM,XB/XEQQN*H12':I..B*@NC66R<*&-&V516LZ$>(2"B];5#@Q@',K!% M@N)#+EJZ51B33 JXHW&.YD=YNMY-9 -IB. M$T@'DW$.IR-&BY6RR5DR12&:;7#+M*:@ M7UTZ0;_:]J'3KGW\ M-^:\|"73&TXG); D:'PT&86@N\;63:QJ?#-9*TNMR0\K^A>@=@:7?RI*FMW$ M.>C_+HL_4$L#!!0 (%6.9EF1';2WD@0 !0+ 9 >&PO=V]R:W-H M965TX:2%3OKN$$?$HO2S)ES9H9#SM;6W?N<*(C'0AL_M[^8AE!>#@4]R*J3OVY(,OF36%3)@Z58#7SJ2:70J]& !'JX,"JE,=S&+[V[< M8F:KH)6A&R=\5132/5V2MNMY=]3=O+A5JSSPB\%B5LH5W5'XH[QG6 U:E%05 M9+RR1CO*YMT/HXO+*=M'@S\5K?W6LV E2VOO>?$IG7>`3(@T8$1)'X>Z(JT M@%HXM@8^-I@=NM0[+CJO$')6J*EJ?7T=&7U%Y6&?-XJZXJ4,6O7OU&CYCZU M$JM]_" 6M>T$$9/*!ULTSE@7RM2_\K')PY;#V? 5AW'C,(Z\ZT"1Y4<9Y&+F M[%HXM@8^-I/T2IT1ODE.&BW 6'KPI^8?$%.4-I$T*&TRIF:C8(.;/@Z0!N:Q! MQJ^ G(MK:T+NQ<\FI737? P!"+:OQAM7E^"#@'95],1GVQ'@XGA[F[0]JQ%O M\G:5XJV2Q\W -U%S_^,#H9_G2 [;1E M.SV$_M::' 393W$TZHM]N?ADA'4I.1&L4$7I[,)|'LG^:O4@K),)8H,_GRO M]FL-S$K0(V:$)R^D20622K)@.D(%+P#E1-; 7TFCOFT08878E:.>"#F)*UN4 MTCQQ<$W8\X%2$=;VI1>$-'X*;<$.)PZU:=,A$YLY4+N?A:21<@T&;< M4Y//(]%H^Q0:+"V62R@'H18PDEVX%9?[$N/^,?:@UIPRP&?*)R#U1-(]@[+5 M:6LK55XS4/Q77T3CUIL,%*K54-1F@#'4H:8| YO"A5RY]$7=IKO= M MYH%\:0F.]IJO:WB5,X;Y2.W<6G -X=4-T7G[##NW&%G2)7DDG.*3MB6'%*/> ^&38N9.ZZ3B4JIYB34>] ML[-IYU>(PL")WV2*;*J>|GSTB^GI<>>S#?AX)*:]T?0\|@WB32U>:"672]. + M*"88!SOC9LX6,1V[+8#DN$IJS,-UKD!T38Y-$AZD,8/1 (\[T[&N<^PIB-D. M:_F?"EUK%\|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{@H \NOZV,*C@Q M5|*YX!NVCQ*=:.R5!)QR44G&JV++G'0%5".>F;H1^/(<+7$83 F2+[]4I>00 ML_I GP38>(A"N\<(GPSA'#'T?O+*L-\;? M]+Z]7_J[9;F@L&1H,OEP&('M+=LOR#3!)AM#;+HPK;C+H?4)O%\:%CHL_ %C MW\S^ %!+ P04 " !5CF99"1|6>J & !3$0 &0 'AL+W=0'6_0=']$XB/H.GM&WR>$_IW,?"CSUR:'D[!# M*3]XEM[X6PJ4?D"Q>*W-+AX\=/^Z_';+6@/>[2'V1\??**,3-#W8IK;.E#^ M(%_.&CQGA-()?A/R?ZG[VOMFFVIQ;<1OJI:J.3E.P|%0A)+$E3+29$KJ=[0CTQL=KXI1[Y3-M?>.8UC#0Z=X=BF6I MLA+MYENC^&LH91#2"$BI<"_R)$C"KQ6+;[72'5JEAY"J:NXV 8D"\4*<@&Q M3ITC&"@:+1W"S& 5BH*A^(PJ38]-\AW0 M*#TG(>M:*ZPO"D@N5U"0SW%4D,Q3P&3CP;(T$/-A/O6 8 ?EF[A$91J_@ MI5-5YSDRK$(I*,: ^ \15 MKPGK-4(Q?@4:+OJB\ %13-QD/D!P$8C(\R'Q*\"IO :8$7M^1\ZQ0CDIC.#%H[$G'=]%&>]JM?&%D:)B7*E4,_EC M.CHA_QY>9\$Z_U)8XI$Q<$%%|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{$ M.9@_ZUN,IB()BXEV&%U>M!$1CL+A<]J*BL(A('QJRD/*[G=SD$>P MA*"$S%@$AJ\-S* L+1#2^+'#]%J3]N#Q>(_ ^V?F.OBR8AIDL'WA5A-OZ)$< M"K8NS9W<_@$[?P86+Y.E=D^RW>T-/)*MM9'5[C RJ+AHWNQ@X?7'(AV!R+' MNS'D6'YBADW'2FZ)LKL1S0ZF5ZQD@_R=QDPDU4M 1!0BCR6_W;%&"/AO[!LW8S7ZV@[Q](*,7(§? DJQ1FIBW':,_Q M*NHG-]3N* DBB(^AUX<>MS[/#B% _"^]243_%]FTX*BST++DN>LR1*1DUL% M&F/0+,B"?.8"8\192>:X")6+S]^7"VT4)M4_IR+4$.B?)F +[4+7+(.)5UM; M:@/>],.[, D^=KC7;JWK=Z%/YUBX^;H$2WW&],KYY ;7/|9\PTK+_Q3I3MC3 MI.?J0 I98FESL23&I@RIE=SP'#*1A6+69Q,B5O(UEACRH>QX(L'4=0HGAG(MF^]FQ8QM%L1(' .^#$J &';"*KFV! 5*;@7AHEG,.DQ@)IXL&;2<8_ - -'U0 M;<> %,@8<]R=DVN-YO7910\3#3DO2N)KE3.QVQ57/SM-=UUJCZX=TP M"M./&*IG!+,&8(D$X5=-]PV..?$_H9N-P*%K)S%&-@KBWHU %&SNUN(!/:1H ML/>@N('?95$@.$G)V4^0SY+&M2B+28,P[1(K:<5*7BW6C=A@B*3B<%*)3J#3 M2APAVGK17)M]@1T$ZJR29Q$]*ID[ML7?E &%;=.6232@83S$03BD:9#T'O!? M;8.-S2(#K4D8TU8OP8#7O8<#G^TG*RE#+7)(HC"46A30<BADXD,WY,D MJ/MG/W85DE_1*-PT!7XM U|^I8J46ND<_U8VX[2U.HWC!)6QUD]$*^<+; /F=> MT*;3UFEMJD;AV*AT1K.=T?)@]'^6;Y\83U8QC+[-:>QAHX'M;\!4UO3#'#9X MK:MM;SWP#+*?A308!+U;)0L4%UL_*F;=XJ@U2=WW<(1]U=UOT+B"!>8*'J4I M)DE$PR#H-?&-:#H:D %-

D[WR[&UQP>2@:7]D_8AI?S ZF1O^T04*^2S=-='& M%'MC#&PO=V]R:W-H965T*B[TPBN-J6=!H/,2*]HO90T"=[925=3@5.T"72N@A4NJ>!"' MX3BH*!->.G=K:Y7.96,X${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}7<./PO85E:(*+QN,/TNB-MX+[]@O[%:2I(TVLMH%$X,]$.W,GW;WL!{XL49^, T-G6,\@W>'-6KSH#;P1W$IA<@W7(L/L=7Q W#]"T0O!6704<('U M&<3,AXA%R1&\N!,<.[SX+;R<*SR=T4-F,.?/E%\&+17B8HW._GVYU$91LOPY M)+[%3@YCVP*ZT#5/<>)1A6A4&_2F']Z% _;I"/.D8YX<0Y\NVKH!N8*%D>G# MZ=*)N)(55:CF+LFOGZR-AZ@?!3J'_3Y'6,Z?Y4CT;213 YZCT6Z MSP);%E"(M&PH#<@ 0U@\M6YT!CA8^/L3^:.: /B3\<#6'DC]BP]Q4%Z2Z=+|^HT@N; MAJXDR3DYMV/8AS#R8Z(7,!"%_=Z]-!3RWW<@,41_:&4P.C*V&A,_"4,GUN_' M SB4G\%>6ZE0K5WSU'1$(TS;8;K=KC]?MFWIGWO;W&^Y6A?THB6N*)2=G?<] M4&W#;!=&UJY)+:6AEN?,G/XQJ*P#?5]):5X6]H#NKS7]"U!+ P04 " !5MCF99R%2J;!4# "Y!@ &0 'AL+W=O\0+OPTDTCS;&#[=#Q[3D[M66A%5R%5J1_N_O>{^'R9;95^,"6BA<=*2#,/2VOKBR@68D5,Z>J1DD[A=(5MLS35F\C4&EGNG2H1)7$\CBK&9;B8^;6E7LQ48P67N-1@FJIB^O<5"K6=A\/P M:>&.;TKK%]+%K&8;7*']4B\US:)>)><52L.5!(W%/+P<7ER-G+TW^,IQ:W;& MX#)9*_7@)N_S>1@[(!286:?Z.\77J,03H@P?G:.81_2.>Z.G]3?^MPIES4S M>*W$-Y[;AY!CP1IA[]3V'7;YG#F]3 GCG[#M;.,0LJ98577.1%!QV?ZS MQ^XJ_()#TCDDGKL-Y"EOF&6+F59;T,Z:U-S I^J]"8Y+=R@KJVF7DY]=?*)S M_Z",@25]6)5,(Y5;[_A&! M]73)]U5A M?%NYT6$Y=V$N3,TRG(=T(PSJ7Q@N7KX8CN,W1V!'>SHF/IB11\[TN$0@FZ[P!4=$=OGIX$7&%U MP89)GZ5).CJ!-^S2'0:\X?)(]/MVCI#\OA|+.$&;W0<)H]NLO@\ODMQ-L1QW;T2GTV8JN9+9#IG*WQ" XJ8@K8$B4XS-@<%>;" M6797@-F@[3:<9JY =@\OH71LG_BR2WPA01U+^22IXRD 4*Q<2[KB0FV8\ IA M%HD7Q70%#0)FY;C>D>>M^2%XK(FX= @L ?.=5F!>O&@7).FE*5=Z\B=`@;R MI,+0^V3 YV/96?#3M:4H]ORF]PJ1_T:1/=(3N:[1=*+JW6GK/(XAC]I&]H:- MATEO29FIX44@G-&6U)4/R0;]]#+IK8 N2-BCI^P1G2F-\A1SH\M0V;V:=L(Y5-4MYZ8&:8^)XR2;'XN#[ZG) VKF-35:73-=*}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}356GV%2GV$RQV%RGV$*GV%*G6*13;*5)K+4V MW&9MN%WJDU_%T2_",?G(U\$/7&IG[8XLK8([K M#MTV;*]"A:%[ILI8*YG!R=!YRJ8:[E>&[90P9S0M]NPI0)FBTW("=JX2(5S M7#OTV[A5Y^# _SZD=-E,[(]S:VS@N\B*#'"7RJ)K&*5=-,B4R;'?9#*] MG='>NX/I%)OI%)OK%%OH%%OVG:E(9]35|-SJH6?[[G>KM]SI->[T.MWYA!BG M:2S-&4.V53G3. ^NOXPS"$U=V1GFO*W6*S72*S76*+72*+?O,4J0SXLH[FI(M:V.=8E0.=8@N=8LM^\Q3IC+G2)%:YW3RJ[>6(;LK:+0,Q*3"OOOR;UJ8\ M?%M614 :[^R;A:UH7]HW457]_2Y?U:(?(-VDF($,K44HZ]H7NP&MZKO5 R>[MLI+W0C@G>7F[13!!5 +$^S4A_/5!!FB*[)-_ 5!+ P04 " !5CF99MUY# MH20$ P& &0 'AL+W=O?\R\',.J;=Y,C\Q_D7L*97@:Y;F8F'LI3S;!G/ MB%2W?&>*Z[Z>$AV>UD.F,OY@>SHFLK/AWNN[LR6$B<9S47"("(LERSMD)|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{PO^,E92)(M8F];JB26.\.9P*4"O2M+JGY.D:RH1IGDJGF2DFC:< ,MS2'3T\>, +>&(KT94C.I1C&ETD7&/5@T'X :(P&L+3>@[75S>G M=/TWS2MY@ZY; \\[/-LM-YA,Y%"A\NT0*8+<<);[QIQL04,YJI1NJ/=)/^J- M8[(_SN<=IU=JAYW:X3MJF]!(82ISP7Z=[/"TX;@[BAS]I6WX5EOX1ALYFH$2 M5>Y7@X94[H11QJ&S=MOGP0\=^>/>K*X%53D3&CAN+33LC6X#4,TZ:"Y&5GZB M-M+8^?3'PFY05,[!?M]*:0X7%Z#;R&PO=V]R:W-H965T]@6BAKN,<37T%EKG?=]7\0(SHIHB1VYF4B$SHDU7SGV52R2) M"]\8'P5!Q\|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|^V^P'_WIBG1(L"006",+>)L%[$,?MO^5, ""'MHDFR|#5ZGQ%45]NP;MWI9VSTM[=|EMUY.+J!?FT+42$BP)!-8(7W\;OOZ3VK'Z M(;,0$BP)!-;(PF";A8%W$K_*&9?55G7!A'3N4 -KG<+>$&)SL3K,!J, ^&AD;ME=>=EF2'6[+#=MOS6R5_G=R'%BG%'0R,(?B_;1F%'OYGDK>-3)O$[UE;YEJ;0[\X;U'T:D3? XG# MY 0CD_DQ5#74LAIZ]6+KLM=WS/L1LB)@F_7P$/;-&!Q#TT(M:J%?U3Y>]"Z(M6#Z;96N53PVY>Z*%?0>Y(1_I1+8N::|W|>V,=!:%OFUK+_&(=^#W07+<|JKGVN69$DY^')%\RGE[I/^ M0!*VCFU(M"046C,%6EZC^$D5/!3R0/PB*%H2"JV9"JWWD5_O[U'PT./ZWF$"MA]%H8*[\8RA\!!4^\BO\%L7.5NT6=8>P-VD?0]0C+>J17]2W*7;VH;3%V58Y M,<\Q_8ZU):YU-?(?6[>M=0;!M$7>:<7:MYKOY+._WKRU,+6:1'\S^4J7C2\:)MI&"N@NB,4B#A6@QH18]ZZ<,AQD: M]6/$JQ#O=V]R:W-H965T MH)O0*.V, M1_FYSV(\XBL51RG[+(!<)0D5/]^QF*\O.[#S=.)+-%^H[$1W/%K2.9LP=;?|M+/11MT0)HX2E,N(1$.S^LO,6OKDB01:0C_@6L;7<>@^R4J:V16+XPQ)Y_%/ =HIKYD%;KJ_0G^?%Z^+F5+)KGC\5Q2JQ64G MZ("0W=-5K+[P]4=6%-3/\&8\EOE?L"[&]CI@MI**)T6PSB")TLTK_5$0L14 M24L *@+09Y65=4T7'(\'70&2C-5KV)NPU0 M#Y&&|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|<4K@+@%Q+\!!J-7,,6,/1"F\K\FS M+$VTVH!VT<3F!MX;CR8U7+I;G%M-4J0SP-KUF7,,C$S7+3)3:GKOL@9.8)+G MW#G-!-S(IER<[X5L-0!ULC!64QU_VV=90SG:3^F^[4M3L0S' 7V\!O4:M@_3MF\%Y]&&?WO]$]D+]J%,_ZF-/[]$US RY7D-$M.[TUE1154ZVIOL@'JBU@ M:ZHIMA!X0K,3PP2"P:R-V&=/_YE*(I2NIL JL 77%E$V*_O8IKUL_^C/6>?/M66^N,UQ8F'=BCV'RPHLY>;'/@(;TW).Z5KU.HR1<[XKJBV@R#7?Z1HEZY=NI MH7NJI6U:2+?:=>R);U3AK_"FW=\RO>+2@, E0:/3=W2Z;EIH,[&J\EUHH2SU M-#\LZ^#V@70_E(INYVX [K_6/H34$L#!!0 (%6.9ED% I+G/ (/P% M 9 >&PO=V]R:W-H965TZ%H!+3Q4<1(&P8Q4 ME FF;85[T-UC)1ND7+957H3K3_EVXNT2@#0QG7U^@]NM]D:'1UC:X0$ ^A[*0^: MBD+'Q-C*G#()NRH6;17A,U5LH!ZC*'B'PB"<#N#+E_$,M%_>CKD2ZLT'59R,S_7-DD]78,VBN4&"I137=K)]HX.&=@*S;R0. ^..:12%GV)R/#=F M*"D(GB9E_U!]J&R%GH^;.Q6]4[9G0B,/.8L'XPPU&]CUKVL#(VD_?5AH[RWY9 MVN,9E$NPSW=2FE/@!KH_|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|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|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

H6CJLTND"1};5=>_)-FA M6SV;0;8)"4JC4!I#T51)I/T>8VOK8VAM'4JC4!I#T51AI$,?GU9;_\F9PMR+ MM5Y0JPZEL8YFW$&A:B%M^-
BJSG[2QG(STCKP4"L.I3$4315'6O$QMJX^AM;5 MH30*I3$4315&^O(Q>&/Y^-2-Y>:.K8,.]>4HFAITZNP\KP_\P#[L$_NPC^S#/K/O)9SX6#KQ,7@[^5B_G;QW#W1SO]8Q
MAYIN%$V-N33=8[/I;NYX<=7>\T+DII.?GV'&6I\44(,.I3$437V2I33H$;9* M'D%M.I1&H32&HJG"2)L>O9>K/6"NOV.MIO&PE";QE#]JEI()S\YP2J-0&D/15(&D MDY[@G?P$ZN2A-
JE,11-%48Z^PDC/Y%&?@(U M\AUMJWUY8_U&#W/'U@&$&GD4K0WZL%QR7M&XBB_/5[RXXU..U6#W[/U$#[\ZRXXU->IB5I[A5W,:B_ M=6U?)2+6]6/&WU^Y@Z%H*0^_/%_'=_Q+7-PE64E2OA!-1V?
U91A%SWE1'R#^OLCSZNF7NH.'O/C>#._R_U!+ P04 " !5 MCF99OK]Y.() "M:P &0 'AL+W=O6EP4DP(YVI$53P9E=K8[V0VC=-IHT[C@I+ZOS MX]=.0EUW@B',S:I?H&WR7'9\VT_-
C9V+I-@72YZK(U,A%TFIWLI9OUA*GDRJH$76#SQOV%\D:=X[.ZD^&\FS$[$] MLS3G(TF*U6*1R,<+GHG[TY[?>_K@.IW-2_U!_^QDFNO*9-T MP?,B%3F1?'K:._>/XT&D
ZHS_IGR^V<-=&7_TX>FH;8"%"<]H"@ M"0A>&Q V >%V0/1,0-0$1%L!SU[#H D8O+:$81,PK-J^;JRJI6E2)F3 M5&N?9.I@W8-U3_A(>9FDV2=UQK<;2!A#PF(0S!+:]\R?
VMY.Y?:F.J N.J51*(U!:3&*9G>3#4?&1Z=X M-[&STD@:A=+8"VWG3/.HFMBZ!D;7P%FWJ^0A7:P6K?HY(SOKAZ11*(U!:3&* M9BMJO"E_M\PI'^I.06D42F-06HRBV=W$6%0^W*-
R$SLK#76IH#3FM_A4P99O M@BK1UL_X5+[;J&H2=|?YN1O:64(DC4)I#$J+431;;..F^E42B-06DQBF8OSC V7.#T;]Z2 MNMW$KDI#:11*8PW-_K?Q5N)&E6CK9_RQP.WQ-
(F[XW3<#>TL(=0B@(8E!:C M:+;8QC0+@IW*Z0'4B8/*3&H+081;.[B7'B J>%\Z:<#C73H#0*I;&&MK44 MZ&!{/HXJU);0N&3!"R[9>]3K=4'DZU(Y5;AH-X8E$:A-
:EQ2B:K:]QT8+! M;F5RJ/\&I5$HC4%I,8IF=Q/COP7NY6SUZ!?5Z"_VR(078YD^GPN@[AF41J$T M]D*S!8,/Y,';]-LB17>>#I<$M%)->;8_3!\EY452CVR7F>KQ3U^N9;068RR4N5
M&4I!REX54Y,33?NL:7J*H#-*HBZ 2%4]77?= M*/_7:Q,JC^G:[).1JHW4%Q/S6[G2Y>DM!'OUM5;PA!1U^FP6SCX5H(6M]FML M-
DG2O.%OGD,NDTR57S6#=;VZZ[SI>ENSQWO8LH&Q90.W+:L;JC5/0+U7*(U" M:0Q*BU$T6T[CT0:'NS5G@!J_4!J%TAB4%J-H=C]=!?<61JH-
0NEQ2B:+:&Q9D/W>L;1,W,M=UCGD0:U4*$T!J7%*)HM MY\9&V]U:S!ABM]IB]]IB-]MB=]N^ATT;&ILV=-NTOSK7VWC^\RUH-8KE$:A--;0MN!JI;\
M#;7'H#0*I;&HS1[;SM_O88Y%QAR+W.98D[]9/M&#]]]Z45A(_JA=EO9Q"K7& MH#0*I3$H+4;1;)V-A1;MUHWU{@;!Z51*(U!:3&*9G<3X\9%\/OKN8F=E88: M:E ::VCVON[M=/X>-
EED;++(;?4$7N"1UIN:MTH'=[T%VD($TY$S(5 MLOKOMEZFWZHYU$YK:(.-Q!D&_J'G>=NWFX8Z9:\M-D85:RM84+#!"R;8>K=& M/9)'*SF>]]%
<)6[RD=V,1FW>_84;VUDDJ!,&I3$H+4;1;+F-9S;8K:5F Z@# M!Z51*(U!:3&*9G<3X\ -W$O-?BU_0^VTAK:92(?#@Y;T#37*7EEJC'JUUJF_ M\32A!9>SZKE/A=X4F)?U@UO6GZZ?
+75>/5%IZ_-+_YCZ+9\S_SBNGQQE\/6# MK*X2.4OS@F1\JHK2>]1[1-;/AJK?E&)9/G0I1/ M;W0!ZR=TG?T/4$L#!!0 (%6.9EF[V'; 000 *L8 9 >&PO=V]R M:W-H965TO_];$-) !"YR3&?
&EK'=M6G2U185D%Z1'<+\R9J4!63\MMR8=%)BR.!\6I(#*(4UIXD+F7WIS?.5 M83%1EJSD3S/NQ^;)RIC/\ =7B$L2@;N/HMRI&!! M'CY'*9153I[%-0(?8\1@EG_B;M^6,?CXX1/X #
(,_MR2BD*<60/^^8.;@3N&"OJOJN(UTU,S MA2)>TQU50 MEH2>K-K5R:I55::&!A(J?EKV\| -PZFY/\WXT,BVPLCM6L5#*\?S;+MKE2BL M(M\-6JM.\'X;O#|>/*%,Z-4#VB-
<(56@HX!SIZ!.6*P3EFB"=:H0M%4(+J - M@<["Z(3%.F&))EBG,).V,)-+:$,-]3M+->A)P] F<*R>, QM;"MR>KJ@,')# M6RT+81MW.!KW ||D+%=;P-
]$0,RU(2<[_JK+5,&.DLZ=ACIAL4Y8H@G6*4?4 MEB.Z@#Y$.@NC$Q;KA"6:8)W"V-9Q+V!=0B$::F?5>E9O_2\45LYD\/J@L HL MQ^_)A,(J=%Q'K1/VR5[('HU_"7-
$I4Q\A>438AG>*,,=|9B/;728]VT1!>M M6P_G6 _G E+10'651RW2/\V[1" 8G!N[$ MF_150V5E#U1C:&4[;G]3DZC,+.N$5F? /#E|+5"YD:?>E =485:?J+6M[BVX-X>=A[Q-?'^/PM99-
A"G*TYEU95Q->VK(^&:]O&-G) MH]]'PA@IY.46P125PH _7Q/"7FY$!^W_$_/_ %!+ P04 " !5CF997??? M:+($!2'P &0 'AL+W=O;IQ2U9KJ6^XLTF!5GB!Y9=BSM65VU!2DF,J'"*.
X^74N?0OH!]I!V/QE>"- MV/D.="AWC-WKBP_IU/'TCG"&$ZD12'T\X&N<99JD]O%/#76:-;7C[OEV"&J'8-]A\(Q#6#N$QZXPJ!T&QZXPK!U,Z&X5NTE< MC"2:33C;
ZM%4U_,=DWWBI?A.I&64BNGA+E)=_JE[\R(0 <\$I8HTX!N_ M0K5C6F88L"6X:60B*:$KL"<24PE05GV'<0D*W6-*RI M@[N]"<24PE05GV'<0D*W6-*RI M!%% &0 'AL+W=OYT7 MC."H$CV ML9
=^FI1X#W9$O&YN&?0TEN4*,E(SA.:(T9V2^W&O-Z8MG2H+/Y(R)&?/2-) MY9'2)]FXBY::(4=$4A(*"8'A[T#6)$TE$HSC[P94:V-*Q_/G9_1?*_) YA%S MLJ;IER02\5+S-
121'2Y3\4"/OY.&D"OQ0IKRZA<=&UM#0V')! M$9/6@"8?*O4K;] KR66A; 6#MPGXB=472".46T@@ZU%9)^]GM*W+!M$=.AD\ MM ;W*<[171ZF940BE.1(Q 3=A"'-
"IQ_2_(J6M,\@FJ"MUN!!8'*$AQJW*&/ M!6%88G#T-B ")RE_!_$^;P/T]LT]$:"?8IIR7$>1&4N@*$8BYF@#X:,1_V#:?S[AKX.RK;S6L[RWUB3@EA17R#9^0I9A.2/C6;_>
MW1ZC\]^B;_YU](X8=EMK=H5GOX#W0+A@4$(EJTN$"P1IAKKBA!T(^O,]V*,[MJ!;^UUCJ:W!G'%Q.J->\P"%9:C!C5HC:ZL^)"*C,,;(UB'O.PW5, MK|=V:&4YGF7TV
ZM7,>=VSVV0RO/,6Q_G.VL93N;9/L;R6'^32N^.(+E)($O M$LNE>HST;)@\PS1Z UV/6)F^Z?9(SP9T;,>RS1I(9;M^'-KG+37DO; ^J:C/ MIYT8LST975LF82Z=8%2"!2K!-HK
.KGPVUSX_ ^<2X*O,D$]P0"781A%8)T/S M-D/SR:^ER@GL^QC,_GDY.B], ER:!95@P7PXM=]JZ7>C*&!"7-,X;;<-92OL M--2E0BM%"QJTSHIHS?I:JXK9%?OL;&.J6-
RG42[6625:T*!U=/9]IZ^SHIA= MG:V3SI;";<4TV,5RJT0+&K1SN1W/[:NM*&!7|=,IRIP\ JP^48'346&5GI"4 MH@4-6F?W;CKSOK)*#S_ZV;5(1F#7)^^C. IIF8OZU-KVMG=>-]5-
3Z_ UKQ> MFR/]@;PCJZYA3O#U!=L'V&0F.4J1 TJQYC M@B/"I &\WU$JGALR0'MSN/H.4$L#!!0 (%6.9EFE+%\8M@((8& 9 M >&PO=V]R:W-
H965T#4VLTW2_ON=#6'92B/U"]CFWKMWS_81[Z1Z MT#F (8\%%WKLY<:4U[ZOTQP*JB]D"0*_K*4JJ,&IVOBZ5$ S!RJX'P;!T"\H M$UX2N[6Y2F)9&P!'-7SA7.
M_)8E8P4(S:0@"M9C;]*[GHYLO OXSF"G#\)$5K*2\L%./F=C+{""@$-J+ /% MUQ9N@'-+A#)^-YQ>F]("|#=[]H^=N=]QE137<2'[/,I/OA4N/9+"F%3<+N?L$ M33T#RY=*KMV3[)K8P"-
II8TL&C J*)BHW_2Q\>$ $(8O ,(&$#K==2*GJ0Z,X)NRF+(W"KPQQ)KE'SW!K4T"'LZIVZIPLZRTBQJ#]BMQ*87)-/H@, MLG_Q/OK0FA'NS9B&1PF74%Z0?
O".A$$8D;OEC)R>G!WA[;ZY*F,/;P)FI06_"2MV]ZP^#]$;51JS8ZQIY,*7>[M2+7=_QFD4*Q D7[/^=+ODEL3#AVA;0/;Y'(0Q?ZV0\6@53$XJJ(Y0UW9:N#@
M(%O4BZZZTPW;=,.CZ>;T"5N-J<^LQ..L",U^X?USJUTJAL]4G$=78= M8]3* M&+W"^R^5@/8\=FD8/?>]_Y\ _Z W%("6V@ZH22HK8>HVT:ZV3792]Y:_X76'
MOL4=84(3#FN$!A&%FZ3K.2!ON6&^;XHP!E _#[6DJSG]@$[:\G M^0-02P,$% @ 58YF6;:R*A0/ P "PT !D !X;"]W;W)K&ULM5=A3]LP$/TK5H8FD 9)T[0=K(T$3:V M+<,8,BJ/>
X,GRRXR*C"J5C:,A= (P/*4MMUG*&=T819_MBL70I_S N5)@PN M!9%%EE'Q^PQ2OIY8/6NS<)4L8Z47;'^WB:1BB?6>XM$L*!%JJ[X^A-4YQEHOI"GTOPE MZRK6L4A82,6S"HP99
DK?^EJI<,6 'F: 6X%<%*Z%> _DL!7@7P'@*&3P & M%< M%:5Y^Z=1E.@13VP2N"L3,!](H$^N>!,Q9+,6 11 WJ:CA|^AP_:|5<0[Y$>D[[XCKN%Z3(.WPSP5KA0?_MONL'1Y B/"><@?
=;Q.C7 M)[-O^/I/\%V!5 +O92$2MB13+A7!>T9P&<0*R/ M6!53L83&@M#*]UI3NB0+2K*A(=-OV)7O];SCL;W:%KNC'7?$'M1B#YX3^U!I ML:]!X-O
U&5R!@P6B6K4NI7NM5IW219T23;KB&S'DV'MR?!_EJAAEPYU219T M23;KB&S'H5'MT*CC$C5Z5 AZGN/L%H+IXR!W]# H:,WLM2(V[#C8VK$4Q][J M!C/
$^HV7)*0%TR5C6&]6G?ZIZ;!M?^&EY\)%RA0PB1)88%0YVB$_V>B;+W+ MB>*YZ2WON,).U0QC_%H!H0/P^8)SM9GH#>KO'_\/4$L#!!0 (%6.9EDC M3"O[-0, $@3 - >&PO-KI4-
/8]/N<>VS?$ M,*C-2K"[.6,F6I9"UD,R-Z;Z$,?U=,Y*6E^HBDF+%$J7U-BNGL5UI1G-:R"5 M(NYU.FE<4B]:" 7Y4UIZFBJ%M(,2=J&(G_[G])-WU//B\W5CD;DH>SMS\6 MRER_B?S]Y-
W)2>?A_'H_?N: &N[T$A-CHEET]W#Z#_YXTP_> M=0\,[&C MO2RV]JT#NR;;IC74-+V,[X#^MIK7WI;MO4@WJOBC,I\6=CK2]:$^V:UF!5^Z M_K)H#6#]75R=5158?
11\)DOF)W]PPM& KGG17&G^RV:#4IG: -,D>F3:\.EV MY*>FU3U;FG4Y+0O<<^\(/?_==9XQR305YZU^3J7UEVOU7V#0<] M-J_>UV[R\AA,IL=@\BAJLG\,)K-
7:3)N7N!;IX2=,T(;C> L-B3?X&0G-DFC MR8(+PV73F_\9_+)4<'*&SJQ?R;LZ-OQ.2OH0IC[%AR23?LKR_FBS-I1M[0 MS:A-^PM,KYNV!T&;B\N<+5D^;KIZ-G'-
R#9LUN8"PCYRXZXP@G$\%D8 P_)@ M#C".9V%Y_J?Y]-'Y> SSU@\B?9331SF>%4+&[H/E"7,R>X5GFF5)DJ;8BH[' M00=C;-W2%'[":I@W8&!Y(-.?
K36^VWB%/%\'V)X^5R'83/%*Q&:*KS4@X74# M1I:%=QO+ PQL%[#:@?SA/%!384Z2P*YBWK G&$>R#$.@%L,UFJ;(ZJ3P">\/ M]I0D29:%$<#"#I($0^!IQ!', 7C D"1Q[\&]]U&\?
D_%F_^=C7X#4$L#!!0 M (%6.9EF7BKL"*

*-8?20$3;8T.P6BP^0"X99K>]9!:GW VCE2V*HH]&FCFDY'=WVMPNM;YEOVJI["19.[;YF9D-P9X9=< KI:C;#P^&=5PR39=6%<5>Q".0P2NU+=4-C7GRG^]%75G;5#W""&YE3@#G-5
MM>#Q(,^UJD!9J-@'+KDJ@;61M0%=1M!EP]"Q5S-N(QA3D#F+P4Y]P2^MV5Z MQ;YMP&#O +(@((MA(,]UC65A'4 >$Y#'+P[I&>=.E[=K+0/($P+R9!#
($^BV=EJ1O5JSLI*9C(AOD.6U -M!:>WH8I)9@TLF%Z\FM+ME9/^2BWI-'E4M?"=4[QEQE+I,.4 M!E4*Z$%2;DDCRV4!IF:?->]-O"B/I)%%+6E$^F M]QEEB2RZ)986?C9^EG*Q?
5(T,LH+660OD/KZD868Y HDLAHH?;%7BQ"34D06 M61$'#(:$'$%Z%YTR11;9%(=,]L 98E*NR%[*%;OX_1.24=+(AI#&7DK*'EED M>SROU'L1*9EDD66RIV3O9:2TD@VS &%'[*RJA
L??U'"*R2,KABR11RS$I(23 M#[@(083WAY)1P\B&%\R,/'DD85#8.+H58A)"2>/+)S# MF,\RG;)/'MD^A_7]#)/23QY9/P8E(*RB,KB,+$' HQ*0OED2U$1K-7 M-
PO*0D5D"Q&8N*8P(29EH2*RA1ZGE@\EJ)'@Y?[0'F)2%BHB6RC$;',;..W#Y MJ_U5B$E9J(ALH;W3X;]EL_?NA7SY$ME"!S&[17"(25FHB&RA/=/V\"8-,2D+ M%9$MM&_JO@OE?1^3LE
1V4(D9K]N4A8JAE@(/:9\B$E9J&@M--J]5J]@A6N5 MZBO^A,7VDLMR9IC_Z!['V%\?^@=VJD?(&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'/-V3MNPD 4A>&M("^
X3X@(8)4:)&;,""X2$>MCP3!78?! 4I_RP>-(6AD6 KL%\18"O17U5@*J M%?56 KWUX6>;0&J%O95 ;T6]E4!O1;V50&]%O95 ;T6]E4!O1;V50&]%O95 M;T.]C4!O0[V-0&]#O8U
;WO8+"'0VU!O(}#;4&\CT-M0;R/0VU!O(}#;4&\C MT-M0;R/0VU%O)#;46\GT-M1;R?0VU%O)#;'S:["?1VU-L)]';4VY^I=\JG74RWGNL:CVZ>274^OQMOG[\LKS<1Y^$%YP!'K> ^_ M4$L#!!0 (%6.9EF<*],/O0$ '<= 3 6T-O;G1E;G1?5'EP97-= M+GAM;,W9R6[",!0%T%]!V2)B/)0.
C9MMRV+_?;AENVH?#W=<(@M:*H MB$}]FT2)*?=;.EL,G[;6O*]35TU?I(4(=@'QGQ64*U]:BPU<61N7*U#?'0+ M9G6VU MB8C@5:'WO(FO?6F;2>*H\DGO<3>QS9HD
MVMJJS'2(XVS=Y-]2!ON$-*[LYOBBM+X?)R3L9${I\G/ ?MWKFIPK<^K-M LO MNHZSV*9B/FPK\NGY$B=Z-/-YF5%NLE4=EZ3>.M*Y+XA"7:6[HOWSR2'N,.VN
M_.K\KLRYP#ASYHSU\<0<71YW.))V]<#&0N1">?X3CXFQ]-7?1^UIYY3_,CMN M[X=QR^X\/.MNU^_QUS,^UK^P#P'2AP3I0X'T<0/2QPBDCUN0/NY ^K@'Z8,/
M41I$96CD,I13.4HJ'(453D*JQS%58X"T>15:#(*E!D%2BR"A19!8JL D56 M@2*K0)%5H,@J4&25*+)*%%DEBJP215:)(JM$D56BR"I19)4HLDH4616*K I%
M5H4BJT*15:'(JE!D52BR*A19%8JLZC]E?3=F^=>_ MM[6NNR.>2S[G_K]!-0 M2P$'"% ,4 " !5CF99!T%-8H$ "Q $ @ $ M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 (%6.9ED<@)6P[P "L"
1 M " :\ !D;V-0&UL4$L! A0#% @ 58YF68ZW7E;*!0 W1X !@ M ("!#@@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0# M% @ 58YF69/1:P"!P 62< !@ ("!^1< 'AL+W=O
M&PO=V]R:W-H965T&UL4$L! A0#% @ 58YF6<_2)5 A M" E20 !@ ("!GR\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 58YF62!R"-7F"@ @AH !D M ("!D#T
'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ 58YF64+@#[LL!@ YA !D ("!_5, 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 58YF M65S2? <"#P P# !D ("!S6<
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 58YF63N$9H/X @ :08 M !D ("!R8('AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 58YF60D?%GJ@!@ 4Q$!D M ("!6(T
'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ 58YF6>235?R-! JPL !D ("!@IP 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ 58YF6J< 'AL+W=O&PO=V]R:W-
H965TYXO:1P0 ' 7 9 " @9"N !X;"]W;W)K&UL4$L! A0#% @ 58YF6;=>02$D! ,!@ !D M ("!#K, 'AL+W=O&PO M=V]R:W-H965T6Y !X;"]W;W)K&UL4$L! A0#% @ 58YF68;34^S$!@
C !D ("! MVKP 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ 58YF604"DN<\ @ _ 4 !D ("!"\T 'AL+W=O&UL4$L! A0#% @ 58YF69T!+-"F M @ \P8 !D ("!*-4
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 58YF66P7*H]0#0 CYD !D M ("!^MT 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ 58YF65WUWVBR! 4A\ !D ("!$OH M
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M58YF6;:R*A0/ P "PT !D ("!1@8! 'AL+W=O&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$'"% ,4 M " !5CF99G"O3#[T! !W'0 $P @
$G% $ 6T-O;G1E C;G1?5'EP97-=+GAM;%!+!08 .0 Y (8/ 5%@$! end XML 57 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR()};var
e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function()
{Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var
d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent)
{a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 58 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /*
v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a
{ display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px;
text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; }
.report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white;
border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report
th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica,
Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report
td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header
rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re,
.report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td
{ border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space:
nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding:
0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more
{ display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-
size: 1em; } XML 60 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 209 210 1 false 63 0 false 4 false false R1.htm 100000 - Document - Document and Entity
Information Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false
false R2.htm 100010 - Statement - Condensed Balance Sheets Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets
Condensed Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Condensed Balance Sheets (Parenthetical) Sheet
http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false*

false R4.htm 100030 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 100040 - Statement - Condensed Statements of Comprehensive Loss (Unaudited) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfComprehensiveLossUnaudited Condensed Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 100050 - Statement - Condensed Statement of Stockholders' Equity (Unaudited) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited Condensed Statement of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 100060 - Statement - Condensed Statement of Cash Flows (Unaudited) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited Condensed Statement of Cash Flows (Unaudited) Statements 7 false false R8.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 8 false false R9.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 9 false false R10.htm 995455 - Disclosure - Description of Business Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusiness Description of Business Notes 10 false false R11.htm 995465 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false false R12.htm 995475 - Disclosure - Revenue and Deferred Revenue Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenue Revenue and Deferred Revenue Notes 12 false false R13.htm 995485 - Disclosure - Fair Value Measurements Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 995495 - Disclosure - Balance Sheet Components Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponents Balance Sheet Components Notes 14 false false R15.htm 995505 - Disclosure - Commitments and Contingencies Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 995515 - Disclosure - Term Loan Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoan Term Loan Notes 16 false false R17.htm 995525 - Disclosure - Equity Incentive Plan Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlan Equity Incentive Plan Notes 17 false false R18.htm 995535 - Disclosure - Income Taxes Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxes Income Taxes Notes 18 false false R19.htm 995545 - Disclosure - Net Loss Per Share Sheet http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShare1 Net Loss Per Share Notes 19 false false R20.htm 995555 - Disclosure - Workforce reduction Sheet http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReduction Workforce reduction Notes 20 false false R21.htm 995565 - Disclosure - Subsequent Events Sheet http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 21 false false R22.htm 995575 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 22 false false R23.htm 995595 - Disclosure - Revenue and Deferred Revenue (Tables) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueTables Revenue and Deferred Revenue (Tables) Tables http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenue 23 false false R24.htm 995605 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurements 24 false false R25.htm 995615 - Disclosure - Balance Sheet Components (Tables) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables Balance Sheet Components (Tables) Tables http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponents 25 false false R26.htm 995625 - Disclosure - Term Loan (Tables) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanTables Term Loan (Tables) Tables http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoan 26 false false R27.htm 995635 - Disclosure - Equity Incentive Plan (Tables) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlanTables Equity Incentive Plan (Tables) Tables http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlan 27 false false R28.htm 995645 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShare1 28 false false R29.htm 995655 - Disclosure - Workforce reduction (Tables) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionTables Workforce reduction (Tables) Tables http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReduction 29 false false R30.htm 995665 - Disclosure - Description of Business - Additional Information (Detail) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail Description of Business - Additional Information (Detail) Details 30 false false R31.htm 995675 - Disclosure - Revenue and Deferred Revenue - Summary of Revenue by Source (Detail) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueSummaryOfRevenueBySourceDetail Revenue and Deferred Revenue - Summary of Revenue by Source (Detail) Details 31 false false R32.htm 995685 - Disclosure - Revenue and Deferred Revenue - Additional Information (Detail) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueAdditionalInformationDetail Revenue and Deferred Revenue - Additional Information (Detail) Details 32 false false R33.htm 995695 - Disclosure - Revenue and Deferred Revenue - Additional Information (Detail) 1 Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueAdditionalInformationDetail1 Revenue and Deferred Revenue - Additional Information (Detail) 1 Details 33 false false R34.htm 995705 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Detail) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFai Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Detail) Details 34 false false R35.htm 995715 - Disclosure - Fair Value Measurements - Schedule of breakdown of the available-for-sale debt securities with unrealized losses (Details) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfBreakdownOfTheAvailableforsaleDebtSecuritiesWithUnrealizedLossesDet Fair Value Measurements - Schedule of breakdown of the available-for-sale debt securities with unrealized losses (Details) Details 35 false false R36.htm 995725 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail Fair Value Measurements - Additional Information (Detail) Details 36 false false R37.htm 995735 - Disclosure - Balance Sheet Components (Additional Information) (Details) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails Balance Sheet Components (Additional Information) (Details) Details http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables 37 false false R38.htm 995745 - Disclosure - Balance Sheet Components - Schedule Of Cash And Cash Equivalents And Restricted Cash (Details) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails Balance Sheet Components - Schedule Of Cash And Cash Equivalents And Restricted Cash (Details) Details 38 false false R39.htm 995755 - Disclosure - Balance Sheet Components - Summary of Allowance for credit losses (Details) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAllowanceForCreditLossesDetails Balance Sheet Components - Summary of Allowance for credit losses (Details) Details 39 false false R40.htm 995765 - Disclosure - Balance Sheet Components - Schedule of Inventories (Detail) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoriesDetail Balance Sheet Components - Schedule of Inventories (Detail) Details 40 false false R41.htm 995775 - Disclosure - Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Detail) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedExpensesAndOtherCurrentLiabilitiesDetail Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Detail) Details 41 false false R42.htm 995785 - Disclosure - Term Loan - Schedule of Term Loan (Detail) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanScheduleOfTermLoanDetail Term Loan - Schedule of Term Loan (Detail) Details 42 false false R43.htm 995795 - Disclosure - Term Loan - Additional Information (Detail) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail Term Loan - Additional Information (Detail) Details 43 false false R44.htm 995805 - Disclosure - Equity Incentive Plans - Additional Information (Detail) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail Equity Incentive Plans - Additional Information (Detail) Details 44 false false R45.htm 995815 - Disclosure - Equity Incentive Plans - Summary of Stock-based Compensation Expense (Detail) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetail Equity Incentive Plans - Summary of Stock-based Compensation Expense (Detail) Details 45 false false R46.htm 995825 - Disclosure - Net Loss Per Share - Schedule of Outstanding Potentially Dilutive Shares were Excluded from Calculation of Diluted Net Loss Per Share (Detail) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedNe Net Loss Per Share - Schedule of Outstanding Potentially Dilutive Shares were Excluded from Calculation of Diluted Net Loss Per Share (Detail) Details 46 false false R47.htm 995835 - Disclosure - Workforce reduction - Summary of Workforce Reduction Plan Included in the Accompanying Condensed Statements Of Operations (Details) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionSummaryOfWorkforceReductionPlanIncludedInTheAccompanyingCondensedStatements Workforce reduction - Summary of Workforce Reduction Plan Included in the Accompanying Condensed Statements Of Operations (Details) Details 47 false false R48.htm 995845 - Disclosure - Workforce reduction - Summary of Changes in Liabilities Resulting from the Severance Charges and Related Accruals (Details) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionSummaryOfChangesInLiabilitiesResultingFromTheSeveranceChargesAndRelatedAccruals Workforce reduction - Summary of Changes in Liabilities Resulting from the Severance Charges and Related Accruals (Details) Details 48 false false R49.htm 995855 - Disclosure - Workforce reduction (Additional Information) (Details) Sheet http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionAdditionalInformationDetails Workforce reduction (Additional Information) (Details) Details http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionTables 49 false false All Reports Book All Reports om-20240930.htm om-20240930.xsd http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 false false JSON 62 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "om-20240930.htm": { "nsprefix": "om", "nsuri": "http://www.outsetmedical.com/20240930", "dts": { "inline": { "local": ["om-20240930.htm"] }, "schema": { "local": ["om-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 182, "keyCustom": 28, "axisStandard": 26, "axisCustom": 1, "memberStandard": 32, "memberCustom": 27, "hidden": { "total": 6, "http://fasb.org/us-gaap/2024": 2, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 209, "entityCount": 1, "segmentCount": 63, "elementCount": 569, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 604, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets", "longName": "100010 - Statement - Condensed Balance Sheets", "shortName": "Condensed Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_7157f517-596c-46d0-8e98-3af4af7ed4cb", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null,

```
"decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_7157f517-596c-46d0-8e98-3af4af7ed4cb", "name": "us-gaap:ShortTermInvestments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "unique": true } }, "R3": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical", "longName": "100020 - Statement - Condensed Balance Sheets (Parenthetical)", "shortName": "Condensed Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_7157f517-596c-46d0-8e98-3af4af7ed4cb", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7157f517-596c-46d0-8e98-3af4af7ed4cb", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited", "longName": "100030 - Statement - Condensed Statements of Operations (Unaudited)", "shortName": "Condensed Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_d82875bb-4ff2-4483-a8fb-74f0667ddd4e", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d82875bb-4ff2-4483-a8fb-74f0667ddd4e", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "unique": true } }, "R5": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfComprehensiveLossUnaudited", "longName": "100040 - Statement - Condensed Statements of Comprehensive Loss (Unaudited)", "shortName": "Condensed Statements of Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_d82875bb-4ff2-4483-a8fb-74f0667ddd4e", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d82875bb-4ff2-4483-a8fb-74f0667ddd4e", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "unique": true } }, "R6": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited", "longName": "100050 - Statement - Condensed Statement of Stockholders' Equity (Unaudited)", "shortName": "Condensed Statement of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_19551b63-a053-4e14-b0de-9cbe37bdc510", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_ca37b89b-4cd8-47f9-93f1-c38061650076", "name": "us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "unique": true } }, "R7": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited", "longName": "100060 - Statement - Condensed Statement of Cash Flows (Unaudited)", "shortName": "Condensed Statement of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:ShareBasedCompensation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "unique": true } }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_d82875bb-4ff2-4483-a8fb-74f0667ddd4e", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_d82875bb-4ff2-4483-a8fb-74f0667ddd4e", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d82875bb-4ff2-4483-a8fb-74f0667ddd4e", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusiness", "longName": "995455 - Disclosure - Description of Business", "shortName": "Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995465 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenue", "longName": "995475 - Disclosure - Revenue and Deferred Revenue", "shortName": "Revenue and Deferred Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurements", "longName": "995485 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponents", "longName": "995495 - Disclosure - Balance Sheet Components", "shortName": "Balance Sheet Components", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "longName": "995505 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoan", "longName": "995515 - Disclosure - Term Loan", "shortName": "Term Loan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlan", "longName": "995525 - Disclosure - Equity Incentive Plan", "shortName": "Equity Incentive Plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxes", "longName": "995535 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShare1", "longName": "995545 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReduction", "longName": "995555 - Disclosure - Workforce reduction", "shortName": "Workforce reduction", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureSubsequentEvents", "longName": "995565 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ],
```

```
"reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995575 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueTables", "longName": "995595 - Disclosure - Revenue and Deferred Revenue (Tables)", "shortName": "Revenue and Deferred Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "longName": "995605 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables", "longName": "995615 - Disclosure - Balance Sheet Components (Tables)", "shortName": "Balance Sheet Components (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanTables", "longName": "995625 - Disclosure - Term Loan (Tables)", "shortName": "Term Loan (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlanTables", "longName": "995635 - Disclosure - Equity Incentive Plan (Tables)", "shortName": "Equity Incentive Plan (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShareTables", "longName": "995645 - Disclosure - Net Loss Per Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionTables", "longName": "995655 - Disclosure - Workforce reduction (Tables)", "shortName": "Workforce reduction (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail", "longName": "995665 - Disclosure - Description of Business - Additional Information (Detail)", "shortName": "Description of Business - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_d82875bb-4ff2-4483-a8fb-74f0667ddd4e", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:PaymentsForOperatingActivities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "unique": true } }, "R31": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueSummaryOfRevenueBySourceDetail", "longName": "995675 - Disclosure - Revenue and Deferred Revenue - Summary of Revenue by Source (Detail)", "shortName": "Revenue and Deferred Revenue - Summary of Revenue by Source (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_d82875bb-4ff2-4483-a8fb-74f0667ddd4e", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_70b9c313-561a-465d-8ac8-5f5d3763b132", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "unique": true } }, "R32": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueAdditionalInformationDetail", "longName": "995685 - Disclosure - Revenue and Deferred Revenue - Additional Information (Detail)", "shortName": "Revenue and Deferred Revenue - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_7157f517-596c-46d0-8e98-3af4af7ed4cb", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d82875bb-4ff2-4483-a8fb-74f0667ddd4e", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "unique": true } }, "R33": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueAdditionalInformationDetail1", "longName": "995695 - Disclosure - Revenue and Deferred Revenue - Additional Information (Detail) 1", "shortName": "Revenue and Deferred Revenue - Additional Information (Detail) 1", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_f6e7190c-464d-4bca-b866-c603bdf9cee4", "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f6e7190c-464d-4bca-b866-c603bdf9cee4", "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa "longName": "995705 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Detail)", "shortName": "Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_7157f517-596c-46d0-8e98-3af4af7ed4cb", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "om:ScheduleOfBreakdownOfTheAvailableForSaleDebtSecuritiesWithUnrealizedLossesTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_e4e4eeb1-e549-4028-877f-4866711d7a6f", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "unique": true } }, "R35": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfBreakdownOfTheAvailableforsaleDebtSecuritiesWithUnrealizedLossesDe "longName": "995715 - Disclosure - Fair Value Measurements - Schedule of breakdown of the available-for-sale debt securities with unrealized losses (Details)", "shortName": "Fair Value Measurements - Schedule of breakdown of the available-for-sale debt securities with unrealized losses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_7157f517-596c-46d0-8e98-3af4af7ed4cb", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "om:ScheduleOfBreakdownOfTheAvailableForSaleDebtSecuritiesWithUnrealizedLossesTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7157f517-596c-46d0-8e98-3af4af7ed4cb", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "om:ScheduleOfBreakdownOfTheAvailableForSaleDebtSecuritiesWithUnrealizedLossesTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "longName": "995725 - Disclosure - Fair Value Measurements - Additional Information (Detail)", "shortName": "Fair Value Measurements - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "om:DebtSecuritiesAvailableForSaleRemainingContractualMaturitiesPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p",
```

```
"ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "om:DebtSecuritiesAvailableForSaleRemainingContractualMaturitiesPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "longName": "995735 - Disclosure - Balance Sheet Components (Additional Information) (Details)", "shortName": "Balance Sheet Components (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_7157f517-596c-46d0-8e98-3af4af7ed4cb", "name": "us-gaap:RestrictedCash", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true }, "uniqueAnchor": null }, "R38": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails", "longName": "995745 - Disclosure - Balance Sheet Components - Schedule Of Cash And Cash Equivalents And Restricted Cash (Details)", "shortName": "Balance Sheet Components - Schedule Of Cash And Cash Equivalents And Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_7157f517-596c-46d0-8e98-3af4af7ed4cb", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9ee6afba-3d93-40fc-a90e-db0b6ded8c86", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "unique": true } }, "R39": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAllowanceForCreditLossesDetails", "longName": "995755 - Disclosure - Balance Sheet Components - Summary of Allowance for credit losses (Details)", "shortName": "Balance Sheet Components - Summary of Allowance for credit losses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_4634819d-f79d-4f4b-8656-74fcb97868fe", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_4634819d-f79d-4f4b-8656-74fcb97868fe", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoriesDetail", "longName": "995765 - Disclosure - Balance Sheet Components - Schedule of Inventories (Detail)", "shortName": "Balance Sheet Components - Schedule of Inventories (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_7157f517-596c-46d0-8e98-3af4af7ed4cb", "name": "us-gaap:InventoryRawMaterials", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7157f517-596c-46d0-8e98-3af4af7ed4cb", "name": "us-gaap:InventoryRawMaterials", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedExpensesAndOtherCurrentLiabilitiesDetail", "longName": "995775 - Disclosure - Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Detail)", "shortName": "Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_7157f517-596c-46d0-8e98-3af4af7ed4cb", "name": "om:AccruedInventoryCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "om:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7157f517-596c-46d0-8e98-3af4af7ed4cb", "name": "om:AccruedInventoryCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "om:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanScheduleOfTermLoanDetail", "longName": "995785 - Disclosure - Term Loan - Schedule of Term Loan (Detail)", "shortName": "Term Loan - Schedule of Term Loan (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_7157f517-596c-46d0-8e98-3af4af7ed4cb", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true }, "uniqueAnchor": null }, "R43": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail", "longName": "995795 - Disclosure - Term Loan - Additional Information (Detail)", "shortName": "Term Loan - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_7157f517-596c-46d0-8e98-3af4af7ed4cb", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_e25569f0-093a-41f9-abfc-f811b0553cda", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "unique": true } }, "R44": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail", "longName": "995805 - Disclosure - Equity Incentive Plans - Additional Information (Detail)", "shortName": "Equity Incentive Plans - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "om:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageVestedInPeriod", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "om:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageVestedInPeriod", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetail", "longName": "995815 - Disclosure - Equity Incentive Plans - Summary of Stock-based Compensation Expense (Detail)", "shortName": "Equity Incentive Plans - Summary of Stock-based Compensation Expense (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_d82875bb-4ff2-4483-a8fb-74f0667ddd4e", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_39869e9b-5720-453f-9aa5-364c6c741102", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "unique": true } }, "R46": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedN
"longName": "995825 - Disclosure - Net Loss Per Share - Schedule of Outstanding Potentially Dilutive Shares were Excluded from Calculation of Diluted Net Loss Per Share (Detail)", "shortName": "Net Loss Per Share - Schedule of Outstanding Potentially Dilutive Shares were Excluded from Calculation of Diluted Net Loss Per Share (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_d82875bb-4ff2-4483-a8fb-74f0667ddd4e", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d82875bb-4ff2-4483-a8fb-74f0667ddd4e", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionSummaryOfWorkforceReductionPlanIncludedInTheAccompanyingCondensedStatements
"longName": "995835 - Disclosure - Workforce reduction - Summary of Workforce Reduction Plan Included in the Accompanying Condensed Statements Of Operations (Details)", "shortName": "Workforce reduction - Summary of Workforce Reduction Plan Included in the Accompanying Condensed Statements Of Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_d82875bb-4ff2-4483-a8fb-74f0667ddd4e", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_36563e6f-9f34-44cb-bee1-3f4a83a0a27c", "name": "us-gaap:CostOfRevenue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "unique": true } }, "R48": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionSummaryOfChangesInLiabilitiesResultingFromTheSeveranceChargesAndRelatedAccrua
"longName": "995845 - Disclosure - Workforce reduction - Summary of Changes in Liabilities Resulting from the Severance Charges and Related Accruals (Details)", "shortName": "Workforce reduction - Summary of Changes in Liabilities Resulting from the Severance Charges and Related Accruals (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_4634819d-f79d-4f4b-8656-74fcb97868fe", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
RestructuringCharges", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "om:ScheduleOfChangesInLiabilitiesResultingFromTheSeveranceChargesAndRelatedAccrualsTableTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_4634819d-f79d-4f4b-8656-74fcb97868fe", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "om:ScheduleOfChangesInLiabilitiesResultingFromTheSeveranceChargesAndRelatedAccrualsTableTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionAdditionalInformationDetails", "longName": "995855 - Disclosure - Workforce reduction (Additional Information) (Details)", "shortName": "Workforce reduction (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_e3a7d35d-6510-470a-bb75-68e4c27d0384", "name": "us-gaap:RestructuringCharges", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "om:ScheduleOfChangesInLiabilitiesResultingFromTheSeveranceChargesAndRelatedAccrualsTableTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3b220e52-2042-46f8-bdcf-fec1b2d59f40", "name": "us-gaap:RestructuringCharges", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "om-20240930.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype":
```

"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label":
"Accounts Payable, Current", "totalLabel": "Accounts Payable, Current, Total", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for
which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of
the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r40", "r707"] }, "us-
gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts
Receivable, Allowance for Credit Loss", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for
credit loss on accounts receivable." } } }, "auth_ref": ["r863"] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AccountsReceivableMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Accounts
Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } },
"auth_ref": ["r653"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"],
"lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "totalLabel": "Accounts
Receivable, after Allowance for Credit Loss, Current, Total", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product
sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r856"] }, "us-
gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Accretion
(Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Amortization of premium on investments, net", "documentation": "The sum of the periodic
adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at
a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in
operations using the indirect method." } } }, "auth_ref": ["r80"] }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AccruedEmployeeBenefitsCurrent", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation and
related benefits", "label": "Accrued Employee Benefits, Current", "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other
postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current
portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r43"] }, "us-gaap_AccruedExchangeFeeRebateCurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedExchangeFeeRebateCurrent", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedExpensesAndOtherCurrentLiabilitiesDetail"], "lang": { "en-us": {
"role": { "terseLabel": "Customer rebates", "label": "Accrued Exchange Fee Rebate, Current", "documentation": "Carrying value as of the balance sheet date of obligations
incurred through that date and payable for rebates of an exchange fee some mutual funds impose on shareholders if they exchange (transfer) to another fund within the same
fund group. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r43"] },
"om_AccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname":
"AccruedExpensesAndOtherCurrentLiabilities", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedExpensesAndOtherCurrentLiabilitiesDetail",
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total accrued expenses and
other current liabilities", "terseLabel": "Accrued expenses and other current liabilities", "label": "Accrued Expenses And Other Current Liabilities", "documentation": "Accrued
expenses and other current liabilities." } } }, "auth_ref": [] }, "om_AccruedInterestNoncurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.outsetmedical.com/20240930", "localname": "AccruedInterestNoncurrent", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label":
"Accrued Interest Noncurrent", "documentation": "Accrued interest, noncurrent." } } }, "auth_ref": [] }, "om_AccruedInventoryCurrent": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.outsetmedical.com/20240930", "localname": "AccruedInventoryCurrent", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedExpensesAndOtherCurrentLiabilitiesDetail"], "lang": { "en-us": {
"role": { "terseLabel": "Inventory", "label": "Accrued Inventory Current", "documentation": "Accrued inventory current." } } }, "auth_ref": [] }, "us-
gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr":
"credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedExpensesAndOtherCurrentLiabilitiesDetail"], "lang": { "en-us": {
"role": { "terseLabel": "Professional services", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations
incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due
within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r43"] }, "om_AccruedResearchAndDevelopmentExpenses": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "AccruedResearchAndDevelopmentExpenses", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedExpensesAndOtherCurrentLiabilitiesDetail"], "lang": { "en-us": {
"role": { "terseLabel": "Research and development expenses", "label": "Accrued Research And Development Expenses", "documentation": "Accrued research and development
expenses." } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other
comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax,
Total", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } },
"auth_ref": ["r11", "r12", "r63", "r133", "r539", "r566", "r567"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel":
"Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions
and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions
resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r1", "r7", "r12", "r441", "r444", "r490", "r562", "r563", "r832", "r833", "r834", "r843",
"r844", "r845", "r847"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text
Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r763"] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital",
"label": "Additional Paid in Capital, Common Stock", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "periodEndLabel": "Additional Paid
in Capital, Common Stock, Ending Balance", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or
stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called
contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r55"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel":
"Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and
amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r576", "r843", "r844", "r845", "r847", "r916", "r977"] },
"om_AdditionalTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "AdditionalTrancheMember",
"presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel":
"Additional Tranche", "documentation": "Additional Tranche [Member]", "label": "Additional Tranche [Member]" } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": {
"role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r776"] }, "ecd_AdjToCompAxis": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": {
"en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r776"] },
"ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock",
"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
"terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r776"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": {
"label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r776"] }, "us-
gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "negatedLabel":
"Adjustment to redemption value on redeemable convertible preferred stock", "label": "Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable
Preferred Stock", "documentation": "Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock." } }
}, "auth_ref": ["r8", "r90", "r94"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Stock-
based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "totalLabel": "APIC, Share-based Payment Arrangement,
Increase for Cost Recognition, Total", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment
arrangement." } } }, "auth_ref": ["r33", "r34", "r369"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel":
"Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating
Activities [Abstract]" } } }, "auth_ref": [] }, "om_AfterSecondAnniversaryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930",
"localname": "AfterSecondAnniversaryMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "After
Second Anniversary [Member]", "label": "After Second Anniversary [Member]", "terseLabel": "After Second Anniversary of Closing Date" } } }, "auth_ref": [] },
"ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate

Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r809"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r735", "r745", "r755", "r787"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r738", "r748", "r758", "r790"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r810"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r776"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r783"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r739", "r749", "r759", "r783", "r791", "r795", "r803"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r801"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation expense", "terseLabel": "Cumulative stock-based compensation", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r400", "r410"] }, "us-gaap_AllowanceForCreditLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForCreditLossAbstract", "lang": { "en-us": { "role": { "label": "Allowance for Credit Loss [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAllowanceForCreditLossesDetails"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss", "periodStartLabel": "Allowance for Credit Loss, Beginning Balance", "periodEndLabel": "Allowance for Credit Loss, Ending Balance", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r134", "r204", "r246", "r250", "r252", "r942"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAllowanceForCreditLossesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease), Total", "label": "Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)", "terseLabel": "Increase in allowance", "documentation": "Amount of increase (decrease) in allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r863"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "crdr": "debit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAllowanceForCreditLossesDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Write-offs", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "terseLabel": "Write-off adjustments", "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance." } } }, "auth_ref": ["r251"] }, "om_Allowancefordebtexpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "Allowancefordebtexpense", "crdr": "debit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAllowanceForCreditLossesDetails"], "lang": { "en-us": { "role": { "documentation": "AllowanceFordebtExpense", "label": "AllowanceFordebtExpense", "terseLabel": "Bad debt expense" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedN], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive shares excluded from calculation of diluted net loss per share", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r182"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedN], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r22"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedN], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedN], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r22"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r435"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r98", "r111", "r127", "r155", "r186", "r190", "r198", "r199", "r240", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r436", "r438", "r473", "r534", "r610", "r668", "r669", "r707", "r725", "r879", "r880", "r930"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r123", "r136", "r155", "r240", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r436", "r438", "r473", "r707", "r879", "r880", "r930"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Holding Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r213"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfBreakdownOfTheAvailableforsaleDebtSecuritiesWithUnrealizedLossesDe "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa], "lang": { "en-us": { "role": { "negatedLabel": "Gross Unrealized Holding Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r214"] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa], "lang": { "en-us": { "role": { "totalLabel": "Amortized Costs", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r210", "r264", "r533"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale", "totalLabel": "Debt Securities, Available-for-sale, Total", "terseLabel": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r211", "r264", "r451", "r528", "r695", "r698", "r857", "r920", "r921", "r922"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfBreakdownOfTheAvailableforsaleDebtSecuritiesWithUnrealizedLossesDe

```
], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r208", "r264" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r798" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r799" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r794" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r794" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r794" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r794" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r794" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r794" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r371", "r372", "r373", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r395", "r396", "r397", "r398", "r399" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r797" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r796" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r795" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r795" ] }, "om_BalanceSheetComponents": { "xbrltype": "stringItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "BalanceSheetComponents", "lang": { "en-us": { "role": { "documentation": "Balance Sheet Components [Abstract]", "label": "Balance Sheet Components" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r279", "r944", "r945" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r35", "r36", "r279", "r944", "r945" ] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusiness" ], "lang": { "en-us": { "role": { "terseLabel": "Description of Business", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r39", "r81", "r82" ] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Capital expenditures included in accounts payable and accrued expenses", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r19", "r20", "r21" ] }, "om_CashAndCashEquivalentMaintainPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "CashAndCashEquivalentMaintainPercentage", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalent maintain percentage", "label": "Cash and Cash Equivalent Maintain Percentage", "documentation": "Cash and Cash Equivalent Maintain Percentage" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails", "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r16", "r125", "r662" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfBreakdownOfTheAvailableforsaleDebtSecuritiesWithUnrealizedLossesDe ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r125" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, Cash Equivalents and Restricted Cash", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r17", "r97" ] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents and short-term investments", "label": "Cash, Cash Equivalents, and Short-Term Investments", "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": [ "r831" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance", "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r16", "r75", "r152" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash as of beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash as of end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r16", "r75", "r152" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
```

```
"crdr": "debit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r75" ] }, "om_CashCashEquivalentsRestrictedCashAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "CashCashEquivalentsRestrictedCashAndShortTermInvestments", "crdr": "debit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents, restricted cash and short-term investments", "label": "Cash Cash Equivalents Restricted Cash And Short Term Investments", "documentation": "Cash cash equivalents, restricted cash and short term investments." } } }, "auth_ref": [] }, "us-gaap_CashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsMember", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa
], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash Equivalents [Member]", "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r125" ] }, "om_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities", "label": "Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities", "documentation": "Cash paid for amounts included in the measurement of operating lease liabilities." } } }, "auth_ref": [] }, "om_CeoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "CeoMember", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "CEO [Member]", "label": "CEO [Member]", "terseLabel": "Ceo Member" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r774" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r771" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r769" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedN
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r120", "r130", "r131", "r132", "r155", "r176", "r177", "r179", "r181", "r188", "r189", "r240", "r300", "r302", "r303", "r304", "r307", "r308", "r337", "r338", "r339", "r340", "r342", "r473", "r570", "r571", "r572", "r573", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r598", "r619", "r637", "r648", "r649", "r650", "r651", "r652", "r814", "r840", "r848" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" }
} }, "auth_ref": [ "r775" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r775" ] }, "om_CollateralMonitoringFee": { "xbrltype": "percentItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "CollateralMonitoringFee", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit, collateral monitoring fee", "documentation": "Collateral monitoring fee", "label": "Collateral monitoring fee" } } }, "auth_ref": [] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfBreakdownOfTheAvailableforsaleDebtSecuritiesWithUnrealizedLossesDe
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa
], "lang": { "en-us": { "role": { "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r89", "r299", "r719", "r720", "r721", "r722" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 6)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r50", "r101", "r535", "r597" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r87", "r292", "r293", "r654", "r866", "r872" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock shares reserved for issuance", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r54" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r715", "r716", "r717", "r719", "r720", "r721", "r722", "r843", "r844", "r847", "r916", "r976", "r977" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r54" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r54", "r598" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "label": "Common Stock, Shares, Issued", "totalLabel": "Common Stock, Shares, Issued, Total", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r54" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r8", "r54", "r598", "r616", "r977", "r978" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value; 300,000 shares authorized as of September 30, 2024 and December 31, 2023; 52,538 and 50,317 shares issued and outstanding as of september 30, 2024 and December 31, 2023, respectively", "label": "Common Stock, Value, Issued", "totalLabel": "Common Stock, Value, Issued, Total", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r54", "r537", "r707" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r780" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r779" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r781" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r778" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel":
```

```
"Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r13", "r140", "r142", "r146", "r529", "r547", "r548" ] }, "om_ConsolesProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "ConsolesProductMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueAdditionalInformationDetail",
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueSummaryOfRevenueBySourceDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Consoles Product", "label": "Consoles Product [Member]", "documentation": "Consoles product." } } }, "auth_ref": [] }, "om_ConsumablesProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "ConsumablesProductMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueSummaryOfRevenueBySourceDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Consumables Product", "label": "Consumables Product [Member]", "documentation": "Consumables product." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue, current", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r344", "r345", "r356" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r344", "r345", "r356" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r357" ] }, "om_ConversionOfRedeemableConvertiblePreferredStockWarrantsToCommonStockWarrantsValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "ConversionOfRedeemableConvertiblePreferredStockWarrantsToCommonStockWarrantsValue", "crdr": "credit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Conversion Of Redeemable Convertible Preferred Stock Warrants To Common Stock Warrants Value", "terseLabel": "Conversion of Series A redeemable convertible preferred stock warrants to common stock warrants" } } }, "auth_ref": [] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfBreakdownOfTheAvailableforsaleDebtSecuritiesWithUnrealizedLossesDe
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa
], "lang": { "en-us": { "role": { "terseLabel": "Corporate debt", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r689", "r691", "r695", "r708", "r713", "r973" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue", "label": "Cost of Goods and Services Sold", "totalLabel": "Cost of Goods and Services Sold, Total", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r66", "r67", "r526" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionSummaryOfWorkforceReductionPlanIncludedInTheAccompanyingCondensedStatements
], "lang": { "en-us": { "role": { "totalLabel": "Cost of Revenue, Total", "label": "Cost of Revenue", "terseLabel": "Cost of revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r68", "r155", "r240", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r473", "r668", "r879" ] }, "us-gaap_CostOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenueAbstract", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue:", "label": "Cost of Revenue [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Revenue", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r299", "r877" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r299", "r877", "r878" ] }, "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditLossFinancialInstrumentPolicyTextBlock", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Losses", "label": "Credit Loss, Financial Instrument [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status." } } }, "auth_ref": [ "r243", "r244", "r245", "r247", "r248", "r253", "r255", "r256", "r257", "r258", "r260", "r261", "r262", "r263", "r265", "r266", "r267", "r270" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "om_DKeithGrossmanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "DKeithGrossmanMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "D. Keith Grossman [Member]", "label": "D. Keith Grossman [Member]", "terseLabel": "D. Keith Grossman" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoan" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r88", "r154", "r274", "r275", "r276", "r277", "r278", "r298", "r299", "r309", "r315", "r316", "r317", "r318", "r319", "r320", "r325", "r332", "r333", "r335", "r482" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r9", "r42", "r43", "r99", "r100", "r157", "r310", "r311", "r312", "r313", "r314", "r316", "r321", "r322", "r323", "r324", "r326", "r327", "r328", "r329", "r330", "r331", "r676", "r677", "r678", "r679", "r680", "r705", "r841", "r867", "r868", "r869", "r927", "r928" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail",
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanScheduleOfTermLoanDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Principal of term loan", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r310", "r482", "r483", "r677", "r678", "r705" ] }, "om_DebtInstrumentInterestOnlyPaymentsYearAndMonth": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "DebtInstrumentInterestOnlyPaymentsYearAndMonth", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument interest only payments end date", "label": "Debt Instrument Interest Only Payments Year And Month", "documentation": "Debt instrument interest only payments year and month." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt interest rate", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r45", "r336", "r482", "r483", "r705" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r157", "r310", "r311", "r312", "r313", "r314", "r316", "r321", "r322", "r323", "r324", "r326", "r327", "r328", "r329", "r330", "r331", "r334", "r676", "r677", "r678", "r679", "r680", "r705", "r841", "r927", "r928" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Loan maturity date", "label": "Debt Instrument, Maturity Date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r128", "r676", "r921", "r922" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r9", "r157", "r310", "r311", "r312", "r313", "r314", "r316", "r321", "r322", "r323", "r324", "r326", "r327", "r328", "r329", "r330", "r331", "r676", "r677", "r678", "r679", "r680", "r705", "r841", "r867", "r868",
```

```
"r869", "r927", "r928" ] }, "us-gaap_DebtInstrumentPaymentTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentPaymentTerms", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Description of payment terms", "label": "Debt Instrument, Payment Terms", "documentation": "Description of the payment terms of the debt
instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment." } } },
"auth_ref": [ "r38", "r46" ] }, "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument,
final payment amount", "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid", "documentation": "Amount of payment greater than the preceding
installment payments to be paid at final maturity date of debt." } } }, "auth_ref": [] }, "om_DebtInstrumentPrepaymentFeePercentage": { "xbrltype": "percentItemType",
"nsuri": "http://www.outsetmedical.com/20240930", "localname": "DebtInstrumentPrepaymentFeePercentage", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument
prepayment fee percentage", "label": "Debt Instrument Prepayment Fee Percentage", "documentation": "Debt instrument prepayment fee percentage." } } }, "auth_ref": [] },
"om_DebtInstrumentPrincipalPaymentTermAfterInterestOnlyPeriodExpires": { "xbrltype": "durationItemType", "nsuri": "http://www.outsetmedical.com/20240930",
"localname": "DebtInstrumentPrincipalPaymentTermAfterInterestOnlyPeriodExpires", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument
principal repayment period", "label": "Debt Instrument Principal Payment Term After Interest Only Period Expires", "documentation": "Debt instrument principal payment
term after interest only period expires." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DebtInstrumentTable", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information
about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r9", "r27", "r28", "r37", "r92", "r93", "r157", "r310", "r311", "r312", "r313", "r314", "r316", "r321",
"r322", "r323", "r324", "r326", "r327", "r328", "r329", "r330", "r331", "r334", "r676", "r677", "r678", "r679", "r680", "r705", "r841", "r927", "r928" ] }, "us-
gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscount",
"crdr": "debit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail",
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanScheduleOfTermLoanDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Unamortized
debt discount", "terseLabel": "Debt discount on Perceptive Term Loan", "label": "Debt Instrument, Unamortized Discount", "totalLabel": "Debt Instrument, Unamortized
Discount, Total", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r882", "r926", "r927", "r928" ] }, "us-
gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Securities in unrealized loss position for more than 12 months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
"documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in
continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [
"r113", "r269", "r671" ] }, "om_DebtSecuritiesAvailableForSaleRemainingContractualMaturitiesPeriod": { "xbrltype": "stringItemType", "nsuri":
"http://www.outsetmedical.com/20240930", "localname": "DebtSecuritiesAvailableForSaleRemainingContractualMaturitiesPeriod", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Debt Securities Available For Sale Remaining Contractual Maturities period.", "terseLabel": "Remaining contractual maturities for available-for-sale securities", "label":
"Debt Securities Available For Sale Remaining Contractual Maturities Period" } } }, "auth_ref": [] }, "om_DeemedDividendOnSettlementOfAccruedDividend": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "DeemedDividendOnSettlementOfAccruedDividend", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel":
"Deemed dividend on settlement of accrued dividend", "terseLabel": "Deemed dividend on settlement of accrued dividend", "label": "Deemed Dividend On Settlement Of
Accrued Dividend", "documentation": "Deemed dividend on settlement of accrued dividend." } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Issuance
Costs", "label": "Debt Issuance Costs, Net", "totalLabel": "Debt Issuance Costs, Net, Total", "documentation": "Amount, after accumulated amortization, of debt issuance costs.
Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r882", "r926", "r927", "r928" ] }, "us-
gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionSummaryOfChangesInLiabilitiesResultingFromTheSeveranceChargesAndRelatedAccrua
], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges", "periodStartLabel": "Balance as of
December 31, 2023", "periodEndLabel": "Balance as of June 30, 2024", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable
to deductible temporary differences from restructuring reserve." } } }, "auth_ref": [ "r914" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "totalLabel": "Depreciation, Depletion and Amortization, Total", "documentation": "The
aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the
assets." } } }, "auth_ref": [ "r5", "r186", "r194", "r199", "r668", "r669" ] }, "om_DescriptionOfBusinessLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://www.outsetmedical.com/20240930", "localname": "DescriptionOfBusinessLineItems", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Description Of Business [Line Items]", "label": "Description Of Business [Line Items]", "documentation": "Description of business." } } }, "auth_ref": [] },
"om_DescriptionOfBusinessTable": { "xbrltype": "stringItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "DescriptionOfBusinessTable",
"presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Description Of Business [Table]", "label": "Description Of Business [Table]", "documentation": "Description of business." } } }, "auth_ref": [] }, "us-
gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems",
"presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueSummaryOfRevenueBySourceDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Disaggregation Of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial
concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },
"auth_ref": [ "r355", "r682", "r683", "r684", "r685", "r686", "r687", "r688" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueSummaryOfRevenueBySourceDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Disaggregation Of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue
into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r355", "r682", "r683",
"r684", "r685", "r686", "r687", "r688" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of
Revenue by Source", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how
nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r883" ] }, "us-
gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlan" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Incentive Plan", "label":
"Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r368", "r370", "r401",
"r402", "r404", "r693" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement
[Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"DocumentFiscalPeriodFocus", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us":
{ "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and
3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] },
"dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year
Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also
provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": {
"xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End
Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported;
for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-
MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"DocumentQuarterlyReport", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": {
"role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly
report." } } }, "auth_ref": [ "r730" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"DocumentTransitionReport", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": {
"role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition
report." } } }, "auth_ref": [ "r762" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType",
"presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "verboseLabel":
"Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the
same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] },
"ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other
Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r773" ] }, "us-gaap_EarlyRepaymentOfSeniorDebt": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarlyRepaymentOfSeniorDebt", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Early Repayment of
Senior Debt", "terseLabel": "Early repayment fee", "documentation": "The cash outflow for the extinguishment of long-term borrowing, with the highest claim on the assets of
the entity in case of bankruptcy or liquidation, before its maturity." } } }, "auth_ref": [ "r74" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [
```

```
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, basic", "label": "Earnings Per Share, Basic", "totalLabel": "Earnings Per Share, Basic, Total", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r147", "r163", "r164", "r165", "r166", "r167", "r168", "r174", "r176", "r179", "r180", "r181", "r185", "r431", "r434", "r448", "r449", "r530", "r549", "r665" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share,diluted", "label": "Earnings Per Share, Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r147", "r163", "r164", "r165", "r166", "r167", "r168", "r176", "r179", "r180", "r181", "r185", "r431", "r434", "r448", "r449", "r530", "r549", "r665" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShare1" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r173", "r182", "r183", "r184" ] }, "us-gaap_EffectOfFourthQuarterEventsByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfFourthQuarterEventsByTypeAxis", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Effect of Fourth Quarter Event Type [Axis]", "terseLabel": "Effect of Fourth Quarter Event Type", "documentation": "Information by type of event or transaction that occurred during the fourth quarter." } } }, "auth_ref": [ "r23" ] }, "us-gaap_EffectOfFourthQuarterEventsTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfFourthQuarterEventsTypeDomain", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Effect of Fourth Quarter Events, Type [Domain]", "documentation": "The type of event or transaction having a material effect on fourth quarter and fiscal year results." } } }, "auth_ref": [ "r23" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated weighted average period over which unamortized share-based compensation are expected to be recognize", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r403" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unamortized stock-based compensation expense amount", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r911" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedN
], "lang": { "en-us": { "role": { "terseLabel": "Shares Committed under ESPP", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "om_EmployeesSharePurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "EmployeesSharePurchasePlanMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Employees Share Purchase Plan (ESPP)", "label": "Employees Share Purchase Plan [Member]", "documentation": "Employees share purchase plan." } } }, "auth_ref": [] }, "om_EndOfYear3Member": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "EndOfYear3Member", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "End Of Year 3 [Member]", "label": "End Of Year 3 [Member]", "terseLabel": "End Of Year 3 [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Bankruptcy Proceedings, Reporting Current", "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r729" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r727" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r727" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r813" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r727" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r812" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant
```

Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r727"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r727"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r727"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r727"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r767"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r808"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r808"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r808"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r8", "r121", "r143", "r144", "r145", "r158", "r159", "r160", "r162", "r167", "r169", "r171", "r187", "r241", "r242", "r272", "r343", "r421", "r422", "r428", "r429", "r430", "r432", "r433", "r434", "r440", "r441", "r442", "r443", "r444", "r445", "r447", "r474", "r475", "r476", "r477", "r478", "r479", "r484", "r485", "r490", "r545", "r562", "r563", "r564", "r576", "r637"] }, "om_EquityIncentivePlanLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "EquityIncentivePlanLineItems", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "terseLabel": "Equity Incentive Plan [Line Items]", "label": "Equity Incentive Plan [Line Items]", "documentation": "Equity Incentive Plan [Line Items]" } } }, "auth_ref": [] }, "om_EquityIncentivePlanTable": { "xbrltype": "stringItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "EquityIncentivePlanTable", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "terseLabel": "Equity Incentive Plan [Table]", "label": "Equity Incentive Plan [Table]", "documentation": "Equity Incentive Plan [Table]" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r777"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r735", "r745", "r755", "r787"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r732", "r742", "r752", "r784"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r783"] }, "us-gaap_ExtendedMaturityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ExtendedMaturityMember", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Extended Maturity", "label": "Extended Maturity [Member]", "documentation": "Loan modification for an extension of the term of a loan in which it must be paid." } } }, "auth_ref": ["r205", "r670"] }, "us-gaap_FairValueAdjustmentToInventoryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentToInventoryMember", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Fair Value Adjustment to Inventory [Member]", "documentation": "Fair value adjustment to acquisition-date inventory allocated (included) to (in) reported pro forma earnings (supplemental pro forma information)." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfBreakdownOfTheAvailableforsaleDebtSecuritiesWithUnrealizedLossesDe "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r451", "r452", "r465", "r695"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfBreakdownOfTheAvailableforsaleDebtSecuritiesWithUnrealizedLossesDe "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r451", "r452", "r465", "r695"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa], "lang": { "en-us": { "role": { "terseLabel": "Asset Class", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": ["r456", "r457", "r458", "r459", "r460", "r461", "r466", "r696"] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa], "lang": { "en-us": { "role": { "terseLabel": "Asset Class", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": ["r456", "r457", "r458", "r459", "r460", "r461", "r466", "r696"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r323", "r360", "r361", "r362", "r363", "r364", "r365", "r450", "r452", "r453", "r454", "r455", "r464", "r465", "r467", "r497", "r498", "r499", "r677", "r678", "r689", "r690", "r691", "r695", "r698"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r451", "r452", "r453", "r455", "r695", "r921", "r924"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurements"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r460", "r462", "r463", "r464", "r467", "r468", "r469", "r470", "r471", "r527", "r695", "r699"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r323", "r360", "r365", "r452", "r465", "r497", "r689", "r690", "r691", "r695"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r323", "r360", "r365", "r452", "r453", "r465", "r498", "r677", "r678", "r689", "r690", "r691", "r695"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } },

```
"auth_ref": [ "r451", "r452", "r453", "r455", "r695", "r921", "r924" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa
], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to
prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r323", "r360", "r361", "r362", "r363", "r364", "r365", "r450", "r452", "r453", "r454",
"r455", "r464", "r465", "r467", "r497", "r498", "r499", "r677", "r678", "r689", "r690", "r691", "r695", "r698" ] }, "us-gaap_FairValueMeasurementsRecurringMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa
], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes,
but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r695", "r918", "r919", "r920",
"r921", "r922", "r924" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis",
"presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa
], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r209", "r210", "r211",
"r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233",
"r234", "r235", "r236", "r237", "r238", "r248", "r249", "r253", "r254", "r259", "r268", "r270", "r271", "r334", "r341", "r446", "r472", "r494", "r495", "r496", "r497", "r498",
"r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521",
"r522", "r523", "r524", "r546", "r671", "r695", "r696", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r708", "r817", "r818", "r819", "r820", "r821", "r822", "r823",
"r858", "r859", "r860", "r861", "r917", "r920", "r921", "r922", "r923", "r924" ] }, "om_FirstAnniversaryMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.outsetmedical.com/20240930", "localname": "FirstAnniversaryMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "First
Anniversary [Member]", "label": "First Anniversary [Member]", "terseLabel": "First Anniversary of Closing Date" } } }, "auth_ref": [] }, "om_FirstRevenueMilestoneMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "FirstRevenueMilestoneMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "First
Revenue Milestone [Member]", "label": "First Revenue Milestone [Member]", "terseLabel": "First Revenue Milestone" } } }, "auth_ref": [] },
"om_FollowOnPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "FollowOnPublicOfferingMember",
"presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Follow-on Public Offering", "label": "Follow On Public Offering [Member]", "documentation": "Follow-On Public Offering [Member]" } } }, "auth_ref": [] },
"ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone
Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r739", "r749",
"r759", "r791" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone
Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r739", "r749", "r759", "r791"
] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone
Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r739", "r749",
"r759", "r791" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone
Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r739", "r749", "r759", "r791" ] },
"ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r739",
"r749", "r759", "r791" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet
Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet
Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r772" ] }, "us-gaap_GainLossOnDispositionOfAssets": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on
Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "terseLabel": "Loss on disposal of property and equipment",
"negatedTerseLabel": "Loss on disposal of property and equipment", "negatedLabel": "Loss on disposal of property and equipment", "documentation": "Amount of gain (loss)
on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property." } } }, "auth_ref": [ "r837", "r864", "r865" ] }, "us-
gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt",
"crdr": "credit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": {
"role": { "terseLabel": "Loss on extinguishment of term loan", "label": "Gain (Loss) on Extinguishment of Debt", "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total",
"documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r5",
"r25", "r26" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionSummaryOfWorkforceReductionPlanIncludedInTheAccompanyingCondensedStatements
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "General
and administrative", "label": "General and Administrative Expense", "totalLabel": "General and Administrative Expense, Total", "documentation": "The aggregate total of
expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the
manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r70", "r621" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "General and Administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption
encompassing general and administrative expense." } } }, "auth_ref": [ "r70" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "GrossProfit", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Gross
profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation
activity." } } }, "auth_ref": [ "r64", "r68", "r110", "r155", "r240", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r473", "r667", "r668", "r850", "r851",
"r852", "r853", "r854", "r879" ] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IPOMember", "presentation":
[ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"IPO", "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss
before provision for income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income
(loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable
to noncontrolling interest." } } }, "auth_ref": [ "r65", "r106", "r110", "r531", "r543", "r667", "r668", "r850", "r851", "r852", "r853", "r854" ] }, "us-
gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role":
{ "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of
income where disaggregated amount has been reported." } } }, "auth_ref": [ "r273", "r279", "r284", "r457", "r461", "r466", "r559", "r561", "r622", "r657", "r697", "r946" ] },
"us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain",
"presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "lang":
{ "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of
income where disaggregated amount has been reported." } } }, "auth_ref": [ "r279", "r284", "r457", "r461", "r466", "r559", "r561", "r622", "r657", "r697", "r946" ] }, "us-
gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": {
"role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax
Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r156", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r423",
"r425", "r426", "r427", "r575", "r694" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Provision
for income taxes", "label": "Income Tax Expense (Benefit)", "totalLabel": "Income Tax Expense (Benefit), Total", "documentation": "Amount of current income tax expense
(benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r114", "r118", "r170", "r171", "r186", "r195", "r199", "r414",
"r415", "r424", "r550", "r694" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaid",
"crdr": "credit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": {
"role": { "terseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local
jurisdictions as income tax." } } }, "auth_ref": [ "r18", "r79", "r838", "r912", "r913" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel":
"Accounts payable", "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
"documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received)
and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel":
"Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one
year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-
gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

"IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": ["r836"] }, "om_IncreaseDecreaseInAccruedWarrantyLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "IncreaseDecreaseInAccruedWarrantyLiability", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accrued warranty liability", "label": "Increase Decrease In Accrued Warranty Liability", "documentation": "Increase (decrease) in accrued warranty liability." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r658"] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation and related benefits", "label": "Increase (Decrease) in Employee Related Liabilities", "totalLabel": "Increase (Decrease) in Employee Related Liabilities, Total", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "totalLabel": "Increase (Decrease) in Inventories, Total", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "om_IncreaseDecreaseInOperatingLeaseLiabilities": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "crdr": "debit",
"presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": {
"terseLabel": "Operating lease liabilities", "label": "Increase Decrease In Operating Lease Liabilities", "documentation": "Increase (decrease) in operating lease liabilities." } }
}, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInPrepaidExpensesOther", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expenses, Other", "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods." } } }, "auth_ref": ["r4"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": {
"role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r739", "r749", "r759", "r783", "r791", "r795", "r803"] },
"om_InitialRevolverCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname":
"InitialRevolverCommitmentMember", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"],
"lang": { "en-us": { "role": { "documentation": "Initial Revolver Commitment [Member]", "label": "Initial Revolver Commitment [Member]", "terseLabel": "Initial Revolver Commitment" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } },
"auth_ref": ["r801"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r731", "r807"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r731", "r807"] },
"ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r731", "r807"] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense, Operating and Nonoperating", "totalLabel": "Interest Expense, Total", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": ["r186", "r190", "r193", "r196", "r199", "r481", "r668", "r669"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr":
"credit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": {
"terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [
"r148", "r150", "r151"] }, "us-gaap_InterestRateFloorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InterestRateFloorMember", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "InterestRateFloor", "label": "Interest Rate Floor [Member]", "documentation": "Contracts in which the floor writer, in return for a premium, agrees to limit the risk associated with a decline in interest rates based on a notional amount. If rates fall below an agreed rate, the floor holder will receive cash payments from the floor writer equal to the difference between the market rate and an agreed rate multiplied by the notional principal amount." } } }, "auth_ref": ["r659"] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": {
"role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoriesDetail"], "lang": { "en-us": { "role": { "terseLabel":
"Finished goods", "label": "Inventory, Finished Goods, Gross", "totalLabel": "Inventory, Finished Goods, Gross, Total", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": ["r827"] }, "us-gaap_InventoryNet": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoriesDetail",
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total inventories",
"terseLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r135", "r663", "r707"] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoriesDetail"], "lang": { "en-us": { "role": { "label":
"Inventory, Raw Materials, Gross", "terseLabel": "Raw materials", "totalLabel": "Inventory, Raw Materials, Gross, Total", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r829"] }, "us-gaap_InventoryWorkInProcess": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoriesDetail"], "lang": { "en-us": { "role": { "terseLabel":
"Work in process", "label": "Inventory, Work in Process, Gross", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": ["r828"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label":
"Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [
"r9", "r42", "r43", "r44", "r48", "r49", "r50", "r51", "r155", "r240", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r437", "r438", "r439", "r473", "r596",
"r666", "r725", "r879", "r930", "r931"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"],
"lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r59", "r102", "r541", "r707", "r842", "r862", "r925"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": {
"en-us": { "role": { "terseLabel": "Liabilities and stockholders' equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities",
"label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r44", "r124", "r155", "r240", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r437", "r438",
"r439", "r473", "r707", "r879", "r930", "r931"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesCurrentAbstract", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role":
{ "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "om_LineOfCreditBorrowingBaseAmount": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "LineOfCreditBorrowingBaseAmount", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Line of credit, borrowing base, amount", "label": "Line of Credit, Borrowing Base, Amount", "documentation": "Line of Credit, Borrowing Base, Amount" } } }, "auth_ref": [] },
"om_LineOfCreditBorrowingBasePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname":
"LineOfCreditBorrowingBasePercentage", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"],
"lang": { "en-us": { "role": { "terseLabel": "Line of credit, borrowing base, percentage", "label": "Line of Credit, Borrowing Base, Percentage", "documentation": "Line of Credit, Borrowing Base, Percentage" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeeAmount", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Commitment Fee Amount", "terseLabel": "Non-refundable facility fee", "documentation": "Amount of the fee for available but unused credit capacity under the credit facility." } } }, "auth_ref": ["r41", "r47", "r299"] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Line of credit, commitment fee percentage", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility,

```
for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit, current borrowing capacity", "label": "Line of Credit Facility, Current Borrowing Capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": [ "r41", "r47" ] }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityExpirationDate1", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit, expiration date", "label": "Line of Credit Facility, Expiration Date", "documentation": "Date the credit facility terminates, in YYYY-MM-DD format." } } }, "auth_ref": [ "r41", "r47" ] }, "us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit, payment terms, description", "label": "Line of Credit Facility, Frequency of Payment and Payment Terms", "documentation": "Description of the frequency of the required periodic payments of interest, principal, or both, and the amount, if set, or a description of a formula upon which payment is based." } } }, "auth_ref": [ "r41", "r47" ] }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit, default interest rate", "label": "Line of Credit Facility, Interest Rate at Period End", "documentation": "The effective interest rate at the end of the reporting period." } } }, "auth_ref": [ "r41", "r47" ] }, "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityInterestRateDuringPeriod", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit, interest rate", "label": "Line of Credit Facility, Interest Rate During Period", "documentation": "The effective interest rate during the reporting period." } } }, "auth_ref": [ "r41", "r47" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r41", "r47" ] }, "om_LineOfCreditPercentageOfPrepaymentPremium": { "xbrltype": "percentItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "LineOfCreditPercentageOfPrepaymentPremium", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit, percentage of prepayment premium", "label": "Line Of Credit, Percentage of Prepayment Premium", "documentation": "Line Of Credit, Percentage of Prepayment Premium" } } }, "auth_ref": [] }, "om_LineOfCreditTerminationFee": { "xbrltype": "percentItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "LineOfCreditTerminationFee", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit, termination fee", "label": "Line of Credit, Termination Fee", "documentation": "Line of Credit, Termination Fee" } } }, "auth_ref": [] }, "us-gaap_LoanRestructuringModificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoanRestructuringModificationAxis", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loan Restructuring Modification [Axis]", "documentation": "Information by concessions made to the terms of loan contracts." } } }, "auth_ref": [ "r205", "r206", "r207", "r670" ] }, "us-gaap_LoanRestructuringModificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoanRestructuringModificationDomain", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loan Restructuring Modification [Domain]", "documentation": "Concessions made to the terms of loan contracts, including but not limited to, interest rate reductions, maturity extensions, principal forgiveness, and payment deferral." } } }, "auth_ref": [ "r205", "r206", "r207", "r670" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanScheduleOfTermLoanDetail", "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan", "label": "Long-Term Debt, Excluding Current Maturities", "totalLabel": "Term loan, noncurrent", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r129" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r294", "r295", "r296", "r297", "r366", "r411", "r455", "r525", "r558", "r560", "r568", "r588", "r589", "r640", "r641", "r642", "r643", "r644", "r655", "r656", "r670", "r681", "r692", "r698", "r699", "r703", "r704", "r710", "r881", "r932", "r933", "r934", "r935", "r936", "r937" ] }, "om_May2024WorkforceReductionPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "May2024WorkforceReductionPlanMember", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "May 2024 Workforce Reduction Plan [Member]", "label": "May 2024 Workforce Reduction Plan [Member]", "terseLabel": "May2024 Workforce Reduction Plan" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r775" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r775" ] }, "om_MilestoneAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "MilestoneAxis", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Milestone [Axis]", "documentation": "Milestone [Axis]" } } }, "auth_ref": [] }, "om_MilestoneDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "MilestoneDomain", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Milestone [Domain]", "documentation": "Milestone [Domain]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r294", "r295", "r296", "r297", "r366", "r411", "r455", "r525", "r558", "r560", "r568", "r588", "r589", "r640", "r641", "r642", "r643", "r644", "r655", "r656", "r670", "r681", "r692", "r698", "r699", "r703", "r710", "r881", "r932", "r933", "r934", "r935", "r936", "r937" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r794" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r884" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r802" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r776" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r149" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r149" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r75", "r76", "r80" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype":
```

"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail",
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited",
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfComprehensiveLossUnaudited",
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited",
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"],
"lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "negatedLabel": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r69", "r80", "r107", "r122", "r139", "r141", "r145", "r155", "r161", "r163", "r164", "r165", "r166", "r167", "r170", "r171", "r178", "r240", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r431", "r434", "r449", "r473", "r544", "r618", "r635", "r636", "r723", "r879"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Recently Adopted Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "om_NonCashInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "NonCashInterestExpense", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Non-cash interest expense", "label": "Non Cash Interest Expense", "documentation": "Non-cash interest expense." } } }, "auth_ref": [] }, "om_NonCashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "NonCashLeaseExpense", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Non-cash lease expense", "label": "Non Cash Lease Expense", "documentation": "Non-cash lease expense." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r775"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r739", "r749", "r759", "r783", "r791"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r766"] },
"ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r765"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r783"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r802"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r802"] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Supplemental non-cash investing and financing activities:", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Nonoperating Income (Expense), Total", "terseLabel": "Interest income and other income, net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r71"] }, "om_OfferingCostsUnderwritingDiscountsAndCommissionsExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "OfferingCostsUnderwritingDiscountsAndCommissionsExpenses", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Offering costs, underwriting discounts and commissions expenses", "label": "Offering Costs Underwriting Discounts And Commissions Expenses", "documentation": "Offering costs, underwriting discounts and commissions expenses." } } }, "auth_ref": [] }, "us-gaap_OneTimeTerminationBenefitsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OneTimeTerminationBenefitsMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "One-time Termination Benefits [Member]", "terseLabel": "One-time Termination Benefits", "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities." } } }, "auth_ref": ["r672", "r673", "r674", "r675"] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r110", "r667", "r850", "r851", "r852", "r853", "r854"] }, "om_OperatingLeaseArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "OperatingLeaseArrangementsMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease Arrangements", "label": "Operating Lease Arrangements [Member]", "documentation": "Operating lease arrangements." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, current", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r487"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r487"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r486"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "totalLabel": "Other Assets, Noncurrent, Total", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r126"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive (loss) income:" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfComprehensiveLossUnaudited",
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain on available-for-sale securities", "verboseLabel": "Unrealized loss on available-for-sale securities", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r137", "r138", "r239"] }, "om_OtherDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "OtherDebtIssuanceCosts", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Other debt issuance costs", "label": "Other Debt Issuance Costs", "documentation": "Other debt issuance costs." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedExpensesAndOtherCurrentLiabilitiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Liabilities, Current", "totalLabel": "Other Liabilities, Current, Total", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r43", "r707"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r775"] }, "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Other-than-temporary impairment losses related to investments", "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale, Recognized in Earnings", "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings." } } }, "auth_ref": ["r112"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r737", "r747", "r757", "r789"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":

"OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r740", "r750", "r760", "r792"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r740", "r750", "r760", "r792"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r764"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForOperatingActivities", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Cash outflow from operating activities", "label": "Payments for Operating Activities", "totalLabel": "Payments for Operating Activities, Total", "documentation": "Total amount of cash paid for operating activities during the current period." } } }, "auth_ref": ["r3", "r77", "r78", "r79"] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionSummaryOfChangesInLiabilitiesResultingFromTheSeveranceChargesAndRelatedAccrua
], "lang": { "en-us": { "role": { "label": "Payments for Restructuring", "terseLabel": "Payments and other adjustments", "negatedLabel": "Payments and other adjustments", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r283", "r835"] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of investment securities", "label": "Payments to Acquire Investments", "totalLabel": "Payments to Acquire Investments, Total", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": ["r72"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r73"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r774"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r774"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r766"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r783"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r776"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r765"] }, "om_PercentageOfLimitationOnPledgesOfCapitalStockOfForeignSubsidiaries": { "xbrltype": "percentItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "PercentageOfLimitationOnPledgesOfCapitalStockOfForeignSubsidiaries", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of limitation on pledges of capital stock of foreign subsidiaries", "label": "Percentage Of Limitation On Pledges Of Capital Stock Of Foreign Subsidiaries", "documentation": "Percentage of limitation on pledges of capital stock of foreign subsidiaries." } } }, "auth_ref": [] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedN
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Performance Shares [Member]", "terseLabel": "Performance Stock Units", "verboseLabel": "PSUs", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "terseLabel": "Plan Name", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r767"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r811"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r766"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r53", "r337"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r53", "r598"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued", "label": "Preferred Stock, Shares Issued", "totalLabel": "Preferred Stock, Shares Issued, Total", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r53", "r337"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding", "label": "Preferred Stock, Shares Outstanding", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r53", "r598", "r616", "r977", "r978"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of September 30, 2024 and December 31, 2023", "label": "Preferred Stock, Value, Issued", "totalLabel": "Preferred Stock, Value, Issued, Total", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r53", "r536", "r707"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r831"] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrimeRateMember", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Prime Rate", "label": "Prime Rate [Member]", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Aggregate net proceeds from IPO", "label": "Proceeds from Issuance Initial Public Offering", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": ["r2"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock upon follow-on public offering, net of issuance costs", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r2"] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Proceeds from Issuance of Long-Term Debt, Total", "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Proceeds from issuance of term loans, net of issuance costs", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r15", "r570"] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Lines of Credit", "label": "Proceeds from Lines of Credit", "totalLabel": "Proceeds from Lines of Credit, Total", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": ["r15",

"r841"] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Maturities of investment securities", "label": "Proceeds from Sale, Maturity and Collection of Investments", "totalLabel": "Proceeds from Sale, Maturity and Collection of Investments, Total", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth_ref": ["r14"] }, "om_ProceedsFromStockOptionsExercisedAndEmployeeStockPurchasePlanPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "ProceedsFromStockOptionsExercisedAndEmployeeStockPurchasePlanPurchases", "crdr": "debit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Proceeds From Stock Options Exercised And Employee Stock Purchase Plan Purchases", "documentation": "Proceeds from stock option exercises and employee stock purchase plan purchases.", "terseLabel": "Proceeds from stock option exercises and ESPP purchases" } } }, "auth_ref": [] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueSummaryOfRevenueBySourceDetail", "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Product Revenue", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": ["r682"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueAdditionalInformationDetail", "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueSummaryOfRevenueBySourceDetail", "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Axis]" } } }, "auth_ref": ["r200", "r526", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r660", "r682", "r709", "r710", "r711", "r712", "r714", "r873", "r874", "r883", "r943", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r974", "r975"] }, "us-gaap_ProductWarrantyAccrualClassifiedCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductWarrantyAccrualClassifiedCurrent", "crdr": "credit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accrued warranty liability", "periodStartLabel": "Balance at the beginning of the period", "periodEndLabel": "Balance at the end of the period", "label": "Product Warranty Accrual, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r43", "r875", "r876"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueAdditionalInformationDetail", "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueSummaryOfRevenueBySourceDetail", "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Domain]" } } }, "auth_ref": ["r200", "r526", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r660", "r682", "r709", "r710", "r711", "r712", "r714", "r873", "r874", "r883", "r943", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r974", "r975"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property, Plant and Equipment, Net, Total", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r6", "r489", "r532", "r542", "r707"] }, "om_ProvisionForInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "ProvisionForInventories", "crdr": "debit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Provision for inventories", "label": "Provision For Inventories", "documentation": "Provision for inventories." } } }, "auth_ref": [] }, "us-gaap_ProvisionForOtherCreditLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForOtherCreditLosses", "crdr": "debit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Provision for Other Credit Losses", "terseLabel": "Allowance for credit losses", "documentation": "Amount of expense related to credit loss from transactions other than loan and lease transactions." } } }, "auth_ref": ["r4", "r105"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r764"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r764"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r294", "r295", "r296", "r297", "r359", "r366", "r396", "r397", "r398", "r411", "r455", "r500", "r509", "r525", "r558", "r560", "r568", "r588", "r589", "r640", "r641", "r642", "r643", "r644", "r655", "r656", "r670", "r681", "r692", "r698", "r699", "r703", "r704", "r710", "r717", "r870", "r881", "r921", "r933", "r934", "r935", "r936", "r937"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r294", "r295", "r296", "r297", "r359", "r366", "r396", "r397", "r398", "r411", "r455", "r500", "r509", "r525", "r558", "r560", "r568", "r588", "r589", "r640", "r641", "r642", "r643", "r644", "r655", "r656", "r670", "r681", "r692", "r698", "r699", "r703", "r704", "r710", "r717", "r870", "r881", "r921", "r933", "r934", "r935", "r936", "r937"] }, "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationsOfTemporaryToPermanentEquity", "crdr": "credit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Reclassifications of Temporary to Permanent Equity", "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2." } } }, "auth_ref": ["r91", "r96"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r732", "r742", "r752", "r784"] }, "us-gaap_RedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemableConvertiblePreferredStockMember", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedN "http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Redeemable Convertible Preferred Stock, on an as-if Converted Basis", "terseLabel": "Redeemable Convertible Preferred Stock", "label": "Redeemable Convertible Preferred Stock [Member]", "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionSummaryOfWorkforceReductionPlanIncludedInTheAccompanyingCondensedStatements "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "totalLabel": "Research and Development Expense, Total", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r412", "r657", "r668", "r938"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r733", "r743", "r753", "r785"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r734", "r744", "r754", "r786"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r741", "r751", "r761", "r793"] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails"], "lang": { "en-us": { "role": { "totalLabel": "Restricted Cash, Total", "label": "Restricted Cash", "terseLabel": "Restricted cash", "verboseLabel": "Restricted cash balance", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r825", "r839", "r939", "r941"] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfBreakdownOfTheAvailableforsaleDebtSecuritiesWithUnrealizedLossesDe], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r125"] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail", "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency

```
on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r115", "r826", "r839" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedN
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel":
"Restricted Stock Units", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs", "documentation": "Share instrument which is convertible to stock or an
equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-
gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReduction" ], "lang":
{ "en-us": { "role": { "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Workforce reduction", "documentation": "The entire disclosure for
restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the
expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods
over which the remaining accrual will be settled." } } }, "auth_ref": [ "r280", "r281", "r283", "r286", "r291" ] }, "us-gaap_RestructuringCharges": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionAdditionalInformationDetails",
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionSummaryOfChangesInLiabilitiesResultingFromTheSeveranceChargesAndRelatedAccrua
], "lang": { "en-us": { "role": { "totalLabel": "Restructuring Charges, Total", "label": "Restructuring Charges", "verboseLabel": "One Time Restructuring Charges", "terseLabel":
"Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued
operation or an asset retirement obligation." } } }, "auth_ref": [ "r5", "r287", "r288", "r871" ] }, "us-gaap_RestructuringChargesMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringChargesMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionSummaryOfWorkforceReductionPlanIncludedInTheAccompanyingCondensedStatements
], "lang": { "en-us": { "role": { "label": "Restructuring Charges [Member]", "terseLabel": "Restructuring Charges", "documentation": "Primary financial statement caption in
which the reported facts about restructuring charges have been included." } } }, "auth_ref": [ "r84", "r86" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring
Type [Axis]", "terseLabel": "Restructuring Type", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r282", "r283", "r288", "r289" ] }, "us-
gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems",
"presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionAdditionalInformationDetails",
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionSummaryOfWorkforceReductionPlanIncludedInTheAccompanyingCondensedStatements
], "lang": { "en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These
concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r282", "r283", "r284",
"r285", "r288", "r289", "r290" ] }, "us-gaap_RestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCosts",
"crdr": "debit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionSummaryOfWorkforceReductionPlanIncludedInTheAccompanyingCondensedStatements
], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Restructuring Costs", "terseLabel": "Restructuring charges", "documentation": "Amount, after cash payment, of
expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." }
} }, "auth_ref": [ "r5" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis",
"presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionAdditionalInformationDetails",
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionSummaryOfWorkforceReductionPlanIncludedInTheAccompanyingCondensedStatements
], "lang": { "en-us": { "role": { "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan", "documentation": "Information by individual restructuring plan." } } },
"auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain",
"presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionAdditionalInformationDetails",
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionSummaryOfWorkforceReductionPlanIncludedInTheAccompanyingCondensedStatements
], "lang": { "en-us": { "role": { "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-
gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit",
"crdr": "credit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail",
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated deficit",
"terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "periodStartLabel":
"Retained Earnings (Accumulated Deficit), Beginning Balance", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "documentation": "Amount of
accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r56", "r94", "r540", "r565", "r567", "r574", "r599", "r707" ] }, "us-gaap_RetainedEarningsMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r121", "r158", "r159",
"r160", "r162", "r167", "r169", "r171", "r241", "r242", "r272", "r421", "r422", "r428", "r429", "r430", "r432", "r433", "r434", "r440", "r442", "r443", "r445", "r447", "r484",
"r485", "r562", "r564", "r576", "r977" ] }, "om_RevenueFromConsolesOperatingLeaseArrangements": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.outsetmedical.com/20240930", "localname": "RevenueFromConsolesOperatingLeaseArrangements", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Revenue from Consoles Operating Lease Arrangements", "label": "Revenue from Consoles Operating Lease Arrangements", "terseLabel": "Revenue from
operating lease arrangements" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } },
"auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueSummaryOfRevenueBySourceDetail",
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue",
"label": "Revenue from Contract with Customer, Excluding Assessed Tax", "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total",
"documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to
customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction,
including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r108", "r109", "r186", "r191", "r192", "r197", "r199", "r200", "r201", "r202", "r354",
"r355", "r526" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenue" ],
"lang": { "en-us": { "role": { "terseLabel": "Revenue and Deferred Revenue", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire
disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue,
credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or
fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r119", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r358" ] },
"om_RevenuePerformanceObligation1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname":
"RevenuePerformanceObligation1", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueAdditionalInformationDetail1" ], "lang": { "en-us": { "role": {
"terseLabel": "Revenue performance obligation", "documentation": "revenue performance obligation 1", "label": "revenue performance obligation 1" } } }, "auth_ref": [] }, "us-
gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Remaining performance obligations", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated
to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r116" ] }, "us-
gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueAdditionalInformationDetail1" ], "lang": { "en-us": { "role": {
"terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]", "label": "Revenue, Remaining Performance Obligation, Expected
Timing of Satisfaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable
information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueAdditionalInformationDetail1" ], "lang": { "en-us": { "role": {
"terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "label": "Revenue, Remaining Performance Obligation, Expected Timing
of Satisfaction, Period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for
example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r117" ] }, "us-
gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueAdditionalInformationDetail1" ], "lang": { "en-us": { "role": {
"terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date", "label": "Revenue, Remaining Performance Obligation, Expected
Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD
format." } } }, "auth_ref": [ "r117" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueAdditionalInformationDetail1" ], "lang": { "en-us": { "role": {
"terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]", "label": "Revenue, Remaining Performance Obligation, Expected Timing
of Satisfaction [Table]", "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation." } } }, "auth_ref": [] }, "us-
gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Revenue:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "om_ReversedStockBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.outsetmedical.com/20240930", "localname": "ReversedStockBasedCompensationExpense", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Reversed Stock-Based Compensation Expense", "documentation": "Reversed Stock-Based Compensation Expense", "label": "Reversed Stock-Based Compensation Expense" } }
}, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
```

"localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Right-of-Use
Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities", "documentation": "Amount
of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r488", "r706"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1
Arrangement Adopted" } } }, "auth_ref": ["r802"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement
Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r802"] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedN
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Sale
of Stock", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } }
}, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember",
"presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Forecast
[Member]", "terseLabel": "Forecast" } } }, "auth_ref": ["r367", "r846"] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Scenario
[Domain]" } } }, "auth_ref": ["r172", "r367", "r815", "r846"] }, "om_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
"presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"], "lang": { "en-us": { "role": { "terseLabel":
"Schedule of Accrued Expenses and Other Current Liabilities", "label": "Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]", "documentation":
"Accrued expenses and other current liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
"presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedN
], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "label": "Antidilutive Security,
Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was
not included in calculation of diluted EPS." } } }, "auth_ref": ["r22"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock":
{ "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Outstanding Potentially
Dilutive Shares were Excluded from Calculation of Diluted Net Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
[Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic
earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share
amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r22"] },
"om_ScheduleOfBreakdownOfTheAvailableForSaleDebtSecuritiesWithUnrealizedLossesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://www.outsetmedical.com/20240930", "localname": "ScheduleOfBreakdownOfTheAvailableForSaleDebtSecuritiesWithUnrealizedLossesTableTextBlock", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Breakdown
of the Available-for-Sale Debt Securities With Unrealized Losses", "label": "Schedule of breakdown of the available-for-sale debt securities with unrealized losses Table Text
Block", "documentation": "Schedule of breakdown of the available-for-sale debt securities with unrealized losses Table Text Block" } } }, "auth_ref": [] }, "us-
gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and
Cash Equivalents", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash and cash
equivalents." } } }, "auth_ref": [] }, "om_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://www.outsetmedical.com/20240930", "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel":
"Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash", "label": "Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block]",
"documentation": "Schedule of cash, cash equivalents and restricted cash." } } }, "auth_ref": [] },
"om_ScheduleOfChangesInLiabilitiesResultingFromTheSeveranceChargesAndRelatedAccrualsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://www.outsetmedical.com/20240930", "localname": "ScheduleOfChangesInLiabilitiesResultingFromTheSeveranceChargesAndRelatedAccrualsTableTextBlock",
"presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionTables"], "lang": { "en-us": { "role": { "documentation": "Schedule of
Changes in Liabilities Resulting from the Severance Charges and Related Accruals [Table Text Block]", "label": "Schedule of Changes in Liabilities Resulting from the
Severance Charges and Related Accruals [Table Text Block]", "terseLabel": "Schedule of Changes in Liabilities Resulting from the Severance Charges and Related Accruals" }
} }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfDebtTableTextBlock", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanTables"], "lang": { "en-us": { "role": {
"terseLabel": "Schedule of Term Loan", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-
debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair
presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of
Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders", "label": "Schedule of Earnings Per Share,
Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of
numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r849"] }, "us-
gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel":
"Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "label": "Share-Based Payment Arrangement, Expensed and
Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not
limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in
financial statements." } } }, "auth_ref": ["r32"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlanTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock-based
Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of
allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial
position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r32"] }, "us-
gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Financial
Assets Measured at Fair Value on Recurring Basis by Level Within Fair Value Hierarchy", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
[Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders'
equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level
within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for
identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r918", "r919"] }, "us-
gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"],
"lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the
carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production
process." } } }, "auth_ref": ["r10", "r60", "r61", "r62"] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionAdditionalInformationDetails",
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionSummaryOfWorkforceReductionPlanIncludedInTheAccompanyingCondensedStatements
], "lang": { "en-us": { "role": { "label": "Restructuring Cost [Table]", "terseLabel": "Restructuring Cost [Table]", "documentation": "Disclosure of information about
restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of
restructuring reserve." } } }, "auth_ref": ["r282", "r283", "r284", "r285", "r288", "r289", "r290"] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionTables"], "lang": { "en-us": { "role": { "label": "Restructuring and Related Costs [Table
Text Block]", "terseLabel": "Schedule of Severance and Related Benefits Charges Related to the May 2024 Workforce Reduction Plan", "documentation": "Tabular disclosure of
costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against
earnings from the write-down of assets." } } }, "auth_ref": ["r24", "r84", "r85"] }, "om_SecondAnniversaryMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.outsetmedical.com/20240930", "localname": "SecondAnniversaryMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Second
Anniversary [Member]", "label": "Second Anniversary [Member]", "terseLabel": "Second Anniversary of Closing Date" } } }, "auth_ref": [] },
"om_SecondRevenueMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname":
"SecondRevenueMilestoneMember", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"],
"lang": { "en-us": { "role": { "documentation": "Second Revenue Milestone [Member]", "label": "Second Revenue Milestone [Member]", "terseLabel": "Second Revenue
Milestone" } } }, "auth_ref": [] }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Secured Overnight
Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "SOFR", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that

```
has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": [ "r915" ] },
"dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security",
"label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r726" ] }, "dei_SecurityExchangeName": { "xbrltype":
"edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange
Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r728" ] }, "us-
gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit",
"presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionSummaryOfWorkforceReductionPlanIncludedInTheAccompanyingCondensedStatements
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Sales and
marketing", "label": "Selling and Marketing Expense", "totalLabel": "Selling and Marketing Expense, Total", "documentation": "The aggregate total amount of expenses
directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpenseMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "Sales and Marketing", "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing
selling and marketing expense." } } }, "auth_ref": [ "r70" ] }, "om_ServiceAndOtherRevenueMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.outsetmedical.com/20240930", "localname": "ServiceAndOtherRevenueMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueSummaryOfRevenueBySourceDetail",
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Service
and Other Revenue", "label": "Service And Other Revenue [Member]", "documentation": "Service and other revenue." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit",
"presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "totalLabel": "Share-based Payment Arrangement,
Noncash Expense, Total", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Stock
options, description", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description", "documentation": "Description of terms of share-based
payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance." } } }, "auth_ref": [ "r29", "r31" ] },
"om_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageVestedInPeriod": { "xbrltype": "percentItemType",
"nsuri": "http://www.outsetmedical.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageVestedInPeriod", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Percentage Vested In Period", "label": "Share Based
Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Percentage Vested In Period", "terseLabel": "Earned units vesting
percentage" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Stock
options outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodStartLabel": "Share-based
Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance", "periodEndLabel": "Share-based Compensation Arrangement
by Share-based Payment Award, Options, Outstanding, Number, Ending Balance", "documentation": "Number of options outstanding, including both vested and non-vested
options." } } }, "auth_ref": [ "r375", "r376" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
"presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Number of common stock issued", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
"documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r30" ] },
"om_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPercentageOfIssuedInPeriodToCeo": { "xbrltype": "percentItemType", "nsuri":
"http://www.outsetmedical.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPercentageOfIssuedInPeriodToCeo",
"presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Share Based Compensation Arrangement By Share Based Payment Award Shares Percentage of Issued In Period To CEO.", "label": "Share Based
Compensation Arrangement By Share Based Payment Award Shares Percentage of Issued In Period To CEO", "terseLabel": "Percentage of restricted stock issued to CEO" } }
}, "auth_ref": [] }, "om_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPercentageOfIssuedInPeriodToExecutiveOfficers": { "xbrltype":
"percentItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPercentageOfIssuedInPeriodToExecutiveOfficers", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Share Based Compensation Arrangement By Share Based Payment Award Shares Percentage of Issued In Period To Executive officers.", "label": "Share Based Compensation
Arrangement By Share Based Payment Award Shares Percentage of Issued In Period To Executive officers", "terseLabel": "Percentage of restricted stock issued to other
executive officers" } } }, "auth_ref": [] }, "om_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodMonthAndYear": { "xbrltype":
"gYearMonthItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodMonthAndYear", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Award
vesting period, month and year", "label": "Share Based Compensation Arrangement By Share Based Payment Award Vesting Period Month And Year", "documentation": "Share
based compensation arrangement by share based payment award vesting period month and year." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award
under share-based payment arrangement." } } }, "auth_ref": [ "r371", "r372", "r373", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385",
"r386", "r387", "r388", "r389", "r390", "r391", "r392", "r395", "r396", "r397", "r398", "r399" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel":
"Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under
share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r368", "r374", "r393", "r394",
"r395", "r396", "r399", "r405", "r406", "r407", "r408" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharePrice", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Share price", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": []
}, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Stock
options, nonvested, number of shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
"periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance", "periodEndLabel":
"Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance", "documentation": "Number of non-vested
options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype":
"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Percentage of fair market value of common stock", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock,
Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel":
"Beginning Balance (shares)", "periodEndLabel": "Ending Balance (shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither
cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShortTermInvestments", "crdr": "debit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets" ],
"lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments", "totalLabel": "Short-term Investments, Total", "documentation":
"Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } }
}, "auth_ref": [ "r103", "r104", "r830" ] }, "us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShortTermInvestmentsMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa
], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments [Member]", "documentation": "Investments which are not otherwise
included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet." } } }, "auth_ref": [ "r645", "r646",
"r647", "r661" ] }, "om_SignificantAccountingPoliciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname":
"SignificantAccountingPoliciesPolicyTextBlock", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel":
"Significant Accounting Policies", "label": "Significant Accounting Policies [Policy Text Block]", "documentation": "Significant Accounting Policies [Policy Text Block]" } } },
"auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SignificantAccountingPoliciesTextBlock", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of
Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the
reporting entity." } } }, "auth_ref": [ "r81", "r153" ] }, "om_SiliconValleyBankTermLoanMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.outsetmedical.com/20240930", "localname": "SiliconValleyBankTermLoanMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "SVB Term Loan",
"label": "Silicon Valley Bank Term Loan [Member]", "documentation": "Silicon valley bank term loan." } } }, "auth_ref": [] }, "om_SlrCreditFacilitiesMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "SlrCreditFacilitiesMember", "presentation": [
```

"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "SLR Credit Facilities [Member]", "label": "SLR Credit Facilities [Member]", "terseLabel": "SLR Credit Facilities" } } }, "auth_ref": [] }, "om_SlrRevolverMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "SlrRevolverMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Slr Revolver", "label": "SLR Revolver [Member]", "documentation": "SLR Revolver [Member]" } } }, "auth_ref": [] }, "om_SlrTermLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "SlrTermLoanFacilityMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "SLR Term Loan Facility [Member]", "label": "SLR Term Loan Facility [Member]", "terseLabel": "SLR Term Loan Facility" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedN
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r120", "r130", "r131", "r132", "r155", "r176", "r177", "r179", "r181", "r188", "r189", "r240", "r300", "r302", "r303", "r304", "r307", "r308", "r337", "r338", "r339", "r340", "r342", "r473", "r570", "r571", "r572", "r573", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r598", "r619", "r637", "r648", "r649", "r650", "r651", "r652", "r814", "r840", "r848"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r8", "r54", "r57", "r58", "r121", "r143", "r144", "r145", "r158", "r159", "r160", "r162", "r167", "r169", "r171", "r187", "r241", "r242", "r272", "r343", "r421", "r422", "r428", "r429", "r430", "r432", "r433", "r434", "r440", "r441", "r442", "r443", "r444", "r445", "r447", "r474", "r475", "r476", "r477", "r478", "r479", "r484", "r485", "r490", "r545", "r562", "r563", "r564", "r576", "r637"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueAdditionalInformationDetail",
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited",
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r158", "r159", "r160", "r187", "r485", "r526", "r569", "r587", "r590", "r591", "r592", "r593", "r594", "r595", "r598", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r611", "r612", "r613", "r614", "r615", "r617", "r620", "r621", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r637", "r718"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": ["r172", "r367", "r815", "r816", "r846"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueAdditionalInformationDetail",
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited",
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r158", "r159", "r160", "r187", "r203", "r485", "r526", "r569", "r587", "r590", "r591", "r592", "r593", "r594", "r595", "r598", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r611", "r612", "r613", "r614", "r615", "r617", "r620", "r621", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r637", "r718"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r736", "r746", "r756", "r788"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] },
"om_StockIssuedDuringPeriodShareRedeemableConvertiblePreferredStockWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "StockIssuedDuringPeriodShareRedeemableConvertiblePreferredStockWarrants", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon net exercises of Series B redeemable convertible preferred stock warrants", "documentation": "Stock Issued During Period Share Redeemable Convertible Preferred Stock Warrants", "label": "Stock Issued During Period Share Redeemable Convertible Preferred Stock Warrants" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": ["r8", "r27", "r54", "r57", "r94", "r326"] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock through employee stock purchase plan (shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r8", "r53", "r54", "r94"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail",
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Stock issued during the period", "terseLabel": "Issuance of common stock upon initial public offering, net of issuance costs (shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r8", "r53", "r54", "r94", "r570", "r637", "r649"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for settlement of RSUs (shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": ["r8", "r94"] },
"om_StockIssuedDuringPeriodSharesStockDividend": { "xbrltype": "sharesItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "StockIssuedDuringPeriodSharesStockDividend", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock on settlement of accrued dividend (shares)", "label": "Stock Issued During Period Shares Stock Dividend", "documentation": "Stock issued during period shares stock dividend." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Stock option exercises (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r8", "r53", "r54", "r94", "r380"] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": ["r8", "r54", "r57", "r58", "r94"] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock through employee stock purchase plan", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": ["r8", "r53", "r54", "r94"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock upon initial public offering, net of issuance costs", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r8", "r53", "r54", "r94", "r576", "r637", "r649", "r724"] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for settlement of RSUs", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": ["r8", "r53", "r54", "r94"] }, "us-gaap_StockIssuedDuringPeriodValueStockDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockDividend", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock on settlement of accrued dividend", "label": "Stock Issued During Period, Value, Stock Dividend", "documentation": "Value of stock issued to shareholders as a dividend during the period." } } }, "auth_ref": ["r8", "r54", "r57", "r58", "r94"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Stock option exercises", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r8", "r54", "r57", "r58", "r94"] }, "om_StockOptionsToPurchaseCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "StockOptionsToPurchaseCommonStockMember", "presentation": [

```
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedN
], "lang": { "en-us": { "role": { "terseLabel": "Stock Options to Purchase Common Stock", "label": "Stock Options To Purchase Common Stock [Member]", "documentation":
"Stock options to purchase common stock." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockholdersEquity", "crdr": "credit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets",
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total
stockholders' equity", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of
equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r54", "r57", "r58", "r83", "r600",
"r616", "r638", "r639", "r707", "r725", "r842", "r862", "r925", "r977" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedBalanceSheets"
], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Stock split conversion ratio", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example
but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": [ "r95" ] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Reverse stock split, description", "label": "Stockholders' Equity, Reverse Stock Split", "documentation": "Description of the reverse stock split arrangement. Also provide the
retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r95" ] }, "us-
gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event
[Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary
line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r480", "r492" ] }, "us-
gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event
[Member]", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or
available to be issued." } } }, "auth_ref": [ "r480", "r492" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SubsequentEventTable", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ],
"lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between
statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r480", "r492" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event
Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } },
"auth_ref": [ "r480", "r492" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventTypeDomain", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "lang":
{ "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are
issued or available to be issued." } } }, "auth_ref": [ "r480", "r492" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent
Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial
statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement
of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } },
"auth_ref": [ "r491", "r493" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsidiarySaleOfStockAxis", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedN
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sale
of Stock", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-
gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponents" ],
"lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Components", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire
disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r824" ] }, "us-
gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SupplementalCashFlowElementsAbstract", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Supplemental cash flow disclosures:", "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang":
{ "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r782" ] },
"om_TemporaryEquityAdjustmentToRedemptionValueOnRedeemableConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.outsetmedical.com/20240930", "localname": "TemporaryEquityAdjustmentToRedemptionValueOnRedeemableConvertiblePreferredStock", "crdr": "credit",
"presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": {
"negatedLabel": "Temporary equity, Adjustment to redemption value on redeemable convertible preferred stock", "label": "Temporary Equity Adjustment To Redemption Value
On Redeemable Convertible Preferred Stock", "documentation": "Temporary equity adjustment to redemption value on redeemable convertible preferred stock." } } },
"auth_ref": [] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel":
"Temporary Equity, Beginning Balance", "periodEndLabel": "Temporary Equity, Ending Balance", "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
"documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a
security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily
redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the
holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a
holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r300", "r302", "r303", "r304", "r307", "r308", "r409", "r538" ] },
"om_TemporaryEquityCashExercisesOfRedeemableConvertiblePreferredStockWarrantsShares": { "xbrltype": "sharesItemType", "nsuri":
"http://www.outsetmedical.com/20240930", "localname": "TemporaryEquityCashExercisesOfRedeemableConvertiblePreferredStockWarrantsShares", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "documentation":
"Temporary Equity Cash Exercises Of Redeemable Convertible Preferred Stock Warrants Shares", "label": "Temporary Equity Cash Exercises Of Redeemable Convertible
Preferred Stock Warrants Shares" } } }, "auth_ref": [] }, "om_TemporaryEquityCashExercisesOfRedeemableConvertiblePreferredStockWarrantsValue": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname":
"TemporaryEquityCashExercisesOfRedeemableConvertiblePreferredStockWarrantsValue", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "documentation":
"Temporary Equity Cash Exercises Of Redeemable Convertible Preferred Stock Warrants Value", "label": "Temporary Equity Cash Exercises Of Redeemable Convertible
Preferred Stock Warrants Value" } } }, "auth_ref": [] }, "om_TemporaryEquityConversionOfConvertibleRedeemablePreferredStockInToCommonStock": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname":
"TemporaryEquityConversionOfConvertibleRedeemablePreferredStockInToCommonStock", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "documentation":
"Temporary Equity Conversion Of Convertible Redeemable Preferred Stock In to Common Stock", "label": "Temporary Equity Conversion Of Convertible Redeemable Preferred
Stock In to Common Stock" } } }, "auth_ref": [] }, "om_TemporaryEquityDeemedDividendOnSettlementOfAccruedDividend": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.outsetmedical.com/20240930", "localname": "TemporaryEquityDeemedDividendOnSettlementOfAccruedDividend", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel":
"Temporary Equity, Deemed dividend on settlement of accrued dividend", "label": "Temporary Equity Deemed Dividend On Settlement Of Accrued Dividend", "documentation":
"Temporary equity deemed dividend on settlement of accrued dividend." } } }, "auth_ref": [] }, "om_TemporaryEquitySettlementOfAccruedDividends": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "TemporaryEquitySettlementOfAccruedDividends", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel":
"Temporary Equity, Issuance of common stock on settlement of accrued dividend", "label": "Temporary Equity Settlement Of Accrued Dividends", "documentation":
"Temporary equity settlement of accrued dividend." } } }, "auth_ref": [] },
"om_TemporaryEquitySharesConversionOfConvertibleRedeemablePreferredStockInToCommonStock": { "xbrltype": "sharesItemType", "nsuri":
"http://www.outsetmedical.com/20240930", "localname": "TemporaryEquitySharesConversionOfConvertibleRedeemablePreferredStockInToCommonStock", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "documentation":
"Temporary Equity Shares Conversion Of Convertible Redeemable Preferred Stock In to Common Stock", "label": "Temporary Equity Shares Conversion Of Convertible
Redeemable Preferred Stock In to Common Stock" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesOutstanding", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel":
"Temporary Equity, Beginning Balance (shares)", "periodEndLabel": "Temporary Equity, Ending Balance (shares)", "label": "Temporary Equity, Shares Outstanding",
"documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals
securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an
asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or
determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the
issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the
holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be
temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held
by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r52" ] },
"om_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname":
"TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
```

"Temporary Equity, Issuance of Series E redeemable convertible preferred stock, net of issuance costs (shares)", "label": "Temporary Equity Stock Issued During Period Shares New Issues", "documentation": "Temporary equity stock issued during period shares new issues." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/StatementCondensedStatementOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Temporary Equity, Issuance of Series E redeemable convertible preferred stock, net of issuance costs", "label": "Temporary Equity, Stock Issued During Period, Value, New Issues", "documentation": "Value of new stock classified as temporary equity issued during the period." } } }, "auth_ref": [] }, "om_TermALoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "TermALoanMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Term A Loan [Member]", "label": "Term A Loan [Member]", "terseLabel": "Term A Loan" } } }, "auth_ref": [] }, "om_TermB1LoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "TermB1LoanMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Term B1 Loan [Member]", "label": "Term B1 Loan [Member]", "terseLabel": "Term B1 Loan" } } }, "auth_ref": [] }, "om_TermB2LoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "TermB2LoanMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Term B2 Loan [Member]", "label": "Term B2 Loan [Member]", "terseLabel": "Term B2 Loan" } } }, "auth_ref": [] }, "om_TermBLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "TermBLoanMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Term B Loan [Member]", "label": "Term B Loan [Member]", "terseLabel": "Term B Loan" } } }, "auth_ref": [] }, "om_TermCLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "TermCLoanMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Term C Loan [Member]", "label": "Term C Loan [Member]", "terseLabel": "Term C Loan" } } }, "auth_ref": [] }, "om_TheAugustTwoThousandTwentyFourRestructuringPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "TheAugustTwoThousandTwentyFourRestructuringPlanMember", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "The August Two Thousand Twenty Four Restructuring Plan [Member]", "label": "The August Two Thousand Twenty Four Restructuring Plan [Member]", "terseLabel": "August 2024 Restructuring Plan [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]", "terseLabel": "Title Of Individual" } } }, "auth_ref": ["r855", "r929"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "om_TotalShareholderReturnMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "TotalShareholderReturnMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Total Shareholder Return [Member]", "label": "Total Shareholder Return [Member]", "terseLabel": "Total Shareholder Return" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r774"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r781"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r801"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r803"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] },
"om_TransferOfInventoriesToPropertyAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "TransferOfInventoriesToPropertyAndEquipment", "crdr": "debit", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "documentation": "Transfer of inventories to property and equipment.", "label": "Transfer Of Inventories To Property And Equipment", "terseLabel": "Transfer of inventories to property and equipment" } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa
], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r334", "r341", "r446", "r472", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r546", "r695", "r696", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r708", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r858", "r859", "r860", "r861", "r917", "r920", "r921", "r922", "r923", "r924"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r804"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r805"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r805"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r803"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r803"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r806"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r804"] }, "om_TwoSeniorSecuredCreditFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "TwoSeniorSecuredCreditFacilitiesMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "TwoSeniorSecuredCreditFacilities", "label": "Two Senior Secured Credit Facilities [Member]", "documentation": "Two Senior Secured Credit Facilities [Member]" } } }, "auth_ref": [] }, "om_TwoThousandTwentyEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "TwoThousandTwentyEquityIncentivePlanMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "2020 Equity Incentive Plan", "label": "Two Thousand Twenty Equity Incentive Plan [Member]", "documentation": "Two thousand twenty equity incentive plan." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail",
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureRevenueAndDeferredRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r435"] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": ["http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureWorkforceReductionAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": ["r282", "r283", "r288", "r289"] }, "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa
], "lang": { "en-us": { "role": { "terseLabel": "USGovernmentSponsoredEnterprisesDebtSecurities", "label": "US Government-sponsored Enterprises Debt Securities [Member]", "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae)." } } }, "auth_ref": ["r884", "r940"] }, "om_USGovernmentSponsoredEnterprisesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "USGovernmentSponsoredEnterprisesMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfBreakdownOfTheAvailableforsaleDebtSecuritiesWithUnrealizedLossesDe
], "lang": { "en-us": { "role": { "label": "U.S. government-sponsored enterprises [Member]", "documentation": "U.S. government-sponsored enterprises" } } }, "auth_ref": [] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfBreakdownOfTheAvailableforsaleDebtSecuritiesWithUnrealizedLossesDe
"http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa
], "lang": { "en-us": { "role": { "terseLabel": "U.S. Treasury securities", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": ["r664", "r689", "r691", "r695", "r940"] }, "om_UnderwritersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "UnderwritersMember", "presentation": [
"http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Underwriters", "label": "Underwriters [Member]", "documentation": "Underwriters." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying

```
Security Market Price Change" } } }, "auth_ref": [ "r800" ] }, "om_UnrealisedLossesAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "UnrealisedLossesAxis", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfBreakdownOfTheAvailableforsaleDebtSecuritiesWithUnrealizedLossesDe ], "lang": { "en-us": { "role": { "label": "Unrealised Losses [Axis]", "documentation": "Unrealised Losses [Axis]" } } }, "auth_ref": [] }, "om_UnrealisedLossesDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "UnrealisedLossesDomain", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfBreakdownOfTheAvailableforsaleDebtSecuritiesWithUnrealizedLossesDe ], "lang": { "en-us": { "role": { "label": "Unrealised Losses [Domain]", "documentation": "Unrealised Losses [Domain]" } } }, "auth_ref": [] }, "om_UnrealizedLosses12MonthsOrGreaterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "UnrealizedLosses12MonthsOrGreaterMember", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfBreakdownOfTheAvailableforsaleDebtSecuritiesWithUnrealizedLossesDe ], "lang": { "en-us": { "role": { "label": "Unrealized losses 12 months or greater [Member]", "documentation": "Unrealized losses 12 months or greater" } } }, "auth_ref": [] }, "om_UnrealizedLossesCausedByChangesInMarketInterestRates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "UnrealizedLossesCausedByChangesInMarketInterestRates", "crdr": "debit", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Losses Caused By Change In Market Interest Rates", "label": "unrealized losses caused by changes in market interest rates", "documentation": "unrealized losses caused by changes in market interest rates" } } }, "auth_ref": [] }, "om_UnrealizedLossesLessThan12MonthsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "UnrealizedLossesLessThan12MonthsMember", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfBreakdownOfTheAvailableforsaleDebtSecuritiesWithUnrealizedLossesDe ], "lang": { "en-us": { "role": { "label": "Unrealized losses less than 12 months [Member]", "documentation": "Unrealized losses less than 12 months" } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r770" ] }, "om_WarrantsToPurchaseCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "WarrantsToPurchaseCommonStockMember", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedN ], "lang": { "en-us": { "role": { "terseLabel": "Warrant to Purchase Common Stock", "label": "Warrants To Purchase Common Stock [Member]", "documentation": "Warrants to purchase common stock." } } }, "auth_ref": [] }, "om_WarrantsToPurchaseRedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "WarrantsToPurchaseRedeemableConvertiblePreferredStockMember", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedN ], "lang": { "en-us": { "role": { "terseLabel": "Warrants to Purchase Redeemable Convertible Preferred Stock", "label": "Warrants To Purchase Redeemable Convertible Preferred Stock [Member]", "documentation": "Warrants to purchase redeemable convertible preferred stock." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Shares used in computing net loss per share, diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r175", "r181" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Shares used in computing net loss per share, basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r174", "r181" ] }, "om_WorkforceReductionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "WorkforceReductionAbstract", "lang": { "en-us": { "role": { "documentation": "Workforce reduction Abstract", "label": "Workforce reduction [Abstract]" } } }, "auth_ref": [] }, "om_YankeeDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.outsetmedical.com/20240930", "localname": "YankeeDebtSecuritiesMember", "presentation": [ "http://www.outsetmedical.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFa ], "lang": { "en-us": { "role": { "terseLabel": "Yankee debt securities", "label": "Yankee Debt Securities [Member]", "documentation": "Yankee debt securities." } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r768" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "270", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph":
```

"1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 3.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-8A" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-42" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-42" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "44", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-44" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-4A" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-5A" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479366/326-20-35-8A" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-5" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-17" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-21" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3C" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3D" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.M.2.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483530/326-20-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479175/326-30-30-1B" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "13A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-13A" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-7A" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3A" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3C" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3D" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.E.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

```
"Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r604": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r605": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r606": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r607": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r608": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r609": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r610": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r611": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r612": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r613": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r614": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r615": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r616": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r617": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r620": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r621": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r622": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r623": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r624": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r625": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r626": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r627": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r628": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r629": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r630": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r631": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r632": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r633": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r634": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r635": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r636": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r637": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r638": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r639": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r640": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r641": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r642": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r643": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r644": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r645": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7",
"Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r646": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7",
"Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r647": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7",
"Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r648": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-
50-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r652": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-
50-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r656": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-
28" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)
(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r660": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40",
"Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "SubTopic": "320", "Topic": "946", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-
```

45-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection":

```
"J", "Paragraph": "a" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F",
"Paragraph": "1" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph":
"1", "Subparagraph": "i" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F",
"Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section":
"6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r738": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence":
"E" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1",
"Subparagraph": "ii" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F",
"Paragraph": "1", "Subparagraph": "iii" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6",
"Subsection": "F", "Paragraph": "2" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph":
"a" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" },
"r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence":
"i" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1",
"Sentence": "ii" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a",
"Subparagraph": "1", "Sentence": "iii" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F",
"Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form
40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F",
"Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section":
"19", "Paragraph": "b" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" },
"r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r754":
{ "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" },
"r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1",
"Sentence": "ii" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",
"Subparagraph": "1", "Sentence": "iii" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR",
"Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form
N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR",
"Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR",
"Section": "18", "Paragraph": "b" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240",
"Section": "13", "Subsection": "a-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "v" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "v", "Paragraph": "1" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r767": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r769": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r771": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r773": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r775": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "vi" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "3" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "v", "Paragraph": "4" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r780": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5",
"Subparagraph": "iii" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r784": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" },
"r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w",
"Paragraph": "1", "Subparagraph": "i" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r788": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1",
"Subparagraph": "i", "Sentence": "C" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r791": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1",
"Subparagraph": "ii" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r797": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2",
"Subparagraph": "ii", "Sentence": "C" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r800": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2",
"Subparagraph": "ii", "Sentence": "F" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "408", "Subsection": "a" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "408", "Subsection": "a", "Paragraph": "1" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r805": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2",
"Subparagraph": "C" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408",
"Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r809": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii",
"Sentence": "A", "Number": "229" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i",
"Number": "229" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" },
"r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r814": {
"role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r815": { "role":
"http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r816": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
"Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number":
"229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)",
"Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r820": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher":
"SEC" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c",
"Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229",
"Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation
S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r824": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/210/tableOfContent" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-
```

10-S99-1" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r888": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B",

"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 63 0000950170-24-122518-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-122518-xbrl.zip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|&@S#IJ1 M*) D<6IZK0R+2@7^Z.RKT"SOLT^#5#[G =15TVBX4M_MO_P_EQ?SMU\^>]P$ M/A8YS#\F?-F7X^$@#]9_PE' 5Z0!7FVX[[GP#]:X)LIWGJ,R0-@9(XB/&E%^ M&4P>_79VVUY$Z)P-|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`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}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

*M%HHHE7#%@$HDL*Q*;5.@COD40F>#4UL#NQO?>%55/__E%E7][L=J6SP"@^<@ MI"C1$<&58(EH25!"EUUFDS35P?K.*K5N%\Q;C[-34!:Y38+@ZC7(.VF)_P!&*
MF/$<2:BCEG=NW7;VO-P6K4+J\1[3$9P$Y(SX MPX"6R%T$ZYSCXRX*Z$SQO*[_BA>F2S[LK$W!*&848Q(M&7"D!(,21Y'S(2&@ M1H<4@7;6!GX8QQ.L@^YII064(-\L4+(2;=10Z)
[(TEOAT40U2[=1%Q7JI0-F MWPS]JP[&KY?W#WW]<4.=4\(@9WV](D++J*.1C%'>U1G1L5(P:X)ESYRB^#B-(XQ+ M&IF0SS$3%IES4F;O8N>*C^LS+&/ZV]V5+80)Z?W;*;<
N<44%}:58>_^F;GX/4(WN'7RS;L8-0LSM^1.>7! MC:$U=4UZ0F#.+Y;0?5PR2D/)Q@GB&#!ILA9)=Y;WKO\$@KV,)LYV'$,@ $0] MAP^8Q,N6/6CB);=$V* TY\S%
[KE.NP7:Z]F7EUQ)5DZ"=DZ# M=78[/3!K/UI\+9,!+;U ,[Y9!2*]S4@#720>@M;X(T;:V2.P1FK;5[Z=M/:MG2D-ERQS:@P!G6RE08['QBRK.BI ME1*H[/>_VX'[ZS)DL&93&-,!-
E4)DB:::')Y0P9117WVM/;E>@H= M29N#82H3@*;@J2\56 PR7_J8%;T$021KDS[84I)>2.=1D M@A&3G12:9V>AE2>>H#Z'4%=YO4;?]R> =-3 MPA7S#9\X#=20B-
2"2!I$9B/B:7>1LT,%;:3YX+\,&IIO_J0I37L,:H8?;8R M$.V3*S&C)CMAH &<%LT$&E2+MK*._RWN,WXKVMM$?HKWH#RW "1<=T4ES(CU% M%69D)BB'D PP3:&S*FS3LSG68P-
HY9GECA$1RJ%_ BUWEQ/.-Y\\TY[GJ#MK MM'=A=V(Y@0,Z1J23:)US7XKRLY)#[$$28[T%*Y)DKK-V>DF6> ^6/ONK,=Y_' M[P['LXD?I7>?\5DGXV\)21 SK+T+=:'P>UT3L%I
M'0E.UB;/FI%@DB$ES-EPK36$SFYO7%-K;#WA?YQ0?DOQ-;=RVX;X#.4NTP(\CAD=N-%/!ALY2\PWWWZXA>MZ34)CG(;"&VQ@_'0+A@9%D$_H!-)Q$SI;J??!6-?K"1,R3)FL MF"'*Z>
(@3I180(-*^"Q]-I#D|\A.KU\:,#1?)8C^)$DX3F2&3H(4DG@(52@C0 MW2U2M:7G AD1LU6!$F2%@!8-34B;D5?P("(+$*E*G64378:BR\? M56$WTBF M!$N*9!<17132/A^%
(!&8ETRHK$5G?0(H$32>H+JC;06K.?_EZ"U;W?NBH)7_=[>=]=FHX12RB4>M,2(2K MR)V64AN&DZ>H4Z5KP\9*0V4H;*&N5+U4V$_+0V+ T0.7.5+A.QO@=-"]
XK7X(TSG,=E4'%6$KD M6&Z(+?85Q& 5^ 0F=+;L4;=4)%^.COS6I\]:\>D;SWW,*I,D6:G*$17QS@BT M)Y6T7N;D=.=*1SI^'%AKL.H15&W.A$93*AR7*()D,D&!.
<|8=6+Y:"']8%P34TJ=6[=:[,1T?W*5L\1\|$9QC: M=\3)YD10A5(I]8XYSX:Q8(SO;I7CLO'V.N^5/9:/<%FWC)&K-P3D<#Q,4".L MS>J;],Q""W:#BU"9*!RGM@DGR$1"R3L3MF0)<[#
<>^2MG8O#*3)Y-YB68[E? MCM+@TR#-_/#K9@Z,VR(U+<^]ASI#$,;S=<2$$G1N:?&M&T-84M&:8'CJGC'3 M^:S5#*IT5<]U>D&MW@\||^C^>N/[?P"4:S MS:R4;\
ZEZ,G,IF2=9P5<8"T(P7DU6CE F.=V\GOSU(]%5V$I)!:Z^ DD5X$ M-(94)#H[*\'H#+ZSG*Y[3'MQ$W4V&LQ%\O[#[\:S^:G\>S?-G?CM]!OYZ]H"S M*V>?RQ.N>-JD<:U=\[SYQ3L^\?
W!L^\>-YB,)6<&M=&SNSX-?RVQ;RC*"9*D M(QREZ)^-AT-?3QIF=/ZNAJ+!Q4>\FN'M?CJN%VS.=]\O?WP&HW%3O/O[Q]YV MT"X]XLGEUE\:C2>#+[OXK/&LCC"9?SPL/L'R-?
S";_]25;_@OJ5D>C+$Y??`M9#!*\&67B*2X>'((@X^'TUWZ6 U

*M(*32E\X2,D638E!E'UL1CD$IZ:;"C[T&+N].8,F. ES*DS79-GO*6S"8*P0; M$'1(226+#5Q^'[L3C@$N+:96C#TUR/;5..4X;$Q1Q2K)5G"J^MY6:L@QLD"S ML=K_HZ[HMXZ^[|)? X1B8,F;J_0'/=SZ*ZWB1^V[_P_U.]] MX.CAH!6+UXV/CPBHXD-SJJLR&@Q)#5%E TIZ+9-VJ:T"^X@>OJ3YO.E66S;^ M<:UG>W;*[=3P7ERV;4Q\:8H"$8U1SM64F8O99T. MSBC5#%L^:LF!0Y;L"*@EC,&J?'^8R32/G(|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|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| M73X2^: =.)-S:L-VABN:3A)VL[QI5UUF\XLU%=Z>P[$SCIV=2NS,Q=0^*1 (MZK?G.)00@W,03+#&)YV$W\OVG.]QM9@M7G4_T^IE#X:_]%CX.(;6'E)YN<8U M=<_KL]>T:H+_ZW(^QU6W> (9H'/':Q6O72:Q=*FGC9$&(M7OK&;E9:O3J:Y=;6W*0F&%;'1;AWSR$++#=2[_I*UM2 M,2H\Q/U_G;4KWE9XC=N6L0C5!911 MD)?:&F25[=>M"I@UZK:*E'9,'>+^O\:Z)9_$VS;1 M\;K%/A>O7;QV/;JUJX%-^ZH+!-\W@XU]O%#H!,6ZAG!5JW%;:]^U.=>W* M23L;3 !)IF^.UM8NK"E!TMD764E6XP]Q_U]C[5)/_&T5[7CMXMYK!TXD;F9O M-[GHJ$QFBZ9.K\|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|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|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|V7YW:UY$P) M6XLC%B2?Z!B-J%EG]:)(UMG1B)U=B""+8H/+]5?T=C.)A9?PC_;^*FD^7Y)K6)+;VF59QWWZ>(H_U64ORBA*5H/1O5[W1Q1$#%E M2$)*(9QPA%O[F 8>Y=||^7PS1;OOKZ9H>6"$WX\|M\H&T;@%R0;1:$3-.CL0 M08["XDB(P52%('R_"XM"AIB5 :^24#:7K'!K7X%T2 5] 9U9&&(C%B0;'J,1->OL0 3).CL:4;/. M#D20HW 6C'$Y.9_!AS[4B*I J*:"ET%X!KF)*UK"S0HO!H?2G1")(@F.S#5]BD0GT!E61P)]2+I?:1 GI5_773K M_G1O]\OR62FS_AIP_C/.RH^+[_!\ML;Y9@?&QC;\[@/3\ 7]^V+6M1MJ]2:LW MLTR7[M +RLM7B\|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|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|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|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`T<$,.[I6/1IN70\XMUM|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{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`_[R>ASUT:]/?I,&-JXJ0P'C$3_/;>M+F1(TD;_+Z_(UV>E_)#,&. M^ZAZ9|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`_[R>ASUT:]/?I,&-JXJ0P'C$3_/;>M+F1(TD;_+Z_(UV>E_)#,&. M^ZAZ9|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

M;M^P;6W1+3"VV'=3_(IN44;6(.V._M[&HZ_=/NQ8!^6$/VQ'^1M5N@+C0W6*TN5#[!DS8]YR5Y@)U\" M:[_YVT*"?GM@,WZXYO%-.P)U8CSK["ATNUR&!]N?*
VT#L/+FB:=X0J*5\3)&8 M<^&5QY)E&0R]%,X'96<\ Z6E_1K#N_Y1!.,3_*?%!;"/0WO1Q;==!&T-.'VQ M!L6$ZN_]YF8:[.>V:UT[!-/C[>+ZVQ)&+J;)
[WR&=V3#UT(_>ZZ2K=QR4.SI!_C:MH]KS_/UW20\M##<9$7Q)V6DO1JT>&Q^S8OO]R[RS?8#*IY!Y[?F M\VX\&RT:RXC $N%$).(J1*0UYR@0(8*ADAFO;F:C16958"(@*0B&:
[!%SBF! MI{<4Q4PTWRG-6L(1@/&]*[;6>P!QVP_+{>B8$7!@=T*)QU-5!LD\LE1N%P49'Q"S MQ2,,>\LQCZW+57U-=S/(^Y S64NR63,=-Y,(FQRR/<Z+5J.7.1.MF>7,
MKW94'5#5=#\FT[U2\9%NZT%-=^L.J#*/G77 VU>)6@YB(6>[]4_86\OMCAD)EA/CDI>(RX31(9(R/23!FJG."4|$WX MFTK9S>\RSWU88;D-G8"D?,).2A#ZX6K(U6(>H5;>: 0E6C
V&F'K,, -R9A M9$+R2.G(N%#>X1@WX0S:+D29 3SRR"]Z2Z@JN ^@HV^C_ 3W_9*K1V%QIZ/ M8<;_*AJ4T7'0+%9%QZKH(#9I+ 1#GAF)N&>YFP?HN42D&+6FAIF-1%-7.0Y>
M#V-^\7X4WJ\PWH8$"1?2H|"0$.64QA4BXY MKKTPQNI-J+J[Q2O)CQRQJF-W^FY(XQ$J4=!A!"NNNG./@K>J +FV!+O24@" M6:X%*+PZ(L,"10GCP&V(UK!G*;PP*^"R?-
SE\QC/_0LMKEB^-LL8W?(Y%R1 MZ6"V\D"1"=O@M).@X20.R!1<0)I;AJSS #!$ID">I=IN%9D,,4>.2]5UNUL5 M-M?
BG,1N6K78HV"O*BM6984VN0^3#2B*K,5BQ9"ACB&0$]8+Z@D/:[+B:5KL M3W,VV[0BJ\UAG7ZIBFP%IPI.O8DM6+2*:L2-B8@SBY$6F*/HF+.82:K.KX81<^1"4$L9@FJ_#:<<#*:?
=^%'[K6;S[Z8]_-R2W&"C56VPE_>*G NN1\@J-%1HW[G8FU"EG#3+2 M!U#9+05HC DQ&SD17G/'-I(_*+0* ;8'):#^D7.F5?=_A'L]MMDG-L) *,! M:19U?
C0=3]I8ZT"])CZKXNJ9A4I(E-H:"VJS$(@S)Y$%91SY$ 4FFC)*GIMO ML62T'\>3GZ[8;$3?&Z.1E!]O47&Q("(,TXP
MYQT1]IF.ZBUCDSKV@P[53[T37397_\I.Z=QF=-S98>^KSC64II?E %W\YZR] MR!9;%2 'S6]5@%P[C>*-9=13E!0&135B V1
>11FFCK^%HIFZ>X>G<*5P37HA'5G[N+7(WA[4,40WX1BBKU%DOO=]!FMN/1/;S]8-ZV'TP]9%C]7.VDU&NM4Q
MAJ0"'IP$Q!4WR#@MD72)I$|)MPL'TT\A/:P4G7JT9P*A!4(MYQ>0JQ+/C%F[8RR0X9(B+PP)PFI./-N$ VN'0'@& MXL"*G>[T(,XSDA>/5S__J1ZJ>96<5<71?HDCD@@&M5PBXQ.
(%A,)QTPIOI%; NCC:?.4_HP.AZ(K1"X'[O:87 YT&6R=GV..%;<.BQFH? A[G'(=Y3+A* MDX-FLRI-5J6)BH08Q2ER"B?$'1=(.ZN0E-98'80E+&Q' 9[SX;S.85>RC#:> M2#_0O-
9DK=!UW%MYH-#E"1%4:((\]0QL=ZZ1P3DA4EOB&7=,X6?59'U9Z.+| ML.K>[?DY^./5AY>I'A?VLN9Y'#Q7':L,V8T_69GD/51*' M=@I?N#B*<$EU+Q\VNQVK0-E5TP,KB%([>1@_KK
M NJ'\XOA^#+&WWMV_GQS.#&BU4-C#DLH555[8],QXN,=WBO@W.,)H*4CO9Q M*R72CGMD#:C0G 5JPMJ)D,VHVIM LONU;G%0Z%4]UWNN%GDPG\:/5H M?Y4N!\USQRI==J-
W"\UBE)JC)%4$'5H+D$$L(1:<\IJK7"-K:W[MS.0K4NK] M*)2(ZZ^+6AY;U,7E@-']JJYHN=][6M%RS]#2>6&IY'*"BB#C640.>\YI M2-Q@NC4W^@NB)1\0?%CI=J^E)5DU
K[8R<2.II=+E?^RBK!7Q&A5A.V7"$N* M$:8I >7=@0@C$013]/"622J<-,&3M;KJC^QQ=]?T^N\Y*R|DU>46DEG$8558 MKUIJA<3CA<0[N@ S+$0,&FF>NP!C*9
3A@&$L80=P!.)\IFMT+8!87^0%7Y8 MWHCJ6]3M?K[F.)B>GJ/ZRN\]UVVL)00FQQZ3K6!U[%MYH&"EA&8V6H>X4?F/ M)454X67T%(FQRR/:Z&YS3B;MP-6=$#
(8973JSG;>ZKD+F,BS3!3=,T6.1H& M.U81LAOG,=..*#,[[<8Y20# MH@ZKP5KU'E=,K)BXY4JCWDG"?$ " !#QJ$%#YU:C0(0.3E >_;..5KXL)AI9
M6P'LRD'!%%5]_W7QO\9IXVUWULRZ&&ZT:@-Z^ERU\MLF[(!$XJ0?ZHFXF#;= M>-B&YK8=N)?%YO=9S.266[TZ$?:(I?D#4OGCQ:DR\&%GGI0C)$2&G)/, MKW53>$HHXN7PG6
Y,.SQI_9K&|C4?XVBGVH%?5J#*;RM"_]>KCQ.-S=YCI; KCQ-^QO]<'QN&%"UO_6]\P/G-^"'"E&G6ZGX4?UH*;[T_16LHG(M/WF-D?_?9A-_9G/-
B'%J+B;9USB]+/4CXC]G[<4Y_*K:HJ_(7U^C7?ME"0;+ M/7-.H8!)M@0Q6'521Z1I9#):AHG;2+_KW^QEYM7NT_B]!\:=Q-_FO/S;T(ZF M[T?AAP4[;R@[3@]5^_BRA3==-
')/C5)X+4Q7)55^R6K M1!0N&=#9-28)<1LT(8 Q.& C!"C::JU1[9-T MZLG8QQBZ'R?C\X\@+>9|>/E^%#Z,A\-8QM3]FK8@9[@:@*PY*#E32TQ4 *L MUI>8D S46^N0%0X
3'"9J[\SQ(*.3JEHL5_+VW^21OQR *;9@(K:<7O++NP# M/[KVS?SLVKM#AU;J(I+'$2J<0M33F*G&@G:M(MD6)66ZV#=WC-1;3!@VP_+1!E>P<=^(#677":2X\< M53SW4DS(!#
XDC$^DN!D4&L.E@V>.WL6'-+PL(,)*ZGS5[$M%FX_NLAL_L. MF:5V9$>^'C*KQW/J=*L5'^ZV'M1*ZKJ;E)5Y^[L7E)VT[_1S.^*IK_!HG MOEWT+/[AXV^_-1>+Q-9J/!ZTD[V&EE9-\U=!(N+($)R640PO) AAB"E3:1" MBI ,>6:IV&M1I['Z8\V#()R/.+X;CRQC+]XL4|WQL8IENOKCU0? M>W7S5|T!%=|.>7K$-+)][560/LY83\EFBC&L"**?YNSV:_IY/#K]!/SX M?
72;.G*1VH(2%8 MMNDUTB6&J_QH#^%2?CO.>:$OKNR-&KIIH^+]5T-<'TMAAL57!K!E+-0-J9 M@&+<*F*E09$IC;AW(*J$I2A%F23%6%F]S830'Q<(L/$,)*D'&NN:@?1B&EU%
MWXJ^%7W_((@HH\.&.&2C!23E)B&KJ4!<"X83]X3N<7\S^VA[Q.J25]!= ^^2 M/UQ[(\S;">:F}-GV&/062"Z4_!EH>C3MDU@FL9M.6C\%FR1_7T?@=0OQ^J? MVM'Y,LTUJX+K?
>UK!=;_U5///+$2>68$XQ!7I+6R*"G!$_8,*TTW82V\E)/N^[2[&G1W^!=#S JZ]WEH[6@6P[RAYWBT*7^:(@/-'A_-.#YW6078 M"K 58.|"6,HC%L8C4B%*Y"28ULI2Q, X(#;(D,(:P!
(C!'&2(8L!CWDD'#D< M(C+>1:9<\(+@0P!8.1!LB^G_!P.P-1ZQ&X,BPC?5E-@PW]$3FADOC&=N&%]2 MUCW,HO^WK0F]VQ?B0,4>U<)9&1UB3H.-
P4L2QF=JO]:A\]5)6+^4S2K,0'S"G$FD5+.)$!:2#EUR MI]W"R' 7D724>&R%UVZMH/533I=L"0_QSI*W7C4>UO2MC2CAP/6QFU:1#P5.
M%3A/+CWE'$@)*Q8<]W7KH80N"D!U0N7@OSOZ'+OBT,K50V[KH52/0AP/ MKQT9M%0J/M)M/:CIUOC/$^_,%VT6A?'K11R%=IJ/_5T+_UCO^YC0A;VTV?S/
M$A(^G,S@^W)55Z,^U6M9O9;/:%G%K#>&,Z0D3XB3?(!"ZH@P,8HI9A@.:RVK MGM;AH_#Z#RNL_M/(SR:3&+Z;3?\ZGOY_<;K!_.&=U=9]U>[)"I,5)BM,/@0F
M"0D4^]B1XY@@CGF&24L1,Q(]PTFP_EG!G1>"2;K-SAH!)3UF,63>.G3Q(ZZ M%"=?FJRU>8K#"YL8-J4:(-49!*0^0QRARN5^W"S9&$CV582W1)9&)6EN' MR=1^C0']*T[&F44T)?
1=1A]!B_JGA<)C1.:=;&Q71>G73-V4]N. M>E#]G'>"+&P!MPH6_<^A</F#4$MX^<=Q7 M_/24'-.KT=SW^/ZG^[Y\]B2;$YA[%<9F5]-)["K>PD)]J4JDBG
M$SML+NRDG+R>GD50Y6%#>WG MQ@_!6>T_B$#CRVN'7^QE]^[-GY<4,;_S M8A,+*)0-6R&"ML7V6|V\A"S(-+!@W[G MLGYG G*1FR2\(H+;39C3W\TZ0,:N^SYV?M)>9/!Z/PK?V:
[M?DV_34"NCJ:E M,=DG>,YWP[`QYL&?FHOX![3R2QN7_ILZNS+!FB G#0KZY0UC\7R[1&A-JM(MO-R;LJ!9<(&*(4ZP5'^Z^:S-Z)'/V:W-0W#S3:[3\Z'7([]M6E AF_/^|\TT
M^K,1C.STLIDKFLT%[&H$)LQGG$!UG'3%K=Q.._0/6+K5*P"P)C',?"R%@/RX MFY9TD7PCT-_ 8,K$$0 N+H&13II/H,6/04XJ_[YSW@^7GS3?+SL $R:;\H/ MOAV 'AI!R0V-
NRPW_MO)QY/FQ_$XE+M_/YF=-N\#+$#;3?MV@[S09GY<+S\9=G\$. ^W?G\WX]O= J66Y%L%Y,69M>!DETFO3HH!XK_ M%&$4?\6<@#\9=]U\2TIGQ=EYW@@/:SIH8
CC+WEOER/O+PJQ"I:7G6@@6F; M%PI>?#F+Y:)1V8S/[60Z*W. KX!(8,#PD+DAL@"#+R 88%*S25G6\FE9@Q$8 MP.?Y5?]@^%6>.5!/[P,874V6">/1?]83I)_F6<"D\)R)D,
[";K])TOE#]. BUG MXT"!?D!MX2QQR$LZG^WT[-R\TR5P-DE0C(=$_P9@S,O24U2<")@V;Z98Q M!VZ^@$T#C^J:8*>VW_+SMNL6D[$E/PJV&W3LR_XW%C87ULUW#=@^TTP?
@_E M"[^-@'//QD,@61B?D'GG%K:*18 M?R" [+0/ZWP$@/F_QQT,_0- #SQVU-J3Y^#P-F#W8$3BPVWWG]M_SEK0Y"Z/ M5 Y];#,2YC]%2Q@T*R*H.;/E'%%)FP7.F)!=UWLL7(43XO-
>-5UK.L!?0FB MP-+?SXIXRO<<@>;1G,-SSP"#1_E@TD=X9#QW $(,#QJ**2|WAA?L^C"60[#+ M060 >SGN^;?;'OV(^\[>)^MQ"D*"UDTD
UV:.Z0M)R@)!#8M[2Q7Y$MUUA#QIWK]P\[V%]C<- MA^RO=R$'1V?EL6&S@$%/KVVE%!O%@A..F ID#)6 V$DC32+\T8EH1K'@9JW9 MAR)")4$4$D9ZX+B D8Y&(V83MTGE_
NWEDP1^^R)'^P$#+'3[OW5SGS?;\R= M'&2N<9!^L)IS0O:)D=Q+H_?)D3H8>JAZ"&!DE6_0*W[Y(.-GH#[^P)]TTGK M2ZI$_C*+P>YL()FB:9R4:N% =
(Y$@5V5@"7$+0MI)G5#$6FE" MJ)!FS5QZ#+C,*^GF__UPM6&_+[M7$F\YIG.+NU)YJ5)'WTH 9_L-)^>-3Y.LDB SS['DQ_._<;SG^:4V/ZV X\TDU[,[/-D9|^:3'/\]S^
M(SLT;RFG|<&JAMFKWYH9!+,,VQ:M*, MX6)8>6"- EVQ+>_O7?U!/^33'.V'.PRS*W4R+*&5BXMAZW/D!4!7!/\N&Y8!A M5?.R%-T+]LW.AG ;($!_OOQ^ZJ*EQX7)Y+22(M 8_%U<-
AX\:328E&==DF M[Z:P=/ &5GE\&LN8^YG.*TKEA9V-2D.214O OB9CC-U'L9JSW-D$_0/6*8P MZRM2S:M3G30_SB;EKB%K+<.R-F,'NCL5D+%5_Z6186PLDE?QI-_Y \77
(7E'DMB'T*RN1%T?CGO-B< M NE,SU;@H03X\@[E-T6ZS_RTCQ1<#&T_"/@PVO.#E47O%_M8*7P.'.?C' P'/>A*[717Z./(!*)N_VB[8?S8?IV/_
MC^87._E'G#8___RA^:;_XEOXD'W1Z=PBB*7,B2K1!DD6=S >8 +"\F M>0QS@5T(,9/5(@)#,YP;!CQ:??YAF.7$[WB$&AV/HXMZ=1FU"Q466C_M)?\
M>3!%DCYP./EG,PR)+IVA.+H/N2LR**_+[MZ;TL7+GM?'J+ M24]FPRP]8#G/[67>KRQ%%O=?WC4/;;E,J7!'QH%QIL.\3?"BO^]" /:2T@; MER[+(MC?O(PW]
(*VZ[*,NM(@N@C_ORH_G#>K'"B0CD"-BQ&W MT])*0" :\?*KK]<0:X#+3#F;)K"---;LBOBU_F^WF4GWFX3SG\)"E-&WIQD MGWF\LX6:BM8Q&?L80W<%!DL4R'KBRE;>HDH
&;59/XH R"G(4?)<,D'&N(I- MH_*8U&]/M [G6/_UVE#Z"(XOGQZ)KK"'R'GX,Q!Y]HY@X>?'#C]'(^2'YH7 M<#5#]$A9;NVLROTT5%3HJZ,JF5_.+!@++N=CP;@N2O[?O,3L)%S!>7+75
VTZNQK5@W)MP=C6%Q3&,XND"VZQ; M:<\(2L>@B,I)/(-=RG9:5AQ78J3SS)OYLXN]U9[/!7'7S#,H8^C] E?" MJ29X+WNOOFQ'O=>E9"^VG8=']+OM(@@P?
+;+@YZF+J]%/\0+,$S+/LEX+QAGJ M$XCR&9>">N_N4EN_B2GW$T&QD'MN[#EXP4"7V?CL^66-^A;0F+GF M9D?9]SV9_UY<>AFS?
|S9U@2C_^<*"]OLU[WW"?";X:I%]/%*MKZKG:5WRN=J-'#2F)VGIL43Z(4ZY0,Y(@106GH6H(A%N$SEN'Z_ M(DY@?[6*&DDCO)&2I6C(9C+?
OZR0P60\@I?]H;.NS/&R_WM,A/%P!\SO,6,1 MV%D_93]JN$@UY;RCQ6U@U/2?LJNQ_S(,7RZ,N/2P5L9:T^YKBKG8"A_-T8 M_FF^^?']Q^^^[9W3X?8?_NVB. ^_>?
_Q;]_"\N&\/CBDTT[,^-SCU0 MDW@Z&]H)L-?\A.I2/?=G;4PK,<>><-U,,J!Q2G/3>B%E/(337Y7.11Y\0^YU),Y_D>Y=3I#1.E?TR?
MP3$NA]3RP&&\>;%/9VWO=,PG>TOH)OMP2NG,V>0A!NH]EBGOO6S=S'6P,GGT M-[QK@]YHC67M%X/+7YZWTZ7O:B4"UV>C9!R,G^UP-L^.R5Z[_OSLPL6_N!.|
M7R&H//X<4;C3N]7// B_<0@72Y@RM "A"Y1$A8S"L,-(,=Y H^' 1O@EQ_ M *GY9+_N'[B91X ; $<&@&L=[>-1SN.9GT?OFB|QN^]I M!;2MQEA7O=2IY'[-+\XI)L
8\T&54)QM_CG+;MMI[^3-+N/N#/2=9:Y1II8Y MIBSGM$B16V&LS).%[9H<,)X!-|:00QS9-Y:W*\]D@7'%NVZ_QMOVKPTKH+4% MK!*/PJ(PAD%E'WB?
Z'((/ZIA,BB7B8T%H9/3+N6L?))OO["#8$FHI&8WS MLAWE@Y&=SC(G9B]FVX=K\I>]JIP#*\5--YYT_ZMDDW4ES[$XQ6',JJE?5|<+
M;RY@&N>B'#"JU927,J!Y4(8TH).2K[94@NRB5,O_REQ2<"GOUPSN^5C+ G$ MQN$B+:$=EK(1?6?.FQD]_T\5/#]$NZP.-L/^7\!|(%F$]694TXSR[N;P9QM-,QV=Y
MJ]/3!1D^6I'L5DGWJ#4= M9KZF30GOKV2:9;[-VM@+ZO[7E=.B5I<5*.<\;U,,;YOW'X47;\:G]SID>'\@ M<6/8:)*./AF%?!0*<^"7:]/K-?TWQ>N8Y=? "O
M;C'U)?]Z+ ^3T@E?!3.G&LXDOZ2T=6,X+:W5NR91H0_%(J2DLW;=O]T/NE,X" MN;= "71<3W'(R]KG,,S3"?)0W:_ES$V\4]5GYXK1-">2K3)PSK M/ZUF0,RGVZ=
/F^:T\D)D^[]*F7D1/0M';[R!.XPO?26.=8Y;G>.R^Z -|#C M8:V^;\/6>]L&WACK[?U6;A%*>Y)\]83>3<<8Z"5&TI%"OI[*_WU\$GN;U.
M!R9VN*T_T\NMSU.4Y;M=$_D@Q"_CY(R7W$HMMZZE(V/*JX"K JZRS&-8AE66 MJ2Q36:9*F9J%[&&ODW^4,?R0ANZP4"^QG,|H]ONA;[/6 M/81|'M'2_G73U)-ZL+_XOO]A*>D-
[>VMZ+7-J9Y7(> :ZS42202F)'.$T4=F1_WP M=9X<_SZ7].QB^&2_WEG@FETK<,W^H,"U&BA|=T.*U\H$FV7QBFM[,.6*:YML MYZ<\$]AS%!W)&?
$X($L!HQ0U#G/N!;%K10V$#10[K)"G,60$9,A)AY'&5GM) M%&;:[^N$3H06%9@J|"V[UM:@6V3S<*B\Z!R::1=5M.4J|@*XU&DC(3 C1V
MO4\IMI@G[%&BTL$U42(KL4,JDJAU,E)%NS_ 1OD Z[M;DKQ6+JC 5H&M MO= MP.8$#0I3B8*-#"Q1!2#E54#11&U\4![+M59+Q@6I<0 (M!BLUV EP\G\ZHGMMG(\4?Q|$.
M'4L>%4D\)%&K#&-,$(UPL 3QQ#C2!"P#EX3A5E+J)+LI:IDE1F!LD"1<(ZX% M13;YA(@GQG">K+FM9>I+.D?,EITC#XFK'CH+5=RLN'D\N$F8$TQC!D8& "$W M.B
C)0$@5!2[.HUEI-9[^,<%8@AL$ZX0:,%99&&A#*FY6W*RX67%$8TD,AGH/^(,-0IQ@$JD M#6B>2A*6G K.NK!FI\?(@%54P4*.BK)L3X.@,NTS$V#9$^,IVQ_
(.&W2"8$(2*6CZV'NTT\8P/! MMNR,.73BKWAV<%MZH'&A%/95)V8"H\ IQQ@G26DJ4720D&1N<6"L8;)CFA$N/ M% T$<9\BZ'09SS"5GL5DE?/[@V?"#(RJ>%;QK&[I,>"9%
H[KI&/SN83N1QI M$3FBWBHP'1GVYI9^!5QHR@UBADK$,6 @J'GP)VAKA3),XCT*EFD\D+P>|#AB M/*MYT,|"CH]Q\KF=M[WKNYI5)VV-
MM9HZ_,$K^3":,ZHHW(:0##9&/4FL*?]89-!&./6;#(& WV"N4)7E&&*/4!:KV)R+ 0$);1$Q&CXWB?PG!\0$7%S8J;%38;3"Z&'#:*3:R:@3PL8E,(H$0P9' MBUC0CB:GC--KM1-
ELCQBHY!BW +T4H(LT?!'>A5=BXLC\PRO" 25IAM,)H MA=$*HUN"49T8QD1&9$CPB&OO1BV3!E&&O0(X9"FMU<6+S*K 1$!2$(RXPA8Y MIP22.@*FJH"9WB.?
O.8#2BN,5ABM,%IA=&NA3865CR0BD8Q /'"]' E@U#/# ME;..$K<&HX$&;YG.I;L5&/6"@R)J(T8X62U))%HPN3\P:LQ RYVZZ"N,OD88 M7772P^M&-U]H^E_FA_U
MMIW"*/R=B_A[/+?M"#BU^2U."N.-?&Q^=3!RFQFK*YGN"QYO?FZM:X?MM+U> M!GRY@JNQ!7&"I?K3/0$&^3)K^K EO&O!WG?-.#4?X\4TGKLX:< Z;G)?Y4$S M/8N-
/3V=1%@

*S|H3F|G% MM EX?-X=DLP2O*KS|KVJ@-]3"0;'[B8 (''1FZ/+G|M)XT:[YEY|MV7[K9NC M+$U,O'6U7S_,IFV!)516.CG<7O> \Q4C%<%4)>Q% [LZ=6J/.S\'I;0["H*-MV)U3G9<8VQ>K1.S4DOQJC0+7M-/S@#|=)ID4[BJ""'C=JYW;*NM.4]@ML+QZ M]><;U\,"+_HR#+O:Y%K@?78$R,I?>I-K-QBH#|\T+TS/@YK,SN!88'&3UE5"]MOF\]9B0":S8M>EGP8M2T/@ 9V^TVZ\L&0AMQ4YW.W6O+FRA1^GVOY[3!VY]= MP9/J;Y\Q'C:7&L?>+>[FVA9O45?6L) IW.L0S,W+ VEB_NAM-/)>.*9 M39ZJPA|Q=9[B'FP=4 ^0(7'1702IZ4>B3E.A:"SK04]"/VMMZ2?+TIV5MF M/?ONL:W&H.<7|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|_ ^^FK I"/'). 8 0(0 ?*D9!FV@ M.F2#))8:GDTT7+F=(E&!2B.A5M#4G0%.N@RKM:W05[SI'" =FDW!T-CT-V^@&N[$'5U[*SIE M2 -["FE6@8D@#&] +DA?]{4:GRN"LIO?: 'H&J1/"]4&]FN7=,NBA]119E. M!J&P;:OO?GO_M[8[^ 4Q4L1K<W7O(K7C*J8(HE]QD&C8[62JQ* WLZA1W M'K^=$5<"QO:,X7PQ0[&WBHQ>:=QE0.AR:3.>;)6C@OXARR#][28%V6TCZAIR=R1'?@LHH1+(F-W2]I,Q0')P? MDY\M\+P7EIV/^C-_#$^Z*$6:2A0]+G=*)>)WZ5YTV,!A/)Y^;/LSNM='F25I ME&6U O;W4S?Y MI0N 7,?/_-J2)/&GR=<5#GMJM7^_D"LYG34?BK-^R>>QY*3=4]]VX:@-QF*Z MMR_=N8@+8*#%8!EC/'W|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{3E?Q M3.V\PY/=E+ 77NBJ%(\@1=G8!O ?.ARZ&@Y\L.1?XY-D&6OPQ.2P:2FHWX)S MHKB@R3(;ZMWDW]L4N'P? 'L7X_1+7M;T>M_)B6I4L?%XVIU_Y)_6Y4+[12I M4@SSNM*7#P-'>/51 %*IW[J.\2G%TTME;-A\\|,;B+>NFTG1OHKX#5WXPN4R M-@"O0G@ :=G5/QQ+%WY7[IHL6@*E]M1FU_K^]\N??^C'MA@*5TD!] ME1XD#!;M@0V+EY.QNYPNYC#73RF^646UG-!OES>4|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|^AK9 [L/:MC+6<_G#5\T*;=;22QKAV10@A0K)0F MU%E-N:6ZECN%WGDM9(X<[I&U)9*90*Q(AIC:&L-!C9/A<8^"S8B+X=3D+M[& M(>1QF74)[->5,3PKW<6:R8?!T3A8,B _9/<^N6RH!\1;Z]XKXTD)9%0QA.QL M2EKNU*OFV0LI8L*]^H+(% SQM5#$):6CHLH;YQJ52EAY7RKNLV?S ;.>T6(^ M4\RJ4NS&IP&XE** 1$P151MI54S>U#L=[+%W),!6@DEIP"S/-'$L.E+' ME+(T=>#Z<3%+C+0:4&MP,[X PV6PTS?1C'E1)^$XX!$WV#&$$QL9&&>R]MK5 M/ :==GI+>EU'06LBM Z 9AA)%"4GTK#D$N/8CN91T4R.C#6#G3ZH8<-Z/G/X MJHVPUM),:!86 $@&XK$4/W4Y)*:, MS!:[S2[XJI(8STG@\)2T9I&2Q*0D,ABPY"U+)-:JSMY0EY3=R<^NF:X9@|NQ M;;%T3!%+K2"&"ZJ5CR'1QXVB!^M?ZGNT_F]2$N19;Y6,*/%/4]%ISZ@0C*0;3I\XDG@F/"3-J:%!I!S6S MMU1IY8C.1@#2>E GG;<$%%)9>\6#<_ 7CIMOPD;BWLC]?YIB7@9PO2:|<%R?IB-Z;>OD<]HUR0:#\#'ZD2, ,0$K5YZ%A*7-;|* MEBH[F:C51 M9O-,.&;@+Q5T\C'Y.CYNW!K8 N9>L_T'M!R[M4V%TU'4D:B:45!.J2/>ZYHH MDP!2=:3"/&XT YZY*. I"]*[1Q@ZZ1JN3ZC2WSZ4?WCO MGKCR[L^^[;DP_G"O*LP=BTPY;G[D,AD&M/R'A@7?MT/ZY^%&I]>$_$FC],G M$IM9*EP)I!POSB9O8M.>C]WE:_SVS;F+L9E\V#CF:+J1]2<#W0=_7[3S)E\N M7UAN)6D2WYQ/VZ8|>Y;&)4(:N/43SA^>^7K%N)]NR)V,?XED7VLSW+2]V]U6MC&TW2.&=RH' MJNQ'-PEI!/=M4<2G<9,N8+3-O&K::C*=PZ+.4C5N_DCPN/DID ,_A! FY<9] M@_C8C,?P))@Q\.L_4SS90L=]&MG!T9**VIH:ZRX:#D:!9C5QQCD"*!JEKJFB M<2>3^C9H^8.; >=_:']-LV(6W TJ[Z"F!%4,GH"5\VKGZ=M6P%AJD*931XX MZ%(SH;FJ8R!9*D.DHC6QUFFB&&?.&BZSW3FIO/N.ZO-KR6J4[EMK0SOME MZ=3S/WWF7G9"^2WOO.5MXD3HVP[VMG-DZGG-\6Z)V_L 8'_LWBZPW*!/^<.$ MF3WHV=|SGB'P!G[[[^H;XYPMK=1>:X74$OCY]HW/RE,VY^0./FY?+ @"0#MDCPTDCQZELG]8\V6L^3V?'$$N07/!H&^\GG&>=_K;75I98&Y@-3TO1TCHZ#Q? MS,*I:Q-F"IY-\15PP9 A^&J-Q+XENXC?\?, X.^^O">XT=Y@C)4%\)Z\ V)F M//$QN:H?=/J!TW-'*TFGHU[?FXSP;KT[E-BC#70 K?3&DZ\WM ?=27(JSN% MRUL%D(V=OP<-%=^_[])>>]VMC54P[X<-+'@Z(OC&5A#BAJR%%&E%,0=' CUG MV.MT,2S3I22\GM<:!U[0]L$@R=@0=DT^WV@02|\0#(QNNU M9 \44H!U\(38*PFLBRF\. GDTS0IKJ=*AH1IEEM3$04H!Y8HHX?;LR0(KF0A MI95)%'AX,1\))H'70:K*%.93_?HF,I8P9=8^9V4#'V+53MVZ#4$Z9[F<-UNS MAO!1?$4)#)]*J,Y5?F>P<0DYC$13*9>*)]*Q2:@FS?NTV3T\&9E!.L,0J-02 ML7FB%\ZIJ6T*.(X+:5VGR6T^M8VJR:=AZB]IFEY3O\&Z0<'EJ@DOMAM?K]C* M-KNP!60)^.Z.7:O>N2MM?H]'D0T[_=&HT_=:[L0?@Z]*MP|'8/ZHTPZ@:= M|6H|M3MQW8[LNU@5!B0?/->:^"#YNDY$]?OCX/>2O;L,THQI]T[1"EV%V4^ M3FYAV^,$2!!IF!@#QLZ:M-80;3MUI\:B.^QW)GZKZ_11W74ZK9$_Z+3<[M"5 MOC,00 &[!7Z[P;%ZFV1YMH4G=0[RO-G:5G>+Q<[80%|HVQN$9?]"E^1DY!*(M+=7E5I.L\#PET$AX0>"3.J$X.@@D"2K^H=OZF/[KQW>BUTA_WV^+%]<-NC MWEZ[R[]=MON<,W)+R#/H)75@#=A>9+>[[W%+659?K#\..!N=$X/=%\G>[(F0QZ MJ*CG'"WG)D!AD/HS+$=AMC=P_+,^EWUY5J/FBYMLK+]8-1XK4FU*P MRPGZ+=D=N;[H3'J. MLQ/%8!CO3>S_5+'=.W68MR-%X=CNVJK^YTCE!^5'*6]^ 04J,Z@8M&2GW^FZ?M#OCE<.=A^C)3]) M*%('N1\,S^U:18Q&FS,!SHO$V9MX*K/|4\:8/4M*0OCP5)CE>.!]PQ$G+DO"M94D>W15[$@Q=O$WFB"%6Z^T&K9$8RY8K.R.O[XR[8K)2_>HQVD:S+VB;-PWF MW:W*Z0TWYU!S00WV6[B@QA'HGX.YX/PRIR)G?--Y$'2&PO7ZK8'ORU:O&_A8M1[_7@D]C&4R\X6BU1M8C V2UY&?,7]V5_K&=WKHR\/OBE>/60??X:33\59BL0|)GP:(59G3;Z M0* +"50-Z]_" U/VX+5>5/K5J;XB(>,13G7] #\V;C+J:X!T'V2 M.&],F-R9I3T1D>I-.I4RQSEQ-I'I-/&-R=]GDS$]<-K.XU.F>Z-'OCELCQ^= M_/SX61_Y&B:5=P\N4YM3G+2T^5_-PX)N6OPD/9U>YU!Z79<= -XT;_I@(_:< MW+;3>*&<@&(=M>2@,|969X/6*.@Y+;"-Q6@X& 6.6+&;>X-N;^2,_58PA/_T M@MZD-0*O#8L?>I/Q< 1OK10__$D&$]_N?A;?WF1XA0[^,-_IF"&F.:0W9"D; M$_E!MUH?YMJ-^GR6]11CXA%G60U'!@9]I&2MF\Q]X|#H3O[*MOTE 1K1<>L M>WC3O.D3DZ5L7#2,B_YDT.E/P)KH>;U6KS/IMD2OZ[0\T?6\2= =]GM/'LH] MJOC%P46 CX:X]Q9U8$.!L/&[6*AR$%6\4OA_%EE.W()6X4WSICDABA.B--PN M'ED8YX$%O<2D-Q&.T^HX [!?.SS'@Q[K>ZDZ_O!9#09^=U=V#1&^/^!YI;M5WX\/6+1TL.6Z+0[/3E<=4-#ALXK.-YTYQIQYEV^XNT M]#U7CMSQL-7KCOJMGI2]UAC[@XS=WF3B.J[7ZPQ7FAX[_6'0=X:M_GC@M7H# MO],:R?&HU15!3P1#Z?>|R>$?XZQKP7MOFK'_Q+2C;9SA]P? J5W1$JX'M##L8@C^ZXV'PZ$SV$FEUV^2R;\O"I^@YX$=\=XJ3^.V[8JN%@$ MF+.M5OY;;/WFY0G:WL[(UB6]A95)S':TYD4ZJ*<"M,'T4P! Y@P&8DLL[3NMB<1M5H2Y=8OYCV&$I; ^O11AG>;TPN&UY(%GA:[3VJ6T&UBF7J0IK"A+O5+F9 MOK4N,BFM7Y-<6H/7C6K+&^41,BNH+C,>&P<), M2*^V9.Q?S9.,2]!?4EW@\$;6_I*M?)M2]WQ%/Y[6HFZ)SRCG.#15+ A+$: M%:Q@<[=(VT>-O!W@:(W)L*+KG|VJ(:4(^YI]<;_ "X!7"GM] 5;TBBP#7'R! M;Z-%%F9?@L-0(N]AM18HD@_EZ-7CJ+O*66[=[R! MG\-8Q-1KX2U(>B)GZZPT"K_:TL/]Y>LH7VH2)W9CYL!R?U^(\&>8PJ;=E M0?B*1JEB>Y&"%C20]1O32O(U@]9].DB+!@//PNL+G'M:13/FH^@,,,5L2A@M%.G7+B!44]0*QM?KS|>@/.MGAM4+8:Q*=4^01>EEU$F;Z=XBX%N+@"Q_ELU M4X@60!!H M@8JKN5440A.UB66=3&I:@EX.P26XU@XQ*ZMJ$6^#""^>1"Q-FKM MXU*IO]&;.8W5. ^F;;W)K"(SY?C7[C=%EU;&GFJ5@FO'E;J=*V/3T$?GRGQ] M*Y>_*;+E;V UY5<)*+X02%&H1A29FA#G^JW(P:VV/D@??5';>A]|S(#-#CNF MMPPUPPG!.$T15.O)W%88|IODI?AB#E@G\M%M/A#A^UY':AK0HCW(K4;T50)UZ M:@2.W>D[.<=BVT! 5I;,L6)#!O<+9("_L2P$?P,=BNN.Y/U94P6*^/A*05(MJP)K_V6&GB9K\"5[ZM?(@JM?1R)>VDP&Q)G^=1@62A MJ2@K>!9$P(P FB(C-2MI73,1O(SE)!6^$]BH >]8)*'Y%G!#Q.!I1H)"=B<<<']9,<54\K*R[H& G&^1HGMVKP(E9_ MIV'V%=90Q-H7S4V/+' ;B]E<[9FV@NOW!.@'I>F!O%]K"'-M@4+)-F"YU<) M_CS%3:L%P2(FN']@3]@EP-L/ U(CN;FYF,"H&M6 %G@?>T*&>*EPH1LZ;N;C M3\A]M V]L?I.M-;34_@R|)P@GTF5:I*Y<|:JLK-2^%GB9;FV6MASFZ^YH!/L*RK)|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|')E=(.B!FF%8QMVY1E^,:E6$"(/Y2#>LV M)/_]7\ZP=V7]2\Z2RWEG:{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|SS$-QL M 9942JAS*7DR.;CF23 QIN8*:4YM6^A1U;Y?!9%JNT 0JDD6?UFWFBU@THHN J:(M"9: M:C:LK0-+(LI*_L;UUF0:R9A,W)"%JE5L*E'AYQ^-.#THU-(/SI]!5@%)U"X*ODDE6."WG=+'1,8"Z9AN-!!E9;> M9'. Z533)FB"EV842,!D#FZ9769EH/J*C!UV1PC*V'.E$54&#.AT.2;9*BM+M5&F24K^"X@,U4!V5U5Y%40U",R*K$#ISNNLB_<_ MO7L-VPPQ6%%:B:6!F,W!)(.UK%B*C974C41EC=7T:F)L8 ^/%@%XM+!E*Q(| MU@0\N5@:ZYU^(OV;%1[X:!DH1G3O;V6E&Z9:DD:-P'"E/EWGVILX_>%UG8 M47)-P2IC*BMS(Z-H(\&2(J)@1"2G,H%Q>CQC6AOG/P8@51#'Y/]'6;I.ID M'_5ZHK#6*RC7BK^@L@%O_^>U_LM.VD,+$!09P_.[;J?=*[\) M=/)(/DTE"L4XGV; V)C/MGI/EM['TVC,5T-IAP8#RAD:=]1KN\V9QN/V>&4F MD#N/G>B,O55T8\C?A)> @J)('7>#%6\R22CO0L<&T@ZOTMSZE513G M(3F!RD#/:2;^Q-$C1.O5&7_F0+9N5\E* M(E_UO(A:P-FQ?>H\EMH>6% *4H6>!2XZ<*[.K?+!)ZQK*)2 M95VM[%!96PI:QOC0T5G@E6G-%R8AC%:%IJ2&[4B/5;:C.=L LT3/4Y[KT:B&M&#&ES^0@8#RX)BK-*>*-"2:HL"-&@LLM9.!^@8SUA_[N%_KN M=658X;DK1?G!1R,3^!;S@9#/:NF/P/4I]TU,CK=<6G%DAS4)[VBB+'IA]&] MX-JE=/* *7>X<2$=T6;#ZYN>7%4$ZU>^!FW5TN\$+&Z$ MS/;-N\'<>#PGOL:^'9:\$5%1!:HWC:LH (J3*WS3F:GQFO6!E]'Q2@N9FR%$ M:G&RB5CH-FLLD1A$JKSVN2A4*7RRDM39>,:P9HVZP!&+&/N&E7J],'0+J;Q M&8JN96Z4:9%9,9F%N3Z^J P(E$/JZ%9@!N@'L=":7>.NB:951ZE*H9-$-^]#Y MI-*")Y0QMB4EHY0T1_9RE M_8MLZ> ?/1.,KF'8%CFX>=-"A0!1[LXQ@R2/X8I4'64J6&9{-UI\.4).)!Y#D\)G?^.IZ<8]%&'F1A)I:\W7./XK1F;7CL3@4AO6-T/"+/ZU8X; M@"F9) ^MO/]1C/L7(+:^MM#66?X/EQ\OQ[/;OE_4"'L-QXFM!LM51[)OR'7 M\I,ZB3]KL6+.LX,BI223.XZH01QHB4&TFH *3*!QK$YXU#WH:[5!Y/(B_K6 M9#*#GX^A>Y,(+2+,-E ' 7A+8])2+C_&9EMXL[1^'&XR.S/KXI?/;][^"X/R M&-+X&M(*XR+-M(@RG= N/OWZ,V;D-2(NM[(ZN7C0E$>PZ5RLJA.691 U2'Q>EZ# M26D@[>-+-#)QS(S"-E&E7CXWM(BY'K9R4$BAQ\H@%#YNB#0&)GH;Y4?!I_*A MIL&E8SG*,'R07=C(N1

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}S21\WML]24>2B?]\ MM\MR^?1P>HK;Y2OY>_55YGPU_XP<^W,-XCB.W>]RX)4#KV> QY/A6YYX/!6>[>.1YYDE"/*U^[V&'3*^?L]78_AJ MS(/H96AWG7O;K)S?S1BVME@TG+MH&-C=P8A% X=36%BPL+CW_I=C#]W=E2<^ M:VG!A@3+AE.2# <[('CHL&UXV*^7WT^7821T[.$K.GPL3NT!XYS,6L>,| CR?#LX[MCG:7['H4N'Y\^LE9%V3\ M;2Y3D8?QM26_S66C@] MQ>UR<82]N"L?929%ZDVI*H(O;V24S&?P$Q]ZGK1S? ZZ!G)'M=, ^LL0;'7L\3 MCZ?"LL[[@S/K#(4GWHR9D^+B[L=N]]YLQ,4UKSGB<<3X=E>$QSX>.W<_XRAP MS:T@]A)V^"0BF!EC#C^G5XGGI1QQ.&G&.E%S#G@\%9YUP?#A MNQ$<(^QX588K/$7B^Q MN_:@O[N+-"6QWN^S\L2G!PH&% MPTKR?-<>=:R;EA=NU1\== MZZ2Y^TT;?U>OW?,R-XS]YY]I(3Y^9#Y>>S8_1TFRYT^ M/[,V9NX]&.YUNNZQW^)_ OMR392]!"?>(VO(++?"V$MFDBXJ)?E4IOH+VXHE MUV4])IYC";MUQ07;Z1UUK(+/=YAESXUE^T.NKL!QB;/$[*DP\= >.F=6;H'U M[GGB\718=C0Z,U.9*Z3L-P"A+|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|LX^^';-E6)_V$<8^K$.507I,.;UZ12,:I#Y]YVKW(-[] M\SN_|'(K72G>].CB<[/0]R/Y N[=K^[N[8PS+O,N\R[> ^+=BZ[MNKMK"WFH*-])) MN6YFXM.2QD?/N\]ZET8.&,U;,NZ]N9?L]AX92EGJ5K#HC^WQD$UGUKHOOEOF MW0=W4^_8@QUVXV/>9=#WVM7Z>P"\P[&)X]SJGN(/IZ/L]V[-O&<<0L%KK]S[Z MBAT? NV]/7I]D>A-ZJN%4DD]ER@?P3V2RERZD^Z+2]D'7I8]2'H_L[F!W,8R7 MKRO,OA)+!I8,NY , WNTP\0 E@QG)!E.&)''SM6.W>]RW),Y]L5WRQR[):9= M]XBQO%W A/,$V 9G&WP= [_=LM\]&.*MT%@TL&I8, ^;'MNKL[!&71<$:BX801 M>>QLW;<[1VWP,\4$; W44^@WN$^0R?DUQ$G,.P4^/6 M;;MHW?I),8GD"SI#^_\W 8.1R^.1_9@L#N1?"?(V#-B2<&2XE@E1;=C=P>[M\[584IR5I#AA1!X[8U\X]F!\'EX9WPY'HPR[V[+NV? MYSNP.8YF^?WWDSH MV>X.CT+8/&=)P9+B)"7%>&R/=G@?G'7%64F*$T;DL3/VA=.W! [WA$:../7EF MWK-EWG-UY4UF!/PKP&B@/\OEUQ,0^NW.8/A]+0N!2B[4MC2 C_M-1%A:RYV3 M;P#*4NL#RY=>*D4F?6NRL+[KMET+AHO")+:2U')ZWUL! _)M/)?POE=*:P4#3 MS)((M_Z).>YG$UD:G4[MN5VW)XE,LM+9G.1PL]Y0B]F8B:MN4S#Q+?"F+Z: MPX?46DB1MJW/TS K5V'=P@]^&L+:<#W"^J]7'14K*I^'86!'60(V7[D/^!], M&,A;6([^,;,F,HRO,56VG-HKTA0@09/;%D#9F]*DL.0\%%&TL)(R&2NIW?: M@W+Z,&Y.7\R0@)97<)TFM_D4GTF*6%XDLNS' M5W-Q+5MQXDN#,Z 2_%D3R=]$G=\N6]VK()+? 6GZ82B^'U5T"^12S^,H/LWDD M%I?XZ]5<^#X H)8X'"K*T*E ZHL_BRP/@X69D%YM 8:OYDD6TMBIC$0.2 'K M^QO2'XQY61KBWS8(@&5V<=S'\|O3.M$_C6.2CC[2_8$/KD#VLO6$U\UK]+Q:0A@ M@PT9>LK4>C,8/4N\4.0P^&T("'X2GG>F @+U5*F("O/(01*M'<:K+ M$+8>>AM1_\|TR3(+)!!\35A57WR@#2U!2K'3FB1@4HQ:1^$N4&4!:>/C+3!J MD@*,D_";]*_4"IQ.IJWYWKP H(C$/).7F00R 5P::)+OI,9^M9P3?1-FX22, MPGQQ:=Y? D^VLINN'@@696=>G>O]*H?ZPX3UG+Z_TV\./.?F/B_?!^II>#MN/N M:7&@*_>$HM'I;:G?.[DM.?O:TKY0-'B.F1Y]!6B=$;'^7M"J<;*\UI>(&+Y MA,]ICWUS98GAP3XOAEZYA|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||5M2E)\/82Z7(&I\%26KE4PG_PU;+6) (RQC::LX3::,K5-IH6 M5J^W1 ;,-9N+%'[.QHAS-IS64:)KYN\08?X5-J+:1(VU;]7-,*9["2&WAY MLK"<3GN(+R*%B6MX*0GC/%M:V;T+@I4[SIT#/=?&/D]E)LV.9A*GA*>N[RKU M:=W*E :!CX!$RT_#&QDC,(0U!1Z %3X M7"KAS0+!!!2%3R>1+)?(R&2NIW?: M@W+Z,&Y.7\R0@)97<)TFM_D4GTF*6%XDLNS' M5W-Q+5MQXDN#,Z 2_%D3R=]$G=\N6]VK()+? 6GZ82B^'U5T"^12S^,H/LWDD M%I?XZ]5<^#X H)8X'"K*T*E ZHL_BRP/@X69D%YM 8:OYDD6TMBIC$0.2 'K M^QO2'XQY61KBWS8(@&5V<=S'\|O3.M$_C6.2CC[2_8$/KD#VLO6$U\UK]+Q:0A@ M@PT9>LK4>C,8/4N\4.0P^&T("'X2GG>F @+U5*F("O/(01*M'<:K+ M$+8>>AM1_\|TR3(+)!!\35A57WR@#2U!2K'3FB1@4HQ:1^$N4&4!:>/C+3!J MD@*,D_";]*_4"IQ.IJWYWKP H(C$/).7F00R 5P::)+OI,9^M9P3?1-FX22, MPGQQ:=Y? D^VLINN'@@696=>G>O]*H?ZPX3UG+Z_TV\./.?F/B_?!^II>#MN/N M:7&@*_>$HM'I;:G?.[DM.?O:TKY0-'B.F1Y]!6B=$;'^7M"J<;*\UI>(&+YP M

*VN2)E\1Y&8SYO[ADJ4@_*E&W2R!?[&TK+K>6Z7ZZ6RN MA28>',G S0RNBQ L3,Z@TI0B791/:)BL0T7; ^JED(4^+7C-13;FL(Y(:C9@E M&?+ :T\@861]B'H1#EC'A 1#[?>]J@**> ^!E.A,"&\2PH0Z(8898%*U<89XG M9%V@S:/KD,%: \|??*,#,%R3&6P$,S,IU2[5-YUU*00D,A40JX@'!O$J M+.A0H3'#Q"11RG>%9>M+CN4U)4I4D;\5WJ H2C."LH9=%*N6$&@(%"-EN'+1 MJL*MSD5K):+H)-ZJG<2KH.VZ:-<*3]RE];&6.B#3*KCO/3Y,\5<,'U;%5F3 ME?,)'(2GY\|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|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|WH[IMOM%KM_:C!7XX^!I!@P$&*TPX2/%%P5 [5X(O\-@TG87Y((8%!VWIW0&Z4!M"!R_=[7;.' MB'=U$ZDI)W!-2A!HGL2E((O"RO'Q%@CQI-"FS)6:RL%DX>_-"W2.._D92;G M H]3#0CH3%B-_0KGAP644@J;?:JLETOSOGX(GO)+X-!TH[8{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{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|^>KR+;F(>$HCCY'7L9>I!6&__ZYK6U9?:9=!<=0OCOJQJ'04IX3.9HPF MX@QUXH5<0H1Z2F9]35-*W@0A(R/FT8R+8E*>WRVE8TYHP@B;CICO,Y]\"M+)MJHR;.A7W:],J@QE@ ,8P !6"S!P|> 0_/?]U8!&R">]IKCUB/,#_2>1%5 MTP4YGXNC7 [:#[T)FU+RAPA)R7D1H+X-HG]&E-\$R+Q6/@I@ ,8P !6"S"$ MI$!38"056?%J]*)HC'UI]5RE@ #&, M!K!:@!6QL?B_?.FJ/U@VW>>*>/EO%*+).,/;?9<9QG_?N19"'E7,9U8]:(8I\5EXL* MR\/+ ^OZGK#?O-9S^571EVL(:S4Z05W+Y ML9+_\'?&T^!J4=Q07=I@D=^?Q3Q092]/MO(-<"8UGG]SJYJ(QEO^5+3=9??\M:Y_'GPV>TB3MT2R-^[M66ZC[6.[E!+::(,[*EIH M'Y D\'|ZXN(7FF8)X5MVTT]Y,X[BT"_#)L.+7]X-/N[XZ?(4%?K]\GQXQ_%M M?#%\|1WP&$]RN)? ^@1(F. YZ] M#:HGXHO7S\(%41E$OC@<<'%\%B?J-B-&9*\4!^2GKKC-B$UH>5$&'U60FC'ZM/"&5[Z8L$A>I\H2+FL2)X/7OOJNT*$MNIW"6XC$DFXI8[CAT%98HC[UTGK(J MTI>*FLO3&^)M&V?BK1G,F=_/;V6UV\WVL^("T;U".N.LQ]F,)C1EA0ER54:5 M?7173KP.># *PB!=](KK-TB"^>W<3M-I'S];=_1+T-S3M^ZYSFYV3[[^*J=Y MVMWA9NY)L^M\|7905G7/[LQK66UCB$+ED9^.[*,Z&N9]EG*6DM^8+_%>DHO(MVYAAJNO#.@U\/V15: D\KS&C+&;_T3U3M4Q^VL1R_;(N_A:SE-(R/%+8K?M M$H9NJV,AS*8I+/%JT2NM8ZQ4K*6J:7=F*>%Q&/BDJ-M&BVVW8? 32V"/L&&+ MM\A;QL. D8\"; RO9^@S#6,8':U_)HX>J*N8[L_@RRKP^,(81AL#OJR3YG2?--?=_Z2Y'UNCV%__.V/K4DZ M#7_ ^'U!+ P04 " !6CF99^EW\RCX0 0!LDP\ #P &]M+3(P,C0P.3,P M+GAS9.R]>W/C.)(O^O_Y%+B]-V*KX\I=Y>KIV>T^.WM"?O7XKLORVJKN,Z?C MQ@9%0C:W(5)#4K8UG_XB\2+XID00)-W>V.F2)3"1"8! (A^__+?_J;HAZ!E' ML1\&?_GF]+M/WR ;KP|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|?^8]Z4[^&!{H@$[I&%\XV&T^EU'^. .DC?DUP$/LK@D^@&8[8 M@HU//L-[PQ^/HY2MM1.OV,/TRPS[N_CDT7&VQ8;BATSC<--ZW0F)"Z,NYNCT MQQ]__A^_>;?_P="*7[FVT8)@O^)0091+5#!?\=2+'[2^.CG]3!?>=Y38 M-R@H?54J!OQC-R;DXCF*";7RCF5"+C/H_8>]?DO79:L>XZK74+Z\)_!';;^E M;_MAG1<6|$=,DAC^JNV^N.Z/DUF^]?"AO;QJKSA25OT=Y/*:]K)G'F%6[/0MM*^SO^-6Z[OL5#"PQY9;UV$IX]^_Y%N;>Z.L&8GI]^5O]=Q;GLN/*4QX 1! MF+ ?X"OYY7;K[^N0?T._@SWAIR@D>$E'#\&'K_?7+??>CXGS&@;A9O\1GOMX M3__S7U(%DO_.^\R2/QD?TU[C3:,G6^03X_3]LTELY)=#U.-RF>"G7Z'_Z/Z MEJ9Z8]J.X"%.#6GD_NUCGDB._"[+&N)D<--ZW0F)"Z

*[^]/?A,P'Y%?BF&BFYK*55 M7>#A"1/2% *0:32D00="+B'(!LNK9J;EXV-:?.WMALI">.''VS!VR,]1N-M"/6VZ M'_#"H]@3*G\UY*Q5%D855BC0)>]V*^*
["WI3@,/J@/#"\N=MI<^"BSG"SGGH ME:;,ZC^/ 0>F_OX]IKCN3.I+4Y1F:=M> &W.Z&S^[H4O5*N'PD:U&-M@5<^G MT+?'N3'A5[5?5S0V::+2+I '!"]DKI'R
MRS)5HY2$+Y7Y1/ING6:(:V)>7AAM(@=T]A4.W@+S09R=VED!IU0"2% M_M1P!M5NU19O&E!#C)$W:41X";EAE3%$+Q&ZP:BF1D_+YP9-N>(0<3$##&&=1 MP3AP,
["PC1KD(31,:I:LV- |"'PX3)RHW'A9T]"LQD$W3!P+$((]3L];&>3C M L=NY&_YJW&VB^G+$, <54.,U;0=TIO$]CQ\QF"5$5"N_5:U'DVR0*QRT :/_ M/WB>!T,W:IETT$AF^ B C#^V
DZHY4,#QH9!Y1#LR2.EH3A?:>/AE R1++0, MY^[?=WZ$I9$:4G"2&C/W$00L^Q%26&##N-ZMQ)!2:#HM35:@X7,PU6.5S#60- MC;O(SR4 BQ" JAM7?QT.-X@I='$WK;
VZMIL)W;K&?A!?3V#S.]C2.VOC^@< M3]V8K,>@\A#(-!K.C6^DSF33S5%XFN79OTSH]$XJ_)3&Z('#Z0R MX,S]JT[XHI'G.V7M...:C.YVSPZH:14#%>KK$%4_,*I8IJN(1?&X^\5:
MZFN!U-R _>K2%,?0&CCC6MF2;\(6<*CUSY@T,M'1HZ_+PXA>`_F!+_#8 $8 M:Z6QJ>&!8<'*>)QK9<6W^K8&AU5!ME2:/_ N0;#'>O3L%4N0V^OE101>L1W*#R
M$,ZU[O2#'[<;=)O'_:KVIK1\:$2ISR*3(UO2C+V0]=VLL3119|#XNXXC\1 M?E1W"!::TG0W:7S,I$=91$JQZ\S7P,/1"ZC'+(:,(S8Q1\AFX[-,G+BB\F@7
M2CT"M90H@E6M!JD3\S6(M]AED,ZEAT=]6ZLL+_V$;YT>U,W>.02"C1C6$TSF MD[]=AGQOJA3D4 H&UT6QJF^+.)?V)8+;$QN#U:HNX+C0;$2'B339"("Q8PZ. M&A)&'9=4D?=D??
E%\(3NO)Y3I,XNJH+UQ_RL$&>>=3R@&W_C"[MP<$>P]PC M.<)&Q)8&7)\C[#\&D)WA>[X3E69"&J Y1N"ABB@ZP_2'QQ0]VVOIJNK.78=M MV>+),8:''!X,,CCFQ_'U,9J43X,=#(]
[A^:.A)1\)[/%AEXL:MVUC[ZE,MPU MGF[R+!*,Z2<[*'U^/B/# A^`]=7'O[\T""=&I0O% EM0G2H?F1$*]:6&=E: MI]2?
L0L#LG$(D;%NE::B;*N1($NP2*^'+1U!JN'^0E4]6!*0HWQ:&1W7\O&1 M8)@W;6-5K:TN(+#H1[MMXNY%0AT$@*AT_O(W^M"G>\F^.F<0;/%UH%W@[G&\ M(] SA+8LG_
#AG,0(BGIR??(+(3BUB>J:1V0@]5+?R."T[T-$\R-R5LJ7)K1 M<@_*7M4K>3"9P03^^K",V'UDGWK_:P_AF@>&N[]D7* UM["2AH/"/V$620+E, U%!*;OS,DU*^T6]
J_>Q+XUNS+UXK07ZD0L4 M0.@@]L1\2'HH4@0G)51VEB1I]$2_Q;Y 5)"WEL3$G*);YV-B.KN\L8)02D MQLTRR7&+?>N-T>GW'4F?#W/-HF_@NI)<+\G_\+2#I=1EQ3A4)LC/$"2-
*&0'I M:0A$!I4%0GY!?V+[KP!A9+&_7>;%441P*T:^H(E<(#IZ*8@N #]*! #GDQ# M$[#S*Q>,Q/?];U)M8I ZK+(%&6T34FC4-'N;:YZE9!(X1CM&4JEU,BCE/X, M\?(4?
0NKS'"B+D&@AJT*TYRW".[AG@57;=K@-@PB^2?S]2^/41CT*0P@J.](74@0W^&6 \HC)#HQ9)J8%1*,AH!T\U/JZDM@B4. MGKN0:CAJ-]?H(4%PAI;09 JRD!HQIL# _XY68:K !1@M?
7HWF*P\^KY@B6VF M:P'P2(2?267- M=(]X_^@#&_26YZ/QT'&K7B=<7-#-T' M F.&?,;+3SVJ_3H*/D^A8?B'LD>, M/!+](4 4Y\D"Z*1!(@Q,X)BX\V-4 ^XZI<9K#>,5LZ$(&1(
(RRPAIEEA.5R| MS58.UQ:&2_[5WR5LL/'*V,/:#M;EP]U=.BB6KFVQB9U#T.CDF52L3PT!E
M24[M.APZL)]QDTR'[:*CY+173TEIM:0.!@1&BQV6=R&O*-^S_<"8)F19U(L MUB@E:2EZGE=+#YA6 46KSG=Q$FYP9,0N+/I@TW,A4,20^'*J\I&L:"R-0W:
M7F@/2'9AQ19L@>_1'>"N8[AWSJ1H2W;H@\BAF$1>1FR@^DTD6* M(_3,(BSHAT@QA=R4*[25;/$8M3W^'^1"$E M4O1NK8(:EF'T^SJD/]'J9L?X/]8VD]M=%&'8-
#AE)$E/0AXQ(V5RV+,LI4'6 MD+H(GNH)DBW:[HE@[&U_-MN5E:PK#&O/7S0J-I8CI4EG@62[E[APG?9*P1- M]"*(JIBAWG(8>A5-3%QI4)@457:BHL*F*6J[D#"GE8:+@1@-219N
FFO8$:0[\C%6QJ-)F??.W2- MJ/;JI(!7YQ@L ^0Z\/#K?^!.6[S N1(4$2.)*,W1"T&&X;!L%>%\PJ< 1.> M2U%'+1N^ZW /\E]#C!>WIV5_4FS0,5IN+/HQD):J55WY\Y&GNG7>-!5
M)DC.$,\X8X"AN+?]U+ T)"/(Q=$YJ)=3TD2/6RF3AQ+H3)I=*IR+_/@1<9- MP;D'-0A<4=,M+:W LT_-Q+%*AN#P3_W4Q["2,85*G((I7_!=HO8 ^)3N?OI!BVF5'2!
<49IA#XU*1]=ZLQOIS_#]50Z/[0X8 MB%I)CMX/Z@(^/.M\$;'2BX%K%/)>@;J*XE,1B@PL3QM@ADI\O%Z *9*G*-P] M/M5B![Z)T9 G3S-,11WJ9.]AL5HU)5Y=$;+H.NY&BBB#
(>%D$="U"LDG\55E MQ(?[.C@BSM-&,1G4-10X+ NG5<<7[Y2UL+(\P.HK@4!FA#%":$ (2$0%RJ0 MZ[KHNFP45JQGM(67'XI."Z@_MH4GP,D?:''R!Q@'\4V#,#A;*.5+CIUHSUB;
MH2PK"F*P1RL9[?&&%!0EEF"W5='AE'?I!?B>. MNWL8X0GNPE69L.4 MUQANW$IP^P3*G<-,3A?89<$OZ/O3&?K\Z?/W;WTH4M2_[$#(OSOZBGW_B0W" MG_J \HC2Z??.RQ?
('O>IC$=?5@0MNK:=%Z3(64*6-")*YCRF0FPDH6EPKUVI M&V:C9P\26 S/ ;.ZH\V$T;!H'\D5O> ^JD*?D$*-GM2:TK&A^AR/I6_+=3G=Q MG#"<)RBZR!W%,[0"HI.01!J=!2TP-
W*7X8SY;8AA/Z&5TIB"TCAV?$)N/^N MP@C"G[.(]_3 W&UV#,,(;3@I5MC/CA]P0QD]<;NL1T87:2!D?PT)P\'^%'GK? ML0<17VF?&;3_&5+,Q%#"\(.#R##&DLH,)0 1'" H1J901'(8W$
M$::H_H..C,E!B)(@A9/.]W-<'1N5LEZ1XIEWG^EBXQ>)]?M#\'2:%=&YB2D M=*8J5LZ=4ZQ7/T.5/IX98OU1\26_@ M9+.RR!/"7FT?%:I6GJW$8K^,1%RIN#XP+5:E,4U;7'*
I'"L#ME)K,]"",,24 MV3B+!*V#A!E J-Q!%AO!0!LO<.I"DZR3IVW+W"9*XM)GX>9S@A$0JS[>?OD!*$^.$D;*;?]#% M$\1[K[76PX1I/H&60EKR$)B7M1A%T%KB0IG
J4J?!@ZTECU;5[!OP2%"']U MNA1,H"00T+!4B*X+RYD2%9)O*R4;BJF"J=)ZMD^;")V6U?EGKT/L1V3QT=5!\,JE(I$0Z9H\&XDA2M^F49L&8PAUE!+.$DQ(P);U/DA'^Q:S(P&(I
M0O^S$&XRT>-G812%+_0MAEV)Y_R;C(M?2?(01X9G4-EGXU)CHL*QL)"O6N1!+ M469H%!(L83IBY4R#PXI7 K$BD"@X)HH(TO:NPNAJE]!]6"99FP+%D9@XD>B(MYZ6*3B8O-
GJAK4?G"B MO9&R^XPTXK211MQ&+0.38LESXHV(D[$]5LD$.Q'5N&#_L9%J=(L3T(<8)H6' MO;/]5ZH(:UACJ8OA#F*KF5*Y S4["Z^F.IBNJ"25DBF7L@NX7WSXRD7^
M5G.+SWN7&3PF_X'JY(F%QFX,E7.Y^ XQHDA2M?$&F#!#^G*FRG\F@B|O1)]% M4D1I5\@1$T!>7=,]&$JW7:7@52R;ZV GV8 9\4$P;(1X2<"TA;2"OF=:,Z&/ M'@-
+SC9PPU\'D)VZZ9*YE@V%7B4HI6DU>\V0.&1X2>IPM=AOQR)%MT(6&PQ" MO'?QI>6R&4J,-^D;);RS5^#.#'FC9LA+Z7Z%B4WYX&[L#=05$&B5YUD#^[B
MA&I=$/N]!5[HJ=%1;V1TF>:%)=$9"G#OYCF3(I&L-#.&^<3-VR6H.]=Y.-MD1:]X$O:"!#?-;2A3B89H ?:?Q9URI91 MYLKQ(Z:+?\$.A$JPF()["!D'-KI;_("^5/85V2D*16KD&2#O4XG(
Q'H:7F3 M%G@18GM0\E2PR #D#::%[C8;X?&Y\@-Z7/H.$6!K2/:.'("AD\,%U]UTP#B> M/7VM;^C)1! <&'Z@M_ZK3U_RR'WJO3K/H$,JKTA:ZJF^P.9I^1Z-E72 2X;4 M7GZJ',!?
Z+X%N_ Q(<6"@J6 8LUO?^=$BXAAVW.CAP0 ,E>T9^M$O-3O!*4B M&8%$_ $E#G4 .`GQKBJ4HQXJ=D4\%S^-WU5[S-5/?O3K/H$,JKTA:ZJF^P.9I^1Z-E72 2X;4 M7GZJ',!?
MS8I)XO#"I@RQW]_(T.0WK(7(E2\,P;PX!(AO39:*TML"*-TR*/250N@"!"GPE4#Q192U&/L1UZ'9B$XXZ#??JT8'8 MBF"8+,VQC5$VCUT;)8;R]SY*6:2N\VNP$;< 7JM I%.N08&Z-
E>823/DL& G M"P[37!W3*]J!7L1#.>4*WBM4N8=M42 _A(\PH12M@L4!(BWI^URWGZEBU#A8G;W>*@2$U1D(*50=N+ M8(H4>7LF!UFBC2M2D'O2.:-%57V34$N,JIT0S^.?%7 M
,T)9WA];B+A"F=^\R#9:A=N#JJBX7JVB*V.V6*J=DI6RCE"RG&A"O[.H!E MHM_9WO985NQV$QE#%2P5)+[GDQT ^:0Z#&0K=X]8U&EG%"0;R=-T[2,M9+)F
M.\]6'("2KUT\SY9P'[JR+&8@ZZU@E,;/>Q8Q2!? M5/D0YU\0OFC5Z@P8 :) MCN@&8M=+"4Y*$E(A1,\6X4+Q5'/C1]T*S*4+Y\]/B @C!:!O6JP700BP\I2 M4I6[#*9_'G@78^3*!#
MEI$34%X-I,TIDDC0'#__ ^>3,@@A6\AC-R$*JIL'>73I;PP8B/SHAP_YI3=F* M.(^=U$5)" &ET;),,'*KUE;H!!D#SI?0\]>^R[.:CE>I@&XN$%>G;$FYRB+_
M&\X)2*.G.>3_8_20,+)R<7R80$" ^4$7 >1N"'2'+EYKK?&O5AY%'%P'D#&*Y"(7 M(Y+;NGEEH5 7TX6%Q=?^MJCOK&T'QU0Z7-T"0P+W]C/H75BH-
!@M87*IAHOJDG<)>1P,/\9'D(WP==*\0QTL?%$"X M?-;!FQX%U-?2+$_G LP$5L[O91E)C&O7X62H@$KA(.)KY_8N"6.-@A<)E,2AA3E8$90 M^V[A-#GRPH^W]);"?>@<].%
(L;1L1L@2U0B#H J$CF-@:?A7W(D.RN+ ")VSQ M_NS$* -:M_39 2J_F]3H9/S%(H/68V0= @.S+47GFX:(V>OC\@\CZ>BS7" M=]=4\O'PDQ" E//>N\H":.GWH,
<:,$*"92].?!:6B6J'0Z53$$DMQ*%4W(T? M.X^/$7X4DIR-?(+:?^1408%(Z4RA=9EHG=4%V,OAOCT M&S_ L8Q#[HC@SHCR.'-&-@T[GHQ$Y"T)DP-NKY;(&F:[CFRAV^Z[+3P)3R%
M)4752SNN"W,RD;PX(IXU68CCC9Q5R2O\||> 3A33%XZ]A=KOHD8+#@4R![H1^4.YZ?) M'V1PY,768%#%;3JH:8S!PQ]I4(NQVWS<5BW'=W7L^ X0^CVJ(4_CQ:T-N-UP
M<\HB7!@!KWD.Q?$EBOBZ"]9E4P]BG).KQT[!4J8B BEP MSZM6V4-& 5S"Q5JS1'1%.SX/">TB%&%%NHF#W>]UO_G9F3S1>T;FH4F(3$Q) M:ZNR'J']%
[U[PVVF>_0KH\9NT380+;KS3LK8MA9^65*-Z>CZ7-IU(D/62GZO M04%(F0P2BE-4?(*T94AE<5Z'JH>CH89PPX"&(&FN$*6(&0A3VE.2BV1$ROC8 M9SKBY11D*GI-&L4;P-
]A7N+4:=%"7NON!F8N689S]^\[/\+'&&5*@R>D;8^= M#*E]S&+-/B.R%7PI["8*P51FZ8SDQ]E@GGJQ;)D2V. ^*>Q=OM)U0_6[*XSO M\8]N* -
VM/,=/10V5%.,&,7>)\]P*&+U"':I(DD64+N*$>[>2U6'N%+2M.R"JKRF)25;8 J"OZ&< +.-LU& ?9<,+09[6*H?W(QO)BS5D M_?#Z:F2MT5X,&U9ID_+D"[5KT\/]B"+-J#?[=%]ABY71@-
^09WSA)(X!.MM4V4ZM#(_^B=TI"DLEFBNC*2! M#XH/^-41V]G6)G8>#15;TUE7:R1U/15-],4MK+L+=9"UT]P[RXS8ZY7Z;'L M^;@SPC?)LFP+G0FJET*0(C%3'R!.M"3+T?
-.LFPS2C84"3K)SSZ4@KX*(UE' MW> ^67Z%(HG48,;N>(#I^,4A> DH.74])@MQ^6CD7O2IS%X*)_]PY$5T99'^/ MZ:[>+25-D$2*)N)$)R
'&4@$M3DY\1/\#T[O9[JQ!$F&_2",V0X70$QB/W)?Z$V\I];$K< M?.V&J6F4AG &VA\XS5MH:MCL^A1U:)Z;L'.%,E5W'50G498!BH1(E$?9Q4SA M]?1K/%/@95V-
H$.!KG61BS2$_D0A)AE/CP>9OW;00\Z,:7-%QZ%>@?NMW6P%4:-2I3@B13QL> ;OHQ4"NA8L-_[T]^S-]J?P]"#1%-A%(X?0M()MD7> M;R.;UW(30N3NYXPD.U4E4014IR-/-
IZQ5JB>8SL@QKZ%"F4Z->^\|%8RRU]) MV'#$5M/X+ Z(=D]^?+]1][M=#.XHHV2)V%2N'QFL5_T^6XXQ8PV4Z89=6FQ0)P^W1!H#]:BN+-8.2(0#::[MT_M_@6,W\K<2C&\KHE\&-
GN M1GN=VJB9)D5^;1CKNS.>V^9T@KWO6'6@FF;*<.PV&U'Q3H9B +H+XVF2PLFW MNP$ZU&9]C@=,Z->/]-3]XD2_8R@P;@#,G+N[X#3=2*K3$40:/CA!)H4B:0N[
MW."TZ+@)=2+U?RWX^O!S""558<-ZV(9!'$;8NX38EVT$!=NZ[=W?/7R''A7] MDUAV@'#:@Y5-O1STT?_'<325 N;+'IY\MTGM--P5V,-9-#5 MP0AAM+&$24M"M,
(HDOS_1<==*E9E>*-I@K^&S2A1&YE!D[*$]A@B]13,^E9 M@%@8C3%;J5YBL,JP@->^$? G&02:75 LL(*P1;H2?4U+1)*53D'"2;+64MEX M7KQR+W=Q56>P 7FZ?>JVEH0G)
(_F[6N=R&7;7>['HE!;T Y0APQ581NWLCX,BU/ M=.]"8-'CL*9$RNV)=EK@B;5XN OJHL#W0F(0H:3
M0M.S=YL=T^U9XF<),%1W"X[6BQQ4LZH:1[[3X$4R# ,F*,IA5WQD;@11B,X%4$RN6Y2FC1;WO'^>V<9[.EH MB6V4V'N*4=7) P->%@*)"M: 09<"GF^ZUI.\HX>2ZV\=
K8,%BE+K!>0/%X24FI0FL%K@A$G.:"A[\8/ M\'6"CPX=S1KZF.=,) L"=?0;T$>L@_YCRYAG._+=;K/W[\-9,;+,-%YO;/!
M*]_;X>JN$B2U$&1SQCMQAD!'%B**>A2*%.29:;FENF79GEU.BS9U20ERB8NU M[HJ_YVŸ?>(OCU)FO,&%-S*_(V[L.P$8+UB (07EC\NIO9W7@ ?K-PHQ3M2*7
M+2#/4BUM8+ZF,R2O"8N ['F>G:WVK3G*HR<2'A,>]O*$! M*#_P4:K%Z-D5B/6-U"4->I=Q))+_ -S0T.7V[>GGH^33(84/DRR$*88A$M!3F
M?/1FQ8+K$]35BD*NRU!&SFD8[@8N3RQS5_3!+,DR?$Z'C*1,O&6%>%:N MOOW(F3=1Z!7"83!5-*2.,&!IP>?UTK_0)) 3"L$;58ZG>>6A*7 MX=SS6 >;%B^=QV<.UL_
17.C3 =;?@BBO:0U\!N69!5([$4L@#-W0R>*4\P MUX#7L.%Y@0QJ&F FVV$XO/&QRSSB4F9830#%#@)^Z&:/!$_X:=")/IPB!Y,JE"Y8Y!:6S'X-^ABW*R,E=H33G%
M2(H+/3'?'>MKLD(WZ$,5<[T'X5FV&_39^SE2@6;"CH&N@"YU)9U9!S,+ "Z] M"M]]J/=N2S_Z$$X.NN]N17R7MJ%[&2O84PKMTZ>65!K'KUU=S_:%VS(+G>>7
M>RV\C,5>+)^<0.A<=$#AWN\\XE8Q/UUP(>X]+%&#\]JVSG+ENG^V1WD[= MR(%QI,P2:60<#UT!YI7JFK*/_/T ;%<_]#3D3%'OD_#4-.0L;,Y44 '9D?W ME!A!>HM
@Q(=#;F5ZI>PRU?(7:0#UOWZS.];" N*@YX61D1L?T1F+]BJP_[K %MCDKX>D5"37'7B^SE;1X12*24OJI.I*(2=,(IC66+%Z3>31P#*'0_C/TCL(-W0E% M!\A1/4Q+/C%AF6 _11;-
)RI5:4'$*M%ZQL?0\=069YQM J+\.I]9OIT M99E8Y%4KI*%@^7D@NG(Y&R@OP-8.C["WZ38W*E3FB"%T#V-77)",%V9D!;+[MERGG"6/ZE>_JV&IG#N4N#.17X1D&2Z5!T]X,K?U
\WTY5F*#; E>;M^3.?6^ MF\6<8[F_T*OZFD,;0,]][B^B0-[^]/-JZ2?=4@@9 3# M0N+179;;.3L:3C)2Z]3_61J'^[>BZ!>-*S]V'2+QB-Q=MW X>?7@5&6<%Z,[
M^6'R5RB+/R=.'!^GGV8L=D + M,6)_%/%)07)[BO>.BO;W'1RES\((WNV*H>CQTAQV^G- 618<&HFT/K]K:-(D_1(BV0/B790+:>-%ZT_:?(T_*G4BI4ZXU*+:GZ^DM@*Q#5JU\ -0
M77[^[/@$3EBJAD'QC?,0H.=VE-&O080= G#)H"5)8]7I9Q8>'2\BT-([)DLI M+B A8*?Z8XY"M)7F,=#7-F&$Z?C117'ZF0=+6_$C#C=.NI,MY8*JL9*/$SHL M)\ )H%Q+7E#*#-
=M)3LS&#?.$2#4<9[Z'L%EY 3QFDZX*E%(5;O%NB1#FU4J MB\M_ZJ07E>5IV]/R1'6>>PR]\;A".FL;N(4L5L3G97PN!>3[TM^PX7F LKEK MB/<)1?1H)YQZP0-4@A9<((T-
E/(Q0Y(3Q%EA=EN-F5G/D;E#CQJ9ZH"!\N][M/E6#8#$0IOS.%:<=;D?H-?_*N 2DA'E+&,RW]"[JQ$\LL;;#WMG^:PP!X+P4 M92;:S$AL+?C-(% PYI&"ONQ&BQ3L/=BV?Y%?-
["1TDEEU!/;TGDUH!"\ :FR M!S;?!V5?Z(5VAF1ONC]#=HAHCV]@$+(^M:-'PI*[30LXX-C-$&E21'0V&7J0 MA:P6E4GJ)7#P#ND(IS +1GP]0A!*N'^'G$D92)Y]#7_""I!2%C),0%SN.]TR
MLW"9>QMV=X;HE MC+:BB-(D4;!U&@NEU%>GU@>+F8HS(96X5Y=7WW*2RS MU=.I"_OZF3HAM@NGJN#=1@SNG8QIOZ 'HI%@8HD6'1&1/2) &1."#,-_@_E1 M^'Q,Y?>"
[9%9A;::[7$M^]"8F-V?N.VLK*HCBVG;%= <#)XEO@?$2 U[V/498],]MM#Y#7*AM!V$N M=$-AC>EO !/'8V!PQ!]\DX-%TG%2PZ3%!%UFADKX%Y9*<@#;$M^29CV7X(7
MX0G/=X^[."F$C5W1)^[U AKF L>>,.*=HK+(.>@X6SU-Q,XA"_N"C>&06]X2 M?!@R#PL?A\^?/O^I5&9+0$M4A(C9F[G*0^W=@[4B]A/,H\(P5RT@O/\Q8%0Z MXP,PC>2$=0Q:7
I@V+-+?:QC([?:N^MSH<%5E[/0<)I9J@Q4 M+Z_Z,-G7X7 MU,=O=>3X]6R23,N2R@*D\T!4SN5I;YJ1K5-*'7RFMU]>G506(=5*1;I%]+]) MRIQU$+QQ:4E64-D!
^@6^%1"T)MI"UI19;?=S/8>$]0<]D+P,QS@M=^Q])Z. M->9$]WMB-7J(2FS"I]8 Y<1@Z$ CWL-ZN0 M=+K8H6@ [Q.0_GFG M*%/7O$]MTL8HB\G.93/2 7#Y *$VR.7=0;S*AH^
*@\3O8$1R*G6(QV)+\X> M#&B_AM'O5'%V\3WV=CQ(S)3EEO; ;72]#Z0ZL9;@W(.88H6_52'T;4R0KQ2Q M]X.GM%()+P]![*9-/685Q_N;C4M*?MB"6S,@KAB\396]+5?RCGGP_|*J5[N
M'[X>MXBSH.X%5STC/BF!2)TDZ .$8GQKS?-A5+),;A85H_"1_YCP !4@D0$ MRH)/"E:ZCV.#I=^U?E#:$9(]351"TDHXFUM'SP+G:[.-1_#]$/,+43=4I,)U M
_47)4@C.QF3QH5)+9EH?)*OX)0NDB_9L3_(YQ%E"E^V;)]2/(%)B17<2 M8I",!#F0%QMZLSE1RR##BJ*2Q@B0-ZA_C:+!?@' MQG&`@0(Q&%TKMUF V!XOEQ"@,5PPQLW[
!N<*=])H@"J+:V=T9RA)*:,U[E,#,"40[G+X=R[E%4*5,4\LR!J2S_ ZC/ AZ!6EV<2,LHYA M]]>0,# ^/G6IH=D?@"* _C054&"O@8H96C \;V":M]O7;D$$S88\EA\3,CZK_ M#GO[;9C\#2?
IKJ^7W.WF@W(V892PP8D;XD$ME6@;Y9BU/2$57S+3A_YJPH+/%!5 M.V(9JZ+G$.8+:UC!(S O+#E,SND)F(N5U*3T-2D364B$'K60I46_4C^[\+H- ME ;*
(MO/88..8G:)XI\3G^Y)J5;10S:HJ-"6=LTAMU3GFD[3IW6A+CF6_7CA M0T9ST*G*:V5J,'S(9 ;+L'A/]-I[EG"08]"X#$1.L'#)RXF#6O> L@D\KG, M'I>9QZ+)A$Z^
N1$]VH"W,^,7Q*;,?&!Z#<]QY[*6L*MJ(;D!XT<_T)"4Y M(7.U)Y'I =U-6,A\795Q"'L-N4\.NI?1M MV+8-"Z?<=F])]"QT9:5D?0D41TF*/?I U[M#]_ N ..'1,_1['HE\,M7'BUY
MZVRZI<8*>D@21$!QL!*0(9@ONVV)4Z40MPS\%I"L"N*G$<G!B?L_L/4X^['PB"/,N$$/01[Z#?\A/]2$8R0L5T3O=2 M8M+)VTHQ]=MQ[\FR"WHG<2 4368)=_T"B5)E1 |>B'$]E-
T5.YVCZNKI%C: MLBL(;T4I.$:WSS?%E"SD;8B1>|N'$D?DYTN9VJH:=%H' MPHS3$@AS_P02)::M7!N,RD,*HFA4K9;+R%6L[A:(FJ]6;2MQQX@0V8C+K"1] MVJ^^.*_^9KO<,/=^?
$3+R76-=Z# ME4IFP8 ZW4R\Q^3D$[,%=-$'(/PM8M\-2OEM1.N8GSSMA6LEH:6X'V5]854I M[_W')RK@UQA#I;U:*S0UZ_#:E!&0/@G7)SN(707]JBQ4)F0K6*L8T1FZEW)1
MPJP^H85(,G_# *ZZZU6,E!5@KHY,DSR_UG2L/'#X!4<\[S+JMP6P])G 49^(M,-)B6(H?C%I0?1=N48:"["&ET"'_,W+R EB/ZT)W\DPS6C2\P6E5'LN\&Y2
M%#*8%"7ZJ%$%>\1\%U7F/H,B53Y :]1<9K\WGB%00]V!D/(MCXB)#<8BY+! MJ(521CR+Q,9]?XCQ&3?JLK+5??:JK1N[3D:6"*RS3BBJ3_7;^RZ2% M+)JK"_+U7APYW;;3/%U9F3D-
-+S"W8K6W&22=57IYYD>I4G[L)0"UY.L&34[M#$XBO-X%'MNAUK+6=8]YXRHOE]UOSXJT_!94![FUV+DV=V)>+#9.8R8/C($* M#?*(,PN%!E5'%@L-
]B=S:2W)#SLIK%Y5TE>"]U]5LCQ6!#:2ZP1O.CG!*X)% MV);)B%L.@#E:*/+&Y&D7U&-!+A:..+T+HK\((TW>BFT=9$NG=D#6.\XQ"*"@-
ME#W*\^9N\0O[Z>!EE04;+4N9@PSPK14C0S\2MLH"W6WI1U_DMFQW*^*[M,T: M Q<5V<+CJ!Y[)+ 0?<;KJ\72/GB+W@ZTU%AVY1-Z=742_!A&G?"0A;&,T4.2
MX,CY)P.P3H^I*$^DUY ^!CE84#K# HESZDW(4SFZ']7R&(-@]//7\(@>8H7 MT<_T!\I;IQGZ6BA7;&^B_"6 MPQ#13QM_MS&)?)>FL<.W6]45?
(2^IBBO;IE:I#!R=QE1TU[0W71%+4/.&Y_(M9V$4A2]4&P)0+3, #?EUO))=H!6+G["S]"#C*56U1E2U-9||*5D$/XC4@ M/=H7$Y1-84V\||F/7(_#3G09>!=TL^^4_R!LJYPH
JJ(DD47/0;%F)2%#"=& MP4'#K;[SP-/<;\)IXRV">\@%%R&ZMR$]Q,6?= 7Y\=$6HG(OU8R'8G'_G.ZM ME.Q X)UBB'MZ-)80X\F*86D4@UCP@DUG_ ,I7 [0G")!GNW3)@(HD@%"_L)M
MU_SFSU15.JKPZG3*U0/*2)K%M*JP/13-DY[2O]-#:X:TL4 OJ*0TDUZUZ&R/ MJ'8*Q9.-H>!(0G8QGE@PPM_>^A#F,/W8$)5@P3K:4*[V()90M),*!%.R''.K ML4\(,)6(";E&8;0_UB>:
>,1M,;/MO2&JAQ80:YOOZ@Y"2KS7Z4DUI)?2U_* M[K7CJA&6IR&1OMLV8"$S/^Z@A?&Z>**YA*O6$EI*H+@)G2"3@/8E]%C-*9"W M4TP24$;9O#N=+=N]A25U.ONBYT2THW-
ER+6*!E^$Y#HV D<-F"<(08$H;$T0XPI*T:08<>/]#ETEF U[](0LJD%/->> MJ9H.80@2]-"C;Z\Y')T7T8<*UNX]&[@GX?A]CDV5$/',(;S40<)B6%;XT0\" M,<'V@EIZ%?)L%=23)(T&_]
[#:-+#CGBX?>BK1WKN"(KP MCI1@[R"N)B0@0S"ODM"A8!)=!&N_6]HYJ[NT971&S#+1N;VSPBV4FX%:-, <5 MW6M6&F-43HCN/.G^7M#T[L4]*.1\URQFWG>#;4J7C?
+YQUWR[8K*Q5<0<8^+D MT]H9+HF2J6\Q "?C.@ #"8-Y%]##73W"S.ZRD3C&GH6[@SDYQ/)BM?E2BAHL M<]JN;9'\O<$1U3L?Z6;^CDS!M=L)*.1,2U2KJ($T:"\D0$(D/*4I=X)V$R
5AC MGMQ))=MDV(^'U\Z.) HX$T46WJL>9259,0M)E0KNE(&5T/N)L'9=]E=E2$K] M)0SP_HL3_8Z3JUW@&:A;SRC2+1%((DBH[#VYS8P,1&>?4T.,G#7T&):3KL5/ M&+!A,)
(3X9MH+.MA)-820TV-OZ;K5PMC2>W_%0/D%/;F4-7R$=_N8"4OUMQ: MO=@E<>($G@@)8&IL405/N$OWWR7/(419+YT,YVD*: S61324:0G)!7)"/3 !1+[U-R: M0.65?
34QC=29TE]D&Y6&>.I.N7=GB8I[R.B0D?#GA]E*O>^CLNJ8<;$R/B13<@(MW&,UY:KBE_3&(BG;BT2_#JB^%]_@9TQ.NU\B&1UT.B'NQ9SH4?
&_(W'4!LBJ^QRZFKRW5J+CF&5"L0%XJE.@GA[6S5&LK!Q<1H3(1FOF)>E]UWQV M? (;(]TUH>CL@ZHQ#(I-^E<7[2BE0H\.V=\)/3I.H,>I2JAK$@UBQJR:KQT5

MH2]IM54ZADGE!SN\=B&]OD-FVX[8TH028H6=L,4YB66,"^=3+(I,<2IV*M(B^)6SZRZ1=P4* [QD"+"Z4I:0QA-23 GGH61++-VW.X(53M31CUR] M ^=>O23EOS-5NU,L*Q"*
<%1T\O:J>D/A][^(I6O'?TF_C79CUI M6;N<593IIH<*2N@W1FODK).!N,Z;O.DA"<"(OBKZPT+Q6DOS(Y2 MC/.L$,[Z'WLB\K6&/)RZIETV] S3">:<49>TJZUI0E$7'*L3 T0L,LZ[]ZB=/ MYSNZ5VJPU-&@)Z'H61"?$@*$SU8-+WF$'!_).B)O08JUBT.Y"7IJX:[B#NF2%:Y0& MN$GJ%H64&8SBDM#MFJ72(2UA*Q[+?'Z9":X5I.!BBR'X)H4\#N47(Y=(/V>+ M8EGQ\U_?+;IOP)3(:/DDBD5['>5R^7&'+?B=NZP,!M_ U!"QKL.@]R/.@ AB MX-.74[BO/P"QW)(XTVO:PQ,FQ!S* 2-G#]N@"_?$/N-:/ U@N0%2$(YCNE(= MU[L&1E^ZPC ,J" Y-C4_..6QZ+?4.
MEIX%%-(A3[B5!LKR&JGNQ.(JK6*Z]"H:T:32X9,R:"XSI'JR5/>('Z]+Y_7: MHYTI!''IC-FT(\|N2MF;A-B04&58>=8CSVCT&0A7G5IR/W?@EJMV+91D?R]+ MY"W6#SCPPPA>VN-ME 30/67-%(:5 #01$)V..)E7F\F4%A)95-J,10?-*^0)78BMZ8PPW+_OK, MJ^E1;*EJ27&I7J7U 6DLLA=6YU+U,TUI,\ATA\[P &%15-:')ZH:+7&T@<&(
M$P9@T#W6OS2&*8:N3FCC#1L0T=ETQ2:ZQ,4 .1"9=7,"_:#KMR!RI@1$HJQ) M3FY+,:O?L79'A6!F-4_Z_/WWWZ=,IVM(#Z1F(_T_TP^S3IT_%^&4^%D$H?Q'9 M9RS@/@4514[,
[2 ;A"G%Z/M/,_3YT^<_L887V!7?GK)OOY_ Z)'\P(E(: DI MQH9A G+HJ[U>F.FL[&+]K";)SE1!+5%\:C)2IF6SFF2\Y&^B)0'/G:U/5PL+ M1J+7J1UM?
AVPLL+>V2ZY#9._X03(X$#=LZ>V;8@MW& M$>YSF1PTU9$@V4'0Z2/9 5KM$D2[0'N<,)_PJ./2503ZA1]OP]@A/T?A;DN? M@'C0$$!1Z+PM5 Q3]VVA1I'+Q:*+ RQ3>,]..
;KQCVBZ!1T\GJ*VW_M(-NC9 MAZ>NI.DIDF'$..8*E\8S6E@+"ASS!+31^LMRF8U/@C4UJX@ ?1WX"02],R3F MA0!B/G0@GW&T"E./]^-CQ&++&&9SS-@M^W7_4;V]2*O6_%,U;=
((%X'TAVTJ=E M\AP@B"+LG(=>MQ)\X+H 0@@HC95C8I/9U =ALN(,>\N1*JQW%F(2S8FA'";V M2_]D2DV:",G)E9SL'3C,B DR[M,-/0#$N8^86]'\&)1E^[W[WP)5BLET\X
M#_B8A7FQH!I?@B*"3* 4-/ 7/X YJ'J9OVP!9R/6^Q M@3-/\Q2-FO$,MOHD6"99;O=0UZCW(UGU=@4PYG2]_QR&7B?_FB2$'H'2-/@0$ M#KV2@M&;(58#?1K"9/-
*ZR7J^;X*F2):X.0!^'>9\$GYY5&6]GSB2":$\E 8 MO&4VD#+]@;'VEH=1::WOP]?57ZN-85H"<-ZR!"!ZD6.6A-F27/(*^C)Q?)_ M'$6J(DZZ\PP7T:,3^/]@K-!7(Z)
[W$HY,"CFUPLV=1P4A3 M2=<(5;UO]CJFO3.CN=Y_%DPE9<%24.M-Z#KD[BD,#,#,0,5J($;.0I->540.!]J#>'&C<2,LA6^>'+!QLR""X 2/5>QELH(HW]UU
MY:8>)B<<47+)'&A!/I?MQ*I-J:\]]R-D/OUD#,+J]=%]'B$.V/LL[N,1!U#> MRQA^HM8'A]G7>[&+]0@>&>R&@3>G)R[B(& UH:N,A3SUF!;*[7'T;HCCNRCT=FYB
56$$2"XMAY)^5LVUA+ M1O@O6M6Y'%M.M,]DP L\G9$ MR:TO723PQ@O2%E"[^"V-6ZHPJZ?OXGWFQ$<4A=9$5=3L++F^1=/78GT1X1G*BFX-/#># M>+@_-NBTU
E4@"^AG/W[$L_PA+Y $K9)T?!'Y07&J,\ M/#D0D@=93(- '00@:LZ!(#J : '1AO*TF"'6"|'ZAW8HG^1,JG0!\O=|YFO M] PY U6/((#?QF!TDF)"CBQ*4A*AA)"|;. [7O57#9XE2\;+#>/N\AW
=PJ MC1,2 +2=_)F9(1%KQX_0QHE^QPG'IENJ@UCC MAZ-'C1JRR[L'=.X0%U1"5C:HW[&)Z6;\Q0_\S6[379<5A$;+*\FP:=4O)/8S M$Q;L_@<:C3%.BCQ;&_5LDGD7);&0F&_%ZM.-?
U+*^KAYUI?Y?19*8MR,9]/A M/$*:&?QN3(3G M2%:0X$4<|V6*F.*'YPE(CF155L:3U3"=@8>Q1'-5&FFJM,YD 3@.PB;@@3A4 M&R^T8C>TR?/89VI\INU
MO!LP0U_!=;37A!U+0AWB00![DAIY[_[T36)3+$#:@P(5ZXSA)*_$M0U9|*0]? M??JM.-M_C:'HDC*ASZ$*#G>RF*AYDO(#EK1(;55U8 M4:7%~HHV2I[^<^=$=&UP[/&S_9)2F+|>
[;GCM%D6"*..!'F.;8Z .I64TI^F ME!FMJ5G4_BUX16A= R%D@^ EFY.%Z&+D,9 '+0%Q%3&D?W>_6$M[:B MJ\!H MI_5XDZL%(>L1P432X\]+8VW>A.@D*W6A0H3J$'Z5.CE+5Q.?
6:_JY_[#L:#R MX&[$->0BW#A^T W]@ITW:15S27I2$LE75:_%+B23A&"L1C!R"A/?2?W)L\X8@7][L-]= 2!$01(Z5RH9&F"OO9_"U(^;X7Q)&Q4 M_2
S6@11ZTLT4BU5&/Q^J/(:/E^O.!27O+9DZH\UBHMP*V/",YNE MS7VN E?XQIZ_T+2$I%2XT*YP]@E,.'9" AKX.'H!9Q%K)P!+Ü+#\L(W&S\& M^+%8.'$[S:CL$[D|+6FG=8L|V2];TV[:
<^^%<2R.!LD-!(\9T#M$JD=6G%'K M4_K1W\(XY.'%NBV,/E-S!1QS+.&8._B'4E("T+MG;Y A[G-S95L*B*1<''@ M1'[X-
8BWV/77/O:ZV5P%O=ZOR<#\TD^XXN_YS[ZW^C<$@N7%8'CP. M-NS6%@0WIU ML6HQ+(6/=Y6FI)!BG4S6@1?-R*>5-:R3SB["8M%"(H.2F8:3L928L NY>D0V
MK^/(\]%7.,!K"];U/@6N-__^R]:W/C.)(H^E<O:A8]IY1MWF6G.'WJB/[U:\8E(#4SA >B>!NPB>2,QD;9 V%NOL7.8_ M'N9D23]TYF:3G<'+7GP+GM.\57
.,4VDZ6#9H&R7\,VG^5LP9AXB2UDJ6;8 M7DT:VU:EJYY[/8]\Q#7ZSOO*V7YBI)K\ J*04_H\G2I]&E?*Y#D:\[8MR7874H?NH29)O.@<*5]%48WZ4.M8M0#UJE: ^C_NPYB<
M_>5_30@Y7XQ7;<[QT]^YG_J1@&\A;965AYLMGGTO=6B#7Q"RRI?L90I>%NLG M]M=H#:ES87!G(C@@]Y87RSBK1MN5"SG+5W*6+@68574Q1XTEL$KAV;!$2A,R]-
MXAA9N1(E+8A6#&?AF=F MC[WLWYB|N&'GX)P]ZDS<3/LJ+=974!:(N$9#^[)(MSSE=L7+&L'9*S)S=X2F M;H<_G+GI B:..?N['R[YREGTF:U_%+YV@B<[52>!>M?L-(\"1W!-
/3&/RUMX* M:CFN>"@*\.[0]^Y-1.5G&RW6;>"RL?.RJ"=Y9^;))]G,9_>F.'Fz*?*$:%X1C'^"1GA(:^?@.5QPHJSAI*&4#AI#4>GBI6&N[? MRNQ*&F=7L>,'1W?
S_N]&$A8XO,5C6N0K]^WL/2R)\IS?!M$,>6F>RX!/>W8 M67 7P:\.J8!9/;++_.F0/>&SGD5\VC.>^IY.?$9'[!$V-H*%CQD:P!3S_R$5 M(L^>"F3SCYP]'@G9LM.?
$65I]$(2AM=>W9=JT\.CIF-"U0B:[.+5_H&&*T) MCX[2>O20[G&X3)CQBO(!9Y4/_>&L^-38LM/(*/NXL(7B($5]\>4&:FY&MT$E
M.NJ11(D/*X%"X2)@8(%>4QN'OO#LQ2RFBL=\.'YT6$)RL[9()3$Y6QX\ MZ-4,QF*%:5??> .E6+-%GF6KY%Z.//8K7>@1TYK1D3DWJ'R0=Q3RRBH&F*;Q MZ-
8\,#=L0MJE^*2^>_!YICGK.[;XU$@!R72/<&$/DJE2TT8$TV;I%3 O2%1> M.'4_0J*V6?^WSP8 K[TA\RPPS_VA[/R/QT#_V].2KC)[MM/ M3S^=Y1.?
1<7,T\$FV[9O3R4:E$"$1J,WY%B,X!7$5Y(/.TY MF.7!5Q."'RC9>LDVJ12:'&Z.2S]V]A_5S_TO8+Y7M3S@_)M_J!:XG#@MA-;J MZJ?2KF[\ Z#)52J4CFI_A??9IX_D-?097S-0#M"G9_ELF-
>?7Q6P5 LJ4Z>=;HT7]>9A'6L_?(M2$6R=?^:8Y;K1SD[D%'S M6U%BN_B@G1+;E1!%7@3PTG>B084':BXGF.F,3S69]?NMI8]?*&H;K'A()&A9 M11#UPD/=R_#%'\/U MC^R;:8'-
L_RK/$LN^RYWW34:$)?]AT^(++4 @YPV"4,VK?YZ%E:(0ZK$*;LY MM-I.CYIQ537\,T$QIU)^0TB9SW%8,MUSS'#-OP"B8EX(?4T(1,JE'YD:DF+7
MQEDY^QF/_NQALOBU$N8T]W'T6A5W@FKV9?2YL8-[URC?ORH^<:2#>P1_3JJ MK9K]Y6>.=)A;\HXHH>3P8OUVTV3,X>0KT#E&J:4B,H<]8"YC$%GQLP-933'K M33IK5M -
/QZY<#W5]=2*#$=PSF"HO:#?VJ6AD%1X-:+|$R641]&7XV2A)G1:U_"^GWVX [VP|+RX*)0" 8I5-- M X%L1RHEOG,TL@G_UVYW@T8HB-9I9-YM>EVWH;X-KAX)6>%A? 5C-
CS%;SH]Q MH:QXQ8)X[CB)BE*1<7C,WJ[V2>4KJ%2N)8[7B=].D3.9"^C-AILFJFT[C2+=[^A5SB']-SF V'()9J>&O><#:O_U(0-E1!<5K];'GQ=8<9>.9% MBV]#H5B\L %4XT2*T-
$9AP+!!W;6[YUMUGY2A$H=PNJBRJR><]=EW"1Z"",F M[/P?;W<9NK5]4$-:10*Z[,!+S$]\IL'R=CO5]4N!4!P:K3I6HK.D-1 %BH4# M,>UC>QY4*UQG/D!W$3R"H 1Z(
.X#P.:_R?/N5S*N(.QR9'<1BA*14&@A.WC MS] E\#JZEU]+Y1 4)^"1P&NTBKF:GR7QB,]T&PX% IR!7(;;'24;$D3>*TF+ MAX&P79QV-4O-ABZ[>'GI>?
Y[WL8&WL3|WTV^;692%"1ZB@T85 L_#:(M"7OU8RB0Q\ZC6$*K@=@^BDSW6*S_21SZ2^I.:1RJY\HJ/SMZ4OX2F@ $OO3
MCAWQD#U;UT#7'06C>]VRT<;KD'E0$*"==@BW@4:5S$.QHM8YS/9Q?/(IE%F M*@MYA)KP7$KA\.Q/VUO 12_^;'M0X91#G;\YU.6^<^F.]9T(!PF:02!"](21 M(K:77LG#*/[Y#X]0-
L5F?|=NC"\S)NB-Q(7D;;!C].>+^RQGE0IPVRP#^, % M, (AHVC\:GNQ;?N,.."7!:XEW/4;:1C+KU/KOO/GK'8DB<$1|^OPU#.*-X$76
M'H3B[B@*]PO*]HBN4[\94"!=%LJH*9YE!0QN)I*:'GH,MXHN-,YEFI3+%KB@ M3X2^>BO29QP*!,\A ..%Y#?_/@R<\B]+]J\H+7.OT%IZ3H$";;;(ME1-
MTMH$Z;4ODH6YQTBEZ6L/1H%JS<0BWT4!F&WVD2F#]3IQP40*][+2]#)+ M<&@P$ZTQMA'C,N GM8CX"8F,*&S<+GJ A$ H;D!FF0,|D)$@V<#.A|_QE$L7A
MEE"E8*0[UOZ1JJ4\G+O_DZ1A/9,'C0S6+-)+HHSYQ12M#] M9T&!?!K'4822=EQP$2@2KIO%_?'E+2@OE!:LU#&"#5@4^Z'R/$JC2/JZ,*43 MH2!!-2X\C=<&SX3J9*I'H$"JC)?
=6PO2#?9_I&AD%T 04F2*5KY/4J6WY(M7::"T3TWN(%%#K3ST/?!!I=%M,COZBB?LRUHLE5=**'M?4C"FHW:BD(&6<7+ I$|@1*?H+7.OT%IZ3H$";;;(ME1-
OM9'5NENEHVX3'%_#0N#+(Y(OC!:GHP6Z^4)8S,3$*$A7FCXRQ*458 M*3 *5/12-7]C>\3>N+7P0O:< @7:2NDD2|#O+=54JP'81O")<-&>/;5?'?J= M5,Z?W [?-08'8F5[(:%;H-
XN2&WOTIG!MF91]]&;$!4#U.L1J\(8@FTQZ+8 MWE2QXZ(8I]?R1I?>]< M+*!(TR)\%;B](ON42B0R_.N94'NU=]1+%AB^"^9Q<6^!'E(ZUGS;(DL0:Z2 M?W"?
2%|;TQ_!0;IDMTN=F(X/|H-DXVN_2RV4"$EZHQ#@6']W&>BCM)T*P*T MS7^KMI]+D-+P+/X)"|^ MT.$'U9O$]CZ>0XM|]NZ%@7L>!IZ$3#I4G-BF D6Q@Y)F0X6D5K;^$6V=_FC;
M>W;U7X1I35RYWTH"1T4@UH-'L\0$,%MFCO&H'86F!$1QS"K"D4[2OY"E]YL" M!=KU] M(88:%/]*O!VL5E(@006/ B&E50U\U0,-LZ! ?LEF;Z0J MRF.YI< H4!&UI(F*$D\!:*=^*
<2@0+"VD?>M;E06M-$VP!CZ @F2_9IET$A-/ MY6<4RZTH? \.75 >,)<*!+E'LD-/E VSK674K?L-TSY/CJXF&\B/ZH%3H=AE MF9!>^E;_$?I@0 ,7*TCN$(1?V)*I%P'?
K0B,*MU@K&^A(&0C<^'2H70/UYF; M@41UT82/6M])4*!>,NA*SEP1]*+QV"G&H4"P'"M.KSD87M666@6\;>8G[!N5 M9C%&/-JPDM%8ICG60D#_OI*Y"SE .M1>;4S_@)FI%E:J!,2Q
M4*V7"D"B*C4E&5W K(!947Q'H-95M/LNVQ -SD.-#DC'#0>QY$$/AV,-Z%"4H MW-(])09%@<9]&!0=P%-Y4Q$B(@5&@4IY%<3ORO7[RD],V; MHWGA3'T%!?'N!#'X7YUW;YML"|?
MI;-CO]03L8>,M_Z,G+,'SN5]D'WGI?ET MU'[$L3>A$]3DBZ^AZZV]-(=4QG0Z!Z% 35PPL,-DW3D(!6J765%WHEO[5SD
M!4IU_YY:MI?!HD"%R@YO5MD,5L2+0V_5$HD*O=>G!9R3=) HH"#7X#B+N MRR8N"JP[LBOR%*YI\0NO%/'TYNS@%U5T]@$3VA:8;SP:Q5V1.F(@%+MY
M3^(ROD'BE2L!4"Q9E%K748-'"(T"&56WT$C8FZ%''(1B%AS(#PU.C? %R7YUJ <6 ^" \O>C#85B\!UR< A->4*RH*'/%BC,WU'8Q@*]$H5 M%(2L/C:B-CP*A$J/UI47[<+
(2S7FU*,MPD@Y 5*#?.I_ H) :V';#X"XVK? ME,9/*'C]A010.1IRXMVM%WC@2 *3C,*.U3$$!5K5?(:L#>?3AI"X+,8>]2]] MC_&VA=LLS4[8]JFVN^"1;%SC,+.RPLE+T6-+[YB:?
DP%3P*A*IMO,#.%^6& M/A$V4F DJ%3]J%W5[>30*)"IFUB^!4Y:6AZJ/D:K9C:.]B 4J'%:/W<+U,^2 MW+;[D)=F)VZ:V;98IYLGE=W-?PH%&=ER@8M4"|:H(C,4X"C0T>J9"H\XA)0M
MO2U4J5H_L;&Z[2,L90'FYD9!9&4.KJTO%V?7E]=4^$@PX;Q-2C3G39I:&7W MJ^!0(, >GYWCV:6?V)7D 8*UI%#)F]4US+:XMPSS_,BT\|\DL1;J:82@ +6-
M!E2$2'AT5I0EK@E1D(&A.&3U"%RUVTT&BP*1-.&A\FK+_*)"0!0H7/I.%&4% M^.7V@C84CL6W Y=5P+[Z5^)!>5/ELZB" M1X%05N#^^IW)'>PFWQ FO#U#[W0Y
^L8@@*M.T$<3;:^P7$XLOH*[KV'UR M:?1&HD#RP%"QB[UX MD;-^+G; M=>6_#3*[-]#9Q0V8%J/40M#1 F1=A!@7R ME5PYL2/@75VPMO>CF0A@IO#586<-(-M'
MBB=F0R[,34CS?*=V\V$)E/6+?16NN4>/UQ.'L@CKJQ\). :^M.RT!PW%LVLF: MK0Y3]3]4((5'[))49"DZD&[^J61MS)8'$Y=4>/&X@?;5[_Y)JCLC_?DC?_4
MJ:YHS8'BD*6<^$L8NM4*2$^A+^D/((.VO8LZU[W+/'O -"CV\GJ))BNV/S=A M0N--QN5Y^D\$%BA%/(C.0!0HUCV)F<$]D*C-E05VO9Q_1:XA+Y!=6TJ$).$ M #CHKX@;4(:&:
U$@:*\H+;0E2.%MG[$GKY RX@ SOS3#BD)0U,/4.AVU(M$ MTKGV(!3[!.9/"/B%S(@=H2IE0P!H>W=R3V;$A8*J*U.X+UW@*'9$JQ-A$;K
MXQDB[FRK_@XBQGT8_Y/$S3Z%G.3_M2*T;*S A1$SPW,&>9Y9V@-D[1X! JD M&KT-N[0?!3@*=,0M"V38R*%1("./D$84"MTJC9%J^U 764;VCB$HT*H+M/+H MSC88BN4SU3?
K,0,Z,0T#]LJ56E'O(?2]U3[]7Z4@V7<.Z\:Y6EF02_;!5V & M;S4]3 &&8M\T2@C+Q2_MP;9%LNQ=5&;D-.T%6F-0[&'N7.,\E<4BRU[76=I_HY?L3YVBS9] MQJ-
N,SK@A*"I0;]2/ASSTO2M7*0U2ED!TYIFS,V+,[L>]V\'1B>"M,S[VR2 M/TR+P-^GI@7>>[@E7APZG6UR5-/SEV%NMJH$+HK?/;U1**Y 43&UDN.H2G=1 MP:- J*S\"G&8XNHS3&JG4
8)_E"MAPMF?7'U4*%B,,J7;!_Y^I6MW*.\[UV+49P759L2H;N\UT#;NSFXR8:"%#N9<1UW^7&^3+&QK!= M0:+T"_F5&Z-%I3ZL+ #]J3JTI$;%OE23$5PU
@5)#M.>?/C\OO=AO'<3F[RAV3N*?BW,) ME;\O/1Q[]8$H4!2%D\K#Q^30*)"I]'[@KWZ:U1NE I)FTPCY0.MW*&?6-TRA M9-I3%JBP2B(95V\!HM@EI0M%8L.4#T"!TET8O
#W!?:L3G,60Z) HBV5G;.G MY TN/'M;RV>U.P1PV$PHB-!H>"9K"[X3SQ8L^' M\VQJ.3<=ZULH""EH2R"GA!38ME7@DH3BL@OYWU'0FAT(V/VB 'NT6!=Y"LN0 M\?^M
RZY]#D3<]@>$]C>D^5;N-R$2>0$[O*-K6]?&T# R.&]RD,K]0>BV-5Z MP?;S5\?S@04P#@KI=)L7N6GS]QR&"TH/#EB/=SL%U 0 M#5JY1&LFNQ59*[R8DL#-QA,>
(O%/BM:G!N='0;"#:U.EXJ4P2-?4W"@(!6^4 MYWJ,(\+ER!0%55,>(3 *5"0]BM,LIT,[?MFL?UR,(9;5LP;>PCT#3$$BAW+ M#;E):7*'=4CLMO@ T!ZM7!/VXA(5Q!DR# OV*?
I[&$8)QI1U=J*GBZTR! NUT M26P32A>R4N]2P:- J%XY1E&&2@!GFWGP& SH>R26+>N_HJ!V[E*_(KEK/5?, MLU*6%B;,O& Y4.6HW(Q+L^9 X<9T,CODYA^+D%!#MMXL15BI
M7-1!K8L=2^J ROJTWSZ'?E/V2EVF-;H.TG$DZ3"2 Z(X#4V??L/C7Q9LX%:9NIQS M09@80"2>)",3HR#1:)6DJHDG(A(>Y<,H2%RRB9H5A:>BE\F^FIQ&:PH4:%>; M%8*%E,
<]K*L1H"),NT>A0$Z5WWHKMU M>5)YNOBE/: ^TC:(PI^&KXP4Q^_JEBF$#/\1MI&[!>6BK<>- MFT(AL /:>BGN(M;AB9'78>=>5)9);"&3=FI?G >5M=.Z=K317 J#@B=663<(
M15^=F"^4AYKX/EEEL;5=W9'Z3V/[_OSF0)YRW*/T@\8(%'M:9'2*ZH))@6SO MAR"RN55#4 %F>_F9$R4WJ(J3:E1P*(Y.P6&K7?6D$:,R8!2HB(J9*.5UY0 4 M*#5R3N3V4R&@]3?
^J_/N;9-M>]FM'U%06Z*UE6$QFB&.0^9!08"NJ#,1LEUC M4"#VA0GR4>H76P37[_ *)EZT24-M94INYR 4J!7/.H\'?_1>-FQUWZ(T7T\I M!X@&H$#I@7I;[E=6=1JK@:!8=C/JZ
H"EL2U8?2@UC6;M.SOJ3O/(/+*|):F M=B.#0[$/DK@7P<^V1BGK6%Q>:&*$(C-B>B0#/-(5+ M%$40V_?CQJ-1K!5]H8"TC40S1K#,CO_"?HA%;:OT1JE&KOH0EDZ;Q?J!EDU: M:
(S]:^LE6T5TA'(<)@2+3O;@C)K*2I"P9' JFW:B2 MP\3MBH@MJ)G# .Y#=]VJ)72$S^TH'[!]D =7D?TUE9K2=XTS(88GG(6F'F3\ M [9)5C@1TC;?>X$,+8="<47$>R*48X20*)" ?+N:=?
=KZ!8%B>0*J<8PVP=L M\)5)Q20O'B3P![$H=D0$@V)_>)PLH[0D M^Z[R,XKEIOWA%7D+-0 42VXZ!I1^1BDP"E3J9:#S^*"F:-|-C>3*7F\)?6'4 M9H?\+=[
N^4$$L.%$!3%GMP)C,75C,#SLN:%KJU9,AP%NDR")_LT[_$F"5Q! MRH\:$@42W"'3;JP@=.V*05&@\1L!3S-QSU\)99++;?0(8$9@()E^@621S%3N!F MJNI*A%RO"5"@G&F3
HD"C6M[^*DR>XW7BMXO@IXRYF= MJ-4? M,!*@GPA 9,D?,81SMVM%W!E&QS:6=",_-9I#42!HG;_TN=J_U+E/3UH1A1$ M:57)DEO8!(H4&AF-I=)AO4<9^&]U1R+
]%6T0S5X91#VS:O9S[T*/>AMW4" M*1'*?1!4[55MA ()#7">2)CBW]"DX=E17#"QJE56>1+_+B^$=UG*WU'L K">+O94_T.540FU9/;?::N+O(@ ^%BNUVLB-V\= M;P4HB-
[1*T0EU&D.18%FJYZU B\9+ I$&H=.;F(1]) H0BNT]6$I. HT*FT MG"F,EWGS-,U6-=)Q*!#,_=.*WJT-$!5#?EC(;T?Q(XJE%@G%]=9)'U2 UE%8>G'*Y5VF M3+F)XT/,'J*"
=DX^V68?^D MR05-&!0+;[]AN4$MJV79^PV4C[=]7*_8@6*< JX68<]R\$1B=MW2C,WLYPD@F\QS/8>V<\@/ MG] V28R5EA,%QYJ='
5/*.II7^PK10(*XXNT['/W,!3H*8*D>L94H4#GX Y8 M2E'?W.PHB%649"61+%^N 8)BV9*N'U?@/B:N5@QLSRE0H/W$'A)>T2*(VT6- MU087K9$HD!PD,O<>C +5=F%\: VOK-
8CA4>!4%OZK>1^ZXG+E0%(K']/6\?W M\X!/L;FO!H)B)^H5?GB8X]..D9@)Z[\R(13.#1!\^"0T9VF.18-H&=`0Z#:HZ,*/)$!6"T$ M>BTWY(G NPS1R>PE?N%VXTR!SIIXZB:4CO$Q%
>_77_^/HQ)ZG+8,3S+!+M' M$$J%-[WO'"@0_:TI%R?VI;@?A\61I3'WF M_JBZ YCLM?62;=11/F783-99FD^9/ACZ[(ZO?_-WU'L&LB,@LBG+#%3-*J M_RPHD^\897@D
^\%K6'!J0/;/GA%6(/ E57[#07-'T'37JS9 >%47#RGJ1ZW M05X__ ":DDF06H8XW?#K;^U:7K'GS QZL=4,D!3MUQZ#8YSM!B%II+93B.& X M"G0+
[B"R[LJCVS2&V3ZF11._=4A==OQ(NTJV' K%WC0[5>I8!+O&H$"LB)?Z M+:.3?H7|*T_?$E;7%/D+:/UDT(IV81U.MA:4G%2B*O6B6G%1;8&7 MG=$5:6E MA[NN*?
J:F17%/N=FUP=GSQ?=;:"M0Z) @D?=+9E\5+"YV^V./45IA'74R!EI MYI:424),S,HR[T0$,/\5%,33ZVHK/!%:(YM(_N^?2QR96/2]\@O_85
M_/]"O/+O$X%O"/'^$?/[U'[O_#"Q>&K^WN/IR&66'#VN^B M,S7"HHID:3:C8$VUGX^TI'/V09>+G;[S(EA3_?>'=W(/XWMF*MEL(=M0E7A)H5N?? MLM?
V_;_(7KK&)MQ1%PF111?2D0N"$/+WO$N0@NJ]6(GM63WJJ ATM*!+5T& M?]1%G[LN$!*B[/^ D>V3=,$B6!N+A1+4"[H,WX*NI58@;2R4G|<%Y5X0)N1W
MK;8);F/)#V$4._[_\7;*6R<$/M9#*RA.7GU M?_K\S--E!$MK@1QI:4SN!V7FH_ M[6+P(I_P3'%S>/\)NXZ#4N9X&D7@A]=[J27C"V_A%0N-]6ACKI 8?AA:X%U MJ*,N\'I+Z
L[<%]H^!9O&ATS6PL50Q]WP>^E0E[OEM5>;1OTN)LO:$+:WOLJ MT%&7URMFL;5NO="Y;D:F?YMSJL:)%A^U6AJQ(*JP/_\X?,/9TG$%A+NTJ):\%OFK;E+ MB2%=(E\?
^_YS&!$.BYT@#>-H1I$__]$L1=B[-Q%Z2.VR.64^93TR;4-P3IK/ MO.*?.GN5)&;ES/2?/GN9)&89-DZ;/(R?*W>9.EY2?)Z6)8XIT;73I<,QF5_C);*;C#_Y/39[:RL,+5E--F
*MML*PU+.54V-VXK#:E9:39[8RL ^`X:>,10BKIO4?/^UL[T3,G7Y92 MF<;O$#^.\U+4@3Q%UB5O4I,==4E&H!KE2-31D*5#41VHJPMDU_^5>*^.3Z#^
M47SI4+IG9[)6<[F!BMY8:ZA5*K#I;8UB@#4DU,G@S;,E!L:P ^R^' M>K@U!'NCA!&)>BD$U84705JD??:"+-99%3#'?PA3N;5S%S2&VKOR_(70>D;L M+U;4#U%&=1&H3<8*?
2/R=AD7)"!K+VXV0&TS6-6@HK>Z!%B2?<$1KO'WPG+3O#)+$=O$?L DA%'\40:X@41=?D"Z^!V*2XF[!C MGM;9VF=UKGF!4]X_3LVI=$=;0T]2_[/S^G>/L_F@)-
N$5R5/>6ZXW5&R8TS8 M>R5E6W-VJA;KI?,N?V-ZS8)D!QLU7[5VKSG&ICZW8RPW>S3S-[-F=Y+K=YTC M<3ZT:KRTAMJSDH3!"ZA%4*RNDV-
(@"T*SFDYY+Q^7N7"7S'=;.7)1>C.@?:8 M@:I%>9,)"&$M&P\Z!'\<%UKR^*G7WC$(@ZFSVYJ)R6"I;:BT?::5AQG%QJM/ MK@=0JGVFHP>CP%0C&X&!]D('P4"_@F5/LI!-JWIC:/KP,N?*

*R:;K?Y;=,13F9 M=VUNI-+RSM6;)\C)/ OBJ]2.7T,4V$SKI>^EJ-[/A!)L%L<2>OS99YGGEM-]# ML4\RH]&GDZ91[^=/Z0.=&\FTGT&U@W869.OW +8=PC,ATK#73_],SH*,W>^B MW'_(P+U4'C$80(9K3Z?-*WTGLA^<0MS(UQO?5$[2F(6E.Q'.YT0C%F0K?L9 M4 =VS(A(&D]!/78DH|TO)TV;?MJ1=LS*W&C7F_MKA,?,@H8]^7[?")Q9T+#[M$>@(Y9D1E;28G$:P4%ZG^:1)UN]QT(M&FAOA^ON1)+%/LR!BHFXO3C\5T!:J.0#-MY,A0E,),#UH|^HHBE M69!)U]$]$W+T8TNBB,.|M-Y!R%>]?$R#4\D']-(-Y 9VY!PK^- M? WLQU_QYX+NP(3%,5A!R$@6 3K8613UPD>W0@O(%NSR*XX%07L*8(KHD*3(MI>6XSI-XPV[@OTFS29_F(%3(W$91T@N1; J).0M\71'82B#T?/JZ(S$@);F MI5&-P(.&|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|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|>09YF:M>LJC<()Y.5S[\8%N/>J# M;!UD,W8GYN6&&TYP)6,]GL_.EO^LTD)N91M:J_#E1N7F2Q0U$=5/L76O0 >SN5]@^-C-KC[1U,32Z!B"TTFX9U0)*8+LB>UI2L&H]XK4MK[<[/]P3 MDA:^3.AJXT0$VOZJI/K>2PV0S69FEQLFAS_4[HRH.8GK6& MY):UX8WXCC7P-#_1LS3[1H1>P#X^&>?B!=1\0$##W E%FLJ%UI?W6VP#&N] MSCOP-_*1$? =_7.PMX6U<(%>PZWORQG^1<;M!4XUXZ%7,5X;+X&E&Q($L9_I MG[P7.EN(]^JY)' U5J|:C.V5Y4, M]93[#;Y!Z6%H+[G/X/$._T$H'# 7RJO1Q8#'Y;CCRM8#<1N1#:N^V$.XZ|<, M^DQL$->]]-)C"3491D-1,/\); >9KTHB!Y9A&0/N;O>2]X/$F4&T(&2_"M>);"A7)'=#\-9-9%% MM];_)%':MGD92OS?_)%:4@8:XJ\F&2E)U(D&5L+7P(^BT@:^ M.-IG/X*ZIQK4K7,T&(X,O8C 'ZH>NZK$61WN^+, M+P(-<;M3>3[X Q_A\:/&ROW^RRJXC,B&HCI^_^5/:' Z7BC![[_\>8*N]M]_ M^0NV:.H[50]BZ*J-$=V_2V6|V*$QRI!S58!K+258'$8ZBX0(90BMI,/@K(IC MRJ->ZS56M<-,9T&U7C&ILR_GVZ.,GYBGS8M*RL>O6UX;(^|*Z5.HS=T[0GWG ME:K6?0O;4<3SHE"?&ZBC78R1Q3?Y*ZD? _#RO*IRR$/Z:M"J0VG(J_3239W() M3>"9'"&U^BP5&8S6-YHZ?Y*E % 6[<8HZ+LE*EJB)Y&J\].AYZ'Y9.,4YJVZD^1 M;L#T1^G:WJDOABO93KW0>X^$G(\ZMGTS>HY9O18SR7KE\N0T^U!.!J=#Y23\ MZ&71([$])I'0PO)A*V<9F:;4TR+9B83QG)ZSKF1Q3A);;D%?|YZAJ$LMIR4 M1I6.Z>F[AR; Y60TZE2:'AE[IL[E5#.JA$R/:@.S\'+JS5D?.32;+Z?AG/63 M Y("<_(9]9*<%OF4"88Y_3[4E&/D*N;4GK.",WXB8T[E.:L]8V<[YH$G9A2@ MJ=J$QLB?S"EK1A^:*F4E29O)TDD,+HAG59$Z' M:'K)I@45C>HR$Z:B,+!UO)_)145.):Q]*!=K".BZ\<.WJ;:?A!;#(5;]I1' MT-+\/'!OO,)5M!P&|Y$1S\(_?'VVI^B$BOD,UV*&$;PI[C!(IE11+?A_$_ M20RRI 1#[>'6$,QEWRN2R\!9E_7@)5M\QR;VF 1DN>K%7#RB*FHQ'M5]/O0 M&FJORD"RVZ5N:\?/NNRZPQ/X3?=2#Z=6UJ'AT]9L5M8=@.VCE$WK@05--9 WI M!V>? &W!63!RGA*V:78AX#^D7,9,:0$C? 8@$V1X3X"C+!993)@;YI'9_EJ$9 M)C/*I^Q6VKEH6J1EMUH,C.T^%V+PH?=9-9'!(FKLLRM'W.B&*8E"1PO<,5D" M5? YO085G0_.:+!=!G2!B>BETF'UE-XBIKX3=EIRA*)A1S\&(A.7*8K6EY.H8 MBZC$A*E<7,5B%T2Z^#H4GG M;Z%5];]5#%IKJ+T=JO C<#0SWDH6Z[LP>%D2NKTBSU()I'N@O6K;WLN&2;GL MP3B/(A(OGM-4Z]O@^IWQS^'%W(2T>/GOX'K?>#IO0\#(#8_/MD5 M:1]'$1"V\R40L ^6T#'QP-S:R02-05;2?)Q%"WZTX9GS3#QZ90>=6V[S:$3X M@9WX^A\]D&ED31L[8(1LR_+G[-&)R?5Z3:3:V9$7@>V2'"Q*!YNE1N!&N2+0 MQ9":<(BN:ZX,/Q)>RTO^V@^:8IJ7N+@I5UZT"R/'_T+#9,=&L/]>A0${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
&K[Q\V1N7X'*8EVMJ)?EFER&41SQ6H#/4 LP M+V_3=4L/F]3>;=9=]T5UW9VW_L!9D7 '(P>EQD4.I?;LN$VEG/&TN$RQ<.V' M7C7"?MMY_2=2.03'S=;8'&%-[9E* "7:JX2'D#X0SBIKX3=EIRA*)A1S\&(A.7*8K6EY.H8 MBZC$A*E<7,5B%T2Z^#H4GG M;Z%5];]5#%IKJ+T=JO C<#0SWDH6Z[LP>%D2NKTBSU()I'N@O6K;WLN&2;GL MP3B/(A(OGM-4Z]O@^IWQS^'%W(2T>/GOX'K?>#IO0\#(#8_/MD5 M:1]'$1"V\R40L ^6T#'QP-S:R02-05;2?)Q%"WZTX9GS3#QZ90>=6V[S:$3X M@9WX^A\]D&ED31L[8(1LR_+G[-&)R?5Z3:3:V9$7@>V2'"Q*!YNE1N!&N2+0 MQ9":<(BN:ZX,/Q)>RTO^V@^:8IJ7N+@I5UZT"R/'_T+#9,=&L/]>A0${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
&K[Q\V1N7X'*8EVMJ)?EFER&41SQ6H#/4 LP M+V_3=4L/F]3>;=9=]T5UW9VW_L!9D7 '(P>EQD4.I?;LN$VEG/&TN$RQ<.V' M7C7"?MMY_2=2.03'S=;8'&%-[9E* "7:JX2'D#X0SBIKX3=EIRA*)A1S\&(A.7*8K6EY.H8 MBZC$A*E<7,5B%T2Z^#H4GG M;Z%5];]5#%IKJ+T=JO C<#0SWDH6Z[LP>%D2NKTBSU()I'N@O6K;WLN&2;GL MP3B/(A(OGM-4Z]O@^IWQS^'%W(2T>/GOX'K?>#IO0\#(#8_/MD5 M:1]'$1"V\R40L ^6T#'QP-S:R02-05;2?)Q%"WZTX9GS3#QZ90>=6V[IS:$3X M@9WX^A\]D&ED31L[8(1LR_+G[-&)R?5Z3:3:V9$7@>V2'"Q*!YNE1N!&N2+0 MQ9":<(BN:ZX,/Q)>RTO^V@^:8IJ7N+@I5UZT"R/'_T+#9,=&L/]>A0${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
&K[Q\V1N7X'*8EVMJ)?EFER&41SQ6H#/4 LP M+V_3=4L/F]3>;=9=]T5UW9VW_L!9D7 '(P>EQD4.I?;LN$VEG/&TN$RQ<.V' M7C7"?MMY_2=2.03'S=;8'&%-[9E* "7:JX2'D#X0SBIKX3=EIRA*)A1S\&(A.7*8K6EY.H8 MBZC$A*E<7,5B%T2Z^#H4GG M;Z%5];]5#%IKJ+T=JO C<#0SWDH6Z[LP>%D2NKTBSU()I'N@O6K;WLN&2;GL MP3B/(A(OGM-4Z]O@^IWQS^'%W(2T>/GOX'K?>#IO0\#(#8_/MD5 M:1]'$1"V\R40L ^6T#'QP-S:R02-05;2?)Q%"WZTX9GS3#QZ90>=6V[S

&;N&,UP=+B=/;D+6G7[)<1WS%]ML%N[\TC[?G[7WF]UZY9M-M(WXLCGZDB2&N#OD+N?3X]{@]/R,?,FZN+SJG0W8X+SFEE?ED(NK MW_J7K+W#O?;N)M}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pre>

&)8$:+A<3Z4C)$5!"EO+K\O%W7D8X2#*!HH!7QT/E8AI?H"?2 MZ6D2UN8*H/_(U!6P/%'W9(|,V_:MXQM?ZE34U];?]8$"%)KZ.O.SP#*>^P;JW!W@H#PV1DR+PF0?/L-UFEU=A?> (EYR M5_Z1KO@TJ1]A]^Q]>J=BAIS++WP%_D>[.K_+&MMQ=>Y5SFG%=*N ?Y M<I?GGKCWV=WV3]>3V;%:: M/ZJ0(W%?&-0M7+G"%_?,%GVUTFM/9,O6M[8N_$LEQZLHO6H]E PK7R]5$51C M-A9J^]WF+83X%JC]/DEWH-`M\Q[93;- #0 &]M+65X,S)? M,2YH=&WM6VUOVS80_KY?P.7HT *6+=EQDTAN "]UL0!,TL8NT'VDI9/%E2(U-MDHKM_?H=*? DM38K.39MV41#$D73DO?"YXQU]&F0FYZ<_D4$&-,%/,C#,<#@= MO?=ZW78PZ%272-"I*093F2R)-DL.+P]RJF9,A(261O[,\D(J0X6)"IHD3,Q" M!FP669"$D0'CDO"KE=SU,2>D47HM_M,1/]X3"2P"+U>E#.Q&AO@-MDT)J9I@4H0).#;N&:"H7GF;_6&Y3J1)0'MV!)H-B-7\JA;D 9^8:)*Y(]_MY)ZE-&=\&4Y8#I%4&B/S,.CB6 ,+XU'.9BB EW3WU^^5)\,*/MC7K M('X=<>M_.9#PZGV_189C,GQU^68R>M58Z>!T99L3_P6Y?$TFOXW(M>'CUZ_!B-/8NW_\^^I,,SR;V2=?WN]_02/N$CWUM\%'X> CE/G?]OTS54M^}):E4;NX"%),) 6$W<3*&PD_^!45Z MZ(M=OWO8(E23E"%(-O*,(2X5;N2H$Q4)&2WBC(H9$.28,ZVM[/AK*1-J@&2@_M_"7>$:Y29"U;BP"-,ZN7)2HQ?5 :EP*9QJ ,2Y%5BQ2ETB7F)\1(L@D?%AY' M414\4%2:2%0AV2&N2*P/U0S&5$VI .U=+C@LR3!V)K4^U,+GU+3L*!2[DS%- M/@@Y1_5G$*XP^.V!06[W^9?,:=:OSQ AKG'F38> <,C!QB!DBLMZL)OE>1;6 M8;_=Z_6>1@G3!:?+,.6PV/89)^!?I4:3+U?L'9&G#6(P<@[B698ZG%(--CG\ MR)4V2M3<'LBW>NW#PZ.3X"0X[?^B|()T=-HCCFF-U5 /X0? H4BJ]MP81+ M=9U)F$"W+K;J]782H,KEH'O/!TQX<-$D@FBO X6:40P6.G.C_RQYOG:=C>^O_;VG^"D5X4+BG,FD$0V.JR! M:U.^3>++7 /@! =S]00#,.!.Y2.74@M$\HLSL"J[.6%;HILQLCLM86R"W[&(U" M,NCT,J4I>^8%$Z#F>VIHVIM]'V'4#^ M7V=9ADXYW..%]L @J@MV*XNMWU%T2^XAJ$Q:[]K?C8BAKN MKV=O;)L/38I#Q,N#[CKH7MO$"U/+&HL(Y*]P+',?>?==B+Z0UU4J^Z+*9'<. M(&Y9B1]>X5^7X1XZKH_=*OG;_0)ED9PE/YCV'=TAOX/&'(=,,)#,;C/%UW&> M[PH__\EFMYS,;8/FNXT*]ZGD=Z78%^"_P7Z#_<>*,;,08KU*:.F]ELE?XIY\5/6VHV M!7A3@.\6X$?]D[T+|.-NORG FP**<"_H "_H%, 3H99#DF3?379UV/*OAKL M-]A_K-BO"O#7ZR_7F@*\<8-'Z ;?L@"_T]F: KSI,_R,YHI4*IA)V_17M]C% M5:,%TV0*]G9:*L%T!HEMAOO,MC_;_",(U WM],BZ4\..T9GMS1#2(^2 &"J M5#<73I?,W1:N/;$H52$U[#8G'>_1B-1RO%$@U,WR1KFFMKLDELC GG\X]&I2 M4"!B^P0IG!2,6TO4'&O96F2> 5XKDM,$<"9K2=LO15,#ZF;,8POGG5&5<-!. M$3OM# 0H=-R-!%8UCBJ4=&;9$UW&67MG8M#UE MZ]RMEKAN/G,M9M4)XNX#-&1UVZUKE<0YAPDIG].E=LG'-D4$L! A0#% @ M5HYF68Q\S,0""0 3P T (!Z<$" &]M+65X,S%?,2YH M=&U02P$"% ,4 "!6CF99=2$]1OX(!/ #0 @ $6 MRP{ ,VTM97@S,5\R+FAT;5!+ 0(4 Q0 (%:.9EE #L34]@8 -XT - M "_3_4 @!O;2UE>#,R7S$N:'1M4$L%!@ % 4 *P$ ' !3; @ $! end XML 64 om-20240930_htm.xml IDEA: XBRL DOCUMENT 0001484612 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001484612 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001484612 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001484612 us-gaap:OneTimeTerminationBenefitsMember 2023-01-01 2023-12-31 0001484612 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001484612 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2024-09-30 0001484612 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001484612 om:USGovernmentSponsoredEnterprisesMember om:UnrealizedLossesLessThan12MonthsMember 2023-12-31 0001484612 om:SlrRevolverMember om:AdditionalTrancheMember 2024-09-30 0001484612 2023-03-31 0001484612 om:SlrRevolverMember 2024-09-30 0001484612 us-gaap:AccountsReceivableMember om:SlrRevolverMember 2024-01-01 2024-09-30 0001484612 us-gaap:USTreasurySecuritiesMember om:UnrealizedLosses12MonthsOrGreaterMember 2023-12-31 0001484612 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001484612 om:SlrCreditFacilitiesMember 2024-09-30 0001484612 us-gaap:ProductMember 2024-01-01 2024-09-30 0001484612 om:ConsumablesProductMember 2024-01-01 2024-09-30 0001484612 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001484612 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001484612 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001484612 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001484612 om:SlrTermLoanFacilityMember om:TermALoanMember 2024-01-01 2024-09-30 0001484612 om:ConsolesProductMember 2023-01-01 2023-09-30 0001484612 2024-01-01 2024-03-31 0001484612 us-gaap:FairValueAdjustmentToInventoryMember om:SlrRevolverMember 2024-01-01 2024-09-30 0001484612 srt:MaximumMember us-gaap:PerformanceSharesMember 2024-01-01 2024-09-30 0001484612 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2023-12-31 0001484612 us-gaap:PerformanceSharesMember 2024-01-01 2024-09-30 0001484612 us-gaap:CorporateDebtSecuritiesMember om:UnrealizedLossesLessThan12MonthsMember 2024-09-30 0001484612 2023-09-30 0001484612 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001484612 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001484612 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001484612 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001484612 om:WarrantsToPurchaseCommonStockMember 2023-01-01 2023-09-30 0001484612 us-gaap:EmployeeStockMember 2023-01-01 2023-09-30 0001484612 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2024-09-30 0001484612 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001484612 us-gaap:ProductMember 2024-07-01 2024-09-30 0001484612 om:SlrTermLoanFacilityMember 2023-12-11 0001484612 om:SlrRevolverMember om:AdditionalTrancheMember 2024-01-01 2024-09-30 0001484612 2023-06-30 0001484612 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001484612 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001484612 2024-11-01 0001484612 om:ServiceAndOtherRevenueMember 2024-01-01 2024-09-30 0001484612 om:ServiceAndOtherRevenueMember 2023-01-01 2023-09-30 0001484612 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001484612 us-gaap:CommonStockMember 2023-06-30 0001484612 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001484612 us-gaap:CorporateDebtSecuritiesMember om:UnrealizedLosses12MonthsOrGreaterMember 2024-09-30 0001484612 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001484612 2024-06-30 0001484612 us-gaap:OneTimeTerminationBenefitsMember 2024-01-01 2024-06-30 0001484612 om:EmployeesSharePurchasePlanMember 2024-09-30 0001484612 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001484612 srt:MinimumMember us-gaap:PerformanceSharesMember 2024-01-01 2024-09-30 0001484612 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001484612 om:SlrRevolverMember om:AfterSecondAnniversaryMember 2024-01-01 2024-09-30 0001484612 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001484612 2023-01-01 2023-03-31 0001484612 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001484612 us-gaap:PerformanceSharesMember 2024-07-01 2024-09-30 0001484612 om:SlrRevolverMember om:InitialRevolverCommitmentMember 2024-09-30 0001484612 om:SlrTermLoanFacilityMember om:TermCLoanMember 2024-01-01 2024-09-30 0001484612 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001484612 us-gaap:RetainedEarningsMember 2024-03-31 0001484612 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001484612 2023-01-01 2023-09-30 0001484612 om:CeoMember us-gaap:PerformanceSharesMember 2024-01-01 2024-09-30 0001484612 us-gaap:USTreasurySecuritiesMember om:UnrealizedLossesLessThan12MonthsMember 2023-12-31 0001484612 us-gaap:RetainedEarningsMember 2023-09-30 0001484612 om:SlrTermLoanFacilityMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-01-01 2024-09-30 0001484612 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001484612 2024-07-01 2024-09-30 0001484612 us-gaap:RetainedEarningsMember 2023-03-31 0001484612 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001484612 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-09-30 0001484612 om:SlrTermLoanFacilityMember om:TermBLoanMember 2023-12-11 0001484612 us-gaap:RetainedEarningsMember 2022-12-31 0001484612 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001484612 om:ConsolesProductMember 2024-01-01 2024-09-30 0001484612 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2024-09-30 0001484612 om:ConsumablesProductMember 2023-07-01 2023-09-30 0001484612 om:TwoSeniorSecuredCreditFacilitiesMember 2022-11-03 0001484612 us-gaap:ProductMember 2023-01-01 2023-09-30 0001484612 2024-01-01 2024-09-30 0001484612 om:UnrealizedLossesLessThan12MonthsMember 2023-12-31 0001484612 om:SlrRevolverMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-01-01 2024-09-30 0001484612 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001484612 us-gaap:RetainedEarningsMember 2023-12-31 0001484612 om:SlrTermLoanFacilityMember om:TermCLoanMember 2023-12-11 0001484612 us-gaap:CommonStockMember 2023-03-31 0001484612 om:SlrRevolverMember om:InitialRevolverCommitmentMember 2024-01-01 2024-09-30 0001484612 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001484612 us-gaap:CostOfSalesMember 2024-01-01 2024-09-30 0001484612 srt:MinimumMember om:SlrRevolverMember 2022-11-03 0001484612 2023-04-01 2023-06-30 0001484612 2021-10-01 2024-09-30 0001484612 om:StockOptionsToPurchaseCommonStockMember 2024-07-01 2024-09-30 0001484612 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001484612 om:SlrTermLoanFacilityMember om:FirstAnniversaryMember 2024-01-01 2024-09-30 0001484612 2022-04-01 2024-09-30 0001484612 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001484612 us-gaap:PerformanceSharesMember 2023-01-01 2023-09-30 0001484612 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001484612 srt:MinimumMember om:TotalShareholderReturnMember 2024-01-01 2024-09-30 0001484612 us-gaap:SellingAndMarketingExpenseMember 2023-07-01 2023-09-30 0001484612 us-gaap:EmployeeStockMember 2023-07-01 2023-09-30 0001484612 om:SlrTermLoanFacilityMember om:SecondAnniversaryMember 2024-01-01 2024-09-30 0001484612 us-gaap:EmployeeStockMember 2024-01-01 2024-09-30 0001484612 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001484612 us-gaap:RetainedEarningsMember 2023-06-30 0001484612 om:WarrantsToPurchaseCommonStockMember 2023-07-01 2023-09-30 0001484612 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001484612 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2024-09-30 0001484612 us-gaap:CommonStockMember 2023-09-30 0001484612 om:SlrTermLoanFacilityMember om:TermB1LoanMember 2023-12-11 0001484612 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0001484612 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001484612 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0001484612 2022-10-01 2024-09-30 0001484612 om:ServiceAndOtherRevenueMember 2023-07-01 2023-09-30 0001484612 om:SlrTermLoanFacilityMember om:TermALoanMember 2023-12-11 0001484612 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001484612 om:SlrRevolverMember om:SecondAnniversaryMember 2024-01-01 2024-09-30 0001484612 om:StockOptionsToPurchaseCommonStockMember 2023-01-01 2023-09-30 0001484612 om:CeoMember 2024-01-01 2024-09-30 0001484612 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001484612 us-gaap:CommonStockMember 2022-12-31 0001484612 om:SlrRevolverMember om:FirstAnniversaryMember 2024-01-01 2024-09-30 0001484612 2022-12-31 0001484612 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001484612 us-gaap:PerformanceSharesMember 2024-01-01 2024-09-30 0001484612 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001484612 us-gaap:CorporateDebtSecuritiesMember om:UnrealizedLossesLessThan12MonthsMember 2023-12-31 0001484612 om:SlrRevolverMember us-gaap:InterestRateFloorMember 2024-01-01 2024-09-30 0001484612 us-gaap:EmployeeStockMember 2024-07-01 2024-09-30 0001484612 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001484612 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001484612 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashEquivalentsMember 2023-12-31 0001484612 us-gaap:RetainedEarningsMember 2024-06-30 0001484612 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001484612 om:SlrTermLoanFacilityMember us-gaap:InterestRateFloorMember 2024-01-01 2024-09-30 0001484612 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001484612 om:SlrCreditFacilitiesMember 2024-01-01 2024-09-30 0001484612 us-gaap:PerformanceSharesMember om:EndOfYear3Member 2024-01-01 2024-09-30 0001484612 2024-03-31 0001484612 srt:MaximumMember om:SlrCreditFacilitiesMember 2022-11-03 0001484612 us-gaap:SellingAndMarketingExpenseMember 2024-07-01 2024-09-30 0001484612 om:UnrealizedLossesLessThan12MonthsMember 2024-09-30 0001484612 us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001484612 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001484612 us-gaap:USTreasurySecuritiesMember 2023-12-31 0001484612 om:UnrealizedLosses12MonthsOrGreaterMember 2023-12-31 0001484612 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0001484612 us-gaap:RestructuringChargesMember 2024-01-01 2024-09-30 0001484612 om:StockOptionsToPurchaseCommonStockMember 2023-07-01 2023-09-30 0001484612 us-gaap:CostOfSalesMember 2024-07-01 2024-09-30 0001484612 om:ConsumablesProductMember 2024-07-01 2024-09-30 0001484612 us-gaap:OneTimeTerminationBenefitsMember 2024-07-01 2024-09-30 0001484612 om:SlrTermLoanFacilityMember om:AfterSecondAnniversaryMember 2024-01-01 2024-09-30 0001484612 om:ConsumablesProductMember 2023-01-01 2023-09-30 0001484612 srt:MaximumMember 2024-01-01 2024-09-30 0001484612 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001484612 2024-04-01 2024-06-30 0001484612 us-gaap:ProductMember 2023-07-01 2023-09-30 0001484612 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001484612 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001484612 2023-12-31 0001484612 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-09-30 0001484612 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2023-12-31 0001484612 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001484612 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001484612 us-gaap:CorporateDebtSecuritiesMember om:UnrealizedLosses12MonthsOrGreaterMember 2023-12-31 0001484612 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2023-12-31 0001484612 om:USGovernmentSponsoredEnterprisesMember 2023-12-31

0001484612 om:WarrantsToPurchaseCommonStockMember 2024-01-01 2024-09-30 0001484612 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashEquivalentsMember 2024-09-30 0001484612 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2023-12-31 0001484612 om:ConsolesProductMember 2023-07-01 2023-09-30 0001484612 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001484612 om:StockOptionsToPurchaseCommonStockMember 2024-01-01 2024-09-30 0001484612 us-gaap:CommonStockMember 2024-03-31 0001484612 om:TwoThousandTwentyEquityIncentivePlanMember 2024-09-30 0001484612 us-gaap:CommonStockMember 2023-12-31 0001484612 2023-07-01 2023-09-30 0001484612 us-gaap:RestrictedStockUnitsRSUMember 2022-02-01 2022-02-28 0001484612 om:WarrantsToPurchaseCommonStockMember 2024-07-01 2024-09-30 0001484612 om:ConsolesProductMember 2024-07-01 2024-09-30 0001484612 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001484612 2024-09-30 0001484612 om:SlrRevolverMember 2024-01-01 2024-09-30 0001484612 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001484612 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001484612 om:SlrTermLoanFacilityMember om:TermBLoanMember 2024-01-01 2024-09-30 0001484612 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001484612 om:UnrealizedLosses12MonthsOrGreaterMember 2024-09-30 0001484612 us-gaap:PerformanceSharesMember 2023-07-01 2023-09-30 0001484612 om:SlrTermLoanFacilityMember om:TermB2LoanMember 2023-12-11 0001484612 us-gaap:RetainedEarningsMember 2024-09-30 0001484612 srt:MinimumMember 2024-01-01 2024-09-30 0001484612 us-gaap:CommonStockMember 2024-06-30 0001484612 srt:MaximumMember om:TotalShareholderReturnMember 2024-01-01 2024-09-30 0001484612 om:CeoMember om:TotalShareholderReturnMember 2024-01-01 2024-09-30 0001484612 om:USGovernmentSponsoredEnterprisesMember om:UnrealizedLosses12MonthsOrGreaterMember 2023-12-31 0001484612 om:ServiceAndOtherRevenueMember 2024-07-01 2024-09-30 0001484612 om:SlrTermLoanFacilityMember 2024-01-01 2024-09-30 0001484612 us-gaap:CommonStockMember 2024-09-30 pure shares iso4217:USD shares Q3 0001484612 false --12-31 10-Q true 2024-09-30 2024 false 001-39513 Outset Medical, Inc. DE 20-0514392 3052 Orchard Dr. San Jose CA 95134 669 231-8200 Common Stock, par value $0.001 per share OM NASDAQ Yes Yes Large Accelerated Filer false false false 52542024 33287000 68509000 142346000 134815000 34259000 32980000 61436000 49215000 3945000 5700000 275273000 291219000 3329000 3329000 9492000 13273000 4312000 5375000 484000 605000 292890000 313801000 4295000 5827000 14719000 19005000 6749000 13459000 2156000 3712000 12766000 11727000 1745000 1593000 42430000 55323000 2222000 896000 77000 101000 3157000 4482000 197182000 130113000 245068000 190915000 0.001 0.001 5000000 5000000 0 0 0 0 0 0 0 0.001 0.001 300000000 300000000 52538000 52538000 50317000 50317000 52000 50000 1111503000 1084515000 352000 68000 -1064085000 -961747000 47822000 122886000 292890000 313801000 20305000 23531000 59971000 80640000 8361000 6831000 24251000 19229000 28666000 30362000 84222000 99869000 11532000 16837000 34680000 59866000 7314000 6368000 21725000 18715000 18846000 23205000 56405000 78581000 9820000 7157000 27817000 21288000 8139000 16076000 30508000 44775000 15417000 24720000 54593000 74038000 10103000 11815000 34231000 34892000 33659000 52611000 119332000 153705000 -23839000 -45454000 -91515000 -132417000 2149000 2573000 7718000 7889000 6068000 3213000 18046000 9258000 -27758000 -46094000 -101843000 -133786000 182000 86000 495000 411000 -27940000 -46180000 -102338000 -134197000 -0.55 -0.55 -0.93 -0.93 -1.98 -1.98 -2.72 -2.72 50501 50501 49913 49913 51685 51685 49364 49364 -27940000 -46180000 -102338000 -134197000 654000 140000 284000 311000 -27286000 -46040000 -102054000 -133886000 50317 50000 1084515000 68000 -961747000 122886000 776 1000 2079000 2080000 607 1000 294000 295000 2 6000 6000 8203000 8203000 -326000 -326000 -39944000 -39944000 51702 52000 1095097000 -258000 -1001691000 93200000 312 70 77000 77000 9820000 9820000 -44000 -44000 -34454000 -34454000 52084 52000 1104994000 -302000 -1036145000 68599000 264 121000 121000 190 6388000 6388000 654000 654000 -27940000 -27940000 52538 52000 1111503000 352000 -1064085000 47822000 48465 48000 1035456000 -564000 -788950000 245990000 307 1000 4593000 4594000 282 162 684000 684000 8538000 8538000 451000 451000 -43971000 -43971000 49216 49000 1049271000 -113000 -832921000 216286000 165 248 1000 1042000 1043000 10105000 10105000 -280000 -280000 -44046000 -44046000 49629 50000 1060418000 -393000 -876967000 183108000 252 2916000 2916000 117 175 1186000 1186000 10893000 10893000 140000 140000 -46180000 -46180000 50173 50000 1075413000 -253000 -923147000 152063000 -102338000 -134197000 24411000 29536000 4322000 4364000 1063000 919000 1898000 1377000 3890000 5099000 644000 672000 -34000 -106000 1813000 141000 3092000 7564000 12989000 -2607000 -1848000 -440000 -1507000 2251000 -3991000 25000 -6327000 -4108000 -1556000 447000 1015000 2114000 -1173000 -962000 -99815000 -106931000 869000 2387000 150467000 121262000 147121000 183250000 -4215000 59601000 2284000 10423000 66524000 0 68808000 10423000 -35222000 -36907000 71838000 76533000 36616000 39626000 472000 403000 15537000 1836000 1173000 962000 8000 207000 148000 0 0 528000 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">1. Description of Business </p><p style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Outset Medical, Inc. (the Company) is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. Tablo® Hemodialysis System (Tablo), cleared by the U.S. Food and Drug Administration (FDA) for use from the hospital to the home, represents a significant technological advancement designed to transform the dialysis experience for patients and operationally simplify it for providers. Tablo serves as a single enterprise solution designed to be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. The integration of water purification and on-demand dialysate production in a single 35-inch compact console enables Tablo to serve as a dialysis clinic on wheels. With a simple-to-use touchscreen interface, two-way wireless data transmission and a proprietary data analytics platform, Tablo is a new holistic approach to dialysis care. The Company's headquarters are located in San Jose, California. </p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Liquidity</p><p style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Since inception, the Company has incurred net losses and negative cash flows from operations. During the nine months ended September 30, 2024 and 2023, the Company incurred a net loss of $102.3 million and $134.2 million, respectively, and cash outflow from operating activities of $99.8 million and $106.9 million, respectively. As of September 30, 2024, the Company had an accumulated deficit of $1.1 billion.</p><p style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of September 30, 2024, the Company had cash, cash equivalents, restricted cash and short-term investments of $179.0 million. The Company is required to comply with certain covenants under the SLR Credit Facility Agreements (as defined in Note 7) including ones relating to financial reporting and the delivery of an unqualified audit opinion, the maintenance of minimum cash or revenue, the incurrence of additional debt, and its ability to make capital expenditures or declare dividends. If the Company fails to comply with any covenants, payments or other terms of either SLR Credit Facility Agreement, its agent or lender, as applicable, could declare an event of default, which would give it the right to declare all borrowings outstanding, together with accrued and unpaid interest and fees, to be immediately due and payable. Further details of obligations under the SLR Credit Facility Agreements are described in Note 7.</p><p style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">While the Company has taken actions to reduce operating expenses and working capital to align with anticipated revenue growth including implementing restructuring plans to streamline its overall organizational structure and renegotiating commitments with suppliers to reduce inventory, management expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth.</p><p style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Furthermore, on September 23, 2024, the Company received notice from the Listing Qualifications staff of the Nasdaq Stock Market LLC (Nasdaq) that it no longer complied with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. If the Company is unable to regain compliance with the minimum bid price requirement within the applicable compliance period, or is unable to otherwise maintain compliance with other applicable Nasdaq listing rules, it may not be able to maintain the listing of its common stock on Nasdaq, which could adversely affect its ability to issue additional securities or obtain additional financing on terms acceptable to it, or at all.</p><p style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Management believes that the Company's existing cash, cash equivalents, short-term investments, cash generated from sales, and proceeds received from the debt financing described in Note 7, will be sufficient to meet its anticipated needs for at least the next 12 months from the issuance date of the accompanying condensed financial statements.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Basis of Presentation</p><p style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The accompanying condensed financial statements are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, that are necessary for the fair statement of the Company's financial position, results of operations, comprehensive loss, and cash flows for the interim periods presented. The financial data and the other financial information disclosed in these notes to the condensed financial statements related to the three- and nine-month periods are also unaudited. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results of operations to be anticipated for any other future annual or interim period. The condensed balance sheet as of December 31, 2023 included herein was derived from the audited financial statements as of that date. </p><p style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">These unaudited condensed financial statements should be read in conjunction with the Company's audited financial statements and related notes for the year ended December 31, 2023, which are included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) on February 21, 2024 (2023 Annual Report).</p><p style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">All share amounts disclosed in the notes to the condensed financial statements are rounded to the nearest thousand except for per share data. </p> -102300000 -134200000 99800000 106900000 -1100000000 179000000 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">2. Summary of Significant Accounting Policies</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Recently Issued Accounting Pronouncements</p><p style="text-

indent:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07), which requires that an entity disclose significant segment expenses impacting profit and loss that are regularly provided to the chief operating decision maker. The update is required to be applied retrospectively to prior periods presented, based on the significant segment expense categories identified and disclosed in the period of adoption. This ASU guidance is effective for our Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent interim periods, with early adoption permitted. The Company is currently evaluating the impact of the adoption of ASU 2023-07 on its financial statements and disclosures. In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (ASU 2023-09), which requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, this ASU requires certain disclosures of state versus federal income tax expense and taxes paid. This ASU is effective for our Annual Report on Form 10-K for the year ended December 31, 2025, with early adoption permitted. The Company does not expect the adoption of ASU 2023-09 to have a material impact on its financial statements. In March 2024, the SEC adopted rules intended to enhance and standardize climate-related disclosures in registration statements and annual reports. The new rules will require disclosure of material climate-related risks, including the material impacts of these risks to the Company, the quantification of material impacts to the Company as a result of severe weather events and other natural conditions and Board of Directors' oversight and risk management activities. The new rules follow a compliance phase-in timeline based on a company's filing status. Large accelerated filers and accelerated filers (other than smaller reporting companies) are required to first incorporate such disclosures for fiscal years 2025 and 2026, respectively, followed by greenhouse gas-related disclosures, if material, for fiscal years 2026 and 2027, respectively. Smaller reporting companies are required to first incorporate such disclosures for fiscal year 2027 and are not required to report greenhouse gas emissions data. In April 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. The Company is currently evaluating the impact of these new rules on its financial statements and disclosures. Significant Accounting Policies There have been no new or material changes to the Company’s significant accounting policies as described in its 2023 Annual Report that have had a material impact on the Company’s condensed financial statements and related notes. Recently Issued Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07), which requires that an entity disclose significant segment expenses impacting profit and loss that are regularly provided to the chief operating decision maker. The update is required to be applied retrospectively to prior periods presented, based on the significant segment expense categories identified and disclosed in the period of adoption. This ASU guidance is effective for our Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent interim periods, with early adoption permitted. The Company is currently evaluating the impact of the adoption of ASU 2023-07 on its financial statements and disclosures. In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (ASU 2023-09), which requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, this ASU requires certain disclosures of state versus federal income tax expense and taxes paid. This ASU is effective for our Annual Report on Form 10-K for the year ended December 31, 2025, with early adoption permitted. The Company does not expect the adoption of ASU 2023-09 to have a material impact on its financial statements. In March 2024, the SEC adopted rules intended to enhance and standardize climate-related disclosures in registration statements and annual reports. The new rules will require disclosure of material climate-related risks, including the material impacts of these risks to the Company, the quantification of material impacts to the Company as a result of severe weather events and other natural conditions and Board of Directors' oversight and risk management activities. The new rules follow a compliance phase-in timeline based on a company's filing status. Large accelerated filers and accelerated filers (other than smaller reporting companies) are required to first incorporate such disclosures for fiscal years 2025 and 2026, respectively, followed by greenhouse gas-related disclosures, if material, for fiscal years 2026 and 2027, respectively. Smaller reporting companies are required to first incorporate such disclosures for fiscal year 2027 and are not required to report greenhouse gas emissions data. In April 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. The Company is currently evaluating the impact of these new rules on its financial statements and disclosures. Significant Accounting Policies There have been no new or material changes to the Company’s significant accounting policies as described in its 2023 Annual Report that have had a material impact on the Company’s condensed financial statements and related notes. 3. Revenue and Deferred Revenue Disaggregation of Revenue Revenue by source consists of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:38.308%;box-sizing:content-box;"></td><td style="width:3.601%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.202%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.32%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.202%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.32%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.202%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.32%;box-sizing:content-box;"></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="8" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Consoles </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,709</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,506 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24,080</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 51,053 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Consumables </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 12,596 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11,025 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 35,891 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 29,587 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"> Total product revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 20,305 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23,531 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 59,971 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 80,640 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Service and other revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8,361 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 6,831 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 24,251 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 19,229 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"> Total revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> <span style="color:#000000;white-space:pre-

wrap;min-width:fit-content;">28,666</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">30,362</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">84,222</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">99,869</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr></table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Remaining Performance Obligations and Contract Liabilities</p><p style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of September 30, 2024, the aggregate amount of the transaction price allocated to the remaining performance obligations related to customer service contracts that are unsatisfied or partially unsatisfied was $12.9 million, which is recorded as deferred revenue on the Company's condensed balance sheets. Of that amount, $12.8 million will be recognized as revenue during the next 12 months and $0.1 million thereafter. </p><p style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">The contract liabilities consist of deferred revenue which represents payments received in advance of revenue recognition. Revenue under these agreements is recognized over the related service period. During the three and nine months ended September 30, 2024, the Company recognized $2.0 million and $10.9 million of previously deferred revenue, respectively.</p><p style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">Revenue by source consists of the following (in thousands): </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:38.308%;box-sizing:content-box;"></td><td style="width:3.601%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.202%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.32%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.202%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.32%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.202%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.32%;box-sizing:content-box;"></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended September 30,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="8" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30,</p></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Consoles</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,709</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12,506</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24,080</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">51,053</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Consumables</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12,596</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,025</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">35,891</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">29,587</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total product revenue</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">20,305</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,531</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">59,971</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">80,640</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Service and other revenue</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,361</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,831</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24,251</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">19,229</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total revenue</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 28,666 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">30,362</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 84,222 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-space:pre-wrap;min-

width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">99,869</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table> 7709000 12506000 24080000 51053000 12596000 11025000 35891000 29587000 20305000 23531000 59971000 80640000 8361000 6831000 24251000 19229000 28666000 30362000 84222000 99869000 12900000 12800000 P12M 100000 2000000 10900000 Fair Value Measurements<div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following tables summarize the Company’s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:39.768%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.922%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.242%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.242%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.242%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.582%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Valuation
Hierarchy</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Amortized
Costs</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Gross
Unrealized
Holding
Gains</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Gross
Unrealized
Holding
Losses</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Aggregate
Fair Value</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Assets:</p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash equivalents:</p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,136 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New

content;">1 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 57,892 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> Level 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"> Total cash equivalents and
  short-term investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">158,130</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 353 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 158,482 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:39.66%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.12%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.56%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Costs </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Holding
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Holding
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate
Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-

break:break-word;"> <td style="vertical-align:top;"> Assets: </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Cash equivalents: </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> Level 1 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">44,883</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44,883 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Short-term investments: </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury securities </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> Level 1 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 53,790 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 58 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (<span style="color:#000000;white-space:pre-

wrap;min-width:fit-content;">32 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 53,816 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. government-sponsored enterprises
  debt securities </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> Level 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29,645 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (38 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29,631 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate debt </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> Level 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33,214 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 56 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33,270 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> Level 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18,097 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (4 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18,098 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"> Total cash equivalents and
  short-term investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">179,629</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 143 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(74</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 179,698 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> As of September 30, 2024, the remaining contractual maturities for available-for-sale securities were one month to thirteen months. The following tables present the breakdown of the available-for-sale debt securities with unrealized losses as of September 30, 2024, and December 31, 2023 (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:35.561%;box-sizing:content-box;"></td> <td style="width:1.001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.001%;box-sizing:content-box;"></td> <td style="width:6.906000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.807%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.807%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.807%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.306999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="22" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized losses less than 12 months </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized losses 12 months or greater </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Corporate debt </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,659</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-

align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,659</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,659</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (1 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,659 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:35.453%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.859%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.858000000000005%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.858000000000005%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.858000000000005%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.858000000000005%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.258000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="22" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized losses less than 12 months </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized losses 12 months or greater </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt

solid #000000;text-align:left;"> Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury securities </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,416</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (16 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">17,925</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26,341 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (32 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. government-sponsored enterprises
— debt securities </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,757 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (22 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,488 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (16 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 27,245 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (38 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate debt </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11,291 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (4 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11,291 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (4 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">38,464</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (42 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">26,413</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (32 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (74 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table> The unrealized losses on the Company’s available-for-sale debt securities were caused by interest rate increases. The contractual terms of those investments do not permit the issuer to settle the securities at a price less than the amortized cost basis of the investments. As of September 30, 2024, the Company does not intend to sell the investments, and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. Additional factors considered in determining the treatment of unrealized losses include the financial condition and near-term prospects of the investee, the extent of the loss related to the credit of the issuer, and the expected cash flows from the security. For the three and nine months ended September 30, 2024 and 2023, the Company did not recognize credit loss related to available-for-sales debt securities. The following tables summarize the Company’s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:39.768%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.922%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.242%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.242%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.242%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.582%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Valuation
Hierarchy </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Costs </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Holding
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Holding
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> <span style="white-

space:pre-wrap;min-width:fit-content;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate
Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Assets: </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Cash equivalents: </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> Level 1 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,136</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,136 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Short-term investments: </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury securities </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> Level 1 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 72,762 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 158 </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="min-width:fit-

content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 72,920 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. government-sponsored enterprises
  debt securities </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> Level 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,520 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate debt </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> Level 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 57,712 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 181 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 57,892 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> Level 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"> Total cash equivalents and
  short-term investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 158,130 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-

space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">353</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (1 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">158,482</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:39.66%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.12%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.56%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Valuation
Hierarchy</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Amortized
Costs</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Gross
Unrealized
Holding
Gains</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Gross
Unrealized
Holding
Losses</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Aggregate
Fair Value</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Assets:</p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash equivalents:</p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Money market funds</p></td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Level 1</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;">44,883 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44,883 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Short-term investments: </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury securities </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> Level 1 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 53,790 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 58 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (32 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 53,816 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. government-sponsored enterprises
  debt securities </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> Level 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29,645 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (38 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29,631 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate debt </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> Level 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33,214 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 56 </td> <td style="white-

space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33,270 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> Level 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18,097 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (4 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18,098 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"> Total cash equivalents and
  short-term investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">179,629</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 143 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(74</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 179,698 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> *16136000 0 0 16136000 72762000 158000 0 72920000 11520000 14000 0 11534000 57712000 181000 1000 57892000 0 0 0 0 158130000 353000 1000 158482000 44883000 0 0 44883000 53790000 58000 32000 53816000 29645000 24000 38000 29631000 33214000 56000 0 33270000 18097000 5000 4000 18098000 179629000 143000 74000 179698000 one month to thirteen months The following tables present the breakdown of the available-for-sale debt securities with unrealized losses as of September 30, 2024, and December 31, 2023 (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:35.561%;box-sizing:content-box;"></td> <td style="width:1.001%;box-sizing:content-box;"></td> <td style="width:1.001%;box-sizing:content-box;"></td> <td style="width:6.906000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.807%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.807%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.807%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.807%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.306999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="22" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized losses less than 12 months </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized losses 12 months or greater </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Corporate debt </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,659</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,659</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,659</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (1 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,659 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (<span style="color:#000000;white-space:pre-

wrap;min-width:fit-content;">1 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:35.453%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.859%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.8580000000000005%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.8580000000000005%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.8580000000000005%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.258000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="22" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized losses less than 12 months </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized losses 12 months or greater </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury securities </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,416</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">26,341</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (32 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. government-sponsored enterprises
  debt securities </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="color:#000000;white-

space:pre-wrap;min-width:fit-content;">18,757 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (22 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,488 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (16 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 27,245 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (38 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate debt </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11,291 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (4 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11,291 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (4 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">38,464</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (42 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">26,413</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (32 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">64,877</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(74 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table> 2659000 1000 0 0 2659000 1000 2659000 1000 0 0 2659000 1000 8416000 16000 17925000 16000 26341000 32000 18757000 22000 8488000 16000 27245000 38000 11291000 4000 0 0 11291000 4000 38464000 42000 26413000 32000 64877000 74000 0 0 5. Balance Sheet Components Cash, Cash Equivalents and Restricted Cash As of September 30, 2024 and December 31, 2023, the restricted cash balance of $3.3 million, was related to collateral for the Company’s building leases in San Jose, CA and Tijuana, Mexico. </p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the amounts shown in the accompanying condensed statements of cash flows (in thousands):</p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash and cash equivalents</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33,287 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">36,297</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted cash</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,329</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,329</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total cash, cash equivalents and restricted cash</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 36,616 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">39,626</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accounts Receivable</p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accounts receivable are recorded at invoice value, net of any allowance for credit losses. The allowance for credit losses is based on the Company’s assessment of its best estimate of the amount of credit losses in customer accounts. The Company regularly reviews the allowance by considering factors such as existing contractual payment terms, historical collection experience, the financial position of the customer and information provided by credit rating services, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay. </p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company writes off accounts receivable when the Company has exhausted collection efforts without success, and payments subsequently received on such receivables are credited to the allowance in the period the payment is received. Credit losses from continuing operations have consistently been within management’s expectations.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;">The following table presents the activity in the Company’s allowance for credit losses (in thousands):</p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.673%;box-sizing:content-box;"></td> <td style="width:1.74%;box-sizing:content-box;"></td> <td style="width:14.923%;box-sizing:content-box;"></td> <td style="width:1.74%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.923%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance as of December 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 203 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-

indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Increase in allowance </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,821 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Write-offs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (7 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">)
</td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,017 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Inventories
Inventories consist of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Raw materials </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">25,138</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,706 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Work in process </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,911 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,728 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Finished goods </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 22,387 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 21,781 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"> Total inventories </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-

align:center;"> 61,436 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">49,215</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accrued Expenses and Other Current Liabilities</p><div style="font-size:10pt;font-family:Times New Roman,"><p style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">Accrued expenses and other current liabilities consist of the following (in thousands):</p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31,</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Inventory</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,384 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,395 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 116 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,050 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Professional services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 716 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,153 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Customer rebates </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,738 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,795 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,761 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"> Total accrued expenses and other current liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td

style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,749</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 13,459 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 3300000 3300000 The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the amounts shown in the accompanying condensed statements of cash flows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash and cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">33,287</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 36,297 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,329 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,329 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total cash, cash equivalents and restricted cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">36,616</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 39,626 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 33287000 36297000 3329000 3329000 36616000 39626000 The following table presents the activity in the Company's allowance for credit losses (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.673%;box-sizing:content-box;"></td> <td style="width:1.74%;box-sizing:content-box;"></td> <td style="width:14.923%;box-sizing:content-box;"></td> <td style="width:1.74%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.923%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance as of December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 203 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Increase in allowance </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,821 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Write-offs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (7 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,017</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> 203000 1821000 7000 2017000 <p style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">Inventories consist of the following (in thousands):</p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31,</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Raw materials</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25,138 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18,706</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Work in process</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">13,911</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,728</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Finished goods</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">22,387</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">21,781</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total inventories</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 61,436 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 49,215 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 25138000 18706000 13911000 8728000 22387000 21781000 61436000 49215000 Accrued expenses and other current liabilities consist of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-

color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Inventory </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,384</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,395 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 116 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,050 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Professional services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 716 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,153 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Customer rebates </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,738 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,795 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,761 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"> Total accrued expenses and other current liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,749</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 13,459 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 1384000 3395000 116000 1050000 716000 1153000 1738000 2100000 2795000 5761000 6749000 13459000 6. Commitments and Contingencies Litigation On August 29, 2024, a purported stockholder class action lawsuit (the Porcelli Complaint), <span style="color:#000000;white-space:pre-wrap;font-

size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Porcelli, et al. v. Outset Medical, Inc., et al., 5:24-cv-06124-EJD, was filed in the U.S. District Court for the Northern District of California, naming the Company, its Chief Executive Officer, and Chief Financial Officer as defendants. On October 18, 2024, a second purported stockholder class action lawsuit (the Plymouth Complaint), Plymouth County Retirement Association v. Outset Medical, Inc, et al., 5:24-cv-06124-HSG, was filed in the U.S. District Court for the Northern District of California. The second lawsuit additionally names the Company's former Chief Financial Officer as a defendant. The Porcelli Complaint alleges that between August 1, 2022 and August 7, 2024, the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (Exchange Act) by making false or misleading statements about the Company's business, operations and prospects related to the sale and marketing of the Tablo Hemodialysis System and TabloCart with Prefiltration, including concerning the impact of certain FDA processes for these products on the Company's revenue growth. The Plymouth Complaint alleges the same violations between September 15, 2020 and August 7, 2024. The Company intends to vigorously defend against this litigation. The cases are at a very early stage and there can be no assurance that the Company will be successful in its defense. For this same reason, the Company cannot currently estimate the loss or the range of possible losses it may experience in connection with this litigation. In addition, from time to time, the Company may become involved in other legal proceedings or investigations, which could have an adverse impact on its reputation, business and financial condition and divert the attention of the Company's management from the operation of the Company's business. Indemnification In the ordinary course of business, the Company often includes standard indemnification provisions in its arrangements with its partners, customers and suppliers. Pursuant to these provisions, the Company may be obligated to indemnify such parties for losses or claims suffered or incurred in connection with its service, breach of representations or covenants, intellectual property infringement or other claims made against such parties. These provisions may limit the time within which an indemnification claim can be made. It is not possible to determine the maximum potential amount under these indemnification obligations due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. To date, the Company has not incurred any material costs as a result of such indemnification obligations and has not accrued any liabilities related to such obligations in these financial statements. 7. Term Loans Term loans consist of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.993%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> December 31, </td><td style="vertical-align:bottom;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Principal of term loans </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">200,000</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 133,476 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr></table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.993%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Unamortized debt discount </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,818 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (3,363 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"> Term loans, noncurrent </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">197,182</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 130,113 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td></tr></table> SLR Credit Facilities On November 3, 2022 (the Closing Date), the Company entered into two senior secured credit facilities, which collectively provide for borrowings of up to $300.0 million as follows: (i) up to a $250.0 million term loan facility pursuant to a loan and security agreement (the SLR Loan Agreement) among SLR Investment Corp., as collateral agent (Agent), the lenders from time to time party

thereto (the Term Loan Lenders) and the Company (the SLR Term Loan Facility), and (ii) up to a $50.0 million asset-based revolving credit facility pursuant to a credit agreement (the SLR Revolving Credit Agreement, together with the SLR Loan Agreement, the SLR Credit Facility Agreements) among Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL, as lender (ABL Lender), and the Company (the SLR Revolver, together with the SLR Term Loan Facility, the SLR Credit Facilities). The maximum amount the Company is permitted to borrow under the SLR Credit Facilities is subject to certain overall borrowing limitations that are tied to achieving certain specified revenue milestones and limit the maximum principal amount outstanding under the SLR Credit Facilities. As of September 30, 2024, the Company borrowed an aggregate principal amount of $200.0 million under the SLR Term Loan Facility, the full amount available under the borrowing limitations. SLR Term Loan Facility Under the SLR Loan Agreement, as subsequently amended on December 11, 2023, the Term Loan Lenders agreed to extend term loans to the Company in an aggregate principal amount of up to $250.0 million, comprised of (i) a term loan of $100.0 million (the Term A Loan), (ii) term loans in an aggregate principal amount of up to $100.0 million that was provided for in two increments, one of $33.5 million (the Term B-1 Loan) and one of $66.5 million (the Term B-2 Loan) and (iii) one or more term loans in an aggregate principal amount of up to $50.0 million (Term C Loans). Each Term A Loan, Term B Loan and Term C Loan is referred to single as a Term Loan and are referred to collectively as the Term Loans. The Term C Loans are subject to compliance with the borrowing limitations, Term Loan Lenders' credit approval and the achievement of a specified net revenue milestone on or before June 30, 2025 and if available, would remain available for funding until one business day prior to November 1, 2027. Any principal amount outstanding under the Term Loans will accrue interest at a rate per annum equal to one-month term Secured Overnight Financing Rate (term SOFR) (subject to a 2.75% floor), plus 5.15% (10.32% as of September 30, 2024), payable monthly in arrears. The Company is permitted to make interest-only payments on the Term Loans through November 30, 2026. Any principal amounts outstanding under the Term Loans, if not repaid sooner, are due and payable on November 1, 2027 (the Maturity Date). The Company is obligated to pay Agent (i) a non-refundable facility fee in the amount of $750,000 in respect of the Term A Loan, (ii) a non-refundable facility fees in the aggregate amount of $750,000 in respect of the Term B-1 and B-2 Loans and (iii) a non-refundable facility fee in the amount of $375,000 in respect of the Term C Loan, to be due and payable upon the earliest to occur of (a) the funding of the first Term C Loan, (b) one day prior to the Maturity Date and (c) the prepayment of the Term Loans. In addition, the Company is obligated to pay a final fee equal to 4.75% of the aggregate amount of the Term Loans funded, such final fee to be due and payable upon the earliest to occur of (i) the Maturity Date, (ii) the acceleration of the Term Loans and (iii) the prepayment of the Term Loans. The Company may voluntarily prepay the outstanding Term Loans, subject to a prepayment premium of (i) 3.0% of the principal amount of the Term Loan, if prepaid prior to or on the first anniversary of the Closing Date, (ii) 2.0% of the principal amount of the Term Loan, if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) 1.0% of the principal amount of the Term Loan if prepaid after the second anniversary of the Closing Date and prior to the Maturity Date. SLR Revolver The SLR Revolving Credit Agreement provides for an asset-based revolving credit facility with aggregate revolving commitments of $25.0 million (the Initial Revolver Commitment). The Company may request to increase the aggregate revolving commitments by $25.0 million (the Additional Tranche) to an aggregate amount of $50.0 million, subject to ABL Lender's approval. Amounts available to be drawn under the SLR Revolver are equal to the lesser of (i) outstanding revolving commitments under the SLR Revolving Credit Agreement and (ii) a borrowing base (the Borrowing Base) equal to the sum of (a) 85% of eligible accounts receivable, plus (b) 25% of eligible inventory (not to exceed the lesser of 50% of the Borrowing Base and $5.0 million), minus (c) customary reserves, minus (d) unposted cash. As of September 30, 2024, no amounts were outstanding under the SLR Revolver. As a result of the overall borrowing limitations set forth in the SLR Credit Facilities, amounts under the SLR Revolver are not currently available. As of September 30, 2024, the Company has not requested or received ABL Lender's approval of the Additional Tranche. Any principal amount outstanding under the SLR Revolver will accrue interest at a rate per annum equal to one-month term SOFR (subject to a 2.75% floor), plus 3.20%, payable monthly in arrears. Interest on any borrowing is payable monthly. The Company is obligated to pay Lender (i) a non-refundable facility fee in the amount of $187,500 in respect of the Initial Revolver Commitment, (ii) a non-refundable facility fee in the amount of $187,500 in respect of the Additional Tranche, to be due and payable upon activation of the Additional Tranche, (iii) a commitment fee of 0.50% per annum of the average daily unused portion of the then commitment amount, payable monthly and (iv) a collateral monitoring fee of 0.10% per month of the average daily Borrowing Base during the prior month, payable monthly. The Company may terminate the SLR Revolver at any time, subject to a termination fee of (i) 2.0% of the aggregate revolving commitments then in effect, if terminated prior to or on the first anniversary of the Closing Date, (ii) 1.0% of the aggregate revolving commitments then in effect, if terminated after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) 0.5% of the aggregate revolving commitments then in effect, if terminated after the second anniversary of the Closing Date through and including the third anniversary of the Closing Date. Such termination fee is waived if the SLR Revolver is terminated after the third anniversary of the Closing Date and prior to the Maturity Date. <span

style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subject to customary exceptions and restrictions, the Company may borrow, repay and reborrow varying amounts under the SLR Revolver at any time subject to the overall borrowing limitations. If at any time the outstanding amount under the SLR Revolver exceeds the lesser of (i) the aggregate revolving commitments then in effect and (ii) the Borrowing Base then in effect, the Company will be required to prepay outstanding amounts under the SLR Revolver. The SLR Revolver shall expire on November 1, 2027. Other Terms of the SLR Credit Facilities As security for its obligations under the SLR Credit Facilities, the Company granted Agent, for the benefit of the Term Loan Lenders, and ABL Lender a security interest in substantially all of the assets of the Company, including the Company's intellectual property, subject to certain exceptions. The SLR Credit Facility Agreements contain customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to financial reporting and insurance and restrictions on the Company's ability to dispose of its business or property, to change its line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on its property or to pay any dividends or other distributions on capital stock. The agreements also include a financial covenant that, beginning with the fiscal quarter ended December 31, 2023, the Company must either (i) maintain certain levels of cash and cash equivalents in accounts subject to control agreements in favor of Agent and ABL Lender of at least 50% of the sum of (a) the outstanding obligations under the Term Loans (as defined below) and (b) the amount of the Company's accounts payable that have not been paid within 120 days from the invoice date thereof or (ii) generate net product and product related revenue in excess of specified amounts and maintain gross profit margins in excess of specified percentages, in each case, for applicable measuring periods. In addition, the SLR Credit Facility Agreements contain customary events of default that entitle Agent, under the SLR Loan Agreement, and ABL Lender, under the SLR Revolving Credit Agreement, to cause the Company's indebtedness under the SLR Loan Agreement or SLR Revolving Credit Agreement, as applicable, to become immediately due and payable, and to exercise remedies against the Company and the collateral securing the obligations owed under the applicable SLR Credit Facility Agreement. Under the SLR Credit Facility Agreements, an event of default will occur if, among other things, the Company fails to make payments under either SLR Credit Facility Agreement, the Company breaches covenants under either SLR Credit Facility Agreement, subject to specified cure periods with respect to certain breaches, the Agent or ABL Lender, as applicable, determine that a material adverse change has occurred under the SLR Loan Agreement or SLR Revolving Credit Agreement, as applicable, or the Company or its assets become subject to certain legal proceedings, such as bankruptcy proceedings. Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to 4.0% per annum will apply to all obligations owed under the SLR Credit Facility Agreements. The debt issuance costs and the facility fees related to the Term A and B Loans were recorded as a direct deduction from the term loans balance on the balance sheets and are being recognized as non-cash interest expense over the term of the loans using the effective interest method, along with the final payment fee. The facility fees related to the Initial Revolver Commitment were recorded as deferred financing costs and are being recognized as non-cash interest expense over their respective commitment period using straight-line method. Term loans consist of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.993%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> December 31, </td><td style="vertical-align:bottom;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Principal of term loans </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">200,000</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 133,476 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr></table><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.993%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Unamortized debt discount </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,818 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (3,363 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"> Term loans, noncurrent </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">197,182</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double

#000000;text-align:center;"> 130,113 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 200000000 133476000 2818000 3363000 197182000 130113000 300000000 250000000 50000000 200000000 250000000 100000000 100000000 33500000 66500000 50000000 0.0275 0.0515 0.1032 2026-11-30 750000000 750000000 375000000 0.0475 The Company may voluntarily prepay the outstanding Term Loans, subject to a prepayment premium of (i) 3.0% of the principal amount of the Term Loan, if prepaid prior to or on the first anniversary of the Closing Date, (ii) 2.0% of the principal amount of the Term Loan, if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) 1.0% of the principal amount of the Term Loan if prepaid after the second anniversary of the Closing Date and prior to the Maturity Date. 0.03 0.02 0.01 25000000 25000 50000000 0.85 0.25 0.50 5000 0.0275 0.032 187500000 187500000 0.005 0.001 0.02 0.01 0.005 2027-11-01 0.50 0.04 8. Equity Incentive Plan Equity Incentive Plans As of September 30, 2024, 3,218,000 shares were reserved for future issuance under the 2020 Equity Incentive Plan (2020 Plan). Employee Share Purchase Plan (ESPP) As of September 30, 2024, 667,000 shares of common stock were reserved for issuance in connection with the current and future offering periods under the ESPP. Restricted Stock The Company issues restricted stock units (RSUs) and performance stock units (PSUs), both of which are considered restricted stock. The Company grants restricted stock pursuant to the 2020 Plan and satisfies such grants through the issuance of new shares. RSUs are share awards that, upon vesting, will deliver to the holder shares of our common stock. RSUs with a service-based vesting condition granted to a grantee, beginning in February 2022, generally vest over a three-year period as follows either: (i) 25% on the first anniversary of the original vesting date, 25% quarterly over the course of the second year, and 50% quarterly over the course of the third year, or (ii) 33% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining two years. Annual RSUs granted to non-executive employees in 2024 vest over a two-year period at a rate of 50% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining one year. Prior to February 2022, RSUs with a service-based vesting condition granted to a grantee generally vest at a rate of 25% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining three years. Since 2022, the Company has granted a mix of 50% PSUs and 50% RSUs to its CEO, and a mix of 20% PSUs and 80% RSUs to its other executive officers and certain other senior leaders on an annual basis. The PSUs are earned and vest based on achievement against two metrics: • The “Home PSUs” are earned based on the number of patients treating at home on Tablo as of the end of the second or third year following the grant date (Year 2 or Year 3), with earned units vesting either (i) 50% after certification of achievement following the end of Year 2 and 50% at the end of Year 3 or (ii) 100% after certification of achievement following the end of Year 3 (performance-based vesting conditions). • The “Relative TSR PSUs” are earned based on the Company's relative total stockholder return (relative TSR) at the end of a two-year or three-year performance period as compared to companies in a pre-determined index of medical device companies, in each case, with 100% of earned units vesting on, or after certification of achievement following, the third anniversary of the grant date (market-based vesting conditions). The number of units earned varies based on actual performance as follows: (i) from 0% to 200% (250% for the CEO) of the target number of the Home PSUs granted, (ii) from 75% to 150% (250% for the CEO) of the target number of Relative TSR PSUs granted in 2022 and 2023 and (iii) from 0% to 200% (250% for the CEO) of the target number of Relative TSR PSUS granted in 2024. The grant date for the Home PSUs is not considered established until the Compensation Committee of the Board approves the target and it is communicated to the award recipients, which then triggers the service inception date, the fair value of the awards, and the associated expense recognition period. Once the grant date for the Home PSUs has been established, the related stock-based compensation expense is recorded based on the forecasted performance, which is reassessed each reporting period based on the probability of achieving the performance conditions. In 2024, the Company also granted a new type of PSU award to executive officers and certain other senior leaders which is earned and vests based on appreciation of the Company’s stock price above pre-determined stock price triggers or achievement of specified operating income targets over a performance period of up to three years. Stock-Based Compensation Expense The following table sets forth stock-based compensation expense included in the accompanying condensed statements of operations (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:51.01%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.698%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.698%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.34%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.418000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.418000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:top;text-align:left;"> Three Months Ended </td> <td style="vertical-align:top;text-align:left;"> </td> <td style="vertical-align:top;text-align:left;"> </td> <td colspan="6" style="vertical-align:top;text-align:left;"> Nine Months Ended </td> <td style="vertical-align:top;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:top;text-align:left;"> </td> <td colspan="6" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:top;text-align:left;"> </td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cost of revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:top;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">296</p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"> 620 </td> <td style="white-space:nowrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,092</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,381 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"> 1,400 </td> <td style="white-space:nowrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"> 2,793 </td> <td style="white-space:nowrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,025 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,232 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Sales and marketing </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"> 945 </td> <td style="white-space:nowrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"> 3,765 </td> <td style="white-space:nowrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,898 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,908 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"> 3,747 </td> <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"> 3,715 </td> <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 12,396 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 10,015 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total stock-based compensation expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,388</p></td> <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"> 10,893 </td> <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24,411</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 29,536 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> *3218000 667000 0.25 25% quarterly over the course of the second year, and 50% quarterly over the course of the third year, or (ii) 33% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining two years. Annual RSUs granted to non-executive employees in 2024 vest over a two-year period at a rate of 50% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining one year. Prior to February 2022, RSUs with a service-based vesting condition granted to a grantee generally vest at a rate of 25% on the first anniversary of the original vesting date 0.50 0.50 0.20 0.80 0.50 0.50 1 0 2 -2.50 0.75 1.50 -2.50 0 2 -2.50* *The following table sets forth stock-based compensation expense included in the accompanying condensed statements of operations (in thousands):* <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:51.01%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.698%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.698%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.34%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.418000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.418000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:top;text-align:left;"> Three Months Ended </td> <td style="vertical-align:top;text-align:left;"> </td> <td style="vertical-align:top;text-align:left;"> </td> <td colspan="6" style="vertical-align:top;text-align:left;"> Nine Months Ended </td> <td style="vertical-align:top;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:top;text-align:left;"> </td> <td colspan="6" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:top;text-align:left;"> </td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> *Cost of revenue* </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:top;"> $ </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"> 296 </td> <td style="white-space:nowrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> <span style="white-space:pre-wrap;min-

width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:top;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">620</p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,092 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,381</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Research and development</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,400</p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,793</p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,025</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,232</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Sales and marketing</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">945</p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,765</p></td> <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,898</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,908</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">General and administrative</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,747</p></td> <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,715</p></td> <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12,396</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,015</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total stock-based compensation expense</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"> 6,388 </td> <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,893</p></td> <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 24,411 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 29,536 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 296000 620000 1092000 1381000 1400000 2793000 6025000 8232000 945000 3765000 4898000 9908000 3747000 3715000 12396000 10015000 6388000 10893000 24411000 29536000 9. Income Taxes For each of the three and nine months ended September 30, 2024 and 2023, the Company incurred an income tax provision of an insignificant amount, which primarily related to foreign income taxes related to the Company's Mexico operations. The U.S. federal and state net deferred tax assets have been fully offset by a valuation allowance, as the Company believes it is not more likely than not that the deferred tax assets will be realized. 10. Net Loss Per Share The following outstanding potentially dilutive shares were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.067%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.377%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.377%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;"> Three and Nine Months Ended </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Stock options to purchase common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,521 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,978 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,961 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,760 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Performance stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 273 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Shares committed under ESPP </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 319 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 42 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Warrant to purchase common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 63 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-

align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 63 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,137 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,938 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> </table> The following outstanding potentially dilutive shares were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.067%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.377%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.377%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;"> Three and Nine Months Ended </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Stock options to purchase common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,521 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,978 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,961 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,760 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Performance stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 273 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Shares committed under ESPP </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 319 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 42 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Warrant to purchase common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 63 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-space:pre-wrap;min-

width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 63 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,137 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,938 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 1521000 1521000 1978000 1978000 3961000 3961000 2760000 2760000 273000 273000 95000 95000 319000 319000 42000 42000 63000 63000 63000 63000 6137000 6137000 4938000 4938000 11. Workforce reduction In order to improve operational efficiencies, reduce operating expenses and streamline its overall organizational structure, the Company implemented two organizational restructuring plans to reduce its workforce in the fourth quarter of 2023 and May 2024 and incurred restructuring charges of $2.5 million in fiscal year 2023 and $2.7 million through the first half of fiscal year 2024 for employee severance and other termination benefits. In connection with steps the Company is taking to help optimize its commercial organization, and to help improve operational efficiencies and reduce operating expenses to align with anticipated revenue growth, in the third quarter of 2024, the Company completed an additional restructuring primarily impacting its commercial organization. The Company incurred restructuring charges of $1.4 million in the third quarter of 2024 for employee severance and other termination benefits associated with this restructuring. The following table sets forth severance and related benefits charges included in the accompanying condensed statements of operations (in thousands):
<table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:75.92%;box-sizing:content-box;"></td> <td style="width:1.84%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:20.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> Nine Months Ended </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cost of revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">530</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Research and development</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,260</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Sales and marketing</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,884</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">General and administrative</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">475</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,149 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The changes in liabilities resulting from the restructuring accruals, which were recorded in accrued expenses and other current liabilities on the accompanying condensed balance sheets, were as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:61.192%;box-sizing:content-box;"></td> <td style="width:1.48%;box-sizing:content-box;"></td> <td style="width:17.924%;box-sizing:content-box;"></td> <td style="width:1.48%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.923%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance as of December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 854 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr

style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Charges </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,149 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Payments and other adjustments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (4,920 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Balance as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">83</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div> 2500000 2700000 1400000 <p style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">The following table sets forth severance and related benefits charges included in the accompanying condensed statements of operations (in thousands): </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:75.92%;box-sizing:content-box;"></td> <td style="width:1.84%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:20.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cost of revenue</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 530 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,260 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Sales and marketing </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,884 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 475 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,149</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table> 530000 1260000 1884000 475000 4149000 <p style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">The changes in liabilities resulting from the restructuring accruals, which were recorded in accrued expenses and other current liabilities on the accompanying condensed balance sheets, were as follows (in thousands):</p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:61.192%;box-sizing:content-box;"></td> <td style="width:1.48%;box-sizing:content-box;"></td> <td style="width:17.924%;box-sizing:content-box;"></td> <td style="width:1.48%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.923%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance as of December 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 854 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">Charges </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,149 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Payments and other adjustments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (4,920 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Balance as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 83 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 854000 4149000 4920000 83000 12. Subsequent Event On October 18, 2024, a second purported stockholder class action lawsuit was filed against the Company, certain of its officers and a former officer (see Note 6). false false false false